Risk assessment and determination of aristolochic acids and heavy metals in Chinese herbal medicines by Cheung, T
 RISK EVALUATION AND DETERMINATION OF 
ARISTOLOCHIC ACIDS AND HEAVY METALS  
IN CHINESE HERBAL MEDICINES 
 
 
 
A thesis submitted in fulfillment of the requirements for  
the degree of Doctor of Philosophy  
 
 
 
 
Thomas Pak Fai Cheung 
(B.Sc.Hons, B.App.Sc., M.Sc., M.App.Sc.) 
 
 
 
 
 
 
Division of Chinese Medicine    
School of Health Sciences 
RMIT University 
March 2007
 i 
Declaration 
 
 
I certify that except where due acknowledgement has been made, the work is that of the author 
alone; the work has not been submitted previously, in whole or in part, to qualify for any other 
academic award; the content of the thesis is the result of work which has been carried out since 
the official commencement date of the approved research program; and, any editorial work, paid 
or unpaid, carried out by a third party is acknowledged. 
           
 
 
 
 
 
………………………………… 
 
 
Thomas Cheung 
 
 
Date:  …………………………. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 i 
Acknowledgements 
 
 
          I wish to thank Professor Charlie Xue, Head of Division of Chinese Medicine, and Director 
of RMIT University World Health Organization Centre for Chinese Medicine, for providing me 
the scholarship to undertake this further study, and also for being supportive as my supervisor. To 
my senior supervisor, Associate Professor Chun Guan Li, I am most thankful for his patience, 
guidance and trust. To emeritus Professor David Story, Professor of Pharmaceutical Science at 
RMIT University, I am grateful for his invaluable help in my Aristolochic Acid manuscript. 
Associate Professor Dayanthie Nugegoda in Ecotoxicology allowed me to use her research 
facilities including the graphite furnace atomic absorption spectrometer during the early days of 
my research. I am most obliged for her generosity and assistance. To Associate Professor Helmut 
Hugel of Department of Applied Chemistry, I express my sincere thanks for his encouragement 
and continued interest in my project. Also, to Dr. Kelvin Leung and Professor Kelvin Chan of the 
School of Chinese Medicine, Hong Kong Baptist University, I am indebted for their excellent 
technical support in the LC-MS confirmation of the aristolochic acid samples.  
 
          To Dr Angela Yang, Dr Anthony Zhang, Joyce Ye Shen, and Ms Xuedong An, I am most 
grateful for their indispensable assistance related to computer editing.  
 
          The past few years of arduous research life would have been rather hard-going and dull but 
for the wonderful friendships I have been lucky enough to have with some young and aspiring 
postgraduate colleagues. Their warm and cheerful companies made many long days and nights of 
experiments go so much faster and more pleasant. They are Dr Anthony Lin Zhang, Ms Iris 
Wenyu Zhou, Ms Joyce Ye Shen, Ms Yanyi Wang, and Ms Xuedong An. To them all, I convey 
my sincere thanks and wish them a bright future.                        
 ii 
Publications 
Papers 
Thomas P. Cheung, Charlie Xue,  Kelvin Leung, Kelvin Chan, Chun G. Li. Aristolochic Acids 
Detected in Some Raw Chinese Medicinal Herbs and Manufactured Herbal Products – A 
Consequence of Inappropriate Nomenclature and Imprecise Labelling? Clinical 
Toxicology, 44:371 – 378, 2006. 
Xue CCL, An XD, Cheung TPF, Da Costa C, Lenon GB, Story DF. Evaluation of Efficacy and 
Safety of Acupuncture in Treatment of Persistent Allergic Rhinitis: A Randomized, 
Single-Blind, Sham-Controlled, Clinical Trial. MJA, 187:337-341, 2007. 
Papers in preparation 
Thomas P. Cheung, Charlie Xue, Dayanthie Nugegoda, Chun G. Li. Risk Assessment of Heavy 
Metals in Chinese Herbal Materials in Victoria, Australia. (in preparation) 
Thomas P. Cheung, Charlie Xue, Chun G. Li. Risk Assessment of Heavy Metals in Chinese 
Proprietary Medicines in Victoria, Australia. (in preparation) 
Thomas P. Cheung, Charlie Xue, Chun G. Li. Effect of Oral Administration of Chinese Herbal 
Capsules on Serum Concentrations of Lead and Cadmium. (in preparation) 
Conference oral presentation 
Thomas P. Cheung, Charlie Xue, Chun G. Li. Determination of Aristolochic Acids in Some 
Commonly Used Chinese Medicines in Victoria. The First World Congress on Chinese 
Medicine. Melbourne, Australia. 
Thomas P. Cheung, Charlie Xue, Chun G. Li. Determination of Heavy Metals in Traditional 
Chinese Herbs and Chinese Proprietary Medicines in Victoria, Australia – How safe are 
they?  World Congress on Chinese Medicine: Charting the course of Development. 2006, 
60. 
 iii 
Table of Contents 
 
Declaration ……………………………………………………………………………………….i 
Acknowledgement ………………………………………………………………………………ii 
Publications ……………………………………………………………………………………..iii 
Table of Contents ……………………………………………………………………………….iv 
List of Figures ………………………………………………………………………………...xviii 
List of Tables …………………………………………………………………………………..xxii 
Abbreviations …………………………………………………………………………………xxxi 
Summary ………………………………………………………………………………………....1 
 
CHAPTER 1 – CHAPTER 5 
Risk Assessment and Determination of Aristolochic Acids in Chinese Herbal Medicines 
 
Chapter 1  Introduction  
1.1     Background of Aristolochic Acids Nephropathy (AAN) ……………………..………..…8 
1.2     Prevalence of Aristolochic Acids (AA) Toxicities ………………………………..............8 
1.3     Government Policies on AA-containing Herbs and Manufactured Products …...………...9 
1.4      Contributing Factors to AA Toxicities and Rationale for This ……………....................10 
1.5      Objectives of Present Project …………………………………………………………....11 
1.6      Research Protocol for Achieving Objectives ………………………………………........12 
1.6.1 Rationale for selecting specific herbal medicinal samples……………………….12 
1.6.2 Laboratory approaches to achieve objectives……………………………….........13 
 
 iv 
Chapter 2  Review of Literature                                                                                             
2.1      Chemistry of AA …………………………………………………………………….….15 
2.2      Toxicities of AA ……………………………………………………………………..….16 
2.2.1 Aristolochic Acid Nephropathy (AAN) ………………………………………....16 
2.2.2 Urothelial carcinoma and cancer……………………………………....................18 
2.3      AA Contents in Chinese Herbal Medicines ……………………………..……………....19 
2.4      Methodology in Determination of AA in Herbal Medicines …………………………....23 
2.4.1 Fluorometric and gas liquid chromatography (GLC) analysis of AA……............23 
2.4.2 Thin layer chromatography (TLC)…………………….………………...…….…24 
2.4.3 Capillary zone electrophoresis (CZE) ………………………………..……….…24 
2.4.4 High pressure liquid chromatography (HPLC) ………………………….............25 
2.4.5 HPLC coupled to mass spectrometry (LC-MS)…………………...……………..26 
 
Chapter 3  Materials and Methods  
3.1        Materials ………………………………………………………………………………...28 
3.1.1       Chemicals ……………………………………………………………….…............28 
3.1.2       Equipments …………………………………………………………………….…..28 
3.1.3       Herbal materials ……………………………………………………………............29 
3.2        Methods …………………………………………………………………….……...........30 
3.2.1       Collection and homogenisation of herbal materials ……………………….............30 
3.2.2       Extraction of herbal samples ………………………………………………………31 
3.2.3       Preparation of mobile phase solvent for HPLC ……………………………………32 
3.2.4       Preparation of AA standards ……………………………………………..…..........33 
3.2.5       Analysis of AA by HPLC ……………………………………………….………...34 
 v 
3.2.6       HPLC recovery study for AA-I and AA-II ………………………………………..36 
3.2.7       Confirmation of HPLC AA results by LC-MS …………………………………....36 
Chapter 4   Results  
4.1    Validity of HPLC Method ……………………………………………………………….39 
4.2    Recovery Study for HPLC Analysis of AA ……………………………………………...40 
4.3    HPLC Analysis of AA in Raw Herbs …………………………………………………....41 
4.4    HPLC Analysis of AA in Manufactured Herbal Medicines ……………………………..44 
4.5    Confirmation of Positive HPLC AA Results by LC-MS ………………………………...47 
4.6    Summary of AA Results for Raw Herbs and Manufactured Herbal Products …………...50 
 
Chapter 5   Discussion and Conclusion  
5.1 Discussion …………………………………………………………………………….….52 
5.2 Conclusion ……………………………………………………………………………….62 
 
CHAPTER 6 – CHAPTER 10 
Risk Assessment and Determination of Heavy Metals, Lead, Arsenic, Cadmium, Mercury 
and Chromium, in Raw Chinese Herbal Materials (CHM), Chinese Proprietary Medicines 
(CPM), And Chinese Medicinal Formulae (CMF) 
 
Chapter 6   Introduction  
6.1         Background ……………………………………………………………………….…….71 
6.2         Research Questions and Research Approaches ………………………………….……..74 
 vi 
Chapter 7   Literature Review  
7.1        Types of Traditional Chinese Medicines ……………………………………………..…76 
7.2        Safety Concerns about Metal Contaminations in Chinese Medicines ………………..…77 
7.3        Lead Clinical Toxicities and Cases of Lead Poisoning …………………………………77 
7.4        Arsenic Clinical Toxicities and Cases of Arsenic Poisoning …………………...…...….81 
7.5        Mercury Clinical Toxicities and Cases of Mercury Poisoning ……………………...…..82 
7.6        Cadmium Clinical Toxicities and Cases of Cadmium Poisoning …………………….....83 
7.7        Chromium Clinical Toxicities and Cases of Chromium Poisoning ……………..............84 
7.8        Methodology of Heavy Metal Analysis in Chinese Medicines ………………………....84 
7.9        Principles of Atomic Absorption Spectrometry ………………………………………...85 
7.10      Rationale for Choosing Graphite Furnace Atomic Absorption Spectrometary   
             (GFAAS) ……………………………………………………………………………..…86 
7.11  Development of Graphite Furnace Technique …………………………………..............87 
7.12  Herbal Sample Treatment by Hot Acid Digestion ……………………………………....89 
7.13  Methodological Considerations of GFAAS for the Measurement  
             of Pb, As, Cd, & Cr in Chinese Medicines ………………………………………….…..89 
7.14  Methodological Considerations of Cold Vapour Atomic Absorption Spectrometry 
             (CVAAS) for the Measurement of Hg in Chinese Medicines …………..........................92 
7.15   Screening of Metals in Chinese Medicines ……………………………………….…....93 
7.16   Screening of Metals in Chinese Proprietary Medicines (CPM) ………………..............93 
7.17   Screening of Metals in Chinese Herbal Materials (CHM) ………………………..........96 
7.18   Interpretation of Metal Intakes in Terms of Tolerable Limits – the Regulatory      
             Standards for Safety) …………………………………………………………….….…..98 
7.18.1 Australian Regulatory Process for Chinese Herbal Medicines ……………..…....98 
 vii 
7.18.2 Regulatory Standards for Metal Intakes …………………….………….…..…....99 
 
Chapter 8   Materials and Methods  
8.1         Materials …………………………………………………………………………........102 
      8.1.1       Chemicals ………………………………………………………………...……....102 
8.1.2        Instruments and Laboratory Wares ……………………………………….…...…103 
8.1.3        Reagents ……………………………………………………………………...…..104 
8.1.4       Preparation of Standard Solutions ……………………………………….…….....105 
8.1.4.1      Standard solutions for lead determination …………………………..….…..105 
8.1.4.2      Standard solutions for arsenic determination …………………….…….…..106 
8.1.4.3      Standard solutions for cadmium determination ………………….……........106 
8.1.4.4      Standard solutions for mercury determination ………………….……..……107 
8.1.4.5      Standard solutions for recovery studies of As, Cd, and Cr ………………....107 
8.1.4.6      Standard solutions for recovery studies of Pb and Hg ……………………...108 
8.1.4.7      Certified reference herbal materials for recovery studies  
                 of Pb & Hg……………………………………………………………...........108 
8.1.5       Purcahse of Herbal Samples  …………………………………..…………………109 
8.1.6       Cleaning of Glassware and Plastic-wares ………………………………………...110 
8.2         Methods – Preparation of Samples for Analysis …………………………….…..........100 
8.2.1      Preparation of Samples into Powder for Acid Digestion –, for 
              CHM, CPM and CMF ……………………………………………………….........110 
8.2.1.1    Preparation of powder for crude Chinese herbal materials (CHM)……….....111 
8.2.1.2    Preparation of powder for Chinese Proprietary Medicines (CPM) ….….…...117 
8.2.1.3    Preparation of powder for Chinese Medicinal Formulae  (CMF) ……….......120 
 viii 
8.2.2 Determination of Dry Weight ……………………………………………..…....123 
8.2.3 Acid Digestion of CHM, CPM and CMF Samples for Determination of  
                              Total Metal Contents ……………………………………………………….......123 
8.2.4 Water Extraction of CHM Samples – Dissolution Study of Metal in  
            Aqueous Decoction after Boiling ………………………………………............124 
8.2.5 Water Extraction of CMF Samples – Dissolution Study of Metal in  
            Aqueous Decoction after Boiling ………………………………………............128 
8.3    Methods of Analysis – Dtermination of Metals by Atomic Absorption      
              Spectrometry (AAS) ………………………………………………………...……..….130 
8.3.1 Introduction …………………………………………………………...…….…..130 
8.3.2 Summary of Total Number of Hebal Medicines Analysed …………..……..….130 
8.3.3 Samples Dilution Prior to AAS Analysis …………………………….…...........131 
8.3.3.1 Dilution of acid-digested samples – for measuring total metal content ..............132 
8.3.3.2 Dilution for water-decocted samples – for measuring  
                              aqueous metal concentration ……………………………………….............132 
8.3.4 Determination of Lead by GFAAS …………….………………………...……..133 
8.3.5 Detarmination of Arsenic by GFAAS ……………………………………….....135 
8.3.6 Determination of Cadmium by GFAAS ……………………………….......…...137 
8.3.7 Detarmination of Chromium by GFAAS ………………………………............139 
8.3.8 Detarmination of Mercury by CVAAS ………………………...........................141 
8.4   Accuracy of Determination of As, Cd, and Cr by Recovery Studies ……………….…144 
8.5   Accuracy of Determination of Pb and Hg by Recovery Studies ………….……….......146 
8.6   Precision of Pb, As, Cd, Cr and Hg Determination.………………………….…..........146 
8.7   Limit of Deection (LOD) and Limit of Quantitaion (LOQ) Determination ………......147 
 ix 
8.8   Protocol of Investigation …………………………………………………….………...147 
 
Chapter 9   Results  
9.1         Method Optimization ……………………………………………………………….....149 
9.1.1      Calibration Curves and UV Absorption Spectra of Standards …………….……...149 
9.1.2      Accuracy of the Method – as Percentage of Recovery …………...........................152 
9.1.2.1     Accuracy of method for lead and mercury determinations ………………….152 
9.1.2.2     Accuracy of method for arsenic, cadmium and chromium 
               determinations ……………………………………………………………......153 
9.1.3      Precision of Method – as Percentage of Relative Standard Deviation              
              (%RSD) ……………………………………………………………………............155 
      9.1.4      Limits of Determination - Limits of Detection (LOD) and  
              Limit of Quantitation (LOQ) ………………………………………………….......156 
9.2         Results of 100 CHM – Total Metal Contents, Aqueous Metal  
              Concentrations, and Estimated Daily Intakes of Metals ……………………………....157 
9.2.1   Results of Total Metal Contents in Acid-digested CHM Samples ………........157 
9.2.1.1        Difference in total metal contents among 100 CHM ……………................161 
9.2.2 Results of Metal Concentrations in Aqueous Decoctions of CHM ….................163 
9.2.3 Estimated Daily Oral Exposure Metals After Consuming Combined  
                  CHM Aqueous Decoctions – as Estimated Dailyor Weekly Intake …………....174 
9.2.4 Interpretation of Estimated Oral Exposure With Respect To Regulatory             
                              Standards – as % of Provisional Tolerable Daily or Weekly Intake –  
                              as % PTDI or %PTWI …………………………………………..……………...191 
9.2.4.1      Estimated daily lead intake from the combined  
 x 
aqueous decoctions of CHM – as % of PTWI ……………………….........…191 
9.2.4.2      Estimated daily arsenic intake from the combined  
                             aqueous decoctions of CHM – as % of PTWI …………………………….....192 
9.2.4.3      Estimated daily cadmium intake from the combined  
                             aqueous decoctions of CHM – as % of PTWI ……………………….............193 
9.2.4.4      Estimated daily mercury intake from the combined                      
                             aqueous decoctions of CHM – as % of PTWI ……………………………….193 
9.2.4.5      Estimated daily chromium intake from the combined                       
                             aqueous decoctions of CHM – as % of PTWI ………………………….........194 
9.2.5 Total Daily Exposure of Metals From Combined CHM Aqueous Decoction                  
                              in Addition to a Normal Australian Daily Diet ………………………………...195 
9.3       Results of the 50 Chinese Proprietary Medicines (CPM) – Total Metal  
              Contents in Acid-digested samples ………………………………………………..…..199 
9.3.1       Results of Total Lead Contents in Acid-digested CPM …………………...…..….202 
9.3.2       Results of Total Arsenic Contents in Acid-digested CPM.………….....................202 
9.3.3       Results of Total Chromium Contents in Acid-digested CPM ………....................203 
9.3.4       Results of Total Mercury and Cadmium Contents in Acid-digested CPM…….....203 
9.3.5       Difference in Total Metal Contents Among 50 CPM ………………………….....204 
9.3.6       Estimated Oral Exposure to Metals After Consuming Recommended Dose  
               of CPM – as Estimated Daily Intake ………………………………......................207 
9.3.6.1      Estimates of daily Lead intakes from CPM compared with 
                               regulatory standard – as % of PTDI …………………………………..........214 
9.3.6.2      Estimates of daily Arsenic intakes from CPM compared with 
                               regulatory standard – as % of PTDI …………………..................................215
 xi 
9.3.6.3      Estimates of daily Cadmium intakes from CPM compared with 
                               regulatory standard – as % of PTDI ……………………..............................216 
9.3.6.4      Estimates of daily Mercury intakes from CPM compared with 
                               regulatory standard – as % of PTDI …………………………………..........216 
9.3.6.5      Estimates of daily Chromium intakes from CPM compared with 
                 Recommended reference Dose – as %AI, %RDI, and %TDI ……………….217 
9.3.7       Total Daily Exposure of Metals from CPM in Addition to a 
                             Normal Australian Daily Diet ………………………………………………….....219 
9.4 Results of Chinese Medicinal Formulae (CMF) ………………………………………......222 
9.4.1       Results of the 5 Metal Contents in Acid-digested CMF ……………….................222 
            9.4.2       Results of the 5 Metal Contents in Aqueous Decoctions of CMF …………..........227 
            9.4.2.1     Results of lead contents in aqueous decoctions of CMF ……………….........233 
            9.4.2.2     Results of arsenic contents in aqueous decoctions of CMF …………............233 
9.4.2.3     Results of mercury contents in aqueous decoctions of CMF……………..…..234 
9.4.2.4     Results of cadmium contents in aqueous decoctions of CMF………………...234 
9.4.2.5     Results of chromium contents in aqueous decoctions of CMF…………….…235 
9.4.3      Estimates of Daily Intake from CMF Aqueous Decoctions  
                    Compared With Regulatory Standard……………………………………………...235 
            9.4.3.1     Estimates of daily Pb, As, Cd, & Hg Intakes from CMF Compared  
                       With Regulatory Standards – as % of PTDI ………………………………...238 
9.4.3.2     Estimates of daily Cr Intakes from CMF –  
                       as % of Reference Doses .................................................................................239 
9.4.4      Interpretation of Daily Metal Exposure from CMF Aqueous Decoctions  
        In Addition to a Normal Australian Daily Diet ……………………………...........239 
 xii 
9.4.4.1       Total daily lead exposure from CMF aqueous decoctions in addition                           
    to a normal Australian daily diet …………………………………………...240 
9.4.4.2       Total daily cadmium exposure from CMF aqueous decoctions in addition                         
    to a normal Australian daily diet …………………………………………...241 
9.4.4.3       Total daily arsenic exposure from CMF aqueous decoctions in addition                           
    to a normal Australian daily diet …………………………………………...242 
9.4.4.4       Total daily chromium exposure from CMF aqueous decoctions in addition                           
     to a normal Australian daily diet …………………………………………..244 
 
Chapter 10   Discussion and Conclusion 
10.1       Introduction …………………………………..……………………………………......246 
10.2       Analytical Methods are Reliable ……………………………………………………...247 
10.3       Total Acid-digested Metal Content in CHM Is Not Relevant                                                            
              for Safety Interpretation ……………………………………………………………....250 
10.4       Low Metal Concentrations in Aqueous Decoctions of CHM                                   
              Indicate Safety of Chinese Medicines …………………………………………...…....251 
10.5       Total Acid-digested Metal Contents and Aqueous Metal Concentrations                            
               in the 5 CMF are low ……………………………………………………………........259 
10.6       Estimates of Daily Intakes From Aqueous Decoctions of CMF                   
              Demonstrate Relative Safety of Crude CMF Administered in  
              Traditional Aaueous Form ………………………………………………………….....262 
10.7       Efficiency of Water Extraction and Its Implication ……………………………...........264 
10.8       Estimates of Daily Metal Intakes from CPM and the Issue of Safety ………………...266 
10.9       Conclusion ………………………………………………………………………….....270 
 xiii 
CHAPTER 11 – CHAPTER 14 
STUDY OF EFFECT OF ORAL ADMINISTRATION OF CHINESE HERBAL 
CONCENTRATED POWDER EXTRACTS ON SERUM METAL CONCENTRATION 
 
Chapter 11   Introduction 
11.1       Introduction ……………………………………………………………...………...…..277 
11.2       Design of the Randomized Clinical Trial …………………………………………......277 
11.3       Relevance of Measurement of Blood Metal Concentrations ……………………….....278 
11.4       Analytical Methodology ……………………………………………………………....279 
 
Chapter 12   Materials and  Methods 
 
12.1       Materials ……………………………………………………………………………....282 
12.1.1    Chemicals …………………………………………………………………….…...282 
12.1.2    Instruments and Laboratory Wares ……………………………………...………...282 
12.1.3    Reagents …………………………………………...................................................283 
12.1.4    Preparation of Standard Solutions ……………………………………………...…284 
12.1.4.1     Standard Solutions for Serum Lead (Pb) Determination ……………..........284 
12.1.4.2     Standard Solutions for Serum Cadmium (Cd) Determination.......................285 
12.2       Analytical Methods …………………………………………………………………...285 
12.2.1      Determination of Serum Lead (Pb) Concentration by Method of Standard   
                             Addition Using GFAAS ………………………………………………………....285 
12.2.1.1      Parameters of Method of Standard Addition Using GFAAS  
                   for Pb Determination ……………………………………………………...288 
12.2.2     Determination of Serum Cadmium (Cd) Concentration by  
 
 xiv 
                             Method of Standard Addition Using GFAAS …………………………….…......289 
 
12.2.2.1      Parameters of Method of Standard Addition GFAAS  
                               for Cd Determination ……………………………………………………....290 
12.2.3      Determination of Lead and Cadmium Contents in Herbal Real Treatment   
                Capsules (NSAR) and in Placebo Capsules (CSAR) …………………………....292 
12.2.4     Protocol of Randomised Clinical Trial for Seasonal Allergic Rhinitis  
                (SAR)……………………………………………….............................................292 
12.2.4.1     Background …………………………………………………………….…..292 
    12.2.4.2     Selection Criteria and Final Sample Size ………………………….….…...293 
12.2.4.3     Inclusion Criteria ………………………………………….........................293 
 
12.2.4.4      Exclusion Criteria …………………………………………………..….....293 
12.2.4.5      Administration of RCT Medications, either Real  
                   Herbal Capsules or Placebo Capsules ………………...............................294 
12.2.4.6      Blood Collection and Metal Assessment ……………………………….…294 
12.2.5     Details of Trial Medications ……………………………………………….........295 
12.2.5.1    The Placebo Medication ……………………………………………….…..295 
12.2.5.2    The Active Chinese Herbal Medication (RCM-102) …………………….…295 
 
Chapter 13   Results 
13.1      Demographics of Participants ………………………………………………………...297 
13.2      Results of Metal Contents in RCT Capsules ………………………………………....297 
 
13.2      Effects of Storage on Metal Concentrations …………………………………..……...298 
 
13.3      Results of Serum Lead Concentrations ……………………………………………….298 
 
13.4      Results of Serum Cadmium Concentrations……………………………………….…..300 
 xv 
13.6      Reference Interval for Serum Lead and Cadmium ……………………………….…...290 
 
Chapter 14   Discussion and Conclusion 
14.1 Discussion ……………………………………………………………………………..303 
14.2      Conclusion ……………………………………………………………………….........307 
 
References……………………………………………………………………………………...309
 xvi 
List of Figures 
 
Chapter 2   
Figure 2.1 Structures of aristolochic acids …………………………………………… 5 
Chapter 3   
Figure 3.1 A typical HPLC chromatogram showing peaks of standards AA-I and 
AA-II at retention times 8.6 and 6.6 minutes respectively ………………... 
 
35 
Chapter 4   
Figure 4.1     Typical calibration curve for aristolochic acid I ………………………….. 39 
Figure 4.2     Typical calibration curve for aristolochic acid II ……………………….… 40 
Figure 4.3a   Showing presence of AA in Aristolochia fangchi Wu (Guang Fang Ji) ......         42 
Figure 4.3b   Showing presence of AA in Aristolochia manshuriensis (Guan Mu 
Tong).............................................................................................................  
 
42 
Figure 4.3c   Showing presence of AA in Aristolochia contorta Bge. (Ma Dou Ling)….  42 
Figure 4.3d    Showing presence of AA in Asarum herba (Xi Xin) …………………......  42 
Figure 4.4a                                                  Stephania tetrandra (Han Fang Ji) showing absence of AA………………                                    43
Figure 4.4b Clemantis armandii (Chuan Mu Tong) showing Absence of AA………… 43 
Figure 4.4c                                                    Poria cocos (Schw.) Wolf (Fu Ling) showing absence of AA ……………                                           43 
Figure 4.4d                                                                  Coix lachrymal jobi L. (Yi Yi Ren) showing absence of AA ………..........                                             43 
Figure 4.5   Showing presence of AA in Chinese proprietary product Dao Chi Pian......   45 
Figure 4.6   Showing presence of AA in Chinese proprietary product Chuan Xiong  
Cha Tiao San ……………………………….……………………………... 
45 
Figure 4.7    Chinese proprietary product Xiao Qing Long Tang showing  
absence of AA …………………………………………………………….. 
46 
 xvii 
Figure 4.8     Chinese proprietary product Xiao Qing Long Tang showing possible 
presence of AA …………………………………..………………………... 
 
46 
Figure 4.9   A typical LCMS 5-point standard curve ………………...………………...  47 
Figure 4.10    A multiple reaction monitoring (MRM) chromatogram of AA-I showing  
the peaks at retention time of 17.15 min of Aristolochia fangchi that  
resulted in product ions at m/z 298, 296 and 324 with relative  
abundances similar to those obtained for the standard  ………….………….
 
 
 
49 
Chapter 7   
Figure 7.1      Basic components of an atomic absorption instrument.  A, Hollow 
cathode lamp. B, Chopper. C, Flame, or a Graphite tube D, Entrance slit. 
E,  Monochromator. F, Exit slit. G, Detector ……………………………... 
 
 
86 
Chapter 8   
Figure 8.1    Picture showing the traditional boiling process of Chinese medicinal 
prescription of raw herbs in claypots …………………………................... 
 
129 
Figure 8.2    A schematic diagram of the cold vapour generation system for Hg 
determination ……………………………………………………………… 
 
142 
Figure 8.3         Flow Chart of a Summary of Investigational Protocol ……………............ 148 
Chapter 9   
Figure 9.1     Typical standard curves for Pb, As, Cd, Cr, and Hg showing standard 
concentrations on x-axis and absorbance on y-axis, %RSD and the  
coefficient of variation (R2) for the linear plots …………………………….   
 
 
150 
Figure 9.2    UV absorption spectral traces of standards for Pb, As, Cd and Cr………... 151 
Figure 9.3  Distributions of lead among the 100 Chinese herbal materials…………….  162 
Figure 9.4 Distributions of arsenic among the 100 Chinese herbal materials…………  162 
 xviii 
Figure 9.5 Distributions of cadmium among the 100 Chinese herbal materials.…....... 162 
Figure 9.6 Distributions of mercury among the 100 Chinese herbal materials ………. 162 
Figure 9.7 Distributions of chromium among the 100 Chinese herbal materials …...... 162 
Figure 9.8 Distributions of the Pb among the 50 Chinese proprietary medicines 
showing heavy distribution at the low concentrations ……………………. 
 
206 
Figure 9.9 Distributions of the As among the 50 Chinese proprietary medicines 
showing heavy distribution at the low concentrations ……………………. 
 
206 
Figure 9.10 Distributions of the Cd among the 50 Chinese proprietary medicines 
showing heavy distribution at the low concentrations ……………….…… 
 
206 
Figure 9.11 Distributions of the Hg among the 50 Chinese proprietary medicines 
showing heavy distribution at the low concentrations ……………............. 
 
206 
Figure 9.12 Distributions of the Cr among the 50 Chinese proprietary medicines 
showing heavy distribution at the low concentrations ……………………. 
 
206 
Figure 9.13    Histograms showing concentrations of five different metals in each gram 
of the formula ………………………………………….............................. 
 
225 
Figure 9.14    Histograms showing concentrations of five different metals in µg per 
whole pack of formula ………………………………………………..…… 
 
226 
Chapter 10   
Figure 10.1 Aqueous lead concentrations and their corresponding acid-digested metal 
contents in the 100 CHM …………………………………………………. 
 
252 
 xix 
Figure 10.2 Aqueous arsenic concentrations and their corresponding acid-digested 
metal contents in the 100 CHM …………………………………………… 
 
252 
Figure 10.3 Aqueous cadmium concentrations and their corresponding acid-digested 
metal contents in the 100 CHM …………………………………………… 
 
253 
 
Figure 10.4 
 
Aqueous lead concentrations and their corresponding acid-digested metal 
contents in the 100 CHM ……………………………………..................... 
 
 
253 
Figure 10.5   Aqueous lead concentrations and their corresponding acid-digested metal 
contents in the 100 CHM …………………………………......................... 
 
254 
Chapter 11   
Figure 11.1   Example of standard addition calibration curve ……………………..........   280 
Chapter 12   
Figure 12.1   A typical standard addition curve of serum lead analysis (sample No. 170) 
showing absorbance and corresponding Pb concentrations of five 
additions of standard…………………………………………..................... 
 
 
287 
Figure 12.2     A typical standard addition curve of serum cadmium analysis (sample No. 
122) showing absorbance and corresponding Pb concentrations of 2 
additions of standard……………………………………………………..... 
 
 
290 
Chapter 13   
Figure 13.1    Comparison of serum lead concentrations from SAR clinical trial……….. 299 
Figure13.2    Comparison of cadmium concentrations in serum from SAR  
clinical trial………………………………………………………………… 
 
301 
 
 xx 
List of Tables 
Chapter 1   
Table 1.1   Levels of aristolochic acids (AA-I and AA-II) in samples from the three 
therapeutic classes of raw herbs …………………………………………... 
 
14 
Chapter 2   
Table 2.1     Reported literatures surveying medicinal plants and proprieatary products 
for the presence of aristolochic acids ………………………………... 
 
22 
Chapter 3   
Table 3.1   Levels of aristolochic acids (AA-I and AA-II) in seven manufactured 
products …………………………………………………………………… 
 
30 
Table 3.2    Details of ASE-100 extraction parameters for aristolochic acids ………… 32 
Table 3.3     Preparation of high-range working standards of aristolochic acids ………. 33 
Table 3.4    Preparation of low-range working standards of aristolochic 
acids ……….. ………... 
 
34 
Table 3.5    Detail of spiking of AA to Poria cocos for recovery study ………………. 36 
Chapter 4   
Table 4.1     Recovery values for AA-I and AA-II by HPLC analysis ……….................         40 
Table 4.2     List of the 11 samples subjected for LC-MS confirmation………………… 48 
Table 4.3   Levels of aristolochic acids (AA-I and AA-II) in seven manufactured 
products …………………………………………………………………… 
 
50 
Table 4.4  Levels of aristolochic acids (AA-I and AA-II) in samples from the three 
therapeutic classes of raw herbs …………………………………………... 
 
51 
Chapter 5   
Table 5.1    Some examples of different varieties of Fang Ji in Chinese medicine ……. 54 
 xxi 
Table 5.2 Some examples of different varieties of Mu Tong in Chinese medicine…... 59 
Chapter 7   
Table 7.1    Summary of reported lead poisonings in children and adults …………….. 80 
Table 7.2     Summary of reports investigating optimal furnace temperature conditions 
for the determination of metals in Chinese medicines ……………………. 
 
91 
Table 7.3    Summary of researches that screen for trace and/or heavy metals in 
Chinese proprietary medicines (CPM) ……………………………………. 
 
95 
Table 7.4    Summary of researches that screen for trace and/or heavy metals in 
Chinese herbal materials (CHM) ………………………………………….. 
 
97 
Table 7.5    Tolerable limits for metals – Figures are for oral intake of metal for a 60 
kg adult ……………………………………………………………………. 
 
101 
Chapter 8   
Table 8.1    Preparation of Pb standard solutions ……………………………………… 105 
Table 8.2     Preparation of As standard solutions ……………………………………… 105 
Table 8.3     Preparation of As standard solutions ……………………………………… 106 
Table 8.4     Preparation of Cr standard solutions ……………………………………… 107 
Table 8.5a     Preparation of Hg stock standard solutions ……………………………….. 108 
Table 8.5b     Preparation of Hg working standard solutions ……………………………. 108 
Table 8.6   List of 100 Chinese herbal materials included in the metal investigation 
showing sample codes, Chinese Pin Yin names, pharmaceutical and 
botanical names……………………………………………………………. 
 
 
112 
Table 8.7   Chinese and English names of the 50 Chinese proprietary medicines 
(CPM), and their manufacturers……………………………………………. 
 
118 
 xxii 
Table 8.8    Chinese and English names of the five medicinal formulae under 
investigation, their compositions, doses and brief description of their 
therapeutic functions………………………………………………………. 
 
 
121 
Table 8.9    List of representative raw Chinese medicines selected from various parts 
of herbal plants for determining efficiency of metal extractions in the 
boiling process with water (i.e., aqueous decoctions), including the weight 
of medicine and the volumes of first and second decoctions……………… 
 
 
 
126 
Table 8.10    Total number of different Chinese medicines analysed in the project ……. 131 
Table 8.11    Details of volumes of standard solutions S1a, S1b, and S1c spiked onto1g 
of Poria …………………………………………………………................ 
 
145 
Table 8.12    Metal concentrations of the spiked samples at three different levels ……... 145 
Chapter 9   
Table 9.1    Results of evaluation of accuracy of the analytical methods for lead  
and mercury ……………………………………………………………….. 
 
152 
Table 9.2    Results of recovery test for arsenic ……………………………………….. 153 
Table 9.3    Results of recovery test for cadmium …….……………………………….. 154 
Table 9.4    Results of recovery test for chromium ………………………………….… 154 
Table 9.5      Precision of the analytical method for the five metals ……………………. 155 
Table 9.6    Summary of limits of determination for the five metals ………………… 156 
Table 9.7 Sample number, sample code, and names of the raw Chinese herbs, their 
pharmacological classes and their metal contents ………………………… 
 
158 
Table 9.8    Lead (Pb) concentration in the aqueous decoctions of the 20 representative 
Chinese herbal materials …………………………………........................... 
 
165 
 xxiii 
Table 9.9    Arsenic (As) concentration in the aqueous decoctions of the 20 
representative Chinese herbal materials …………………………………... 
 
166 
Table 9.10     Cadmium (Cd) concentration in the aqueous decoctions of the 20 
representative Chinese herbal materials …………………………………... 
 
167 
Table 9.11    Mercury (Hg) concentration in the aqueous decoctions of the 20 
representative Chinese herbal materials …………………………………... 
 
168 
Table 9.12    Chromium (Cr) concentration in the aqueous decoctions of the 20 
representative Chinese herbal materials …………………………………... 
 
169 
Table 9.13    Summary of metal contents in combined aqueous decoctions (first and 
second) for different metals and different types of CHM ………………… 
 
171 
Table 9.14    Estimated daily intake (DI) of Lead (Pb) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g 
prescribed for each herb in a prescription to be decocted twice…………... 
 
 
175 
Table 9.15    Estimated Daily Intake of arsenic (As) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g 
prescribed for each herb in a prescription to be decocted twice…………... 
 
 
178 
Table 9.16   Estimated weekly Intake of cadmium (Cd) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g 
prescribed for each herb in a prescription to be decocted twice…………... 
 
 
181 
Table 9.17 Estimated Daily Intake of mercury (Hg) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g 
prescribed for each herb in a prescription to be decocted twice…………... 
 
 
184 
 xxiv 
Table 9.18 Estimated Daily Intake of Cr from consumption of aqueous decoctions of  
an individual raw herb based on an averaged weight of 10 g prescribed 
for each herb in a prescription to be decocted twice………………………. 
 
 
187 
Table 9.19    Summary of daily metal exposure expressed as % PTWI, from normal 
Australian dieta (ATDS; from consuming combined aqueous decoctions of 
a 10g CHMb; and from the total exposure to both Diet and CHM………... 
 
 
197 
Table 9.20    Range of combined estimated daily exposures to Cr as a percentage of the 
AIa, RDIb, and TDIc after the lowest and highest estimated daily intakes of 
Cr from combined aqueous decoctions of a single CHM are added to the 
range of the mean daily dietary exposures to Cr ………………………….. 
 
 
 
199 
Table 9.21    Total metal contents in Chinese proprietary medicines showing proprietary 
name and manufacturer ……………………………………………………. 
 
200 
Table 9.22    Estimated daily exposure to Lead (Pb) from ingestion of CPM, and 
interpreted as % of maximum weekly allowable Intake (%PTWI) for Pb 
which is 25 µg/kg bw per week (WHO guideline 2000) ………………….. 
 
 
201 
Table 9.23 Estimated weekly exposure to arsenic (As) from ingestion of CPM, and 
interpreted as % of maximum weekly allowable intake (%PTWI) for As 
which is 21 µg/kg bw/week (ANZFA, 1999); Also 15 µg/kg bw per week 
(WHO, 1999 recommendation)……………………………………………. 
 
 
 
210 
Table 9.24   Estimated weekly exposure to cadmium (Cd) from ingestion of CPM, and 
interpreted as % of maximum weekly allowable intake (%PTWI) for Cd 
which is 7 µg/kg bw/week(or 7,000 ng/kg bw /week (WHO, 2001) ............ 
 
 
211 
Table 9.25 Estimated weekly exposure to mercury (Hg) from ingestion of CPM,  
and interpreted as % of maximum weekly allowable intake (%PTWI)  
 
 
 xxv 
for total Hg which is 5 µg/kg bw per week(WHO, 2000);  
[Hg (methyl mercury) is 3.3 µg/kg bw per week (WHO, 1999)]…………..    
 
212 
Table 9.26   Estimated total daily exposure to chromium (Cr) from ingestion of CPM,  
and interpreted as % of Adequate Intake (%AI) of Cr which are  
35 µg/day, and 25 µg/day for young men and women respectively.  
Recommended daily intake (RDI) is 120 µg/day, and maximum  
tolerable level has been suggested to be 200 µg/day ……………………… 
 
 
 
 
213 
Table 9.27   Range of total (Diet + CPM) daily exposures to metals as a percentage of 
the tolerable limits after the CPM containing the lowest or highest levels 
of metals detected in the present projecta are added to the corresponding 
lower and higher percentage range of mean estimated PTDIb of the same 
metals reported in The 20th Australian Total Diet Survey (ATDS) ………. 
 
 
 
 
220 
Table 9.28    Range of combined estimated daily exposures to Cr as a percentage of the 
AIa, RDIb, and PTDIc  after the lowest and highest estimated daily intakes 
of Cr in Chinese proprietary medicine (CPM) are added to the range of the 
mean daily dietary exposures to Cr reported by Institute of Medicine, 
2001………………………………………………………………………… 
 
 
 
 
221 
Table 9.29      Total concentrations (acid-digested) of 5 different metals in five Chinese 
medicinal formulae ………………………………………………………... 
 
224 
Table 9.30 Raw data for the extraction of Lead (Pb) in the aqueous decoctions of five 
Chinese herbal formulae – including estimated daily intake of lead from 
herbal administration ………......................................................................... 
 
 
228 
 xxvi 
Table 9.31       Raw data for the extraction of Arsenic (As) in the aqueous decoctions of 
five Chinese herbal formulae – including estimated daily intake of lead 
from herbal administration…………………………………………………. 
 
 
229 
Table 9.32       Raw data for the extraction of Mercury (Hg) in the aqueous decoctions of 
five Chinese herbal formulae – including estimated daily intake of 
mercury from herbal administration……………………..…………………. 
 
 
230 
Table 9.33      Raw data for the extraction of Cadmium (Cd) in the aqueous decoctions of 
five Chinese herbal formulae – including estimated daily intake of 
cadmium from herbal administration…………………………………….… 
 
 
231 
Table 9.34       Raw data for the extraction of Chromium (Cr) in the aqueous decoctions 
of five Chinese herbal formulae – including estimated daily intake of 
chromium from herbal administration…………………………………….... 
 
 
232 
Table 9.35     Adult daily exposure to different metals in the aqueous decoctions of CMF 
(µg/day), and as a percentage of the tolerable daily intake (% TDI)……….   
 
236 
Table 9.36    Adult daily exposure to chromium in the aqueous decoctions of CMF 
(µg/day), and as a percentage of the daily adequate intake (% AI), as a 
percentage of the recommended daily intake (% RDIc), as a percentage of 
the maximum tolerable daily intake (% TDId) …………………………….. 
 
 
 
237 
Table 9.37    Range of total (combined) daily exposures to lead (Pb) as a percentage of 
the tolerable limit after the daily exposures to Pb as % of TDI in the 
aqueous decoctions of CMF determined in the present studya are added to 
the percentage range of mean estimated daily dietary exposuresb to Pb, 
reported in The 20th Australian Total Diet Survey (ATDS)………………... 
 
 
 
 
240 
 xxvii 
Table 9.38    Range of total (combined) daily exposures to cadmium (Cd) as a 
percentage of the tolerable limit after the daily exposures to Cd, as % of 
TDI in the aqueous decoctions of CMF, determined in the present studya 
are added to the percentage range of mean estimated daily dietary 
exposuresb to Cd, reported in The 20th Australian Total Diet Survey 
(ATDS)…………………………………………………………………….. 
 
 
 
 
 
241 
Table 9.39    Range of total (combined) daily exposures to cadmium (As) as a 
percentage of the tolerable limit after the daily exposures to As in the 
aqueous decoctions of CMF, determined in the present studya are added to 
the percentage range of mean estimated daily dietary exposuresb to As, 
reported in The 20th Australian Total Diet Survey (ATDS)……………….. 
 
 
 
 
243 
Table 9.40    Range of combined daily exposures to Cr as a percentage of the AIa, RDIb, 
and PTDIc after the estimated daily intakes of Cr in aqueous Chinese 
medicinal formulae (CMF) were added to the range of the mean daily 
dietary exposures to Cr ….............................................................................. 
 
 
 
245 
Chapter 10   
Table 10.1   Hypothetical worse case scenario of consuming combined aqueous 
decoctions of six CHM containing the highest metal 
contents……………………………………………………………………... 
 
 
256 
Table 10.2    Summary of total acid-digested content of each metal of the 5 herbal 
formulae, in µg/g (or ng/g) of the formula, and in µg per whole formula 
pack………………………………………………………………………… 
 
 
260 
 xxviii 
Table 10.3    Summary of concentrations of each metal in aqueous decoctions of the 5 
herbal formulae, in µg/g (or ng/g) of the formula, and in µg consumed per 
day …………………………………………………………………………. 
 
 
261 
Chapter 12   
Table 12.1    Preparation of Standards for serum Pb analysis …………………………... 284 
Table 12.2    Preparation of Standards for serum Cd analysis …………………………... 285 
Table 12.3   Composition of the active herbal medication (RCM-102), reported 
therapeutic effects and side effects ………………………………………... 
 
296 
Chapter 13   
Table 13.1       Distribution of age and gender between the two RCT groups …………….. 297 
Table 13.2       Pb and Cd concentrations in capsules ……………………………………... 298 
 xxix 
Abbreviation 
AA Aristolochic acids 
AA-I Aristolochic acid I 
AA-II Aristolochic acid II 
AAN Aristolochic Acid Nephropathy 
AAS Atomic absorption spectrometry 
AI Adequate Intake (for Cr interpretation) 
ANZFS Australian New Zealand Food Standard 
As Arsenic 
ATDS Australian Total Diet Survey 
bd Below  detection limit 
Cd Cadmium 
CHM  Chinese herbal materials, Chinese herbal medicines 
CMF Chinese medicinal formulae (here it refers to the raw herbal formulae) 
CPM Chinese proprietary medicines (also known as Chinese patent 
medicines, or manufactured products) 
Cr Chromium 
CRM Certified reference material 
CV (R2) Coefficient of variation 
CVAAS Cold vapour atomic absorption spectrometry 
EPA  Environmental Protection Agency 
FDA Food and Drug Administration of USA 
FSANZ Food Standard Australian New Zealand  
GFAAS Graphite furnace atomic absorption spectrometry 
 xxx 
GLC Gas liquid chromatography 
Hg Mercury 
HPLC  High performance liquid chromatography  
LC-MS Liquid chromatography coupled with mass spectrometry 
LOD Limit of Detection  
LOQ Limit of Quantitation 
ND Not detected 
OTC Over-the-counter 
Pb Lead 
PTDI Provisional Tolerable Daily Intakes (µg/kg bw/day 
PTWI Provisional Tolerable Weekly Intakes (µg/kg bw/week) 
RCM-101 Placebo capsule for RCT patients 
RCM-102 Active herbal capsule for RCT patients 
RCT  Randomised clinical trial 
RDI Recommended Daily Intake (for Cr interpretation) 
RfD Reference Dose 
RSD Relative standard deviation 
SAR Seasonal allergic rhinitis 
SD  Standard deviation 
SEM Standard error of mean 
TCM  Traditional Chinese medicine 
TDI Tolerable Daily Intake  
TGA Therapeutic Goods Administration of Australia 
TLC Thin layer chromatography 
 xxxi 
UV Ultraviolet  
WHO World Health Organisation 
 
 
 
 1 
Summary 
 
 
          Chinese medicine as a healthcare modality is rapidly gaining popularity in many Western 
countries including Australia. The latest survey by Maclennan et al. (2000) estimated the yearly 
Australian expenditure on complementary medicines, excluding cost to practitioners, to be 
around $1.7 billion. With this increasing popularity there is also heightened concern about toxic 
contaminants in Chinese herbal medicines. The two areas of contamination that attract most 
attentions are the nephrotoxic chemical, aristolochic acids found to be present in some Chinese 
herbs and resulting in renal failure of over 200 patients in Belgium in the early 90s, and heavy 
metals such as lead, arsenic, cadmium and mercury, which can cause systemic, CNS, 
neurological and developmental pathologies. 
 
          While there are several notable researches reported in English literature on the above two 
areas of contamination in Chinese herbal medicines, there is still a lack of systematic information 
about the aristolochic acid content in Aristolochia species and related genera, nor has there been 
any studies on metal contamination conducted in Australia which can provide some scientific 
basis for assessment of potential risk of Chinese herbal medicines posed to consumers in 
Australia, in particular, in the State of Victoria. The objectives and the sequence of this research, 
therefore, were firstly to carry out a systematic measurement of the contents of aristolochic acids 
in 27 Chinese raw herbs, and 7 manufactured patent medicines that might be potential 
contributors to aristolochic acid toxicities, secondly to analyse the contents of five heavy metals 
in 100 crude Chinese herbal materials (CHM), 50 Chinese proprietary medicines (CPM), and 5 
commonly used Chinese medicinal formulae (CMF) in the form of crude herbs, and finally to 
evaluate the potential systemic metal toxicity caused by routine ingestions of Chinese medicines 
 2 
in the common form of encapsulated concentrated powder extracts formulated for the treatment 
of seasonal allergic rhinitis (SAR), by measuring the metal concentrations in blood collected 
from 71 patients in a randomised double-blind control clinical trial (RCT).  
 
          In the aristolochic acid project, analyses revealed that four of the 37 raw herbs and two of 
the 7 manufactured proprietary products contained the banned toxic aristolochic acids. Some of 
these contaminated medicines could still be purchased over-the-counter in Victoria. The reasons 
and the clinical and commercial implications of these alarming findings were discussed in detail 
in the thesis. In particular, the current confusing Chinese nomenclature for Chinese herbs, some 
having many different generic botanic species bearing the same Chinese Pin Yin name, thereby 
contributing to the mis-identification of herbal samples was highlighted. These results were 
published in the Journal of Clinical Toxicology, 44:371-378, 2006.                  
  
          In the quantitative screening of metal contamination in Chinese herbal medicines, both the 
acid-digested and water-decocted concentrations of metals were determined. It was found that the 
aqueous concentrations of metals were much lower than the total acid-digested contents, and that 
almost all herbal samples contained the five heavy metals analysed. In fact, the concentrations of 
the aqueous decoctions which are the ingestible form for crude Chinese herbs, were extremely 
low. Only one to three herbs out of the 100 crude CHM, and 50 CPM investigated in this project 
contained moderately higher but non-toxic concentrations. Based on these results it was 
concluded that, contrary to popular perception, neither the crude herbs nor the manufactured 
products pose significant risk to consumers. This conclusion was based on assessment of their 
contents as percentages of the universally recognised regulatory safety standards for oral 
consumption, namely, the WHO provisional tolerable daily or weekly intake (PTDI or PTWI) 
above which intake is not recommended to safeguard health. All herbal samples when taken in 
 3 
the clinically prescribed doses produced only small percentage of the PTWI for the metal 
concerned. This was true even when the metal intakes from Chinese herbs were added to the 
metal exposure from a normal Australian daily diet. Nevertheless, a couple high-metal-containing 
herbs might result in a combined herb-plus-diet metal intakes up to the high 60 – 80 % of PTWI. 
Even though these combined intakes were still within the regulatory safety guidelines, it was 
recommended that cautions should be exercised and continuing monitoring be carried out.  
 
          Similarly, the aqueous metal contents in the five crude herbal medicinal formulae were also 
extremely low. When ingested at dosage as recommended in general Chinese medicine practices, 
their metal contributions to the total daily exposure in addition to the normal Australian diet were 
well within the regulatory safety standards.  
 
          Traditionally, metal measurements are all carried out by acid digestion which provided the 
absolute total contents present in the Chinese medicinal materials. The present project also 
determined their water dissolution, and applied their aqueous concentrations for the calculation of 
estimated intakes which were consequently used for assessment of risks. This approach of 
aqueous determination, as well as interpretation of their results with reference to the WHO 
regulatory standards and in combination with the Australian normal daily diet, are more relevant 
and realistic. Two manuscripts reporting these findings are being prepared for submission. 
 
          Finally, a RCT was conducted to further investigate the in vitro results obtained above. The 
RCT in vivo results demonstrated that the concentrations of lead and cadmium in serum samples 
from the real treatment group (n = 38) were not significantly different at the end of the trial to 
those from the placebo group (n = 33) after ingestion of the real herbal powder versus the starch 
placebo for eight weeks at a dosage of two capsules each time, twice a day.  
 4 
Nor was there any significant difference between the baseline and post-treatment serum levels, 
either within group or between groups. These findings supported the theoretical conclusion of the 
in vitro results described above, and categorically confirmed the safety of routine oral intake of 
Chinese herbal medicines, at least, for this particular SAR herbal formula in the form of 
concentrated powder extracts. 
 
           In conclusion, the project demonstrated that there is still much to improve in terms of 
enforcing the regulation of prohibiting the sale of Chinese herbal medicines that might contain 
the highly nephrotoxic aristolochic acids, since they are still available over the counter in Victoria. 
The findings that estimated metal exposures due to intake of Chinese medicines contributed only 
insignificantly small percentages of the PTWI for the great majority of samples, even when 
dietary metals were included into consideration suggest relative safety of Chinese medicines. 
These encouraging results were further attested by the in vivo RCT serum measurements. The 
perception that Chinese medicines are highly contaminated with heavy metals may be refuted 
based on these new evidences. 
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CHAPTER 1 
 
 
INTRODUCTION 
1.1 Background of Aristolochic Acid Nephropathy (Formerly known as Chinese   
           Herbs Nephropathy) 
 
           In the early 1990s, a weight management clinic in Belgium formulated a product intended 
for weight control which contained two Chinese herbs. One of the herbs specified for the product 
was Stephania tetrandra (Chinese name: Han Fang Ji), which does not contain aristolochic acids; 
however, instead of this species, another was incorporated into the product, Aristolochia fangchi 
(Chinese name: Guang Fang Ji), which does contain aristolochic acids (AA). The unfortunate 
result of the mis-formulation was that, in a relatively short time, a substantial number of users of 
the product suffered serious renal toxicity. The first occurrences were in 1993, when three female 
users developed subacute interstitial fibrosis of the kidney (Vanherweghem, 1994) and urothelial 
carcinoma (Nortier et al., 2000), and by 1995 approximately 100 female users had developed 
severe renal failure, about one-half of whom required a renal transplant (van Ypersele de Strihou 
& Vanherweghem, 1995). The toxic syndrome, which was referred to as “Chinese herbs 
nephropathy” (CHN), and now better called “Aristolochic Acid Nephropathy” (AAN) (Gillerot et 
al., 2001; Solez et al., 2001), was allegedly due to the AA present in Aristolochia fangchi.  
 
1.2 Prevalence of Aristolochic Acid Toxicitities      
 
           Since the Belgium reports, many more cases of CHN have been reported from various 
parts of the world. In 1999 two cases of aristolochic acid-related nephropathy were reported in 
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the United Kingdom (Lord, Tagore, Cook, Gower, & Pusey, 1999). In both cases there was 
extensive atrophy of cortical tubules and interstitial fibrosis. The Chinese herb involved was 
identified as Aristolochia manshuriensis (Chinese name: Guan Mu Tong), which is used for the 
treatment of eczema. In addition to the herbs mentioned above, aristolochic acids have been 
reported to be present in other herbal species, such as, Asarum splendens, Asarum himalaicum 
(Chinese name for both: Xi Xin) (Hashimoto et al., 1999), and Aristolochia contorta (Chinese 
name: Ma Dou Ling) (Lee, Wu, Deng, & Hwang, 2002). Moreover, there have also been reports 
of toxicity linked to medicinal herbs containing aristolochic acids from China (Gillerot et al., 
2001; Solez et al., 2001), Japan (Tanaka et al., 2001), France(Stengel & Jones, 1998), Taiwan 
(Chen, Chen, & Li, 2001), and USA (Meyer, Chen, & Bennett, 2000). Clearly, herbs and herbal 
products that contain or have been adulterated or substituted with aristolochic acid–containing 
species are continuing to appear in the market at the risk of damaging the health of users of 
Chinese herbal medicines.  
 
1.3 Government Policies on Aristolochic Acid-containing Herbs and Products 
 
           In some countries, such as Australia and the United States, the supply of herbal products in 
which aristolochic acid has been detected is prohibited by therapeutic regulatory authorities 
(FDA website, TGA website). The Australian Therapeutic Goods Administration (TGA) has 
worked closely with overseas regulatory agencies including those in UK and the USA to identify 
herbal species and herbal products that are known to contain or suspected to contain aristolochic 
acids (FDA/CFSAN, April 9 2001) (see Group A, Appendix 1.1), or may be adulterated with AA 
(Group B, Appendix 1.1) or contain Fang Ji, Mu Tong and Xi Xin as declared ingredients in the 
proprietary products (Group C, Appendix 1.1). To this end, Australian TGA issued a  
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Practitioner Alert in July 2001  which adopted the FDA/CFSAN concern statements above 
listing the twelve botanical genera and their relevant botanical species therein, 
including various species in the Aristolochia genus, as well as fourteen proprietary herbal 
products (refer to Appendix 1.1 for full detail of the alert list).  Some herbs in this list had been 
banned for sale, while other proprietary products had been recalled . 
 
1.4      Contributing Factors to Aristolochic Acid Toxicities and Rationale for this Study  
 
           Although, to date, no cases of serious adverse reactions of renal damage or urinary tract 
cancers associated with the use of herbs or herbal products containing aristolochic acids have 
been reported in Australia, it is probable that users of Chinese herbal medicines, even in countries 
where AA-containing herbs are banned, are still at risk of exposure to aristolochic acids. 
Contributing substantially to this risk is the possibility of mis-identification of herbal species and 
also of inadvertent or intentional substitution of herbs in herbal formulae. Firstly, in regard to 
mis-identification, many botanically related species of medicinal herbs have the same or similar 
Chinese pharmaceutical names, which can lead to errors in prescribing, formulation and supply. 
For example, the non-toxic Stephania tetrandra is called Han Fang Ji in Chinese and the toxic 
Aristolochia fangchi is called Guang Fang Ji. Often, the two are used synonymously and/or 
interchangeably, both being referred to simply as “Fang Ji”, omitting the prefixes. Secondly, in 
regard to mis-identification, different species of herbs in their raw state may have similar 
macroscopic morphological characteristics. Identification of herbal species is even more difficult 
after even minimal processing, such as drying and slicing. Such similarities applies to the pair of 
Fang Ji mentioned above, and to the toxic Guan Mu Tong (Aristolochia manshuriensis) and its 
non-toxic counterpart, Chuan Mu Tong (Clemantis armandii), as well as other herbs. Hence, 
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morphological similarities are further confused by the imprecise Chinese nomenclature in 
pharmaceutical names. 
 
1.5      Objectives of Present Project 
 
          To date, analyses of aristolochic acid in herbs tend to focus on particular Aristolochia 
genus or local products in countries other than Australia. Furthermore, AA may be present in 
botanicals other than Aristolochia spp. There appears to be a lack of comprehensive 
determination of AA for herbs belonging to the Aristolochiae family and related herbs which 
have been described as having similar therapeutic properties, but belonging to different botanical 
families . Certainly, no such studies in Australia have been reported on imported herbs that may 
be used in the management of weight reduction, or on any of the 14 proprietary herbal products 
listed in the TGA alert.  
 
          In order to assess the extent of the risk for users of Chinese herbal medicines in Victoria 
being exposed to aristolochic acid, the objectives of this project, therefore, are: 
 
1. To conduct a comprehensive and quantitative determine the content of AA-I and AA-
II contents in commonly used Chinese raw herbs belonging to the Aristolochia and 
related genera that are commonly  prescribed by Chinese medicine practitioners. 
2. To analyse the AA-I and AA-II contents in some manufactured proprietary products 
that contain Fang Ji, or Mu Tong or Xi Xin on their labels. Seven such 
                over-the-counter proprietary products had been identified. Four of them are named 
                 in the TGA alert list. 
3. To highlight the consequences of inappropriate nomenclature and imprecise  
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           labelling as potential contributing factors in  aristolochic acid toxicity. 
 
           The findings of this study may provide safety information to the local public, the 
Chinese medicine practitioners and government regulatory authorities so that appropriate 
measures may be taken. 
 
1.6    Research Protocol for Achieving Objectives       
 
1.6.1 Rationale for Selecting Specific Herbal Medicinal Samples 
 
            Twenty seven commonly used and relevant Chinese raw herbs (Table 1.1), and 7 
manufactured products known to contain aristolochic acids, were selected to demonstrate the 
potential risk of contamination, substitution or adulteration. Like Fabg Ji and Mu Tong, the 27 
raw herbs belong to pharmaceutical classes of herbs that are often employed to treat arthritis and 
overweight. Since Fang Ji, Mu Tong and Xi Xin have been alleged to contain the toxic 
aristolochic acid, it is therefore, logical to examine this pharmaceutical group of herbs. The 
selection of the 7 proprietary products was based on the list issued by the Australian TGA which 
banned 14 formulated proprietary products. The seven Chinese medicinal formulated proprietary 
products included in this investigation are probably the only formulated patent medicines still 
available in the State of Victoria that included Fang Ji, Mu Tong, or Xi Xin despite the ban of 
these herbs. Four of these seven patent medicines were included in the list of the 14 products 
banned by the Australian TGA. The other ten products are not available in Victoria, and 
presumably Australia. They were therefore not included in this study. Only those that are banned 
and still available in the market, and those that are not in the banned list but contain suspect 
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herbal constituents bearing the Chinese name of Fang Ji or Mu Tong or Xi Xin were included for 
investigation. 
 
1.6.2 Laboratory Approaches to Achieve Objectives 
 
            The collected herbal samples were extracted by organic solvent and then analysed for the 
presence of aristolochic acids by the method of high pressure liquid chromatography (HPLC). 
This technique served as a screening as well as a quantitative procedure. Any positive findings or 
incriminated samples were then confirmed by the more sophisticated technique of liquid 
chromatography coupled with electrospray mass spectrometry (LC-ESMS) 
in order to definitively identify the presence or otherwise of aristolochic acids. The method 
finalised in the present project was a compromise between simplicity (time and ease of operation) 
and reliability (specificity, precision and accuracy). It involved minimal extraction and 
purification steps in the HPLC screen, but provided high degree of reliability by the LC-ESMS.  
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Table 1.1  Levels of aristolochic acids (AA-I and AA-II) in samples from the three therapeutic classes of 
raw herbs 
 
 
Herbal Sample 
 
Botanical name 
Common 
Chinese name 
 
Diuretics 
 
Aristolochia manshuriensis Guan Mu Tong 
Clematis armandii  Chuan Mu Tong 
Aucklandia lappa Decne Mu Xiang 
Aristolochia contorta Bge. Ma Dou ling 
Poria cocos (Schw.) Wolf Fu Ling  
Pyrrosia lingua (Thunb.) Farw Shi Wei 
Dioscorea Hypoglauca Palif.       Bei Xie 
Coix lachryma jobi L. Yi Yi Ren 
Plantago asiatica L. Che Qian Zi 
Polyporus umbellatus (Pers.) Fr.  Zhu Ling 
Alisma plantago-aquatica 
  L. var. orientale Samuels 
 
Xe Xie 
Artemisia capillaries Thunb. Yin Chen Hao 
Tetrapanax papyriferus 
  (Hook) K. Koch 
 
Tong Cao 
 
Anti-rheumatics 
 
Aristolochia fangchi Wu Guang Fang Ji 
Stephania tetrandra S. Moore Han Fang Ji  
Asarum sieboldii    (either:  
 A. splendens or A. himalaicum) 
 
Xi Xin  
Acanthopanax gracilistylus Wu Jia Pi 
Viscum coloratum (Kom.) Nakai Sang Ji Sheng 
Chaenomeles lagenaria 
  (Loisel.) Koidz 
 
Mu Gua 
Clematis chinessis Osbeck Wei Ling Xian 
Gentiana macrophylla Pall Qin Jiao 
Angelica pubescens Maxim Du Huo 
Lysimachia christinae Hance Jin Qian Cao 
 
Purgatives 
 
Prunus japonica Thunb. Yu Li Ren 
Rheum palmatum Da Hunag 
Cassia angustifolia Vahl Fan Xie Ye 
Aloe vera L. var. chinesis         
  (Haw.) Berger 
 
 
Lu Hui 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Chemistry of Aristolochic Acids 
    
           Plants belonging to the Aristolochia genus, such as Aristolochia fangchi Y.C. Wu contain, 
apart from other chemicals, an acid called aristolochic acid, commonly designated as AA  which 
is a mixture of structurally related nitrophenanthrene derivatives. Of these, two carboxylic acids 
received most attention because of their nephrotoxic and carcinogenic properties. They are 8-
methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AA-I), and 6-nitro-
phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AA-II), differing from each other by one 
methoxy group (Figure 2.1).  
 
Fig. 2.1    Structures of aristolochic acids  
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2.2 Toxicities of Aristolochic Acids  
 
2.2.1   Aristolochic Acid Nephropathy (AAN) 
 
          A year or two after the inadvertent introduction of Aristolochia fangchi which contained 
aristolochic acid, instead of the intended Stephania tetrandra which contained tetrandrine in the 
weight-loss regimen, more than half of the 100 or so cohort who develpoed AAN following the 
consumption of the slimming regimen formulated by a weight control clinic in Brussels in 
Belgium, required kidney replacement (Stengel & Jones, 1998). The aetiology of the tragic AAN 
was unequivocally traced to and identified to be aristolochic acids, after a series of intriguing 
scientific investigations (Vanherweghem, 1994). Aristolochic acids caused a unique type of 
progressive renal interstitial fibrosis after prolonged intake. There was extensive hypocellular 
interstitial sclerosis, tubular atrophy and global glomerular sclerosis decreasing from the outer to 
the inner cortex; mild to severe hyalinisation, fibromucoid or fibrous intimal thickening mainly of 
interlobular arteries, and normal or collapsed residual glomeruli according to findings by Jean-
Pierre Cosyns (Cosyns, 2003).  Apart from the 100 or so patients in Belgium who had developed 
AAN, and about half of them had undergone renal transplant, there has been about 170 more 
cases of renal toxicities world wide stretching from Asia to Europe and USA as a result of taking 
various forms of Chinese herbal remedies. China alone has accounted for over 100 cases (Chen et 
al., 2001), Taiwan more than 30 cases (Chang, Wang, Yang, & Chiang, 2001; C. S. Yang, Lin, 
Chang, & Hsu, 2000; S. S. Yang, Chu, Lin, Chen, & Lin, 2002), Japan 6 cases (Nishimagi et al., 
2001; Tanaka, Nishida, Maeda, Sugawara, & Kuwahara, 2000; Tanaka, Nishida et al., 1997; 
Tanaka et al., 2001; Tanaka, Shinkai et al., 1997; Ubara et al., 1999), France 4 cases (Pourrat et 
al., 1994; Stengel & Jones, 1998), UK 3 cases (Cronin et al., 2002; Lord et al., 1999), and USA 
and Germany 1 case each (Krumme, Endmeir, Vanhaelen, & Walb, 2001; Meyer et al., 2000). 
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Most of these cases were results of prolonged consumption of Chinese herbal remedies 
containing Aristolochia herbs, such as A. manshuriensis, or A. pistolochia prescribed for weight 
loss, or eczema, or edema, or treatment of hepatitis B. A number of the remedies did not list 
Aristolochia on their labels, but were subsequently identified to contain the toxic AA.  
 
           Several attempts had been made to reproduce the typical nephrotoxic features of AA using 
animal models. In 1998 Cosyns et al. (Cosyns et al., 2001) administered orally 10 mg/kg, 5 d/wk, 
for 3 months to Wistar rats managed to induce only tumors in the forestomach but no interstitial 
nephropathy, or renal insufficiency. Later they tried another animal model using New Zealand 
white rabbits, and applying intraperitoneal injections of 0.1 mg/kg AA (5 d/wk, for 17 to 21 
months). This led to the typical development of interstitial fibrosis and urothelial atypia (Cosyns 
et al., 2001). Thus, the role of AA in causing AAN appeared to be supported experimentally. This 
finding was later reaffirmed by Debelle FD, Nortier JL, et al. (Debelle et al., 2002) who greatly 
reduced the length of AA exposure from 21 months to 35 days by giving daily subcutaneous 
injections of either a low-dose of 1 mg/kg body wt AA, or a high-dose of 10 mg/kg body wt AA 
to salt-depleted male Wistar rats. Tubular necrosis by day 10 and tubular atrophy surrounded by 
interstitial fibrosis by day 35 were found in the high-dose AA-treated rats. Thus, animal 
experiments confirmed the nephrotoxic nature of AA in human AAN.        
 
           It is interesting to note from the references above that the oral administration of 
aristolochic acids failed to induce nephropathy in Cosyns’s study (Cosyns et al., 1998) whilst 
other studies (Cosyns et al., 2001, Debelle et al., 2002) in which aristolochic acids were given 
parenterally via intraperitoneal or subcutaneous injections demonstrated the desirable renal 
damage. This discrepancy and the possible clinical relevancy of the later part of these results 
warrant some explanation given the fact that most of the patients previously affected ingested the 
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aristolochic acid-containing herbs via the oral route. Chronic nephrotoxicity of AA is more 
complex than the well known acute nephrotoxic and carcinogenic effects of AA.  The mechanism 
of pathology due to AA can be better studied and better defined by chronically induced toxicity. 
The variation in interstitial fibrosis chronically induced by AA in rats turned out to be at least in 
part a result of different routes of administration. It is also animal specific. For example, Cosyns 
et al (1998) failed to induce renal fibrosis after the oral administration of a high dose of AA to 
Wistar, while Debelle et al (2002) was successful in causing renal interstitial fibrosis rats by 
giving subcutaneously daily high dose of AA in the same species of salt-depleted Wistar rats. 
Thus, dehydration, as in the salt-depleted rat model, accelerates renal functional impairment 
(Debelle et al., 2002).  In this respect species difference also exists between human and rodents. 
In CHN, patients developed end-stage renal failure within a few months with concurrent rise in 
serum creatinine level, whereas rodents creatinine levels rise only very slowly after being treated 
with AA, unless they were dehydrated (Cosyns et al., 2001). Furthermore, the experimentally 
high dose used in rats, and the lower dose in rabbit  were ~ 300 times and 4 times higher 
respectively than that used in the CHN patients. This reflects differences in species in the 
susceptibility to AA, most likely due to differences in interspecies metabolism of aristolochic 
acids (Krumbiegel et al, 1987). 
 
 
2.2.2 Urothelial Carcinoma and Cancer 
 
            Aristolochic acids not only were nephrotoxic but also carcinogenic. It was noted that a 
neoplastic lesion was present in the urinary tract of one of the AAN patients in the Belgium 
slimming program patients, thus alerting to the possible mutagenic nature of AA. As a result, 
patients in this cohort with end-stage renal disease were encouraged to have prophylactic removal 
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of their kidney. A further 39 patients agreed. Of them 18 cases were found to have urothelial 
carcinoma – a prevalence rate of 46 %. Seventeen were carcinoma of the ureter, renal pelvis, or 
both and 1 papillary bladder tumor (Cosyns, Jadoul, Squifflet, Wese, & van Ypersele de Strihou, 
1999; Nortier et al., 2000). In the early 80s, Mengs and co-workers in 1982 (Mengs, 1983) 
already identified the carcinogenic action of aristolochic acid in rats, and in 1986 Schmiser et al. 
(Schmeiser, Pool, & Wiessler, 1986) further identified the mutagenicity of metabolites of 
aristolochic acid formed by rat liver. This was rapidly followed by more demonstrations of AA 
forming covalent DNA adducts in rodents by several groups of investigators (Pfau et al., 1999; 
Schmeiser, Schoepe, & Wiessler, 1988; Stiborova et al., 1994), and later in the AAN patients 
(Nortier & Vanherweghem, 2002). Thus, the carcinogenic nature of AA was confirmed. Since 
then, the AA-DNA adducts have been extensively used as marker to study the mechanisms of 
mutagenic mechanisms of AA in numerous animal models.    
 
2.3      Aristolochic Acid Contents in Chinese Herbal Medicnes 
 
          The Chinese used plants containing AA for medicinal purposes since antiquity. In China 
and in other parts of the world such plants or their extracts have been commonly used for the 
treatment of arthritis, rheumatism, gout, oedema, inflammation and pain (Rucker & Chung, 1975), 
until early 1990 when the nephrotoxicity and carcinogenicity of AA became well publicized after 
the Belgium Aristolochia fangchi tragedy. Since then, numerous analyses have been carried out 
to identify the presence or otherwise, of AA in plants from the genus of Aristolochia and related 
genera as well as in proprietary herbal products that contain herbs from the suspect genera in   
that aristolochic acids exist not only in the Aristolochia species, but also in other botanicals. 
These researches are summarised in Table 2.1. One of the earliest studies was by Zhu and 
Philipson in 1996 who reported the presence of the toxic chemicals, AA, in Fang Ji (Arictolochia 
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fangchi) samples in Hong Kong (Zhu & Philipson, 1996). This was followed by a larger analysis 
in 1999 by Hashimoto et al. (Hashimoto et al., 1999) of 37 samples covering 4 botanical families 
including the genera of Aristolochia, Akebia and Asarum. Aristolochic acids were detected in all 
plants originating from the genus Aristolochia and in two of the 13 species from the genus 
Asarum. In 2001 AA were found, not surprisingly, in 6 samples of Aristolochia fangchi (major 
component being AA-I), and 5 samples of Aristolochia contorta (major component being AA-II), 
but also in 12 out of the 16 slimming pills and powders (both AA-I and AA-II, but mainly A-II), 
purchased from different herbal stores in Taiwan (Chen et al., 2001). Alarmingly, the potential 
risk of AA in slimming products still existed long after the Belgium disaster. Aristolochic acid-
containing plants are not confined to herbs produced in China. Schaneberg et al., in 2002, 
(Schaneberg, Applequist, & Khan, 2002) surveyed North American species of Asarum and 
Aristolochia for the presence of AA. Both AA-I and AA-II were detected in macrophylla and 
serpentaria species of the Aristolochia genus, and in the arifolia var. arifolia of the Hexastylis 
genus. Aristolochic acid I alone was also found in all sixteen samples of Asarum canadense 
purchased from across USA, and in two samples of Asarum caudatum purchased in Oregon. AA 
was not detected in Asarum wagneri. The positive finding of AA-I in Asarum canadense by 
Schaneberg et al. described above confirmed the very early report by Dosktch and Vanevenhoven 
in1967 which led to the US Food and Drug Administration (FDA) to ban this herbal species from 
commerce for safety issues (FDA Asarum caudatum). Interestingly, earlier investigation by 
Hashimoto et al. (Hashimoto et al., 1999)on eight different species (13 samples) belonging to the 
Asarum genus also demonstrated the presence of AA-I alone in two species only, namely, the 
Asarum splendens and Asarum himalaicum, and absence in the remaining six Asarum species 
(Doskotch & Vanevenhoven, 1967). Therefore, unlike Aristolochia, AA are not necessarily 
present in all species of the Asarum genus. Hitherto, aristolochic acids are found in all the 
Chinese species of Aristolochia genus which had been analysed, including A. debilis, A. 
 21 
manshurienesis, A. fangchi, A. contorta, A. kaempfen heterophylla, A. moupinensis, and A. 
kwangsiensis, as well as in two of the three North American species mentioned above. Beside 
raw plants and some slimming products, a number of Chinese herbal teas and 14 Chinese herbal 
products (CHP) manufactured based on traditional Chinese medicine formulae had recently been 
analysed for presence of AA by Ioset et al. in 2003 (Ioset, Raoelison, & Hostettmann, 2003). 
Four out of the 42 samples were found to be positive of AA. Three of them were due to Fang Ji, 
i.e., Aristolochia fangchi, although the label listed the non-toxic species of either Stephania 
tetrandra or Sinomenium acutum. The fourth positive sample belonged to the very commonly 
used patent formula of Ba Zheng San (English name: The Eight-Herb Powder for Rectification). 
Thus, this result raises new concern regarding the potential health risks among the large number 
of over-the-counter (OTC) proprietary herbal products manufactured based on TCM classical 
formulae. They too need to be examined. To date, there is no systematic analytical approach to 
examine the risk potential of this group of OTC proprietary products. 
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Table 2.1    Reported literatures surveying medicinal plants and proprieatary products for the 
presence of aristolochic acids 
 
 
 
Authors 
 
Raw plants &/or manufactured 
products studied 
 
Findings 
 
Doktch & Vanevenhoven, 
1967 
 
Analysed North American 
Asarum canadense 
 
 
AA was deteced 
 
Zhu & Philipson, 1996 
 
Analysed Aristolochia fangchi 
plants in Hong Kong 
 
 
AA was found in all 
 
Hashimoto,  et al., 1999 
 
Analysed 37 samples covering 4 
botabical families including 
Aristolochia, Akebia, and 
Asarum 
 
AA was found in all 
Aristolochia genera, negative 
in all Akebia genera, and 
positive in 2 of the 13 
Asarum species  
 
 
Chen W , et al., 2001 
 
Analysed 58 random samples 
from  
Aristolochia fangchi, A. contorta, 
and 16 slimming pills and 
powders 
 
 
AA was positive in 6 A. 
fangchi, in 5 A. contorta, and 
in 12 of the 16 slimming 
products  
 
Scaneberg Applequist & 
Klan, 2002 
 
Surveyed North American 
species of Asarum and 
Aristolochia genera 
 
AA was positive in 16 
samples of Asarum 
canadense, and in 2 samples 
of Asarum caudatum. AA 
was not detected in Asarum 
wagneri. 
AA was found in 
Aristolochia macrophylla & 
A. serpentaria, and in arifolia 
var. arifolia 
 
 
Ioset, Raoelison & 
Hostettmann, 2003 
 
Analysed 43 samples of 
formulated Chinese herbal 
products 
 
 
Four products were positive. 
Three were due to A. fangchi. 
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2.4      Methodology in Detection of Aristolochic Acids in Herbal Medicines 
 
          To detect aristolochic acids (AA) in high levels from materials of simple matrix is 
relatively easy. However, to detect AA in minute concentrations in complex matrix from crude 
single herbal extracts or from multi-component herbal extracts becomes an analytical challenge. 
It generally requires tedious steps of sample clean-up to remove interfering substances. The 
challenge is made all the more difficult when a large number of samples are to be processed, as 
often the case in the investigation of herbal medicines. On the one hand, it is desirable to 
minimise steps of sample preparation to save time and to reduce the likelihood of losses and 
contamination inherent in a method involving multiple solvent purification steps. On the other 
hand, reliability of analytical results in terms of the identity and accuracy need to be ensured. In 
this section, various analytical techniques ranging from the superseded and antiquated to the 
common and the highly sophisticated that have been employed for AA detection will be reviewed. 
A background knowledge will help to decide on the methodology best suited for all the 
circumstances of this project. 
 
2.4.1 Fluorometric and Gas Liquid Chromatography (GLC) Analyses of Aristolochic   
            Acid  
 
          Rao KV and co-workers (Rao, Tanrikut, & Killion, 1975) described a fluorometric assay 
for AA based on the reduction of AA to the lactam and measurement of the fluorescence intensity. 
Although the method sensitivity was 0.05 µg/mL, it lacked specificity. In the same publication 
the investigators also reported a GLC method equipped with flame ionization detector based on 
flash methylation of aristolochic acid and its lactam using trimethylanilinium hydroxide. While 
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the precision was superior to the fluorometric method, its sensitivity was only 1 – 5 µg/mL. 
These techniques had never become popular. 
 
2.4.2    Thin Layer Chromatography (TLC) 
 
          TLC technique is often used by most investigators to purify the mixture of commercial 
standards of AA-I and AA-II. The Pharmacopoeia of the People’s Republic of China (1997, 
Englsih version) described a TLC detection method following soxhlet extraction of the 
aristolochic acids from medicinal plants. Ioset J-R et al. (Ioset et al., 2003) employed TLC as a 
preliminary detection method followed by confirmation by a HPLC/UV-DAD/MS analysis. A 
methanol: THF extract was applied to a silica gel 60 F254 TLC glass plate and the elution phase 
was Chloroform:methanol:acetic acid (65:20: 2, by volume). After development, 0.5% 
diphenylamine in H2SO4 60% was used as spray. AA-I appeared as a dark blue spot uner visible 
light and a yellow fluorescence when viewed at 366 nm. The Rf for AA-I was at 0.72. While the 
sensitivity of the TLC method was as low as 0.2 µg at 366 nm, the method was prone to 
interference appearing as co-eluting bands giving falsely higher and/or falsely positive results. It 
also required prior tedious extraction procedure. It too lacks specificity. 
 
2.4.3    Capillary Zone Electrophoresis (CZE) 
 
         For the determination of AA-I and AA-II in medicinal plants, Ong E.S. and Woo S.O. 
explored the suitability of capillary zone electrophoresis (CZE) as a convenient method to 
circumvent the time consuming multi-step extraction necessary in HPLC analyses (Ong & Woo, 
2001). They found that using a single-step extraction pressurized liquid extraction with CZE 
which employed a buffer of 30 mM sodium tetraborate at pH 9.5, detection at 254 nm, voltage at 
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18 kV and a temperature of 25º C, AA-I and AA-II were reasonably well separated within 15 
minutes with good precision and limits of detections of 1.2 and 0.9 mg/L for AA-I and AA-II 
respectively, These results compared relatively well with HPLC technique. However, 
reproducibility generally is a problem with capillary electrophoresis, and in this case, use of 
internal standard was necessary to overcome this problem. Furthermore, co-eluting interfering 
bands could occasionally produce falsely elevated values as indicated by their result for AA-II in 
Aristolochic fangchi (314.6 ppm compared to 57.0 ppm measured by HPLC). The authors 
suggested that standard addition be used when applied to unknown samples. This makes the 
technique impractical for multi-sample analysis common in herbal medicine investigation.  
 
2.4.4    High Pressure Liquid Chromatography (HPLC)     
 
          HPLC coupled to a UV spectrophotometric detector (HPLC/UV) is the most commonly 
used technique in the analysis of aristolochic acids in medicinal plants. This method gives good 
resolution, precision, accuracy and acceptable limits of detection. Generally, a reverse phase 
column C18 is used. Variation in methodology among investigators lies in the processes of 
extraction and purification, and in the choice of the solvents used in the mobile phase. The 
earliest description of HPLC analysis of AA applied to a field unrelated to AA was by Nishida 
and Fukami in 1989 . One of the earliest reports of HPLC/UV for the determination of 
aristolochic acids in medicinal plants was from Hashimoto K. et al. in 1999 who used 1%acetic 
acid/methanol (1:1) as eluent to a C18 column (Hashimoto et al., 1999). Each chromatographic 
run took 60 minutes. A two-step solvent extraction, first with n-hexane followed by twice with 
methanol, and then centrifugation was adopted to prepare for the analyte for HPLC injection. Lee 
T.Y. et al. in 2002 employed a silica gel RP-18 column and a mobile phase system of 0.3% 
ammonium carbonate solution/acetonitrile (75:25, v/v) with a pH 7.5 (Lee et al., 2002). Each 
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analysis took approximately 25 minutes. However, preparation of the tested solution was rather 
time-consuming. It involved initial methanol extraction thrice, followed by solid phase extraction 
(PHP-LH-20 column, 1.5X2 cm I.D.) using sequential elution with 3 different solvents. The final 
AA fraction was evaporated in vacuum to dryness and then redissolved in methanol and finally 
filtered through a polyvinylidene fluoride (PVDF) syringe filter before submitted to HPLC 
analysis. Schaneberg et al. (Schaneberg et al., 2002) used a more simplified extraction procedure 
adapted from the method recommended by the FDA  which involved extraction three times with 
a solvent mixture in a Falcon tube by sonication for 10 minutes, followed by centrifugation. The 
pooled supernatants were filtered through a 0.45 µm PTFE syringe filter prior to injection. HPLC 
analysis was carried out using a C18 column and complicated gradient elution steps involving 3 
solvent pumps and several program changes of solvent ratios. The total run time was 45 minutes. 
It can be seen from the above literatures that it is essential to clean up samples for detecting AA 
in herbal medicines, hence, the reason for the stringent preparation using multi-steps.  A single-
step solvent partition is not sufficient because of the complex matrix. 
 
2.4.5    High Pressure Liquid Chromatography Coupled to Mass Spectrometry 
 
          In recent years determination of AA in herbal medicines tend to combine HPLC with mass 
spectrometry. This greatly increases the specificity and sensitivity of the assay. Identification of 
the aristolochic acids is no longer entirely based on the retention time of the eluted peaks of the 
HPLC, but also on the charge to mass ratio of the characteristic ionised fragments at specific m/z 
produced by mass spectrometer. Mass spectrometry is capable of detecting low levels of target 
analyte at ng compaed to theµg concentrations by HPLC. Kite et al. coupled HPLC to a 
quadrupole ion-trap mass spectrometer (LC/MS/MS) to detect and quantify AA (Kite, Yule, Leon, 
& Simmonds, 2002). Ioset et al. 2002 also reported a similar liquid chromatography equipped 
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with a UV photodiode array detector (DAD-UV), and coupled to mass spectrometer  LC/DAD-
UV/MS performed by atmospheric pressure chemical ionization (APCI) (Ioset, Raoelison, & 
Hostettmann, 2002). The method showed that AA-I exhibited specific UV spectral maxima at 
224, 251, 321 and 393 nm. However, because of easy loss of NO2 in the API mode, the mass 
spectrum of AA-I showed displayed a predominant ion at m/z 295 [M-NO2]+. Using this method 
the same group confirmed the presence of AA-I in four out of 42 herbal medicines and teas (Ioset 
et al., 2003). Recently, another group of researchers in Taiwan developed a liquid 
chromatography-electrospray-ion trap mass spectrometry (LC-ES—ITMS) method for the 
determination of AA-I and AA-II in medicinal plants and in samples obtained from renal failure 
patients (S. Chan et al., 2003). They found that the [M+NH4]+ ion from both the AA-I and AA-II 
was the precursor ion for target MS/MS analysis.  The MS/MS product ion was [M+H-44]+ 
which could be used for quantitative measurement of AA-I and AA-II. This technique was both 
sensitive and accurate giving limit of detection similar to LC/MS/MS described earlier.                       
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1     MATERIALS 
 
3.1.1   Chemicals 
 
           The following chemicals were purchased from Aldrich-Sigma, Sydney, Australia: 
aristolochic acids standard (lot: 092k1249), ammonium carbonate, methyl alcohol (HPLC grade), 
acetonitrile (HPLC grade). Water was obtained from Millipore Q filtration system (Bedford, MA, 
USA). The above chemicals were used for the initial HPLC screening for the presence of 
aristolochic acids (AA). For confirmation of the HPLC findings of AA, a LC/MS/MS was used 
and the aristolochic acid standard was purchased from National Institute for the Control of 
Pharmaceutical & Biological Products (Beijing, China). Formic acid and ammonium acetate were 
purchased from BDH (Hong Kong). 
 
         Other materials included PTFE syringe filter (0.2µm pore size, polytetrafluoroethylene,  
from Altech, Australia). An inert material, Ottawa sand, was used as filler in the ASE extraction 
procedure. Falcon plastic tubes were used for storage of homogenized Chinese herbal medicines. 
 
3.1.2   Equipments 
 
          Initial screening for aristolochic acids was carried out using a Shimdzu liquid 
chromatograph LC 10AD (Shimadzu, Australia), equipped with auto-injector, a photo-diode 
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array UV detector, and software (Class vp7.0). LiChrospher 100RP-18 reverse-phase HPLC 
column, 5µm, 25 x 0.5 cm I.D. was purchased from Supelco, Australia. All Chinese herbal 
medicines were homogenized with an electric stainless steel heavy duty herbal grinder (Wan Ya 
Tian Yuan Engineering Company, P/L, Beijing, China). An Accelerated Solvent Extractor ASE-
100 (Donex, Australia) was used for solvent extraction of the Chinese medicines. Solvent 
evaporation was carried out using a rotary evaporator, Model RE-300 (Stuart), and solvent drying 
using a digital heater with heater blocks, model SHT200 (Stuart Scientific, Australia). A Buchner 
filtration apparatus was employed for HPLC solvent purification, and a TPS digital pH meter for 
pH adjustment. 
 
          For LC/MS confirmation of HPLC findings of aristolochic acids, a liquid chromatography 
mass spectrometer (Perkins-Elmer) SCIEX API365 LC/MS/MS system, and a reverse-phase C18 
column, 5µm, 250 x 2.1 mm (Altech, USA) were employed.  
 
          Other materials included PTFE (polytetrafluoroethylene) syringe filter, 0.2µm pore size 
(Altech, Australia), Millipore filter - 0.45µm (Cat No., GSWP04700, Millipore)) for mobile 
phase filtration, and Falcon plastic tubes for storage of homogenized Chinese herbal medicines. 
 
3.1.3 Herbal Materials 
 
           Twenty-one dried raw herbs (see Table 1.1) and seven manufactured products were 
purchased in September 2003, from two local herbal wholesalers in Victoria, Australia. The two 
wholesalers were Hong An Phat Acupuncture & Herbs P/L, Richmond, and Win-Sing Herbs 
Trading P/L, Kensington. Another six raw herbs, Stephania tetrandra (Han Fang Ji), Aristolochia 
fangchi (Guang Fang Ji), Clemantis armandii (Chuan Mu Tong), Aristolochia manshuriensis 
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(Guan Mu Tong), Asarum herba (Xi Xin), and Aristolochia contorta (Ma Dou Ling), were 
supplied by the herbal teaching museum of the Division of Chinese Medicine, RMIT University. 
Seven manufactured products (i.e., Proprietary patent herbal medicines with Australian 
Therapeutic Goods Administration list numbers) (Table 3.1), were obtained from the same 
wholesalers. 
 
 
Table 3.1  Levels of aristolochic acids (AA-I and AA-II) in seven manufactured products 
 
Manufactured product 
 
Chinese proprietary name 
 
Pharmaceutical Co. (China) 
(1) Chuan Xiong Cha Tiao Wan 
(2) Dao Chi Pian 
(3) Xin Yi Wan 
(4) Xiao Qing Long Tang 
(5) Ba Zheng San 
(6) Xiao Feng San 
(7) Long Dan Xie Gan Tang 
 
 
Lanzhou Fu Ci 
Tian Jin 
Lanzhou Minshan 
Lanzhou Minshan 
Lanzhou Fu Ci 
Lanzhou Fu Ci 
Lanzhou Da Bao 
 
 
 
 
3.2      METHODS 
 
3.2.1   Collection and Homogenization of Herbal Materials 
 
          Twenty-one dried raw herbs (see Table 1.1) and seven manufactured patent products were 
purchased by method of convenient sampling based on traditional Chinese medicine theory in 
September 2003, from two local herbal wholesalers in Victoria, Australia. Another six raw herbs, 
Stephania tetrandra (Han Fang Ji), Aristolochia fangchi (Guang Fang Ji), Clemantis armandii 
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(Chuan Mu Tong), Aristolochia manshuriensis (Guan Mu Tong), Asarum herba (Xi Xin), and 
Aristolochia contorta (Ma Dou Ling), were supplied by the herbal teaching museum of the 
Division of Chinese Medicine, RMIT University. These six herbs were bought to be used for 
display only from the same wholesalers in 2000, prior to prohibition of their sale by the 
Australian Therapeutic Goods Administration (TGA) in July, 2001.  From a Chinese herbal 
medicine perspective, the twenty seven herbs studied are classified as diuretics, purgatives or 
anti-rheumatics  and some of them are often used clinically for weight control. The seven 
manufactured products (see Table 3.1), were also collected because, according to their labels, 
contain either Fang Ji or Mu Tong or Xi Xin as part of their formulae. Raw herbal samples were 
ground into powder using a stainless steel heavy duty grinder. Care was taken to clean the grinder 
with MilliQ water followed by alcohol between homogenizations of different herbs. 
Manufactured herbal medicines in the form of tablets were ground manually in a porcelain mortar 
and pestle. The powder was stored in plastic containers at 4º C for subsequent analysis. 
 
 
3.2.2    Extraction of Herbal Samples 
 
          
  Each herbal sample (1 g of powder) was placed in a special stainless steel extraction cell (size = 
34 mL) and was extracted twice with 34 mL of HPLC grade methanol using the Accelerated 
Solvent Extraction (ASE) system. at 100º C and approximately 1500 psi. This was done by 
loading a layer (approximately 0.5 cm) of Ottawa sand onto the cellulose filter at the bottom of 
the extraction cell. Exactly 1 g of the herbal powder sample was then carefully placed on top of 
this celite layer, and the cell was filled fully with the powder. The cell was ready for installation 
into the ASE system for extraction (For procedure of cell assembly, please refer to the company 
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manual). Extraction was carried out at 100º C and approximately 1500 psi. Detail of the 
programmed parameters are summarised in Table 3.2. At completion the solvent extract was 
centrifuged at 10,000 rpm to remove any particulate matters, if present. The supernatant solvent 
was transferred to a pear-shaped flask for evaporation to complete dryness using a rotary 
evaporator at approximately 40° C.  The dried residue was then redissolved thoroughly in 1 mL 
methanol, and stored refrigerated in glass tube at -4° C. The solution was filtered through 
polytetrafluoroethylene (0.2 µm PTFE) syringe filter prior to separation by liquid 
chromatography. 
 
Table 3.2   Details of ASE-100 extraction parameters for aristolochic acids 
Method Editor Set Up Status 
Method 1 Method  1 Status Idle 
Temperature 100 Cell size 34 mL Method 1 
Static Time 5 min Units Psi Pressure 0 Psi 
Flush 60% Reduce Relief Off Volume 5 mL 
Purge Time 100 sec Preheat Time 0 min   
Static Cycle 2 Preheat Purge Off   
Save  1 Bypass heatup Off   
  Key Sound On   
  Error Sound On   
 
 
3.2.3     Preparation of Mobile Phase Solvent for HPLC 
 
           The solvent used as the mobile phase in HPLC analyses was a mixture of 0.3% ammonium 
carbonate solution and acetonitrile (75:25, v/v, pH 7.5). This was prepared by dissolving 3 g of 
ammonium carbonate in 1 litre of MilliQ water, and then mixing 750 mL of this solution with
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250 mL of HPLC grade acetonitrile in a large beaker. The mixture was filtered through a 
Millipore filter under vacuum created by running water tap. The filtrate was then adjusted to a pH 
of 7.5 with either 0.1 M HCl or 0.5 M NaOH prior to liquid chromatogrphic application.  
 
 
3.2.4      Preparation of Aristolochic Acids Standards 
 
             Twelve and a half milligrams (12.5 mg) of the aristolochic acids (Lot: 092k1249, 
Aldrich-Sigma) was dissolved in 25 mL of methanol giving a stock standard concentrations of 
200 µg/mL of aristolochic acid I (AAI), and 280 µg/mL of aristolochic acid II (AAII). From this 
stock standard (SS), two sets of working standards were prepared by serial dilutions with 
methanol to cover a high calibration range (between 10 and 280 µg/mL) as well as low 
calibration range (between 0.1 and 10 µg/mL). The latter set of low working standards was rarely 
used except when accurate determinations of low concentrations of AAI and/or AAII were 
suspected. Details of their concentrations and dilutions are summarised in the following Tables 
3.3, 3.4: 
 
 
 
Table 3.3    Preparation of high-range working standards of aristolochic acids 
 
Code of 
Standards 
AAI 
(µg/mL) 
AAII 
(µg/mL) 
Detail of dilution 
H1 200 280 Use SS neat 
H2 100 140 2 mL of SS + 2 mL of methanol 
H3 50 70 2 mL of H2 + 2 mL of methanol 
H4 20 28 2 mL of H3 + 3 mL of methanol 
H5 10 4 2 mL of H4 + 2 mL of methanol 
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Table 3.4   Preparation of low-range working standards of aristolochic acids 
 
Code of 
Standards 
AAI 
(µg/mL) 
AAII 
(µg/mL) 
Detail of dilution 
L1 10.0 14.0 Use H5 neat 
L2 5.0 7.0 2 mL of H5 + 2 mL of methanol 
L3 1.0 1.4 0.5 mL of L2 + 2 mL of methanol 
L4 0.1 0.14 0.5 mL of L3 + 4.5 mL of methanol 
 
 
 
 
3.2.5    Analysis of Aristolochic Acids by HPLC 
 
           The amounts of AA-I and AA-II in the herbal methanol extracts were determined by a 
modified HPLC method (Lee et al., 2002) using a Shimadzu liquid chromatograph LC 10AD 
(Shimadzu, Australia), under the following conditions: column, LiChrospher 100 RP-18 reverse-
phase, 5 µm, 25 x 0.5 cm I.D. (Supelco, Australia); mobile phase, a mixture of 0.3% ammonium 
carbonate solution and acetonitrile (75:25, v/v, pH 7.5); flow rate, 0.8 ml/min. The detector, a 
photo-diode-array UV detector was set at 251 nm. Aliquots of 20 µl of the methanol extract and 
of AA-I and AA-II working standards (either the set of high-range standards or the low-range 
standards), prepared as described above, were injected. AA-I and AA-II were identified by their 
retention times (AA-I = 8.6 min, AA-II = 6.6 min) (Figure 3.1). The total run time was 12 min. 
The range of working standard solution was chromatographed to construct standard curves for 
AA-I and AA-II (quadratic fit) over the range 10 – 280 ppm. AA-I and AA-II in test samples 
were identified from chromatographic peak corresponding to the retention times of reference 
standards and were quantified from sample/reference peak area ratios. 
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Figure 3.1:  A typical HPLC chromatogram showing peaks of standards AA-I and AA-II at 
retention times 8.6 and 6.6 minutes respectively 
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3.2.6     HPLC Recovery Study for AA-I and AA-II 
 
          The recoveries of the aristolochic acids were determined by spiking 1g amounts of Poria 
cocos (Chinese name: Fu Ling), which does not contain AA, with various amounts of AA-I and 
AA-II representing four levels of 10-fold difference in concentrations between the highest and the 
lowest concentrations. Each level was prepared in duplicate and was taken through the ASE 
extraction and evaporation procedure as described under “Extraction of Herbal Sample”, Section 
3.2 above. Each methanol extract was analysed in triplicate by HPLC for the determination of 
recovery. Detail of spiking is summarized in Table 3.5 below. 
 
Table 3.5   Detail of spiking of AA to Poria cocos for recovery study 
Concentrations of AA spiked (µg/g herb) Sample 
No. 
Poria cocos  
(Fu Ling) 
Volume of AA 
standards added AA-I AA-II 
RS1 1 g 1 mL of H5 standard 10 14 
RS2 1 g 1 mL of H4 standard 20 28 
RS3 1 g 1 mL of H3 standard 50 70 
RS4 1 g 1 mL of H2 standard 100 140 
 
 
 
3.2.7     Confirmation of HPLC AA Results by LC-MS 
 
            Positive findings of aristolochic acids from the HPLC screening were confirmed by liquid 
chromatography-mass spectrometry (LC-MS). The LC-MS work was performed with the help of 
Dr. Kelvin Leung in the Quality Research Laboratory, School of Chinese Medicine of the Hong 
Kong Baptist University, Hong Kong, between November and December, 2003 while the 
candidate spent two weeks there. Eleven samples that were found/suspected to be positive by 
HPLC were designated for confirmation.  
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          A LC-MS analytical protocol modified from a protocol in the FDA laboratory 
Information Bulletin (Flurer, Jones Vela Ciolino & Wolnik, FDA Lab Information Bulletin 
#4212) was adopted. The method involved initial solvent extraction of the aristolochic acids from 
herbal samples and subjected the extract to electrospray ionization mass spectrometric analysis to 
obtain a chemical fingerprint. The LC/MS used was a Perkins-Elmer SCIEX API365 LC/MS/MS 
system. Separation was done on a 5 µm 2.1 mm x 250mm Alltech C18 column at a flow rate of 
0.5 mL/min using gradient elution. The column was maintained at room temperature (20º C). The 
components of the mobile phase were as follows: 
 
Part A – 0.1% (v/v) formic acid and 0.1% (w/v) ammonium acetate in de-ionized water 
Part B – 0.1% (v/v) formic acid and 0.1% (w/v) ammonium acetate in methanol 
 
The program for mobile phase gradient was as follows:  
 
           Time (min)                      Part A (%)                        Part B (%) 
                  0                                      80                                      20 
                 20                                       0                                     100 
 
 
          The voltages of the electrospray, orifice and ring were maintained at 5 kV, 30 V and 170 V, 
respectively. The flow rate of the nebulizing gas was maintained at 1.04 L/min and the 
collision energy was 17 eV (lab. Scale). Nitrogen was used as the collision gas and its density 
was maintained at 1.56 x 1015 molecule/cm2. The product ions ([M+NH4+]+) of the mass 
spectrometer were set at m/z 298, 296 and 324 to detect the presence of aristolochic acid I.-A 
composite peak of AA-I was identified at retention time of 17.2 min. 
 38 
3.2.8 Flow Chart of Methodological Procedures – Homogeniastion, Extraction and AA 
Analyses 
 
Purchases of 27 CHM and 11 CPM 
                   Homogenisation by grinding in stainless steel grinder 
CHM and CPM powder 
                   1 g each of powder extracted using ASE at 100º C and ~1500 psi 
Ethanol extracts of CHM and CPM 
                   Centrifuged at 10,000 rpm to remove particulate matters 
Centrifuged ethanol extracts 
                   Rotary evaporation at 40 º C 
Dried extracts 
                   Re-dissolution  
1-ml ethanol 
                     
Stored at -4 º C 
                    Filter through 0.2 µm PTFE syringe filter 
Filtrate analysed/screened by HPLC for presence of AA 
         ________________________ 
AA negative               AA positive or suspected positive 
                                                           Confirmation by LC-MS 
                                    Presence or absence of AA in CHM or CPM confirmed 
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                                                        CHAPTER 4 
RESULTS 
 
4.1  Validity of HPLC Methodology    
 
         This simple modified HPLC method served reasonably well as a screening procedure for 
detecting the presence of aristolochic acids. The peaks for AA-I and AA-II were well separated 
with good peak sharpness, symmetry and resolution, as shown in Figure 3.1 above. The 
correlation coefficients for the calibration curves using a quadratic plot were 0.998 and 0.997 for 
AA-I (Range: 0 – 200 µg/mL) and AA-II (Range: 0 – 280 µg/mL) respectively (Figures 4.1 and 
4.2). The detection limits for AA-I and AA-II are approxiately 0.05 µg/g and 0.07 µg/g 
respectively. 
 
 
Figures 4.1    Typical calibration curve for aristolochic acid I 
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Figures 4.2    Typical calibration curve for aristolochic acid II 
     
 
4.2  Recovery Study for HPLC Analysis of Aristolochic Acids 
 
         The efficiency of extraction was evaluated by spiking a Chinese raw herb, Poria cocos, 
(Chinese name: Fu Ling) with four different levels of AA-I and AA-II, and the spiked samples 
were carried through the routine extraction procedures as described in Section 3.6 above. The % 
of recovery ranged between 83% and 95%, with mean values of 87% for AA-I and 92% for AA-
II (Table 4.1). 
 
Table 4.1    Recovery values for AA-I and AA-II by HPLC analysis          
 
 
AA-I AA-II Sample 
Code 
(n = 3) 
AA-I added 
(µg/g) 
Measured  
(µg/g ± 
SD) 
% of 
Recovery 
AA-II added 
(µg/g) 
Measured 
(µg/g ± 
SD) 
% of 
Recovery 
RS1 10 8.8 ± 0.7 83 14 12.6 ± 0.2 89 
RS2 20 17.2 ± 0.4 86 28 25.2 ± 1.0 92 
RS3 50 45.6 ± 2.8 95 70 64.9 ± 1.9 94 
RS4 100 85.0 ± 1.5 85 140 126.5 ± 2.9 91 
                     Averaged % of Recovery = 87%       Averaged % of Recovery = 92% 
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4.3      HPLC Analysis of Aristolochic Acids in Raw Herbs 
 
           HPLC analyses were carried out on all the raw herb methanol extracts. Of the 21 Chinese 
raw herbs purchased in 2003 from the two herbal wholesalers in Victoria, none contained 
aristolochic acids. Of the six raw herbs sourced from the teaching museum, four contained AA-I 
and/or AA-II. They were Aristolochia fangchi Wu (Guang Fang Ji), Aristolochia manshuriensis 
(Guan Mu Tong), Aristolochia contorta Bge. (Ma Dou Ling), and Asarum herba (Xi Xin). 
Figure 4.3a to 4.3d are the HPLC chromatograms of these four samples clearly showing the 
presence of AA-I and AA-II peaks. For the purpose of comparison a few representative 
chromatograms from herbs that did not contain aristolochic acids, and therefore absence of the 
respective peaks are shown in Figure 4.4 abcd. These examples include the two herbs that bear 
the same Chinese names to their positive counterparts, namely, Stephania tetrandra (Han Fang Ji) 
and Clemantis armandii (Chuan Mu Tong). The other two examples belong to Poria cocos 
(Schw.) Wolf (Fu Ling), and Coix lachrymal jobi L. (Yi Yi Ren). The former was used in the 
recovery study for aristolochic acids by HPLC as in Section 3.6 and Section 4.2. The levels of 
AA-I and AA-II in the four positive samples are shown in Table 4.3. Results are expressed as 
µg/g of the herbal material (i.e., ppm). Both AA-I and AA-II were found in Aristolochia fangchi 
(Guang Fang Ji) and Aristolochia contorta (Ma Dou Ling), the amounts of AA-I being higher 
than AA-II for both herbs. The total concentration of aristolochic acids (AA-I and AA-II) in A. 
Fangchi (1002 ppm) was about fivefold that in A. contorta (228 ppm). Mainly AA-I (41 ppm) 
was found in Aristolochia manshuriensis (Guan Mu Tong), and mainly AA-II (28 ppm) was 
found in the Asarum species tested. 
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     Figure 4.3a  Showing presence of AA in         Figure 4.3b  Showing presence of AA in 
     Aristolochia fangchi Wu (Guang Fang Ji)        Aristolochia manshuriensis (Guan Mu Tong)    
 
 
 
 
 
 
 
    Figure 4.3c  Showing presence of AA in           Figure 4.3d   Showing presence of AA in   
    Aristolochia contorta Bge. (Ma Dou Ling)         Asarum herba (Xi Xin)  
       
 
 
. 
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        Figure 4.4a                                                               Figure 4.4b  
        Stephania tetrandra (Han Fang Ji)                           Clemantis armandii (Chuan Mu Tong) 
        showing absence of AA                                            showing absence of AA 
 
 
 
 
 
 
 
Figure 4.4c                                                                  Figure 4.4d  
       Poria cocos (Schw.) Wolf (Fu Ling)                           Coix lachrymal jobi L. (Yi Yi Ren) 
       showing absence of AA                                               showing absence of AA 
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4.4      HPLC Analysis of Aristolochic Acids in Manufactured Herbal Medicines  
 
           Of the seven manufactured herbal formulated products analysed by HPLC, two contained 
both AA-I and AA-II. The product marketed under the Chinese proprietary name Dao Chi Pian 
was found to contain 40 ppm of AA-I and 210 ppm of AA-II. Another proprietary product, 
Chuan Xiong Cha Tiao San, was found to contain low levels of aristolochic acids (8 ppm of 
each AA-I and AA-II). Their chromatograms clearly showing the presence of AA-I and /or AA-II 
are shown in Figures 4.5 and 4.6. For the purpose of comparison another chromatogram 
demonstrating unequitable absence of aristolochic acids, and belonging to the proprietary product 
of Xiao Qing Long Tang, is also included in Figure 4.7. The remaining 4 proprietary products 
possibly possessed aristolochic acids. However, it is difficult to be certain based solely on HPLC 
analysis. An example of such ambiguous results was the proprietary product, Xiao Feng San, 
whose chromatogram (Figure 4.8) appeared to contain aristolochic acids, but subsequently was 
proven to be negative by LC/MS technique.  Accordingly, all (raw herbs and manufactured 
products) positive and tentatively positive findings using the HPLC methodology were 
necessarily checked by LC-MS analysis. 
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Figure 4.5   Chinese proprietary product Dao Chi Pian  
showing presence of AA     
                                                                                        
 
 
 
 
 
 
Fig 4.6  Chinese proprietary product Chuan Xiong Cha Tiao San  
showing presence of AA  
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Fig 4.7   Chinese proprietary product Xiao Qing Long Tang  
showing absence of AA 
 
  
 
 
Fig 4.8    Chinese proprietary product Xiao Qing Long Tang  
 
showing possible presence of AA 
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4.5      Confirmation of Positive HPLC Findings of Aristolochic Acids by LC-MS 
 
         As described in 3.6 above, to confirm the presence of aristolochic acids, LC-MS method 
using electrospray ionization (ESI) mass spectrometric analysis was employed to obtain chemical 
fingerprints.         
 
         A series of typical multiple reaction monitoring (MRM) chromatograms of aristolochic acid 
standards ranging between 0.02 ppm and 0.15 ppm is shown in Figures 6a to 6d showing the 
standard AA-I peak at retention time of 17.21 min. (x-axis), and the corresponding increase in 
measurement intensity (cps) in the y-axis as the standard concentrations increased. A 5-point 
calibration curve for AA-I was thus obtained from these measurements for this concentration 
range as shown in Figure 4.9. The coefficient of variation (R2) for the calibration curve was 
better than 0.99.  
Figure 4.9  A typical LCMS 5-point standard curve    
Concentration (ppm) 0.00 0.02 0.05 0.08 0.15 
Relative abundance 0 4587 9647 16340 32710 
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         A total of 11 samples after the preliminary screening by HPLC method were subjected to 
LC-MS analysis for confirmation of aristolochic acids as tabulated in Table 4.2. These included 
the four positive raw herbs and two positive manufactured herbal products mentioned above plus 
the remaining 5 manufactured proprietary products.Of these all four raw herbs were confirmed to 
be positive of aristolochic acids. Two out of the 7 manufactured herbal products were confirmed 
positive while the rest were negative of AA-I and AA-II. Composite (of the three m/z) ESI mass 
spectral fingerprints of all eleven LC-MS analyses can be examined in Appendix 4.1. A tpical 
MRM chromatogram of aristolochic acid is also included for comparision.  
Table 4.2    List of the 11 samples subjected for LC-MS confirmation 
Sample 
No. 
Name of Raw herb, or 
Manufactured Product 
AA: 
Detected 
(D) or Not 
detected 
(ND) 
Sample 
No. 
Name of Raw Herb, 
or Manufactured 
Product 
AA: 
Detected 
(D) or Not 
detected 
(ND) 
1 Chuan Xiong  
Cha Tiao Wan 
 
 
D 
7 Ma Dou Ling 
 
D 
 
2 Xiao Feng San 
 
D 
 
8 Guan Fang Ji 
 
D 
 
3 Ba Zheng San 
 
ND 
 
9 Dao Chi Pian 
 
ND 
 
4 Xiao Qing Long Tang 
 
ND 
 
10 Guang Mu Tong 
 
D 
 
5 Xin Yi Wan ND 11 Xi Xin (Bei)  
 
D 
 
6 Long Dan Xie Gan Tang 
 
ND 
 
   
 
         A typical ESI mass spectral fingerprint using Aristolochia fangchi (Guang Fang Ji) as an 
example, is shown in Figure 4.10. It can be seen that AA-I is present in this herbal sample 
indicated by the peaks at retention time of 17.15 min that resulted in product ions, NH4+, at m/z 
298, 296, and 324 with relative abundances similar to those obtained for the standard. These 
peaks did not occur in herbal samples such as Xiao Qing Long Tang and Xiao Feng San (Refer to 
MS chromatograms for comparison). 
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Figure 4.10.   A multiple reaction monitoring (MRM) chromatogram of AA-I showing the peaks at 
retention time of 17.15 min of Aristolochia fangchi that resulted in product ions at m/z 298, 296 
and 324 with relative abundances similar to those obtained for the standard 
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4.6    Summary of Aristolochic Acids Results for Raw Herbs and   
         Manufactured Herbal Products 
 
         The Results of all raw herbs and manufactured herbal products screened by HPLC and 
confirmed by LC-MS methodologies are summarised in two tables, detailing the levels of 
aristolochic acids (AA-I and AA-II) in the 7 over-the-counter manufactured herbal products 
(Table 4.2), and those from the 27 samples from the three pharmacological classes of raw herbs 
(Table 4.3). 
 
 
Table 4.3  Levels of aristolochic acids (AA-I and AA-II) in seven manufactured products 
 
Manufactured product 
 
 
Level (ppm) 
 
 
Chinese proprietary name 
Pharmaceutical Co. 
(China) 
  
AA-I 
 
  AA-II 
 
 AA-I + AA-II 
(1) Chuan Xiong Cha Tiao Wan 
(2) Dao Chi Pian 
(3) Xin Yi Wan 
(4) Xiao Qing Long Tang 
(5) Ba Zheng San 
(6) Xiao Feng San 
(7) Long Dan Xie Gan Tang 
 
 
Lanzhou Fu Ci 
Tian Jin 
Lanzhou Minshan 
Lanzhou Minshan 
Lanzhou Fu Ci 
Lanzhou Fu Ci 
Lanzhou Da Bao 
 
  
8 
40 
-- 
-- 
-- 
-- 
-- 
 
 
8 
210 
-- 
-- 
-- 
-- 
-- 
 
16 
250 
-- 
-- 
-- 
-- 
-- 
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Table 4.4  Levels of aristolochic acids (AA-I and AA-II) in samples from the three therapeutic 
classes of raw herbs 
 
Herbal Sample 
  
Level (ppm) 
 
 
Botanical name 
Common 
Chinese name 
  
AA-I 
 
  AA-
II 
 
AA-I +AA-
II 
 
Diuretics 
     
Aristolochia manshuriensis Guan Mu Tong  41   -- 41 
Clematis armandii  Chuan Mu Tong  --   -- -- 
Aucklandia lappa Decne Mu Xiang  --   -- -- 
Aristolochia contorta Bge. Ma Dou ling  195   33 228 
Poria cocos (Schw.) Wolf Fu Ling   --   -- -- 
Pyrrosia lingua (Thunb.) Farw Shi Wei  --   -- -- 
Dioscorea Hypoglauca Palif.       Bei Xie  --   -- -- 
Coix lachryma jobi L. Yi Yi Ren  --   -- -- 
Plantago asiatica L. Che Qian Zi  --   -- -- 
Polyporus umbellatus (Pers.) Fr.  Zhu Ling  --   -- -- 
Alisma plantago-aquatica 
  L. var. orientale Samuels 
 
Xe Xie 
  
-- 
 
  -- 
 
-- 
Artemisia capillaries Thunb. Yin Chen Hao  --   -- -- 
Tetrapanax papyriferus 
  (Hook) K. Koch 
 
Tong Cao 
  
-- 
 
  -- 
 
-- 
 
Anti-rheumatics 
     
Aristolochia fangchi Wu Guang Fang Ji  943   59 1002 
Stephania tetrandra S. Moore Han Fang Ji   --   -- -- 
Asarum sieboldii    (either:  
 A. splendens or A. himalaicum) 
 
Xi Xin  
  
trace 
 
  28 
 
28 
Acanthopanax gracilistylus Wu Jia Pi  --   -- -- 
Viscum coloratum (Kom.) Nakai Sang Ji Sheng  --   -- -- 
Chaenomeles lagenaria 
  (Loisel.) Koidz 
 
Mu Gua 
  
-- 
 
  -- 
 
-- 
Clematis chinessis Osbeck Wei Ling Xian  --   -- -- 
Gentiana macrophylla Pall Qin Jiao  --   -- -- 
Angelica pubescens Maxim Du Huo  --   -- -- 
Lysimachia christinae Hance Jin Qian Cao  --   -- -- 
 
Purgatives 
     
Prunus japonica Thunb. Yu Li Ren  --   -- -- 
Rheum palmatum Da Hunag  --   -- -- 
Cassia angustifolia Vahl Fan Xie Ye  --   -- -- 
Aloe vera L. var. chinesis         
  (Haw.) Berger 
 
 
Lu Hui 
  
-- 
 
  -- 
 
-- 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
5.1     Discussion 
          The recently reported incidences of nephropathy linked to ingestion of Chinese herbs 
containing aristolochic acids raises broader concerns about the safety of Chinese herbal remedies 
(Gillerot et al., 2001; Hashimoto et al., 1999; Lee et al., 2002; Lord et al., 1999; Tanaka et al., 
2001). In many countries, there are relatively lax regulatory controls on the importation and 
supply of raw Chinese herbs and manufactured herbal products, with scant regard to their 
botanical authenticity, quality and toxicity. Under such circumstances it is inevitable that herb-
related adverse events, such as those resulting from ingestion of Aristolochia species (Lord et al., 
1999; van Ypersele de Strihou & Vanherweghem, 1995; Vanherweghem, 1994) will continue to 
occur. 
 
           Species mis-identification and confusion about herb nomenclature are likely to be major 
factors in the occurrence of adverse events associated with the Chinese herbal medicine. Many 
Chinese herbs have similar morphological characteristics to other herbs and, frequently, different 
species of herb have the same Chinese pharmaceutical name, or, more commonly, the first 
component (stem) of the Chinese name of several species of herb is the same. Often the prefix in 
the common name designates the original region that an herb was grown. The present study, in 
which aristolochic acids were detected in two manufactured Chinese herbal remedies commonly 
used for weight control and the management of arthritis (Hashimoto et al., 1999; Lee et al., 2002), 
highlights these problems. It is likely that the presence of aristolochic acids in these manufactured 
products can be explained by species mis-identification and/or confusion about Chinese herb 
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nomenclature. There are many herbs that belong to groups of herbs with similar Chinese names. 
The name may consist of a stem, common to all members of the group, and a prefix. Table 3 and 
4 list examples from the Encyclopaedia of Chinese Materia Medica (PRC, 1997) of the Mu Tong 
and Fang Ji groups, respectively. From a Chinese medicine perspective, these two groups of 
herbs have the actions of expelling wind-cold, and promoting diuresis, and are often used in 
conditions such as oedema and arthritis. It can be seen that within each group, there are marked 
similarities in the Chinese names of the herbs, despite each herb being a different species. There 
are even instances of different species having exactly the same common name, that is, the same 
stem and the same prefix. For example, in Table 5.1, under the botanical name of Stephania 
tetrandra there are three different varieties of Fang Ji (Fen Fang Ji, Fang Ji and Han Fang Ji 
produced from different regions of China. All are non-toxic and commonly used in China and are 
effective in the treatment of arthritis and pain, because of their analgesic and anti-inflammatory 
effects. Of these three, Fen Fang Ji is recorded in the Compendium of Materia Medica as the 
genuine species. On the other hand, other Fang Jis listed in this table are either proven to be toxic 
with aristolochic acids, e.g., Aristolochia fangchi (Guang Fang Ji) or not yet been analysed but 
belonging to the family of Aristolochia. In any case all aristolochia herbs should be used with 
great caution or not at all until proven safe. Note that one of the varieties of Aristolochia 
heterophylla hemsl. produced in Zhen Ba in China is also called Han Fang Ji, thus causing 
confusion with another species under the botanical the Stephania tetrandra. 
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Table 5.1   Some examples of different varieties of Fang Ji in Chinese medicine  
Botanical name 
 
Common Chinese 
name 
Region of growth in 
China 
Genuine/Toxic?/ 
Comments 
 
Stephania tetrandra  
   S. Moore. 
 
 
 
 
 
 
 
 
 
Fen Fang Ji    
 
 
Fang Ji 
 
Han Fang Ji 
 
Zhejiang, Jiangxi, 
Guangdong, 
Lianjiang & Youxi  
in Fujian Province;  
 
 
Lin’an 
 
Kaihua 
 
 
All S. tetrandra are not 
toxic and have analgesic 
and anti-inflammatory 
effects; Fen Fang Ji was 
recorded as the genuine 
species according to the 
Compendium of Materia 
Medica (13); All are 
commonly used in China 
and exported;  
 
Aristolochia fangchi   
 
 
Aristolochia  
moupinensis Franch. 
 
 
Aristolochia 
kaempferi Willd. 
 
 
 
 
Aristolochia 
Kwangsiensis 
Aristolochia  
heterophylla Hemsl. 
 
 
 
 
Guang Fang Ji 
 
 
Mu Fang Ji (Note 
also called: Huai 
Mu Tong) 
 
Mu Fang Ji (also 
called: Huai Mu 
tong) 
 
 
 
Yi Bin Fang Ji 
 
 
Han Zhong Fang Ji 
 
 
 
Han Fang Ji  
 
 
Guangdong, Guangxi  
 
 
As Mu Fang Ji, the 
roots rather than the 
stems of these two 
species are used in 
some regions of 
China, mainly 
Mianning in Sichuan 
(compare to Table 
11) 
 
Gongxian in Sichuan 
 
 
Han Zhong in 
Shaanxi, Shaanxi, 
Gansu, Guizhou 
 
Zhen Ba 
 
Guang Fang Ji is  
toxic containing 
aristolochic acids  
(AA), but is still  
used in China  
and sometimes  
exported overseas; 
The two  
Mu Fang Ji,  
and the Yi Bin Fang Ji 
as well as the 
Han Zhong Fang Ji  
have not been  
analysed for AA; 
Nevertheless,  
all Aristolochia  
species should  
be used with  
great caution,  
or not all until  
proven safe  
 
Cocculus trilobus    
  (Thunb.) DC. 
 
 
Mu Fang Ji  
(also called:  
Qing Teng Xiang) 
 
 
Mainly in Henan, 
Shaanxi 
 
 
Non-toxic; Used locally 
in some regions of 
China; analgesic effect 
 
Aristolochia tagala 
 
Fang Ji 
 
Hainan 
 
Fake Fang Ji; Cannot  
be used as drug 
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            Similar confusions in nomenclature and in potential mis-use of toxic or not-so-effective 
botanical species also exist among the Mu Tong. For example, in Table 11, the two Akebia 
species, namely, Akebia trifoliata (San Ye Mu Tong) and Akebia quinata (Wu Ye Mu Tong), are 
recorded as genuine Mu Tong in the Compendium . In fact only the A. trifoliata had been 
demonstrated to possess the diuretic and anti-bacterial properties whereas the A. quinaata has 
little or none. They are now rarely used, except regionally in China, and yet Akebia species are 
commonly labelled in manufactured products exported overseas. The other commonly exported 
and widely used Mu Tong are the Clematis armandii (Chuan Mu Tong), and the C. montana 
(also called Chuan Mu Tong). Yet both are not genuine  and contain little or no diuretic and anti-
bacterial effects (Schaneberg et al., 2002). The remaining three examples in the table all belong 
to the Aristolochia family, with A. manshuriensis (Guang Mu Tong) known to contain the toxic 
aristolochic acids, and yet commonly used in China and occasionally inadvertently exported 
overseas.        
 
           Clearly, the Chinese nomenclature, at least for Fang Ji and Mu Tong is problematic. The 
problem of two species having Chinese names with the same stem, even where they have 
different prefixes, is compounded by the practice of some traditional Chinese medicine 
practitioners, of omitting the prefixes in their prescriptions. Furthermore, even when a unique 
Chinese name is specified by a practitioner that is, both stem and prefix, incorrect herbs may be 
supplied because of lack of precision of botanical labelling by herbal suppliers. Thus, A. trifoliata, 
A. quinata, A. manshuriensis and Clematis armandii are all called Mu Tong (see Table 5.2) by 
some practitioners or are often all traded under this Chinese pharmaceutical name. Indeed, they 
are often erroneously regarded as equivalent and are frequently used for a therapeutic purpose 
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without regard to their botanical, chemical and consequently, toxicological differences. There are 
similar problems with the Fang Ji group (Table 5.1). 
 
          In the present study three groups of herbal medicines were analysed. The first group of 21 
raw herbs, purchased in Victoria in 2003, were found to be free of aristolochic acids. The second 
group of six banned raw herbs were included in the study because of the potential for them to be 
supplied to wholesalers, retailers or to patients as a result of nomenclature confusion between the 
toxic and non-toxic species that share the same stem name. The banned herbs were purchased 
prior to prohibition of their sale, and were obtained from the herbal teaching museum of the 
Division of Chinese Medicine, RMIT University. Of these six herbs, four were found to contain 
aristolochic acids. There were differences in the chemical form and levels of aristolochic acids 
found in the herbs tested. The sample of Aristolochia contorta (Ma Dou Ling) contained both 
AA-I and AA-II, with a total aristolochic acid concentration of 228 ppm. Aristolochic acids were 
not detected in Stephania tetrandra (Han Fang Ji), the species that was specified for 
incorporation into the Belgian slimming formulation (see Introduction). However, the species 
substituted in the formula, Aristolochia fangchi (Guang Fang Ji) had a total aristolochic acid 
level of 1002 ppm. Aristolochic acids have also been detected in Aristolochia fangchi in other 
studies. Thus, Lee, et al. (Lee et al., 2002) found levels between 581-1082 ppm and Hashimoto, 
et al. (Hashimoto et al., 1999) reported levels between 1070-2440 ppm.        
 
          In regard to two other herbs tested, which have the same Chinese stem name, Mu Tong, 
aristocholic acids were detected in one but not the other. Thus, Aristolochia manshuriensis 
(Guan Mu Tong) had 41ppm of AA-I, whereas no aristocholic acids were detected in Clematis 
armandii (Chuan Mu Tong). The sample of Aristolochia manshuriensis was imported from 
China by a herbal wholesaler. The area in China in which it was harvested is not known. The 
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relatively low level of aristolochic acids found in our sample contrasts with the much higher 
levels (1690 to 8820 ppm) reported by Hashimoto et al. (Hashimoto et al., 1999) for specimens of 
Guan Mu Tong harvested in various provinces of China. The discrepancy may be due to 
different agronomic conditions or, more likely, to different species being tested. 
 
         Herbs of the Asarum species are commonly used to treat pain such as headache and 
toothache. The botanical identity of the Asarum (Xi Xin) sample tested in the present study is not 
known. It was imprecisely labeled as Asarum herba, and was found to contain 28 ppm of AA-II. 
In another study (Hashimoto et al., 1999), in which six different species of the Asarum genus 
were analysed, aristolochic acids were detected in trace amounts in only two species, namely, the 
Asarum splendens and Asarum himalaicum, both having been collected from Sichuan province in 
China. Aristolochic acids were not detected in A. sieboldii Miq., A. heterotropoides, A. sieboldii 
Miq. Var. seoulense, and A. forbesii, which had been collected in either China or Korea. In 
another study, three North American species of Asarum were analysed (Schaneberg et al., 2002). 
Samples of one of the species Asarum canadense, was found to contain differing amounts of AA-
I, depending on where the samples had been purchased. Asarum canadense has been proclaimed 
as a prohibited herb by the U.S. Food and Drug Administration . The positive AA result in the 
present study suggests that the Asarum species analysed in the present study may have been 
either Asarum splendens or Asarum himalaicum, possibly sourced from the province of Sichuan 
in China. Again, the presence of aristolochic acids in some but not all Asarum species illustrates 
the risks associated with ambiguity or lack of precision of botanical identification of Chinese 
herbs. 
 
          Of the third group of herbal medicines investigated, the 7 manufactured herbal products, 
two were found to contain aristolochic acids, namely, Chuan Xiong Cha Tiao Wan, and Dao Chi 
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Pian. Chuan Xiong Cha Tiao Wan contains eight different Chinese herbs, being manufactured by 
Fu Ci Pharmaceutical Company in Lan Zhou province, China. One of the constituent herbs is Xi 
Xin, which on the product label, was referred to imprecisely as Asari herba. Therefore, it is likely 
that a toxic species, either A. splendens or A. himalaicum, was used to manufacture the product. 
Another product tested, Xiao Qing Long Tang, did not have a detectable level of aristolochic 
acids, despite its label also listing Asari herba as a constituent. This product, produced by Mian 
San Pharmaceutical Company in Lan Zhou, China, would appear to use a non-toxic Asarum 
species. These findings again point to the problems of inadequate and inaccurate labelling of 
herbal materials in regard to botanical names. Frequently only the genus of the herbs is provided, 
making it impossible to precisely identify the species used in manufacture. 
 
          The problems mentioned above for Chuan Xiong Cha Tiao Wan were also reflected in the 
findings with Dao Chi Pian, a formula often prescribed by Chinese medicine practitioners to 
promote diuresis. This formula was found to contain a total amount of 250 ppm of aristolochic 
acids. One of the four herbal ingredients of the formula is Mu Tong. The label on the product 
tested in the present study listed the botanical name Caulis Akebia. As shown in Table 5.2, the 
two herbs, Akebia trifoliata and Akebia quinata are regarded as genuine Mu Tong and are not 
toxic. The Mu Tong used in the product tested is likely to be derived from a toxic Mu Tong 
species, such as Aristolochia manshuriensis or Aristolochia moupinensis rather than from the 
Akebia species, as labelled. This appears to be another example of inaccurate botanical labeling.  
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Table 5.2  Some examples of different varieties of Mu Tong in Chinese medicine  
Botanical name 
 
Common Chinese 
name 
Region of growth 
in China 
 
Genuine/Toxic?/ 
Comments 
Akebia trifoliata 
(Thunb.) Decne. 
 
Akebia quinata  
  (Thunb.) Koidz. 
San Ye Mu Tong 
 
 
Wu Ye Mu Tong 
 
Mainly in Sichuan 
 
 
Mainly in Zhejing  
 
 
 
 
 
 
 
 
 
 
Both are genuine 
according to ancient 
record; now rarely 
used, except 
regionally in China; 
yet Akebia species 
often labelled in 
manufactured 
products; A. trifoliata 
has strong diuretic 
and anti-bacterial 
effects 
 
 
Clematis armandii  
  (Franch.) 
 
 
Clematis montana  
  Buch.-Ham  
 
Chuan Mu Tong 
(also called: Xiao 
Mu Tong) 
 
Chuan Mu Tong  
 
Sichuan, Hubei, 
Jiangxi, Guizhou, 
Yunan, Guangdong 
 
Sichuan 
 
Both are not genuine 
according to ancient 
record; non-toxic; 
next most often used 
in China and exported 
overseas; No diuretic 
& only weak anti-
bacterial effects 
 
 
Aristolochia    
  manshuriensis Kom. 
 
 
Aristolochia   
  moupinensis Franch. 
 
 
Aristolochia  
  kaempferi Willd. 
 
Guan Mu Tong 
 
 
 
Huai Mu Tong 
(also called: Mu 
Fang Ji) 
 
Huai Mu Tong 
(also called: Mu 
Fang Ji) 
 
 
 
 
Jinin, Liaoning, 
HeilongJiang,  
 
 
As Huai Mu Tong, 
the stems rather the 
roots of these two 
species are used in 
some regions of 
China, mainly 
Sichuan (compare to 
Table 10) 
 
 
All three are not 
genuine; Guang Mu 
Tong is toxic with 
aristolochic acids; yet 
is most commonly 
used in China at 
present, and 
sometimes exported 
overseas; No diuretic 
& weak anti-bacterial 
effects; All should 
not be used until 
proven safe 
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            The 7 Chinese medicinal formulae studied here are probably the only formulae available 
in the State of Victoria that include Fang Ji, Mu Tong, or Xi Xin. However, only one brand of 
each formula was sampled for this study. Many other proprietary brands of each formula (i.e., 
different proprietary products with the same formula names, but manufactured by different 
pharmaceutical companies) are available. Four of the proprietary products tested were included in 
the list of 14 products banned by the Australian TGA. The other 10 products banned are not 
available in Victoria, and presumably, not throughout Australia. Note that the name of a specific 
formula may end with “Wan” or “Pian” (i.e. pills), or “Tang” (i.e. decoction) or “San” (i.e. 
granules), but the names of the herbs that make up the formula are basically unchanged.  
However, the sources of herbs used to manufacture the products cannot be guaranteed.  
 
           Because Tian Xin Teng, Ma Dou Ling and Qing Mu Xiang were listed as banned herbs 
by the Australian TGA, these herbs being derived from the toxic Aristolochia species 
(Aristolochia contorta Bge or Aristolochia debilis Sieb. Et Zucc), I also attempted to obtain 
samples of the herbs, and of any patent formulated products containing them. I was unable to 
obtain such samples in Victoria after these herbs were banned by the TGA in 2001. However, it 
seems that the possibility of substitution of a non-toxic herb with a toxic one, due to incorrect or 
inadequate labelling, is more likely to occur with the commonly used herbs Fang Ji, Mu Tong 
and Xi Xin, as discussed above. 
 
          Since storage conditions and length of storage might affect the concentrations of 
constituents in raw herbs, it should be pointed out that some of the raw herbs in the current study 
were obtained from the herbal teaching museum and may have been stored there for a lengthy 
period of time. This applies to three raw herbs in particular. They are Aristolochia manshuriensus 
(Guan Mu Tong), Aristolochia contorta Bge. (Ma Dou Ling), and Aristolochia fangchi Wu 
 61 
(Guang Fang Ji). They were used because fresh samples are no longer available in Victoria after 
the TGA ban. Despite this condition, analysis revealed that their concentrations were in ranges 
similar to other published results quoted in the relevant references in this thesis. 
 
                Broad chromatographic peaks were observed for AA-I and AA-II in Fig. 4.3a to d (in 
fact, AA-I in Fig.4.3a eluted for a minute). This deserves an explanation. AA-I in Fig. 4.3a 
belongs to Aristolochia fangchi Wu (Chinese name: Guang Fang Ji). This herbal species is 
known to contain very high concentrations of AA, in particular, AA-I. In this investigation, the 
concentrations were the highest among all samples tested. AA-I was 943 ppm. The peak actually 
went off the chromatographic scale. This accounts for the long elution time of almost one minute. 
Other samples containing lower AA concentrations demonstrated much shorter elution times 
(please compare to Figures 4.3b to d). Nevertheless, peak sharpness can be further improved by 
(a) using a gradient elution system involving two solvents, and/or (b) introducing purification 
step such as solid phase elution (SPE) column prior to HPLC injection. However, neither of these 
two procedures was explored because one of the aims of the project was to deliberately employ 
the simplest and quickest procedure to screen for presence of AA, and because it was always 
intended to have the samples first identified by HPLC to contain AA, and then subsequently 
confirmed by the definitive method of LC-MS technique. In fact, eleven samples including the 
four HPLC-positive raw herbs and two HPLC-positive patent medicines were subject to LC-MS 
analyses.  Results showed that only the positive HPLC findings were confirmed to be positive by 
LC-MS. In other words, the simple HPLC screening method did not produce false positive or 
false negative. 
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5.2   Conclusion 
 
          In the present study some clinically related Chinese herbs and manufactured herbal 
products were screened for AA-I and AA-II, The findings of significant levels of aristolochic 
acids in some of the raw herbs and also in some manufactured products highlight concerns about 
the potential for serious adverse effects due to imprecise and inaccurate labelling of Chinese 
medicinal herbs and, by extension, of the precise identity of herbs used in the manufacture of 
formulated Chinese herbal products. Of particular concern is the use of similar Chinese 
pharmaceutical names, that is, the same stem name with different prefixes, to identify herbs, and 
the lack of scientific rigour to distinguish unambiguously between herbs with similar appearance 
and morphological characteristics. There would appear to be a strong case for requiring effective 
monitoring of medicinal herbs, in regard to both their botanical authenticity and the absence of 
toxic substances. In addition, the labels of herbal products need to provide complete and accurate 
details of the herbs that they contain. The Australian TGA has recently introduced quality 
standards  for herbal medicines, including authentication and clear labelling of herbal ingredients. 
The full botanical names must be given on labels and non-specific genus names, such as “Asari 
herba” are not permitted. In addition, there needs to be wider recognition of health risks of herb 
substitution and of mis-identification of medicinal herbs amongst the Chinese medicine 
profession and insistence by practitioners of greatly improved standards of quality assurance in 
terms of accuracy in botanical labelling for raw herbs and herbal products. 
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CHAPTER 6 
 
INTRODUCTION 
 
 
6.1     Background 
 
          Chinese herbal medicines have been in use as a mainstream healthcare system for centuries 
in China, and for many decades in many Asian countries. In recent years traditional Chinese 
medicines (TCM) have grown in popularity in the west. In the United States, it was estimated that 
about one-third of the population used complementary medicines, and spent about $14 billion a 
year in 1990 (Eisenberg et al., 1993). A follow-up survey by the same group in 1997 (Eisenberg 
et al., 1998) found that the number of users had increased from the one-third to 42 per cent the 
population, and expenditure went up to US $27 billion. Similar trend is also happening in the UK 
where usage is becoming widespread among the non-Asian groups (Atherton, 1994). In Australia 
the usage is growing at an even faster rate in recent years, with more than 50 per cent of the 
Australians using complementary and alternative medicines (CAM), and one-fifth of the 
population consulting practitioners of alternative medicines each year in 1993 (MacLennan, 
Wilson, & Taylor, 1996). The expenditure was estimated to be around $620 millions in 1996 
(Ban, 1998; MacLennan et al., 1996). A later survey also by Maclennan et al. in 2000 
(MacLennan, Wilson, & Taylor, 2002) estimated that the national Australian expenditure on 
complementary medicines, excluding cost to practitioners, had jumped to about $1.7 billion, 
representing many fold increase in six years. Of this burgeoning cost, much of it was spent in the 
area of herbal medicines. With this increase in popularity there has also been a parallel rise in the 
importation of raw Chinese herbal medicines, largely from China. There are now at least 400 
raw/crude Chinese herbal materials (CHM) and hundreds of Chinese proprietary medicines 
(CPM) available in Australia . The widespread use of herbal medicines has come at a price, with 
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regular reports of herbal toxicities. Among other toxic substances, heavy metal poisonings appear 
to be most commonly reported (T. Y. Chan & Critchley, 1996; Saper et al., 2004). Concerns are 
therefore increasingly expressed regarding the safety and efficacy of herbal medicines (K. Chan, 
1995; Myers & Cheras, 2004).    
 
            To date, there are several reviews (T. Y. Chan & Critchley, 1996; Ernst, 2000; Ernst & 
Thompson Coon, 2001) on the toxicity of Chinese proprietary medicines (CPM) resulting in lead 
(Pb) poisoning (Cheng et al., 1998; Levitt, Godes, Eberhardt, Ing, & Simpson, 1984; Lightfoote, 
Blair, & Cohen, 1977), arsenic (As) poisoning  (Tay & Seah, 1975; S. T. Wong, Chan, & Teo, 
1998), mercury (Hg) poisoning (Kang-Yum & Oransky, 1992; A. M. Li et al., 2000), cadmium 
(Cd) poisoning  (Wu, Hong, Lin, Yang, & Chien, 1996), and multiple metal poisoning (Espinoza, 
Mann, & Bleasdell, 1995). This concern about metal toxicity is further reinforced by more recent 
reports of highly toxic levels of metals in the Indian Ayurvedic herbal remedies as a result of 
deliberate inclusion of metals in many Ayurvedic remedies in large quantities for therapeutic 
purposes (Ernst, 2002a, 2002b; Saper et al., 2004). Thus, the common perception that herbal 
medicines are natural and therefore safe is increasingly under challenge within the academic 
circle of complementary medicine (Ernst, 2006), even though 90% of CAM users consider herbal 
products safe (MacLennan et al., 2002). In this respect, Chinese and Indian herbal medicines are 
the two most commonly quoted for concerns (Dwivedi & Dey, 2002; Ernst, 2002c).  
 
            The above approach of referring to reported cases of metal poisoning to define the relative 
risk of TCM lacks rationality and rigour. Clearly to evaluate the relative risk or safety of TCM, a 
systematic determination of the levels of metal contents in all forms of Chinese medicines is 
urgently needed. Metal contents in herbal medicines are largely dependent on (a) regions of 
growth influenced by soil, environmental pollution, and agronomic practice , (b) manufacturing 
 73 
process (Koh & Woo, 2000), and (c) deliberate inclusion of metals for alleged therapeutical 
functions (PRC, 1997). Therefore, the sources of supply or production of herbal medicines may, 
to a large extent, pre-determine the metal contents in the crude herbs and the manufactured herbal 
products. There have been numerous publications reporting the metal contents in Chinese herbal 
medicines. However, many of them analysed only one metal, such as, lead in herbal proprietary 
preparations in Malaysia (Ang, Lee, & Matsumoto, 2003), lead in eight kinds of Chinese crude 
herbs in China  or arsenic in a few herbal capsules or syrups in Singapore (Ong, Yong, & Woo, 
1999). Others measured several heavy metals in a limited number of CPMs. For example, 
Chuang et al. (2000) (Chuang, Chen, Huang, Lee, & Lin, 2000)determined 7 metals including 
lead, arsenic, mercury and cadmium, in five Chinese medicines of plant origin in China, and 
Caldas and Machado (Caldas & Machado, 2004) analysed cadmium, mercury and lead in ten 
medicinal herbs in Brazil. Of these Brazilian herbs, only two, the Brazilian ginseng, and Ginkgo 
resembled Chinese herbs. Garvey et al. in the US (2001) (Garvey, Hahn, Lee, & Harbison, 
2001)determined the arsenic, mercury, and lead contents in about 50 crude and proprietary herbal 
medicines purchased in different states of USA, Vietnam, India, Hong Kong, and China. The 
small number of samples in the above studies, and the random selection of samples from around 
the world in the US study make it impossible to reliably evaluate the issue of safety of herbal 
medicines used by the community. In Australia, there have not been any systematic studies 
published on metal contamination of the Chinese herbal medicines available locally. In Victoria, 
Australia, there are several major Chinese herbal wholesalers, which obtain their supplies mainly 
from fixed sources in China. They are responsible for retailing to large majority of the Chinese 
medicine practitioners who dispense both the crude Chinese herbal materials (CHM) and Chinese 
proprietary medicines (CPM) to patients in Victoria. Hence, a systematic and large selection of 
herbal medicines from these major herbal outlets for the purpose of metal determination will 
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produce a reliable indication of the quality of the Chinese herbal medicines commonly used in 
Victoria with respect to metal contamination.     
 
            Traditionally, analyses of metal contents in herbal medicines reported in literature 
involved acid digestion or microwave acid digestion of the herbal materials. This also applies to 
all the references cited above. This initial step renders all the complex metal molecules turning 
into analysable metal elements. The metal results, thus obtained, represent the absolute total 
content. While this concentration may be used to directly estimate the metal intake of Chinese 
medicines that are ingested directly in the commercial form, such as the CPM as tablet, or 
capsule or syrups, it is, however, not applicable for the crude Chinese herbal medicines (CHM), 
which are mainly herbs, plus a few minerals, and animal parts. In Chinese medicine clinical 
practice, these CHM are usually boiled in water to produce herbal decoctions either singly or 
more likely, as part of a herbal prescription (i.e., Chinese medicinal formula) that may consist of 
up to 20 individual CHM, usually between 8 and 12. The aqueous decoctions are then consumed 
orally for their therapeutic property. Thus, the water-soluble metal contents rather than the acid-
digested contents, represent the more appropriate concentration to be used to calculate the daily 
metal intake as far as the crude Chinese herbal medicines (CHM) are concerned. Furthermore, 
current interpretation of the acid-digested metal results generally ignores the metal contribution 
from the normal daily dietary intake, thus under-estimating the combined potential risk.  
 
6.2       Research Questions and Research Approaches 
 
            The overall aim of these studies, therefore, was to evaluate the safety/risk to the 
consumers of the use of Chinese herbal medicines in terms of metal contamination in the state of 
Victoria, Australia. This was accomplished by systematically purchasing from two largest herbal 
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wholesalers in Victoria one hundred most commonly used crude Chinese herbal medicines 
(CHM), fifty popular Chinese proprietary medicines (CPM), and five frequently prescribed 
Chinese medicinal formulae (CMF) packed in raw herbs, and then carrying out both acid 
digestion to assess the total metal contents for the CHM, CPM and CMF, as well as performing 
the process of boiling in water to determine the water-soluble metal concentrations in the aqueous 
decoctions for the CHM and the CMF. The toxic heavy metals analysed included lead (Pb), 
arsenic (As), mercury (Hg), cadmium (Cd), and chromium (Cd). These analytical findings were 
then used to assess the daily metal intakes due to individual crude herb or the herbal formulae, as 
well as due to their combination with the Australian total daily dietary intake (ATDS) in order to 
give a realistic combined daily intake of the metals. These overall levels of daily intakes were 
then compared to the regulatory standards of provisional total daily intake (PTDI) or provisional 
total weekly intake (PTWI) to evaluate the safety of traditional Chinese medicines. Finally, a 
separate in vivo study, which involved more than one hundred patients in a randomised clinical 
trial (RCT), with the participants divided into two groups, with the treatment group taking 
Chinese herbal capsules (containing concentrated herbal powder extracts from 8 crude herbs) for 
seasonal allergic rhinitis, and the control group taking placebo (containing starch and cornflour), 
twice daily for four weeks. Blood samples were collected during the baseline period and at the 
end of the four-week treatment period. Blood levels of two metals lead and cadmium, were 
determined to evaluate the potential risk of metal accumulation in blood. 
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CHAPTER 7 
LITERATURE REVIEW 
 
7.1       Types of Traditional Chinese Medicines 
 
            Traditional Chinese medicines include (a) the crude Chinese herbal medicines (CHM) 
which are mostly plants, plus some animal parts and minerals, (b) Chinese proprietary medicines 
(CPM) which are manufactured as finished products, such as tablets, pills, capsules, concentrated 
powder extracts, and liquids including syrups, and (c) Chinese medicinal formulae (CMF) which 
are prescriptions made up of individual CHM – usually between 8 and 12 CHM, but can be more 
or less.  
 
            The CPM are the final dosage forms and are therefore consumed directly as purchased. 
The CHM, on the other hand, are crude/raw medicines that have undergone minimal processing 
such as drying, cutting, roasting, or frying. They are generally boiled in water to produce aqueous 
decoction to be drunk for their therapeutic property. Usually a number of them are prescribed to 
make up a Chinese medicinal formula (CMF) for the treatment of a certain Chinese clinical 
syndrome. Such packs of crude CMF also undergo boiling process to extract the medicinal 
ingredients into the aqueous solution (i.e., the aqueous decoction) for oral administration. As a 
result, metals in the CPM are ingested in totality. On the other hand, the metal contents in the 
aqueous decoctions i.e., water-soluble fraction of CHM and CMF are the ingestible amounts. 
Whether the metal concentrations of the water-soluble fraction are the same as or less than the 
total amount of metals present in the raw herbs remains to be determined.  
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7.2       Safety Concerns about Metal Contaminations in Chinese Herbal Medicines  
             
            As discussed in Introduction, Chinese medicines are increasingly being widely used in the 
west. With the rise in its popularity, reports of adverse effects from Chinese medicines also 
increase. To date, several reviews on metal poisoning associated traditional Chinese medicines 
have been published (T. Y. Chan & Critchley, 1996; Ernst, 2002c; Ernst & Thompson Coon, 
2001; Garvey et al., 2001). The four most studied heavy metal contaminants are lead (Pb), arsenic 
(As), cadmium (Cd) and mercury (Hg). These reports have raised serious concerns and led to 
establishment of regulatory standards in metal levels in many countries (ANZFA, 1999; WHO, 
1999, 2000, 2001) including Singapore (Koh & Woo, 2000; Status, 1999).  
 
7.3       Lead (Pb) Clinical Toxicities and Cases of Pb Poisoning  
 
             Lead is ubiquitous, being present in air, water, food and sediment and soil (U.S.DH&H, 
1999b; WHO, 1995). It, therefore, can accumulate in plants including Chinese medicinal herbs 
via soil. Adverse clinical effects of exposure to lead are primarily related to aspects of 
development in children, gastrointestinal and haematological conditions, and neurological effects 
(Goyer & Clarkson, 2001; U.S.DH&H, 1999a; Ubara et al., 1999). Children are especially 
susceptible to lead poisoning due to high gastrointestinal absorption and the permeable blood-
brain barrier. Thus, short-term exposure of lead among children may cause behavioural, and 
learning difficulties, while long-term exposure may diminish their intellectual capacity as 
evidenced by a weighted mean decrease in IQ of 2 points for a 10 µg/dl increase in blood lead 
level (WHO, 1995). In adults, on the other hand, organic lead compounds, such as tetramethyl 
lead, may cross the blood-brain barrier, and, therefore, can result in encephalopathy characterized 
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by restlessness and sleeplessness in acute lead poisoning. Severe case of lead encephalopathy 
may lead to acute psychosis, and even reduced consciousness. 
 
             Generally, mortality due to lead toxicity is rare but mor+bidity is high. Symptoms of 
acute lead poisoning are irritability, headache, nephrotoxicity, and neurological and 
gastrointestinal manifestations. Thus, it has been reported that acute lead poisoning caused 
proximal renal tubular damage (WHO, 1995), and prolonged exposure damaged the kidney 
(Mortada et al. 2001). The gastrointestinal symptoms commonly include abdominal pain, nausea, 
vomiting, constipation, cramps, and anorexia (U.S.DH&H, 1999a). 
 
             Lead is the most common metal contaminant in Chinese medicines, and lead poisoning is 
especially prevalent among children. One of the earliest childhood lead poisonings was reported 
in Hong Kong in 1977 by Chan, Billmeier, Evan and Chan (1977)(H. Chan, Billmeier, & Evans, 
1977). In this case a 4-month-old infant developed acute plumbism with a one-week history of 
fever, cough, anorexia, and vomiting after he had been given various kinds of Chinese patent 
medicines since birth. Measurements of whole blood lead concentration, and 24-hour urine lead 
were above normal, being 137 µg/100mL and 54 µg/24 hr respectively (normal for blood: < 40 
µg lead/100mL; normal for 24-hr urine: < 50 µg lead /24 hr). Subsequent analysis of 11 brands of 
Chinese proprietary medicines (CPM) revealed that one of them, Po Ying Tan, contained a toxic 
mean lead content of 2.5 mg/100 mg sample which was equivalent to 7.5 mg /unit dose. In 
another lead poisoning case due to CPM, also in Hong Kong, the infant presented with acute lead 
encephalopathy (Yu & Yeung, 1987). In both cases the signs and symptoms were normalised 
with chelation therapy. A 61/2-year-old child also was discovered through routine screening to 
have suffered from lead poisoning but was largely asymptomatic (Levitt et al., 1984). Among 
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adults, the earliest report of lead poisoning associated with TCM was in America in 1977 
(Lightfoote et al., 1977) where a 59-year old woman developed mild signs and symptoms of lead 
toxicity after consuming as much as 15 mg of lead daily. A more severe case of poisoning also 
occurred in the US in 1994 (Markowitz et al. 1994). In this case, a 45-year-old Korean man 
developed acute intermittent porphyria the cause of which was initially misdiagnosed until an 
elevated blood lead level of 76 µg/100mL was discovered. The source of lead was traced to 
clamshell powder (Hai Ge Fen) which was one of the many ingredients in the Chinese herbal 
medicine prescribed to the patient. The same clamshell powder also resulted in a second case of 
lead poisoning in the following year (Hill & Hill, 1995). Elsewhere in Taiwan, two cases of adult 
lead poisoning were caused by contaminated Cordyceps (Chinese name: Dong Chong Xia Cao) 
(T. N. Wu et al., 1996). This report differed from others in that the TCM involved was a 
contaminated crude Chinese herb (CHM) instead of Chinese proprietary medicines (CPM). 
Furthermore, lead in combination to thallium in a TCM medication known as Nutrien had also 
been the cause of alopecia and sensory polyneuropathy in two women . These articles reporting 
Pb as well as other heavy metal poisonings are summarised in Table 7.1. Overall, the number of 
publications cited above may not be very large. However, some of them represented case reports 
as well as case series. Hence, the total number of metal poisoning was much higher, especially, if 
allowance was given to cases that were not published, or published in some non-retrievable 
journals including Chinese data. Nevertheless, it needs to be pointed out that these incidents 
spanned over three decades. 
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Table 7.1   Summary of reported lead poisonings in children and adults 
 
Authors 
 
 
Poisionings 
 
Comments 
 
Chan, Billmeier, Evan,  
& Chan, 1977 
 
Four-month-old Hong Kong infant 
overdosed with lead involving Po 
Yin Tan 
 
Developed acute plumbism 
 
Yu & Yeung, 1987 
 
Hong Kong infant poisoning from 
Chinese patent peoduct 
 
Developed lead encephalophy 
 
Levitt, et al., 1984 
 
61/2-year-old child overdosed with 
lead, discovered through routine 
blood screening 
 
Asymptomatic  
 
Lightfoote, Blair, &  
Cohen, 1997 
 
59-year-old woman had prolonged 
ingestion of more than 15mg lead 
daily 
 
Usual signs and symptoms of 
lead poisoning 
 
Markowitz, et al., 1994 
 
45-year-old Korean man 
developed lead poisoning from 
clamshell powder (Chinese patent 
product: Hai Ge Fen) in the US 
 
Severe acute intermittent 
porphyria 
 
Hill, 1995 
 
Also poisoned from clamshell 
powder in the US 
 
Mild signs and symptoms 
 
Wu, et al., 1996 
 
Adult poisoning from 
contaminated Cordyceps (Chinese 
name: Dong Chong Xia Cao) in 
Taiwan 
 
Poisons involved was raw herb 
instead of proprietary products 
as reported in other cases 
 
Schaumberg, & Berger,  
1992 
 
Two cases of women poisoned by 
TCM product called Nutrien 
 
Patient developed alopecia and 
sensory polyneuropathy 
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7 .4       Arsenic (As) Clinical Toxicities and Cases of As Poisoning 
 
             Inorganic arsenic is present in groundwater, and is, therefore, a contaminant in drinking 
water and soil (e.g., in China). Consequently, it may become part of the metal residues in plants 
including Chinese medicinal herbs. This is the toxic form of arsenic, and intake of contaminated 
food and herbal materials may result in disturbances of the gastrointestinal, cardiovascular, 
central nervous systems, and even death. Exposure of arsenic in drinking water may lead to 
cancer of the lung, kidney, bladder and skin (WHO, 2001). Organic arsenics (e.g. arsenobetaine) 
are present in fish, which may contribute to human exposure. 
 
            Arsenic (As) is probably the second most common toxic heavy metal encountered next to 
lead, in poisoning associated with TCM use. Chronic exposure to arsenic associated with TCM is 
mainly related to dermatological problems such as hyperkeratosis and changes in pigmentation 
(Jarup, 2003). Skin cancer and other forms of cancers may also occur. For example, Tay (Tay, 
1974) published in the Australian Journal of Dermatology a case of cutaneous manifestations of 
arsenic poisoning due to ingestion of Chinese herbal medicine. In the following year, Tay and 
Seah (1975)(Tay & Seah, 1975) in Singapore, reported 74 cases of arsenic poisoning related to 
various types of Chinese herbal products, mostly for asthma conditions. Of these 10 cases had 
developed malignant carcinoma. Many more cases and case series of TCM-induced chronic 
arsenicism were reported in Singapore, including two Chinese males and a female, all in their 50s 
(S. T. Wong et al., 1998), and 17 patients with cutaneous lesions (S. S. Wong, Tan, & Goh, 
1998). Upon review of the 17 cases, it was found that 14 out of the 17 patients had been regularly 
taking TCM and that 11 of the 17 had developed carcinoma of the squamous cells. A 3-year-old 
Chinese girl in Hong Kong suffered a lethal As poisoning in 1998 (Cuncha, Pereira, Pun, Poes, & 
Vong, 1998) as a result of prolonged ingestion of a popular CPM by the proprietary name of Lu 
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Huang Chieh Tu Pien which contained very high content of arsenic. Metal poisoning was not 
confined to a single element. Multiple poisoning involving arsenic and mercury had also been 
reported (Espinoza et al., 1995).   
 
7.5       Mercury (Hg) Clinical Toxicities and Cases of Hg Poisoning   
 
            Mercury exists as cinnabar, i.e., mercury sulphite (HgS), or calomel, i.e., mercuric 
chloride (Hg2Cl2). Inorganic mercury is converted to organic compounds, such as methyl 
mercury. This organic mercury is the more toxic entity, and because of its very stable nature, it 
accumulates in food and plants, particularly in fish. Chronic poisoning of mercury mainly relates 
to the central nervous system, gastrointestinal tract, and kidney, giving rise to neurological and 
psychological symptoms , and conditions of male reproductive system (Popescu, 1978), whereas 
acute mercury exposure may damage the lung (Jarup, 2003). Most symptoms are reversible upon 
cessation of exposure. Several publications of mercury poisoning due to Chinese medicines have 
been reported. In the US several cases of Chinese male patients aged between 4 and 37, and one 
50-year old presented with symptoms of mercury poisoning after taking CPM called Tse Koo 
Choy, or Qin Fen were reported by Kang-Yum & Oransky (Kang-Yum & Oransky, 1992)(1992). 
In Taiwan, a male presented with severe polyneuropathy and slowly progressed to generalised 
paralysis of all limbs after 3 months ingestion of herbal drugs containing mercuric sulphate. His 
muscle strength was only mildly improved after two years (Chu, Huang, Ryu, & Wu, 1998).  A 
more recent case in Hong Kong involved a 5-year-old boy who was treated for mouth ulcer using 
a Chinese medication of mouth spray, which contained high concentration of mercury (A. M. Li 
et al., 2000). As a result, motor and vocal tics developed. Mixed heavy metal poisoning involving 
mercury and arsenic in TCM tablets had also been reported (Espinoza et al., 1995). 
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7.6      Cadmium (Cd) Clinical Toxicities and Cases of Cd Poisoning 
 
          Industrial usage of cadmium has decreased considerably over the last decade. The major 
source of exposure of this toxic heavy metal mainly comes from food in the general non-smoking 
population(WHO, 1992). Cadmium toxicities are mainly related to damage to the kidney, 
beginning with tubular dysfunction (Jarup, Berglund, Elinder, Nordberg, & Vahter, 1998) 
manifested with increased excretion of low molecular proteins, such as α1- and/or β2-
microglobulin, or enzyme, such as N-Acetyl-β-D-glucosaminidase (NAG). This may progress to 
more severe kidney damage evidenced by decreased glomerular filtration rate (GFR) (Bernard, 
Lauwerys, & Ouled Amor, 1992), or even end stage renal disease (ESRD) (Hellstrom et al., 
2001). On the other hand, even prolonged low level cadmium exposure may result in skeletal 
damage, leading to osteoporosis and fractures (Alfven et al. 2000; Nordberg et al. 2002). 
Cadmium accumulates in kidneys. Thus, dietary cadmium intake is directly related to cadmium 
levels in kidney cortex (Morgan & Sherlock, 1984). In fact (WHO, 1992) had estimated that in 
chronic low level cadmium exposure, a 200 µg Cd/g kidney cortex, equivalent to a urinary 
excretion of circa 10 nmol/mol creatinine, could be considered to be the “critical limit” above 
which there was a 10 % probability of having kidney dysfunction in some populations (E. 
Foulkes, 1993; E. C. Foulkes, 1990), or even up to 50 % in “high-risk” groups (Buchet et al., 
1990; Jarup et al., 1998). 
 
          Cadmium poisoning is rather uncommon. Hitherto, only one report has been published in 
English journal pertaining to cadmium poisoning due to ingestion of Chinese herbal medicine. 
Wu et al. (1996) in Taiwan reported the case of a 34-year-old female suffering from multiple 
tubular dysfunction induced by mixed Chinese herbal medicines containing cadmium. 
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7.7       Chromium (Cr) Clinical Toxicities and Cases of Cr Poisoning 
 
             Chromium occurs commonly in the trivalent state (Cr 3+) and the hexavalent state 
(Cr6+). Cr3+ is the most stable (National Institues of Health), biologically active and is found in 
food. Cr6+ is a strong oxidising agent, and its industrial fume is recognised to be a carcinogen 
when inhaled (National Institues of Health, ; O'Flaherty, 1993). Chromium (Cr3+) is an essential 
micronutrient. Its main action is to potentiate the action of insulin and is used in total parenteral 
nutrition (TPN) in chromium deficiency patients (Brown, Forloines-Lynn, Cross, & Heizer, 
1986). Thus, serum glucose can be improved by chromium supplementation in both type1 and 
type 2 diabetes, and the effect appears to be dose dependent (Lamson & Plaza, 2002). Toxicity 
from dietary chromium is rare, such that a tolerable upper intake level has not been officially 
established (Stoecker, 2001). No report of chromium poisoning related to TCM could be found in 
the literature.        
 
7.8      Methodology of Heavy Metal Analyses in Chinese Medicines  
 
          Metal analyses commonly employ the techniques of atomic absorption spectrometry 
(AAS). There are several variations of AAS, each having their unique advantages. The more 
commonly used methods are Flame Atomic Absorption Spectrometry (FAAS), Graphite Furnace 
Atomic Absorption Spectrometry (GFAAS), Cold Vapour Atomic Absorption Spectrometry 
(CVAAS), Inductively-coupled Plasma Atomic Absorption Spectrometry (ICP-AAS), and 
Inductively-coupled Plasma Mass Spectrometry (ICP-MS). In this project, the more commonly 
used techniques, GFAAS and CVAAS, were employed because GF-AAS has advantages of 
higher sensitivity and simplicity, and CV-AAS is capable of analysing certain elements that 
cannot be performed by GF-AAS, such as Hg as discussed in sub-sections below. 
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7.9        Principles of Atomic Absorption Spectrometry 
 
              The basic components of an atomic absorption spectrophotometer (Evenson & Carmack, 
1979) (Figure 7.1) consist of (A) hollow cathode, (B) chopper, (C) flame or a Graphite tube (in 
the case of GF-AAS), (D) entrance slit, (E) monochromator, (F) exit slit, and (G) detector. The 
hollow cathode lamp is the light source, and is made of the metal of the substance to be analysed. 
In FAAS, a nebulizer spays the sample into the flame in which the chemical bonds of the element 
are dissociated and a cloud of atoms are produced in the ground state rather than in the excited 
state as in the emission methods. Being in the ground state at a low energy level, the atoms are 
capable of absorbing radiation at a very narrow bandwidth corresponding to its own line 
spectrum. In GFAAS, on the other hand, the atomiser is an electrically heated graphite furnace 
inside which the sample containing the element is placed prior to the furnace being heated up. 
When the incident light from the cathode lamp enters the flame or the heated furnace, some of it 
is absorbed by the ground state atoms in the flame or in the furnace, thus producing an emergent 
light of lower intensity than that of the incident beam. The net loss of intensity in the emergent 
beam as recorded by the detector is directly proportional to the concentration of the element in 
the sample being analysed. The monochromator (see E in Figure 7.1), such as filters, or prisms, 
or diffraction gratings, is a system for isolating radiant energy of a desired wavelength and 
excluding that of other wavelengths. Slits (d and f in Figure 7.1) are inserted before and/or after 
the monochromator to isolate a narrow beam of the light source and improve its chromatic purity. 
A chopper is used to pass the incident light alternately through the sample and a reference onto 
the same detector. The system described above together with the unique specificity of the 
wavelength from the hollow cathode lamp makes the technique of atomic absorption 
spectrometry highly specific for the element being measured.  
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Figure 7.1     Basic components of an atomic absorption instrument.  A, Hollow cathode lamp. B, 
Chopper. C, Flame, or a Graphite tube (in the case of GF-AAS). D, Entrance slit. E,  
Monochromator. F, Exit slit. G, Detector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.10         Rationale for Choosing Graphite Furnace Atomic Absorption Spectrometry  
                over Flame Atomic Absorption Spectrometry 
 
               While FAAS is a simple, convenient and rapid technique giving excellent results, it has, 
however, many disadvantages when compared to GFAAS. These comparisons are listed below 
(Brodie 1988): 
(a) The volume required for analysis is large, approximately 5 mL compared to about 5 µL 
used in GFAAS. 
(b) The nebulizer system has a very low efficiency, with only about 10% of the sample     
       reaching the flame. Up to 90% of the aspiration are lost as waste, whereas in GFAAS 
       practically 100% of the sample are vaporised, thus eliminating wastage. 
(c) The absorption zone of the flame is only a small part of the whole flame, and the      time 
period in which the atoms are resident in that zone is extremely brief – typically 10-4 
seconds, thus resulting in inefficient and incomplete absorption. On the other hand, in the 
case of GFAAS a much denser atomic cloud at ground state is produced by a 
programmed rising temperature, and is trapped in a confined zone inside the furnace 
A B C D E F G
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chamber in the optical path for a much loner period of time, thus resulting in efficient 
atomic absorption. 
(d) The gases used in FAAS to create flame cause interferences and much background noises 
that are difficult to overcome, thus reducing measurement sensitivity. On the other hand, 
interferences to the ground state atoms in GFAAS can be more easily amended by 
controlling the graphite furnace parameters, and using chemical treatment. 
 
             Thus, GFAAS is at least about 100 times more sensitive than FAAS. It requires much 
lower volume, as little as 5 µL compared to the 5 mL or more in FAAS. It also requires less 
sample preparation than FAAS, such that even samples in strong acid can be used directly for 
measurement. For these reasons GFAAS technique is adopted in this project for the 
determinations of Pb, As, Cd, and Cr. The Cold Vapour Atomic Absorption Spectrometry 
(CVAAS) is adopted for the measurement of Hg.  Applications of these two methods for the 
measurement of metals in Chinese medicines are reviewed separately below. 
 
7.11      Development of Graphite Furnace Technique 
 
             In GFAAS, one of the most important developments has been the furnace technology. 
The application of “furnace” techniques in analytical chemistry can be accredited to Massmann . 
In 1969 West and Williams produced the first large open-top graphite furnace with two 
electrodes at both ends, known as “West” rod, which was very limited in many aspects . Later 
commercial developments in Europe and America were modelled on Massmann’s graphite tube, 
which incorporated heating system. Modern graphite tube combines the virtues of the West rode 
and Massmann furnace, and is typically small with an enclosed space, and has a very thin 
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pyrolytic graphite coating (about 30 µm). The graphite rod allows operation at a very high 
temperature for atomization. The confined space inside the tube increases the density and the 
residence time of the atomic cloud, thus improving the sensitivity. The development of pyrolytic 
coating also greatly improves analytical sensitivity of atomic absorption technology, because (a) 
the coating is relatively impermeable to hot gases or atoms, (b) it is highly resistant to oxidation, 
(c) it is inert chemically, thus reducing the formation of some interfering metal carbides, and (d) 
it prolongs the operating lifetime. 
 
             The graphite furnace allows the generation of a cloud of free atoms for atomic absorption 
and measurement. Modern instrumental development with sophisticated computer programming 
achieves this in three steps (Brodie, 1988):  
(1) Drying step – removing solvent from the sample. 
(2) Ashing step – removing organic or inorganic molecules/materials. 
(3) Atomization step – producing free atoms within the confined zone inside the graphite tube 
in which atomic absorption takes place. 
 
             Published analytical methods employing GFAAS generally revolve around selection of 
appropriate furnace operating parameters to suit specific matrix of the materials being analysed. 
In the present project, a Varian SpectraAA-220 model is used. This model allows programming 
flexibilities for the graphite tube in the following 9 steps:  
(a) Steps 1 – 3 are the drying stage. 
(b) Steps 4 and 5 are Ash stage. 
(c) Step 6 is the gas stop stage. 
(d) Step 7 is the “Ramp” step and Read Command. 
(e) Step 8 is the Atomize “Hold” step and Read Command. 
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(f) Step 9 is a Tube Clean with maximum gas flow. 
 
             The following sections review GFAAS methodologies designed specifically for the 
determination of metals in Chinese medicines in the form of CHM and CPM. 
 
7.12       Herbal Sample Treatment by Hot Acid Digestion 
 
              The two most common methods of digestions of plant materials, such as Chinese herbal 
medicines, are hot acid digestion using heater block, and acid digestion using special microwave 
instrument. While microwave digestion technique requires an expensive instrument and the 
procedures are relatively standard, hot acid digestion using heater block, on the other hand, 
usually comprises nitric acid and perchloric acid mixture (Clinton, 1977). However, perchloric 
acid poses potential safety risk , and is often avoided in the digestions of organic materials. 
Instead, sulphuric acid and hydrochloric acid have been used successfully for the digestion of 
plant materials (Hoenig & de Borger. 1983). For organic materials that are difficult to digest, 
hydrogen peroxide, H2O2, may be added to aid the oxidising action (Brodie, 1988). 
 
7.13     Methodological Considerations of Graphite Furnace Atomic Absorption   
            Spectrometry (GF-AAS) for the Measurement of Pb, As, Cd & Cr in Chinese    
            Medicines  
 
            There is a scarcity of reports in the English literature concerning the studies of 
methodological conditions of graphite furnace atomic absorption spectrometry in the 
determination of metals specifically in Chinese medicines. There are, however, several Chinese 
studies investigating the optimal furnace conditions for measuring metals in Chinese herbs. Wang 
 90 
and co-workers in 2001 investigated the effect of Ashing and Atomization temperatures on the 
atomic absorption behaviour (Z. H. Wang, Wang, & Huang, 2001). It was found that the optimal 
Ashing temperatures for the determination of arsenic and lead in CPM were 1,200oC (30 sec) and 
900oC (30 sec) respectively. The Atomization temperature was 2,000oC for both As (5 sec) and 
Pb (10sec), while for the tube Cleaning step 2,900oC and 2,600oC were used for As and Pb 
respectively. These workers also investigated the effects of varying concentrations of matrix 
modifier, palladium (PdCl2), on atomic absorption by As, as well as ammonium hydrogen 
phosphate [(NH4)2HPO4] on atomic absorption by Pb. The authors chose a PdCl2 concentration of 
100 µg/mL as the optimal modifier concentration for the determination of As, and 4% of 
(NH4)2HPO4 as the optimal concentration for the determination of Pb. Ding et al. (2001) 
described details of the effects Ashing and Atomization temperatures on the determination of Cd 
in the Chinese herbal medicine, Lou Lu. It was found that optimal conditions were achieved at 
much lower temperature than for As and Pb. They were 600oC (30 sec) and 1,700oC (5 sec) for 
Ashing and Atomization respectively. The concentration for optimal modifier, NH4H2PO4, was 
determined to be 0.5%. Other investigators (X. Li, Gao, & Zhao, 2002) used even lower Ashing 
temperature of 350oC (2 sec), and a similar Atomization temperature of 1,800oC (3 sec) for Cd 
determination. Again, for the determination of Pb, their Ashing temperature was also low at 
450oC (2 sec), but the Atomization temperature was similar to others at 2,100oC (for 3 sec). Even 
lower Ashing temperatures were used by Yi et al. (2003) at 120 ~ 300oC (8 sec) for Cd and 120 ~ 
400oC (12 sec) for Pb. The Atomization temperatures were at a low 1,500oC (3 sec) for Cd and 
2,100oC (3 sec) for Pb. These authors also analysed chromium by GFAAS using an Ashing 
temperature of 120 ~ 700oC (15 sec) and a very high Atomization temperature of 2,900oC (3 sec).  
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             Despite the variations in the furnace programming conditions, all papers except Yi and 
co-workers, reported excellent recoveries of approximately between 95 – 105% from spiked 
Chinese herbal samples for the above metals. The recovery rates for Yi et al. (2003) who adopted 
the lowest Ashing temperatures obtained 112% for Cd and 91% - 105% for Cr and Pb, suggesting 
that the higher Ashing temperatures might be more appropriate. The above researches 
investigating the optimal temperatures conditions for the determination of metals in Chinese 
medicines are summarised in Table 7.2. 
 
 
Table 7.2    Summary of reports investigating optimal furnace temperature conditions for the 
determination of metals in Chinese medicines 
 
Pb As Cd Cr Authors 
Ashing 
(sec) 
Atomiza-
tion (sec) 
Ashing 
(sec) 
Atomiza- 
tion (sec) 
Ashing 
(sec) 
Atomiza- 
tion (sec) 
Ashing 
(sec) 
Atomiza- 
tion (sec) 
Wang, 
et al. 
(2001) 
900oC 
(3 s) 
2000oC 
(10 s) 
1200oC 
(30s) 
2000oC     
Ding,  
et al. 
(2001) 
    600oC 
(30s) 
1700oC 
(5s) 
  
Li, et al 
(2002) 
450oC 
(2s) 
2100oC 
(3s) 
  350oC 
(2s) 
1800oC 
(3s) 
  
Yi,  
et al. 
(2003) 
120 - 
400oC 
(12s) 
2100oC 
(3s) 
  120 - 
300oC 
(8s) 
1500oC 
(3s) 
120 - 
700oC 
(15s) 
2900oC 
(3s) 
 92 
7.14       Methodological Considerations of Cold Vapour Atomic Absorption                   
              Spectrometry (CVAAS) for the Measurement of Hg in Chinese Medicines  
 
             FAAS is not suitable for measurement of Hg because of poor sensitivity. GFAAS is not 
suitable either because of the extreme volatility of Hg. The cold vapour atomic absorption 
technique, however, is the only method approved by EPA of the U.S.A. (U.S.A. EPA.1979). In 
1983 Shrader and Hobbins described this method using a Varian model VGA-65 Vapour 
Accessory (Schrader & Hobbins, 1983). They studied the effect of acid, and the stability of 
organic mercury. It was found that acid concentrations of 10 – 20% (v/v) HCl or HNO3 produced 
best results, and that organic mercury could be recovered only following acid digestion of the 
sample. Among the acids used for digestion, potassium permanganate and perchloric acid, nitric 
acid (Stux & Rothery, 1971), sulphuric acid and sodium hydroxide had been used. In 1985, 
Dominski & Shrader determined the optimum parameters for measuring mercury using the 
Varian model VGA-76 with EPA methodology of stannous chloride as reductant (Dominske & 
Shrader, 1985). It was concluded that a 25% SnCl2 in 20% HCl (v/v) provided maximum 
sensitivity and precision. The Hg detection limit was 0.05 µg/L.  Hydrochloric acid was used as 
the sample matrix because it has a stabilizing effect on mercury solutions. Further stability can be 
achieved with potassium dichromate, K2Cr2O7.  In this research project the latest Vapour 
Accessory, Varian model VGA-77 was used (Varian 2004). These accessories are a continuous 
flow cold-vapour atomic absorption system employing a peristaltic pump to deliver the acidified 
Hg sample and the reductant, stannous chloride (SnCl2) into a reaction coil external to the AA 
instrument. The mixing of these two solutions produces ground state mercury atoms. The mixture 
of liquid and atomic gas is then transported to a gas-liquid separator where the liquid is drained 
away as waste. The ground state Hg atoms are swept into a quartz flow-through cell placed in the 
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optical path of an atomic absorption spectrophotometer. The absorption by the Hg atoms in the 
quartz-cell produces a steady state signal which is proportional the mercury concentration. 
 
7.15       Screening of Metals in Chinese Medicines      
 
The majority of the reports in Sections 7.3 to 7.7 above were related to cases or case 
series of metal poisonings after consuming Chinese proprietary medicines (CPM). Measurements 
of metals in these reports were generally directed at the suspected CPM. There are very few 
studies that systematically screened large number of readily available CPM for heavy metals, and 
least still, screening crude Chinese herbal materials (CHM). The following sub-sections discuss 
such metal screenings in CPM and in CHM separately. 
 
7.16       Screening of Metals in Chinese Proprietary Medicines (CPM) 
 
              Two government or government-related organisations had published results of large 
scale screening of CPMs for heavy metals. They are the California Department of Health 
Services, USA, and the Ministry of Health, Singapore. The California Department of Health 
analysed 251 CPMs on sale in Californian stores for Pb, As and Hg (Ko, 1998). It was found that 
less than 10% (24 products) of the products contained 10 ppm or more of Pb, just over 14% (36 
products) contained an average of 14.6 ppm As, 14% (35 products) contained 1046 ppm of Hg, 
and 9% (23 products) had more than one metal contaminants. A later publication from the same 
department by Au et al. (Au et al., 2000), reported the screening results of over 500 CPM samples 
collected and analysed over 5 years since1995. Approximately 10% contained undeclared 
pharmaceutical drugs and/or toxic levels of lead, mercury or arsenic. Of these, 15 CPMs 
contained toxic levels of either one, or two or all three heavy metals. Another US (Florida) study 
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of heavy metal screening (Garvey et al., 2001) evaluated 54 Asian traditional remedies randomly 
purchased from groceries and health food stores in Hong Kong, China, Vietnam, New York and 
Florida found some contained levels of As, Pb, and Hg that ranged from toxic (49%) to 
exceeding public health guidelines for prevention of illness (74%) when consumed according to 
package instruction. However, the products were inadequately labelled such that less than 1/3 
might be identified as possible Chinese proprietary products. 
 
              In a joint investigation between Singapore University and the Ministry of Health, 
Singapore, a large screening experiment for Pb, As, Hg and Cu (copper) was conducted on 2080 
CPM (Koh & Woo, 2000) that had been on sale in Singapore over 8 years between 1990 and 
1997. It was found that 42 different products contained these metals in excess of the legal limits, 
with mercury being the most common among these four metals (28 of the 42, 66.7%), followed 
by lead (8 of 42, 19.0%), arsenic (6 of 42, 16.7%) and copper (1 of 42, 2.4%). One of these 42 
samples contained toxic levels of both Hg and Pb, while another one contained both Hg and As. 
These findings led to new regulations on the control of CPM being enforced in Singapore with 
effect from 1 September 1999. 
              
              Khan et al. in 2001 analysed 21 over-the-counter ginseng (Panax ginseng) proprietary 
products in different dosage forms (Khan et al., 2001). Chromium, mercury and arsenic were not 
detected while Cd, Pb, and Ni (nickel) were present in most CPM. The reports above are 
summarised in Table 7.3. 
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Table 7.3   Summary of researches that screen for trace and/or heavy metals in Chinese 
proprietary medicines (CPM) 
 
 
Authors 
 
Method of 
sampling 
 
Number of 
CPM 
samples 
 
Trace / 
heavy metals 
analysed 
 
% of number of 
samples with toxic 
metal levels 
 
 
Ko. 1998 
 
California  stores 
 
251 
 
Pb, As, & Hg 
 
10%: ≥ 10ppm Pb 
14%: Av 14.6ppm As 
14%: Av 1046ppm Hg 
9%: had more than 1 
metal.  
 
 
Au, et al. 2000 
 
California stores 
 
Over 500 
over 5 years 
since 1995 
 
Pb, As, Hg & 
pharmaceutic
al drugs 
 
 
3% contained either 1 
or 2 or all 3 metals. 
 
Garvey et al. 
2001 
 
Random from 
Vietnam, Hong 
Kong, China, & 
Florida (USA) 
 
54 
 
Pb, As, Hg 
 
74% exceeded public 
health guidelines for 
health prevention 
49% contained toxic 
levels of metal(s). 
 
 
Koh & Woo. 
2000 
 
Singapore stores 
 
2080 over 8 
years 
between 1990 
& 1997 
 
Pb, As, Hg, 
& Cu 
 
2% (42) exceed legal 
limits:- Of these,  
28 were Hg; 
8 were Pb;  
6 were As; & 
1 was Cu. 
 
 
Khan, et al. 
2001 
 
Different 
Ginseng products 
from stores 
 
21 
 
Chromium 
(Cr), Pb, Hg, 
As, Cd, Ni 
 
Cr, Hg & As were not 
detected; 
Pb, Cd & Ni were 
present in most. 
 
 
Av = Averaged 
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7.17       Screening of Metals in Chinese Herbal Materials (CHM) 
 
              The largest screening of CHM for heavy metal contents was performed in a German 
hospital of Chinese medicine on 317 batches of CHM delivered to the hospital over a 5-year 
period . Three and a half percent of these samples were detected to have heavy metal contents 
exceeding the legal limits. However, it is not clear if how many of them were repeated analysis of 
the same species but different batches from the numerous deliveries over the 5-year period. Wong 
and co-workers (M. K. Wong, Tan, & Wee, 1993) screened 42 Chinese herbal plants for nine 
heavy metals, including Pb, Hg, Cd, Cu and Ni. Generally, the concentrations were comparable 
to those present in Asian foods and vegetables, with only a few containing higher levels of 
cadmium, lead and mercury.  
 
              Further English publication specifically concerning screening of CHM for heavy metals 
cannot be found. Among the Chinese literature, there was one research report in which Pb, Cd 
and Hg were supposed to have been analysed in 264 Chinese herbal species as mentioned in the 
Abstract (X. Li et al., 2002). However, there were no data in the Results section of the paper, 
apart from citing several different herbs being used for reproducibility analyses. Ye et al. 
screened 38 samples of Astragalus (Chinese Pinyin name: Huang Qi) produced in different 
provincial regions of China for Pb, As, Hg and Cd (Ye, Deng, Gu, Xiao, & Fang, 2002). In 
general, the contents of As, Hg and Cd were very low, and below the limits of national food and 
hygiene standards, while that of Pb was high in Astragali and its extracts.  
 
              There are numerous reports published in Chinese concerning metal analysis. However, 
they were mostly analysis of either single heavy metal, such as, As or Hg or Pb on a number of 
herbal samples belonging to same species but collected from different regions in China, or 
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analysis of many trace and heavy metals on one species of herbal sample. Hence, they are not 
suitable to be used for general safety assessment of TCM. The reports above are summarised in 
Table 7.4. 
 
Table 7.4   Summary of researches that screen for trace and/or heavy metals in Chinese herbal 
materials (CHM) 
 
Authors 
 
Method of 
sampling 
 
Number of 
CPM 
samples 
 
Trace / 
heavy metals 
analysed 
 
% of number of 
samples with toxic 
metal levels 
 
 
Melchart, et al. 
2001 
 
Deliveries of 
samples to a 
German hospital 
of TCM 
 
 
314 batches 
 
Pb, As, & Hg 
 
3.5%: Exceeded legal 
limits.  
Wong et al. 
1993 
Random 
collection from 
China 
42 herbal 
plants 
9 heavy 
metals 
including Pb, 
Hg, Cd, Cu 
& Ni 
 
None were toxic; with 
only a fewhaving 
higher levels of Cd, 
Pb, Hg 
Li, et al. 2002 
(in Chinese) 
Random 
collection from 
different regions 
of China  
264 herbs (23 
species) – 
names mostly 
not specified 
Pb, Cd, Hg The number of 264 
herbs was mentioned 
in the abstract, but no 
metal results were 
described in the paper. 
The paper only dealt 
with analytical 
technique. 
 
Ye, et al. 2002 
(in Chinese) 
Collection of 
Astragali from 
different 
provinces and 
production 
regions in China 
38 herbal 
samples of 
Astragali 
Pb, As, Cd & 
Hg 
As, Hg & Cd contents 
varied between 
Astragali samples from 
different production 
regions, but were all 
below limits of 
national standards. 
But, Pb contents were 
generally higher, and 
some were above the 
health limit. 
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7.18       Interpretation of Metal Intakes in Terms of Tolerable Limits (the   
              Regulatory Standards of Safety)  
 
7.18.1   Australian Regulatory Processes for Chinese Herbal Medicines   
               
              In the USA, herbal medicines are regulated as “dietary supplements”, and are subject to 
much lower standards than conventional medicines. In Australia, however, medicines such as 
Ayurvedic and traditional Chinese herbal medicines are classified as “complementary medicines”, 
and are generally required to meet the same standards of quality and safety as other medicines. 
They are regulated as medicines under the Therapeutic Goods Regulation 1990 (called the 
Regulations). Traditional Chinese herbal medicines are licensed by the Therapeutic Goods 
Administration (TGA) of Australia to one of two groups, namely, the low risk Listed medicines, 
and the high risk Registered medicines. Listed and Registered medicines are differentiated on the 
product label by the designated “AUST L” or “AUST R” respectively, followed by a unique 
number. The TGA maintains a database of all these products in the Australian Register of 
Therapeutic Goods (ARTG), and the great majority of these products are Listed medicines. In 
support of the Act, it is the role of TGA to carry out (a) Licensing and audit of manufacturers, (b) 
Pre-market assessment, and (c) Post-market regulatory activity, in order to ensure, among other 
things, the quality, safety, product labelling, and efficacy of therapeutic goods. The safety of 
Listed complementary medicines is established through an evaluation process to ensure low risk. 
The quality standards are defined by those of the British Pharmacopeia (BP), supplemented by 
Therapeutic Goods Orders (TGOs) developed by TGA of Australia. The Regulations provides 
TGA the power to effect its enforcement. When there is a health concern regarding any 
complementary product, the TGA publishes Alerts and Advisories in its website to the public and 
stakeholders. For example, alerts were published that all herbal products containing Aristolochia 
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species were prohibited for sale in Australia, because of concerns of nephrotoxicity (TGA., July 
2001). Similar Alert was also published (TGA, 2005) after toxic levels of heavy metals were 
found in Ayurvedic medicines (Saper et al., 2004).     
 
7.18.2   Regulatory Standards for Metal Intakes  
 
              In terms of heavy metal contamination in herbal medicines, the TGA requires that 
sponsors of complementary medicines supplied in Australia must ensure that their products 
contain safe amounts of incidental metals that may be potentially hazardous. The levels of such 
metal components should not represent an unacceptable risk to public health and safety (TGA, 
2005). The sources regarding the safety levels for metals are generally based on the regulatory 
standards of Tolerable Daily Intake (TDI) levels established by the World Health Organization 
(WHO), and those set by the Food Standards Australia New Zealand (FSANZ). These regulatory 
standards are summarised in Table 7.5. The Figures in Italics were adopted by the Food 
Standards Australia New Zealand in the 20th Australian Total Diet Survey (ATDS) (FSANZ, 
2003a). These tolerable levels are recommended by the Joint FAO/WHO Expert committee on 
Food Additives. For example, the 49th report of the Joint FAO/WHO Expert Committee on 
Additives recommended a Provisional Tolerable Weekly Intake (PTWI) of inorganic arsenic of 
15 µg/kg bw/week (WHO, 1999). In Australia, however, a much higher tolerable level of 21 
µg/kg bw/week (ANZFA, 1999) was adopted in the latest 20th ATDS. In the same report, FSANZ 
had incorporated the WHO recommendations of 7 µg/kg bw/week and 25 µg/kg bw/week for Cd 
and Pb respectively.  
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             Of mercury, the organic compound, methylmercury, is recognised as the toxic entity. The 
FAO/WHO Expert Committee at its 16th WHO meeting established a PTWI for total mercury of 
300µg/person (WHO, 1989b), of which no more than 200µg should be present as methylmercury. 
This is equivalent to a PTWI of 3.3 µg/kg bw/week for methylmercury, and it was confirmed at 
subsequent meetings (WHO, 1999). The FSANZ also recommended different safety levels of 
total mercury for different age groups. Among these, the tolerable level for pregnant women was 
listed as 2.8 µg/kg bw/week, nearly half of that for normal adults. 
 
             The WHO has not yet established any Provisional Tolerable Intake standard for 
chromium, Cr. Its tolerable level appears to be very high. Nevertheless, the Australian 
Therapeutic Goods Administration (ANZFA, 2001)and the US Environmental Protection Agency 
(USA EPA, 1979) have provided Reference Doses (RfD) for Cr intake. They are 3.5 mg/kg/day, 
and 10.5 mg/kg/day respectively for Australia and the US. Thus, in Australia, A weekly reference 
dose of 24.5 mg/kg/week was recommended in the 19th ATDS (ANZFA, 2001), whereas in the 
US, a much higher reference dose of 73.5 mg/kg/week was recommended.  
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Table 7.5   Tolerable limits for metals – Figures are for oral intake of metal for a 60 kg adult 
 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Metal                    Tolerable dose             Reference        Tolerable limits    Tolerable limits 
                                                                                              (PTDI)                   (PTWI) 
                                                                                              µg/kg bw/day        µg/kg bw/week   
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Arsenic                    0.003 mg/kg                FSANZ, 2003                  3                         21 
(inorganic)               bw/day 
 
Arsenic                    0.015 mg/kg               WHO, 1999                   2.1                        15 
(inorganic)               bw/week 
 
Cadmium                 7 µg/kg                       WHO, 2001                     1                          7     
                                 bw/week                
 
Lead                         25 µg/kg                    WHO, 2000                    3.6                       25 
                                 bw/week 
 
Mercury                   0.3 mg/                       WHO, 1989b                  0.7                        5 
(total mercury)         person/week 
 
Mercury (total Hg)                                     FSANZ, 2003                 0.4                      2.8 
( pregnant women) 
 
Mercury                   0.198 mg/                   WHO, 1999                  0.47                     3.3 
(methyl mercury)     person/week 
___________________________________________________________________________ 
Chromium      AUS: 3.5 mg/kg/day           TGA a                          3,500             24.5 mg/kg/wk                
(Reference      US: 10.5 mg/kg/day           US EPA, a                   10,500           73.5 mg/kg/wk 
dose: RfD) 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Figures in italic were used by Food Standards: The 20th Australian Total Diet Survey as the limits 
of tolerable dietary intake [available at the Food Standards Australia New Zealand (FSANZ, 
2003a)] 
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CHAPTER 8 
MATERIALS AND METHODS 
 
8.1     Materials 
 
8.1.1   Chemicals 
 
           All chemicals were at least analytical grade unless otherwise specified. The following 
chemicals were purchased from Sigma-Aldrich, Sydney, Australia: nitric acid (HNO3, 65%), 
hydrochloric acid (HCl, Fluka 37%) (both for trace analysis, max 0.0000001% Pb, 0.000005% 
As, 0.0000005%Hg, 0.0000001% Cd), ammonium dihydrogen phosphate (NH4H2PO4), 
potassium dichromate (K2Cr2O7), Tin (II) chloride (stannous chloride: SnCl2) for reduction, 
hydrogen peroxide (H2O2), and perchloric acid (H2ClO4). Palladium matrix modifier (10 ± 0.2 
g/L in 15% v/v Pd(NO3)2/HNO3 ca) was purchased from Merck. Deionised water obtained from 
MilliQ filtration system (Bedford, Ma, USA) at a minimum resistance of 18.2 mΩ cm was used 
for all analytical work. Nitrogen and air gas cylinders were supplied by Linde Gas (Australia). 
All atomic absorption metal standard solutions were purchased from Sigma-Aldrich. Their 
concentrations and batch No. are listed as follows: Lead (1014 µg/mL in 1 wt % HNO3, Batch No. 
03407MB), Arsenic (1004 µg/mL in 2% KOH, Batch No. 10221LO), Mercury (995 µg/mL of Hg 
in 1wt % of HNO3, batch No. 16707AB), Cadmium (1001 µg/mL of Cd in 1wt % HNO3, Batch 
No. 08024EC), and Chromium (994 µg/mL of Cr (III) in 1 wt % HCl,  Batch No. 02623CC).   
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8.1.2       Instruments and Laboratory Wares 
 
               The atomic absorption spectrophotometer (SpectrAA 220, Version 4.10, Varian, 
Australia), equipped with a diode array detector, and a data handling system, coupled with a 
graphite tube atomizer, and a SPS-5 auto-sampler together with a 50-sample carousel (which has 
cup positions for bulk standard, modifiers and make-up solutions). Single-element cathode lamps 
for Pb, As, Cd, Cr, and Hg were purchased from Varian Australia. The graphite furnace was non-
platform partitioned graphite tube (Part No. 6310001200, Varian, Australia).  
 
               For mercury (Hg) determination, a vapour generation accessory unit (VGA-77, Varian, 
Australia) was used. It consists of a continuous flow vapour generation peristaltic pump system, a 
reaction mixing coil, a gas-liquid separator and a cell holder to fit a Varian Mark 7 burner. The 
cell used was a flow-through mercury absorption cell (Part No. 9910040700, Varian, Australia). 
This was chosen in favour of the standard absorption cell, since this will provide better analytical 
sensitivity and precision. A heater (Crown Scientific, Australia) and a tailor-made aluminium 
heater block with round holes to hold glass tubes (19 x 90 mm diameter tubes) were used for hot 
acid digestion. A heavy-duty stainless steel high-speed grinder (Beijing Wan Ya Tian Yan 
Engineering Co., China) was employed to pulverise herbal medicines.  
 
               Other instruments and laboratory consumables included partition pyrolytic GTA tubes, 
and disposable 1.5 mL polyethylene auto-sampler cups for graphite furnace analysis (Varian, 
Australia), analytical balance, oven, Pyrex glass tubes (18 x 90 mm diameter), 15-mL and 50-mL 
graduated conical bottom sterilized polyethylene tubes (Crown Scientific, Australia).  
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8.1.3      Reagents 
 
8.1.3.1    5% HNO3 (v/v) was prepared by diluting 50mL of the concentrated nitric acid (cHNO3) 
to a final volume of 1,000mL with MilliQ water. This 5% HNO3 was used to make up the 
digested herbal samples, and the total analytical volume in the graphite furnace atomic absorption 
spectrometry (GFAAS) determinations.  
  
8.1.3.2    HNO3 5% in 0.05% K2Cr2O7 reagent was used to prepare metal standard solutions. This 
reagent was prepared by dissolving 0.05g of K2Cr2O7 in 100mL of 5% HNO3. 
 
9.1.3.3    10% HNO3 used for decontaminating containers was prepared by diluting 500 mL trace 
metal grade concentrated HNO3 to 5 litres of MilliQ water in a plastic bucket. 
 
8.1.3.4    20% HCl (v/v) was prepared by mixing 20 mL of the concentrated HCl with 80 mL 
MilliQ water. 
  
8.1.3.5    SnCl2 25% (w/v) in 20% HCl (v/v) was used in the determination of Hg. This reagent 
was prepared by adding 25g of SnCl2 crystals to 20 mL of concentrated HCl in an acid-washed 
conical flask, and then warming the mixture on a hot plate to complete the dissolution (seen as a 
clear solution) before making up the volume to 100 mL with MilliQ water. If necessary, a piece 
of granulated tin added to the mixture would reduce any Sn (IV) to Sn (II) and produce a clear 
solution.  
 
8.1.3.6   NH4H2PO4 0.5% or 2.5% in 5% HNO3 – The 0.5% was used as chemical modifier for 
GFAAS analysis of lead (Pb), while the 2.5% was for cadmium (Cd). To prepare these reagents, 
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0.5g or 2.5g of NH4H2PO4 was dissolved in 100mL of 5% HNO3 solutions.  
 
8.1.3.7   Pd(NO3)2 0.08% in 5% HNO3 was another chemical modifier used for the determination 
of arsenic (As) and chromium (Cr) by GFAAS technique. It was prepared by dissolving 0.08g of 
Pd(NO3)2 in 100 mL of 5% HNO3.  
 
8.1.4    Preparation of Standard Solutions  
 
8.1.4.1    Standard solutions for lead (Pb) determination             
 
               From the commercial atomic absorption stock standard (SS) for Pb (1,014 µg/mL in 1wt 
% HNO3), a standard solution No.1 (S1) of 10 µg/mL (i.e.10,000 µg/L) was prepared by diluting 
986.2 µL of SS to a volume of 100 mL in 5% HNO3 – 0.05% K2Cr2O7 (or 493.1 µL of SS diluted 
to 50 mL). A second standard No. 2 (S2) of 0.1 µg/mL (i.e.100 µg/L) was prepared by diluting 1 
mL of S1 to 100 mL of 5% HNO3 – 0.05% K2Cr2O7. The bulk standard of 50 µg/L was prepared 
fresh prior to GFAAS analysis by diluting 5 mL of S2 with 5 mL of 5% HNO3 – 0.05% K2Cr2O7. 
The S1 standard solution was kept for up to 1 year. The S2 standard solution was discarded after 
one week. All solutions were kept refrigerated at 4º C. The above preparations are summarised in 
the Table 8.1 below:   
 
 Table 8.1   Preparation of lead standard solutions 
Standard Solution Concentration Procedure of Preparation Comment 
SS 1014 µg/mL 1014 µg/mL in 1wt% HNO3 Commercial product 
S1 10  µg/mL 493.1µL of SS diluted to 50mL  StoreABd 1 year at 
4o C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL 4o C; prepare weekly 
Bulk standard 50 µg/L 5 mL of S2 diluted 10 mL Prepare daily 
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8.1.4.2    Standard solutions for arsenic (As) determination 
               The preparation of standard solutions for As determination was similar to the procedure 
described for Pb above, and is summarised in Table 8.2 below. All dilutions were carried out 
using 5% HNO3 – 0.05% K2Cr2O7. 
 
Table 8.2    Preparation of arsenic standard solutions 
 
 
8.1.4.3    Standard solutions for cadmium (Cd) determination 
 
               The preparation of standard solutions for Cd determination was similar to the 
procedures described for Pb and As above, and is summarised in Table 8.3 below. All dilutions 
were carried out using 5% HNO3 – 0.05% K2Cr2O7. 
 
Table 8.3    Preparation of cadmium standard solutions 
 
 
 
 
Standard Solution Concentration Procedure of Preparation Comment 
SS 1004 µg/mL 1004 µg/mL in 2% KOH Commercial product 
S1 10  µg/mL 498 µL of SS diluted to 50 mL  Stored 1 year at 4o C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL 4o C; prepare weekly 
Bulk standard 50 µg/L 5 mL of S2 diluted 10 mL Prepare daily 
Standard Solution Concentration Procedure of Preparation Comment 
SS 1001 µg/mL 1001 µg/mL in 1 wt% HNO3 Commercial product 
S1 10  µg/mL 999 µL of SS diluted to 100mL  Stored 1 year at 4o C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL  4o C; prepare weekly 
Bulk standard 5 µg/L 1 mL of S2 diluted to 20 mL Prepare daily 
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8.1.4.4    Standard solutions for chromium (Cr) determination 
  
               The preparation of standard solutions for Cr determination was similar to the procedures 
described for Pb, As and Cd above, and is summarised Table 8.4 below. All dilutions were 
carried out using 5% HNO3 – 0.05% K2Cr2O7. 
 
Table 8.4    Preparation of chromium standard solutions 
 
 
 
 
 
8.1.4.5    Standard solutions for mercury (Hg) determination 
 
               Analysis of Hg was by method of cold vapour generation atomic absorption 
spectrometry. Standard solutions S1 and S2 were made similarly to the other metals above. In 
addition, a series of working standards (WS) ranging in concentrations from 0.5 to 6.0 µg/L (i.e. 
0.5 – 6.0 ng/mL) were also freshly prepared just prior to analysis. All dilutions were carried out 
using 5% HNO3 – 0.05% K2Cr2O7. Details stock standards are shown in Table 8.5a below, and 
preparations of mercury working standards from the stock standard, S2 (see Table 8.5a) are 
shown in Table 8.5b: 
 
 
 
Standard 
Solution 
Concentration Procedure of Preparation Comment 
SS 994 µg/mL 994 µg/mL of Cr(III) in 1wt% HCl Commercial product 
S1 10  µg/mL 1006 µL of SS diluted to 100 mL  Stored 1 year at 4o C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL 4o C; prepare weekly 
Bulk standard 40 µg/L 4 mL of S2 diluted to 10 mL Prepare daily 
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Table 8.5a    Preparation of mercury stock standard solutions 
 
Table 8.5b    Preparation of mercury working standard solutions 
 
 
8.1.4.6    Standard solutions for recovery studies of As, Cd and Cr 
 
               The S1 standard solutions of As, Cd and Cr, each being 10 µg/mL, were used for adding 
onto 1 gram of herb, Poria (Fu Ling), as described in section 9.4 below, in the recovery studies of 
As, Cd and Cr determinations. 
 
8.1.4.7    Certified reference herbal material for recovery studies of Pb and Hg     
 
               A certified reference material for trace and heavy metal analysis was purchased from 
the Institute of Nuclear Chemistry and Technology, Poland, through a Melbourne company 
(Graham Jackson P/L). This quality control material, Mixed Polish Herbs (INCT-MPH-2), was 
Standard 
Solution 
Concentration Procedure of Preparation Comment 
SS 995 µg/mL 995 µg/mL of Hg in 1wt % HNO3 Commercial product 
S1 10  µg/mL 1005 µL of SS diluted to 100 mL  Stored 1 year at 4o C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL 4o C; prepare weekly 
Working 
Standard 
Solutions 
Concentration 
(µg/mL; 
i.e. ng/mL) 
Procedure of Preparation 
(diluting stock standard S2 using 
5% HNO3 – 0.05% K2Cr2O7) 
Comment 
WS1 0.5 0.25 mL of S2 diluted to 50 mL Prepare daily 
WS2 1.0 0.5 mL of S2 diluted to 50 mL  Prepare daily 
WS3 2.0 1.0 mL of S2 diluted to 50 mL  Prepare daily 
WS4 3.0 1.5 mL of S2 diluted to 50 mL  Prepare daily 
WS5 4.0 2.0 mL of S2 diluted to 50 mL  Prepare daily 
WS6 6.0 3.0 mL of S2 diluted to 50 mL  Prepare daily 
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used to monitor the accuracy of determination of Pb by GFAAS and of Hg by cold vapour AAS 
techniques. 
 
8.1.5  Purchase of Herbal Samples and Sample Cataloguing System 
 
            One hundred crude Chinese herbal materials (CHM) and fifty Chinese proprietary 
medicines (CPM) were purchased between October and November, 2004, from a Melbourne 
herbal wholesaler, Hong An Phat Acupuncture & Herbs P/L, Richmond. This wholesaler is one 
of the three or four larger wholesalers in Victoria, and therefore represents a very significant 
proportion of the herbal distribution and by reference, consumption in Victoria. The 100 CHM 
selected for analysis represented 25 different pharmaceutical classes of Chinese materia medica. 
They were commonly used crude herbs. Similarly, the fifty CPM were some of the most 
commonly prescribed Chinese patent medicines. Both the crude herbs and the proprietary 
products could be purchased over the counter without referral or prescription. Furthermore, five 
common medicinal formulae consisting of 4 to10 crude herbal components were prepared from 
the crude CHM. These herbal packs were also subjected to the whole process of metal 
determinations. 
 
           All dried raw herbal specimens were given a voucher number as soon as purchased, 
ranging from #1 to #100 to ensure original sources during subsequent uses. The voucher numbers 
are affixed to the containers. These specimens were further coded according to their Chinese 
medicine pharmacological classifications. Thus, for herbs that expel external attacks due to wind-
cold, samples are coded with HWC (based on the acronym of Herb Wind Cold) followed by a 
number in incremental order in that group of classification. Similarly, herbs that remove blood 
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stasis, are coded as HBS followed by a numerical number. For examples of the voucher system 
and herbal codes, please refer to Table 8.6, page 104.  
 
 
8.1.6      Cleaning of Glassware and Plastic-wares 
 
               All containers including glassware and plastic-wares were acid washed to remove any 
metal contamination. Containers were first rinsed with water before soaking in 10% trace metal 
grade nitric acid solution for at least 24 hours. The containers were then rinsed at least 5 times 
with MilliQ water and then dried in oven at ~ 45o C overnight.   
 
8.2      Methods  
 
8.2.1   Preparation of Herbal Samples into Power for Acid Digestion – for CHM, CPM,     
              and CMF  
 
              Traditional Chinese medicines includes the crude Chinese herbal Materials (CHM) 
[plants, animals and minerals], the Chinese proprietary medicines (CPM) [the final 
manufactured/patent dosage forms], and the prescription that is a composition of a number of 
individual CHM in various doses, often designed according to some classical Chinese medicinal 
formulae (CMF) or their modification. The CPMs are usually manufactured in the form of tiny 
pills/tablets and are consumed orally as purchased. Both the CHM and CMF need to be boiled in 
water for a period of time to prepare for the final aqueous decoction for oral consumption. This 
procedure of boiling will be described later in appropriate sections. These three groups of 
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medicines are under investigation in this project. The following three sub-sections describe the . 
determination of total metal contents (i.e., the acid-digested content). 
 
8.2.1.1    Crude Chinese herbal materials (CHM) – preparation of powder  
            
               Upon delivery of the CHM by the wholesaler to the RMIT University teaching clinic, 
suitable quantities (usually about 150 – 200 g for CHM) were immediately collected and stored in 
plastic boxes at room temperature. About 50 g of each was pulverized into fine powder using a 
stainless steel high speed grinder, then stored in 50-ml size polyethylene tubes until analysis of 
metal contents as described in Methods below. Care was exercised to select all parts of the herb 
in proportional portions to provide equal representation of the herbal medicine. Table 8.6 is a list 
of the 100 Chinese herbal materials (CHM), in Chinese Pin Yin, pharmaceutical and botanical 
names. Photographs of all CHM are shown in Appendix 8.7. 
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Table 8.6  List of 100 Chinese herbal materials included in the metal investigation showing 
sample codes, Chinese Pin Yin names, pharmaceutical and botanical names. 
 
No. 
 
Code 
 
Chinese Name 
 
Pharmaceutical Name 
 
Botanical Name 
 
Drugs  for Dispelling Wind-Cold  
51 
 
HWC1 
 
Gui Zhi 
 
Ramulus Cinnamomi 
Cassiae 
Cinnamomum cassia Blume 
 
61 
 
HWC2 
 
Zi Su Ye 
 
Folium Perillae Frutescentis 
Perilla frutescens (L.) Britt. var. crispa
（thunb.) Hand.-Mazz. 
94 
 
HWC3 
 
Jing Jie 
 
Herba seu Flos 
Schizonepetae Tenuifoliae 
Schizonepeta tenuifolia Briq. 
 
6 HWC4 Fang Feng Radix Ledebouriella Ledebouriella seseloides (Hoffm.) 
17 
 
HWC5 
 
Qiang Huo 
 
Rhizoma et Radix 
Notopterygii 
Notopterygium incisum Ting ex H. T. 
Chang 
20 
 
HWC6 
 
Bai Zhi 
 
Radix angelicae Dahuricae 
Angelica dahurica (Fisch. Ex Hoffm.) 
Benth et Hook f.  
44 
 
HWC7 Xin Yi Hua 
 
Flos Magnoliae 
 
Magnolia lilflora Desr., M. biondii Pamp., 
M. sprengeri Pamp., or M. denudata Desr. 
Drugs for Dispelling Wind-Heat 
34 HWH1 Bo He  Herba Menthae 
Haplocalycis 
Mentha haplocalyx Briq. 
87 HWH2 Ju Hua Flos Chrysanthemi Morifolii Chrysanthemum morifolium Ramat 
35 
 
HWH3 
 
Chai Hu 
 
Radix Bupleuri 
 
Bupleurum chinense D.C. or B. 
Scorzoneraefolium Wild. 
 
Drugs for Eliminating Heat 
23 
 
HEH1 
 
Zhi Mu 
 
Rhizoma Anemarrhenae 
Asphodeloidis 
Anemarrhena asphodeloides Bge. 
 
60 HEH2 Lu Gen Rhizoma Phragmitis Phragmites communis 
52 
 
HEH3 
 
Huang Qin 
 
Radix Scutellariae 
Baicalensis 
Scutllaria baicalensis Georgi 
 
19 
 
HEH4 
 
Huang Bai 
 
Cortex Phellodendri 
 
Phellodendron amurense Rupr. or P. 
chinense Schneid. 
67 
 
HEH5 
 
Zhi Zi 
 
Fructus Gardeniae 
Jasminoidis 
Gardeniae jasminoides Ellis 
 
75 
 
HEH6 
 
Ku Shen 
 
Radix Sophorae 
Flavescentis 
Sophora flavescens Ait 
 
95 
 
HEH7 
 
Long Dan 
Cao 
 
Radix Gentianae 
Longdancao 
Gentiana scabra Bge, G. Triflom Pall., G. 
manshurica Kitag., or G. regescens Fransh. 
 
Drugs for Eliminating Heat and Toxins 
85 HHT1 Jin Yin Hua Flos Lonicerae Japonicae Lonicera japonica Thunb.  
45 
 
HHT2 
 
Lian Qiao 
 
Fructus Forsythiae 
Suspensae 
Forsythia suspensa (Thunb.) Vahl 
 
90 
 
HHT3 
 
Ban Lan Gen 
 
Radix Isatidis seu 
Baphicacanthi 
Baphicacanthus cusia (Nees) Brem., Isatis 
tinctoria L., or I. indigotica Fort. 
 
Drugs for Eliminating Heat and Cooling Blood 
96 HCB1 Sheng Di 
Huang 
Radix Rehmanniae 
Glutinosae 
Rehmannia glutinosa (Gaertn.) Libosch 
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93 
 
HCB2 
 
Xuan Shen 
 
Radix Scrophulariae 
Ningpoensis 
Scrophularia ningpoensis Hemsl. 
 
74 HCB3 Mu Dan Pi Cortex Moutan Radicis  Paeonia suffruticosa Andr. 
22 HCB4 Chi Shao Radix Paeoniae Rubrae Paeonia veitchii Lynch or P. lactiflora Pall. 
62 
 
HCB5 
 
Zi Cao 
 
Radix Arnebiae seu 
Lithospermi 
Lithospermum erythrorhizon Sieb. Et Zucc. 
or Arnebia euchroma (Royle) Johnst 
 
Drugs for Eliminating Deficiency Heat 
47 HDH1 Di Gu PI Cortex Lycii Radicis Lycium chinense Mill. or L. bararum L. 
 
Drugs for Purgation 
32 
 
HPU1 
 
Da Huang 
 
Radix et Rhizoma Rhei 
 
Rheum palmatum L. or R. tanguticum 
Maxim. Et Reg.; or R. officinale Baill. 
 
Drugs for Eliminating Wind-Damp 
38 HWD1 Du Huo Radix Angelicae 
Pubescentis 
Angelica pubescens Maxim. 
70 
 
HWD1 
 
Qin Jiao 
 
Radix Gentianae Qinjiao 
 
Gentiana macrophylla Pall, G. straminea 
Maxim 
9 
 
HWD3 
 
Sang Ji Sheng 
 
Ramulus Sangjisheng 
 
Taxillus chinensis (DC.) Danser or 
T.sutchuensensis (Lecomte) danser 
 
Aromatic Drugs for Dispelling Damp 
30 
 
HAD1 
 
Cang Zhu 
 
Rhizoma Atractylodis 
 
Atractylodes lancea Thunb., or  A. 
chinensis Koidz. 
79 HAD2 Huo Po Cortex Magnoliae Offinalis  Magnolia officialis Rhd. Et Wils  
49 
 
HAD3 
 
Huo Xiang 
 
Herba Agastaches seu 
Pogostemi 
Agastache rugosa (Fish et Mey.) O. Ktze., 
or Pogostemon cablin (Blanco) Benth. 
69 
 
HAD4 
 
Sha Ren 
 
Fructus Amomi 
 
Amomum villosum Lour. or A. xanthioides 
Wall. 
 
Diuretics 
97 HDU1 Fu Ling Sclerotium Poriae Cocos Poria cocos (Schw.) Eolf 
36 
 
HDU2 
 
Ze Xie 
 
Rhizoma Alismatis 
Orientalitis 
Alisma plantago-aquatica L. var. orientale 
Samuels 
68 HDU3 Yi Yi Ren 
Semen Coicis lachrymal-
jobi Coix lachrymal jobi L. 
Drugs for Warming Interior 
54 
 
HWI1 
 
Gan Jiang 
 
Rhizoma Zingiberis 
Officinalis 
Zingiber officinale-Rosc 
 
63 HWI2 Rou Gui Cortex Cinnanomi Cassiae Cinnamomum cassia Presl. 
1 HWI3 Wu Zhu Yu Frucus Evoliae Rutaecarpae Evodia rutaecarpa (Juss.) Benth. 
 
Drugs for Regulating Qi 
64 HRQ1 Ju Pi Percarpium Citri Reticulate Citrus reticulata Blanco 
72 
 
HRQ2 
 
Qing Pi 
 
Percarpium Citri Reticulate 
Viride 
Citrus reticulata Blanco 
41 HRQ3 Zhi Ke Fructus Citri Aurantii Citrus aurantium L. 
59 HRQ4 Mu Xiang Radix Aucklandiae lappae Aucklandiae lappa Decne 
3 HRQ5 Xiang Fu Rhizoma Cyperi Rotundi Cyperus roundus L. 
8 
 
HRQ6 
 
Wu Yao 
 
Radix Linderae 
Strychnifoliae 
Linders stychnifolia (Sieb. Et Zucc.) Villar 
7 
 
HRQ7 
 
Yan Hu Suo 
 
Rhizoma Corydalis 
Yanhusuo 
Corydalis yanhusuo W. T. Wang.  
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Digestives 
55 HDG1 Shan Zha  Fructus Crataegi Crataegus pinnatifida Bge. 
16 
 
HDG2 
 
Mai Ya 
 
Fructus Hordei Vulgaris 
Germinantus 
Hordeum vulgare L. 
 
Anthelmintics 
33 HAN1 Da Fu Pi Percarpium Arecae Catechu Areca catechu L. 
 
Hemostatics 
48 HHM1 Ce Bai Ye Cacumen Biotae Orientalis Biota orientalis (L.) Endl. 
91 
 
HHM2 
 
Bai Mao Gen 
 
Rhizoma Imperatae 
Cylindricae 
Imperata cylindrica (L.) P. Beauv. Var. 
major (nees) C.E. Hubb. 
 
Drugs for Activating Blood Circulation & Removing  Blood Stasis 
92 HBS1 Chuan Xiong Radix Ligustici Chuanxiong Ligusticum chuanxiong Hort. 
66 HBS2 Yu Jin Tuber Curcumae Curcuma longa L., or C. aromatica Salisb. 
2 HBS3 Dan Shen Radix Salvise Miltiorrhizae Sallvia miltiorrhiza Bge. 
80 HBS4 Ye Mu Cao Herba Leonuri Heterophylli Leonurus heterophyllus Sweet 
27 HBS5 Hong Hua Flos Carthami Tinctorii Carthamus tinctorius L. 
71 HBS6 Chuan Niu Xi Radix Cyathulae Officinalis Cyathula officinalis Kuan. 
89 
 
HBS7 
 
Huai Niu Xi 
 
Radix Achyranthis 
Bidentatae 
Achyranthes bidentata Bl. 
Expectorants, Anti-tussives & Dysnea-relieving Drugs 
40 HRP1 Ban Xia Rhizoma Pinelliae Ternatae Pinellia ternata (Thunb.) Breit. 
76 HRP2 Jie Geng Radix Platycodi Grandiflori Platycodon grandflorum (Jacq.) A. DC. 
11 
 
HRP3 
 
Qian Hu  
 
Radix Peucedani Peucedanum praeruptorum Dunn, or P. 
Decursivum (Miq.) Maxim. 
65 
 
HRP4 
 
Gua Lou 
 
Fructus Trichosanthis Trichosanthes kirilowii Maxim., T. uniflora 
Hao, or T. rosthornii Harms 
77 HRP5 Chuan Bei 
Mu 
Bulbus Fritillariae Cirrhosae Fritilaria cirrhosa D. Don. 
 
Drugs for Relieving Cough & Dysnea 
37 
 
HDC1 
 
Ku Xing Ren 
  
Semen Pruni Armeniacae Prunus armeniaca L. var. ansu Maxim., or 
P. armeniaca L. 
39 
 
HDC2 
 
Bai Bu 
 
Radix Stemonae Stemona sessilifolia (Miq.) Franch. Et Sav., 
S. japonica (BL.) Miq., or S. tuberosa Lour. 
99 HDC3 Zi Wan Radix Asteris Tatarici Aster tataricus L. 
81 HDC3 Su Zi Fructus Perillae Frutescentis Perilla frutescens (L.) Britt. 
82 HDC5 Sang Bai Pi Cortex Mori albae Orientalis Morus alba L. 
 
Sedatives (Drugs for Calming the Spirit) 
57 HSD1 Long Gu Os Draconis Not applicable 
31 
 
HSD2 
 
Suan Zao Ren 
 
Semen Zizyphi Spinosae Ziziphus spinosa Hu. Also known as Z. 
jujube Mill. 
73 HSD3 Bai Zi Ren Semen Biotae Orientalis  Biota orientalis (L.) Endl 
14 HSD4 Yuan Zhi Radix Polygalae Tenuifoliae Polygala tenuifolia Willd. 
98 HSD5 Mu Li Concha Ostreae Ostrea gigas Thunb., O. rivularis Gould 
 
Drugs for Calming Liver & Suppressing Wind 
83 
 
HCL1 
 
Tian Ma 
 
Radix Astrgali 
Membranaceus 
Gastrodia elata Blume 
25 
 
HCL2 
 
Gou Teng 
 
Ramulus cum Uncis 
Uncariae 
Uncardia ehynchophylla (MIq.), or U. 
sinensis 
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Qi Tonics 
53 
 
HQT1 
 
Huang Qi 
 
Radix Astrgali 
Membranaceus 
Astragalus membranaceus (Fish.) Bge., or 
A. membranaceus Bge. var. mongholicus 
Hsiao.  
56 
 
HQT2 
 
Bai Zhu 
 
Rhizoma Atractylodis 
Macrocephalae 
Atractylodes macrocephala Koidz. 
4 
 
HQT3 
 
Shan Yao 
 
Radix Dioscoreae Oppositae Dioscorea opposite Thunb. 
24 
 
HQT4 
 
Gan Cao 
 
Radix Glycyrrhizae 
Uralensis 
Glycyrrhiza uralensis Fischer. 
42 
 
HQT5 
 
Zhi Gan Cao 
 
Radix Gycyrrhizae 
Uralensis 
Glycyrrhiza uralensis Fischer. 
 
Yang Tonics 
28 
 
HYT1 
 
Du Zhong 
 
Cortex Eucommiae 
Ulmoidis 
Eucommia ulmoides Oliv. 
43 HYT2 Xu Duan Radix Dipsaci Asperi Dispsacus asper Wall. 
46 
 
HYT3 
 
Bu Gu Zhi 
 
Fructus Psoraleae 
Corylifoliae 
Psoralea corylifolia L. 
100 
 
HYT4 
 
Ron Cong 
Rong  
Herba cistanches 
Deserticolae 
Cistanche deserticola Y. C. Ma 
101 
 
 
HYT5 
 
 
Yin Yang 
Huo 
 
 
Herba Epimedii Epimedium grandiflorum Morr., E. 
sagittatum (Sieb. Et Zucc.) Maxim, or E. 
brevicorum Maxim 
 
Blood Tonics 
10 HBT1 Dang Gui Radix Angelicae Sinensis  Angelica sinensis (Oliv.) Diels 
78 HBT2 He Shou Wu Radix Polygoni Multifori Polygonum multiflorum Thunb. 
50 
 
 
HBT3 
 
 
Shu Di Huang 
 
 
Radix Rehmanniae 
Glutinosae Conquitae 
Rehmannia glutinosa (Gaertn.) Libosch., or 
R. glutinosa Libosch. F. hueichingensis 
(Chao et Schih) Hsiao  
12 HBT4 Bai Shao Radix Paeoniae Lactiflorae Paeonia lactflora Pall. 
 
Yin Tonics 
13 
 
HYN1 
 
Bei Sha Shen 
 
Radix Adenophorae seu 
Glehiae 
Adenophora tetraphylla (Thunb.), A. stricta 
Miq., or Glehnia littoralis F. Schmidt ex 
Miq. 
88 
 
HYN2 
 
Mai Men 
Dong  
Tuber Ophiopogonis 
Japonici 
Ophiopogon japonicus Ker-Gawl 
15 
 
HYN3 
 
Yu Zhu 
 
Rhizoma Polygonati 
Odoeati 
Polygonatum odoratum (Mill.) Druce 
var.pluriflorum (Miq.) Ohwi 
29 HYN4 Shan Zhu Yu Fructus Corni Officinalis Cornus officinalis Sieb. Et Zucc. 
21 HYN5 Gou Qi Zi Fructus Lycii Lycium barbarum L. or L. chinense Mill. 
86 HYN6 Mo Han Lian  Herba Ecliptae Prostratae Eclipta prostrata L. 
18 HYN7 Nu Zhen Zi Fructus Ligustri Lucidi Ligustrum lucidum Ait. 
 
Astringents 
58 
 
HAS1 
 
Wu Wei Zi 
 
Fructus Schisandrae 
chinensis 
Schisandra chinensis (Turcz.) Baill. 
26 HAS2 Fu Ziao Mai Semen Tritici Aestivi Levis Triticum aestivum L. 
5 
 
HAS3 
 
Lian Zi 
 
Semen Nelumbinis 
Nuciferae 
Nelumbo nucifera Gaertn 
84 HAS4 Qian Shi Semen Euryales Ferocis Euryale ferox Salisb. 
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Legend to Table 8.6 above 
 
(a) Purchased in October / November 2004 
(b) From either Hong An Fat, Richmond, Vic. 
(c) Coding system: e.g.,HWC1   
               (1) First alphabet refers to the company source where H refers to Hong An Fat. 
               (2) The second and third alphabets refers to the class of herbs, 
                     e.g., WC means Wind Cold, and EH means Eliminate Heat, etc.  
               (3) The numerical number refers to the no. of that herb in its group.    
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8.2.1.2    Chinese proprietary medicines (CPM) – preparation of powder 
 
               Upon delivery of the 50 CPM by the wholesaler to the RMIT University teaching clinic, 
one bottle of each of the CPM products was kept as the analytical samples. Each bottle usually 
contained between 100 and 200 tiny pills/tablets. The total weights of all pills in each bottle were 
measured, and the averaged weight of one pill for the particular CPM product was calculated. 
Then, 100 pills from each CPM product were pulverized into fine powder and stored in 50-mL 
size polyethylene tubes until analysis of metal contents. Table 8.7 shows the Chinese and English 
names of the 50 Chinese proprietary medicines (CPM), and their manufacturers. Photographs of 
the 50 CPM are shown in Appendix 8.8.
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Table 8.7  Chinese and English names of the 50 Chinese proprietary medicines (CPM), and their 
manufacturers. 
 
No. Chinese Name English Name Aust L 
No. 
Manufacturer Batch  
No. 
02 Ba Zheng San  Eight-Herb Powder for Rectification L 73121 Lanzhou Foci, China 000601 
03 Xiao Qing Long Tang Minor Blue Green Dragon 
Decoction plus Gypsum  
L 11727 Lanzhou Minshan, China 010608 
04 Long Dan Xie Gan Tang Gentiana Longdancao Decoction to 
Drain the Liver  
L 11692 Lanzhou Tai Bao, China 030125 
05 Xin Yi Wan Magnolia Flower Powder L 11736 Lanzhou Minshan, China 020418 
06 Tao Chih Pien  Guide Out the Red Powder L 57730 Tianjin Drug Co., China  N / A 
07 Chuan Xiong Cha Tiao 
Wan 
Ligusticum Chuanxiong Powder 
to be Taken with Green Tea 
L 68047 Lanzhou Foci, China 0203061
08 Ba Zhen Tang Eight-Treasure Decoction L 11654 Lanzhou Tai Bao, China 040218 
09 Liu Wei Di Huang Wan Six-Ingredient Pill with Rehmannia L 55976 Lanzhou Foci, China 0305158
010 Po Chai Pills Po Chai Pills Chinese 
Grocery
Li Chung Shing Tong, 
Hong Kong 
20512 
011 Duo Huo Ji Sheng Tang Angelica Pubescens and 
Sangjisheng Decoction  
L 55488 Lanzhou Foci, China 0210041
012 Jian Pi Wan Strengthen the Spleen Pill L 55430 Lanzhou Foci, China 9901137
014 Er Chen Tang Two-Cured Decoction L 11676 Lanzhou Tai Bao, China 030702 
016 Shen Ling Bai Zhu San Ginseng, Poria, and Atractylodes 
Macrocephala Powder 
L 11704 Lanzhou Minshan, China 030101 
017 Yu Ping Feng San Jade Windscreen Powder  L 11742 Lanzhou Minshan, China 040509 
018 Chai Hu Shu Gan San Bupleurum Powder o Spread the 
Liver 
L 55432 Lanzhou Foci, China 0210011
019 Huo Xiang Zheng Qi San Agastache Power to Rectify the 
Qi 
L 11684 Lanzhou Tai Bao, China 020809 
020 Xiao Chai Hu Tang Minor Bupleurum Decoction L 11724 Lanzhou Minshan, 
China 
030830 
021 Qing Qi Hua Tan Wan Clear the Qi and Transform Phlegm 
Pill 
L 55977 Lanzhou Foci, China 030706 
022 Xiao Yao San Rambling Powder L 55893 Lanzhou Foci, China 2004064
7 
024 Yin Qiao Wan Honeysuckle and Forsythia Powder L 11740 Lanzhou Minshan, 
China 
031009 
026 Fang Feng Tong Sheng San Ladebouriella Powder that Sagely  
Unblocks  
L 69602 Lanzhou Foci, China 990801 
027 Niu Huang Qing Xin Wan Cattle Gallstone Pill to Clear the 
Heart 
   N / A Beijing Tong Ren Tang, 
China 
0010281
029 An Shen Ding Zhi Wan Calm the Spirit & Settle the 
Emotions Pill  
L 68036 Lanzhou Foci, China 990501 
031 Huang Lian Jie Du Tang Coptis Decoction to Relieve 
Toxicity 
L 11683 Lanzhou Mian San, 
China 
031102 
032 Xue Fu Zhu Yu Tang Drive Out Stasis in the Mansion of 
Blood Decoction 
L 11738 Lanzhou Tai Bao, China 040606 
033 Sang Ju Wan Mulberry Leaf and Chrysanthemum 
Decoction 
L 73299 Lanzhou Foci, China 0305022
034 Mai Wei Di Huang Wan N / A L 46687 Lanzhou Foci, China 970909 
035 Shen Qi Da Bu Wan N / A L 41617 Lanzhou Minshan, China 030723 
037 Tian Ma Gou Teng Wan Gastrodia and Uncaria Decoction L 11712 Lanzhou Tai Bao, China 040530 
038 Qian Bai Bi Yan Pian N / A L 60817 Guangzhou Qixing, China C 0901 
039 Zuo Gui Wan Restore the left (Kidney) Pill L 11748 Lanzhou Minshan, China 030117 
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040 You Gui Wan Restore the Right (Kidney) Pill L 59014 Lanzhou Foci, China 0211021
046 Wen Dan Tang Warm the Gallbladder Decoction L 11717 Lanzhou Tai Bao, China 031202 
047 Zhi Bai Ba Wei Wan Anemarrhena, Phellodendron, 
and Rehmannia Pill 
L 11746 Lanzhou Minshan, China 990115 
049 Bi Min Gan Pian Hayfever Tablet L 76471 King Tim International, 
Australia 
041109 
050 Kun Bao Wan Women’s Treasure Pills L 78816 Tong Ren Tong, 
Australia 
0307022
023 Bao He Wan (Sheng Neng 
P/L) 
Preserve Harmony Pill (9 Herbs) L 55807 Lanzhou Foci, China 020511 
041 Bao He Wan 
(Cathay P/L) 
Preserve Harmony Pill (6 Herbs) L 11660 Lanzhou Foci, China 970711 
013 Bu Zhong Yi Qi Wan Tonify the Middle and Augment the 
Qi Decoction 
L 11663 Lanzhou Minshan, China 031208 
042 Bu Zhong Yi Qi Tang Tonify the Middle and Augment the 
Qi Decoction 
L 60713 Lanzhou Foci, China 971035 
015 Zhi Sou San & Addition Stop Coughing Powder L 11747 Lanzhou Tai Bao, China 2000031
5 
043 Zhi Sou San & Addition Stop Coughing Powder L 11747 Lanzhou Foci, China 970801 
030 Gui Pi Wan  Restore the Spleen Decoction L 55974 Lanzhou Foci. China 970412 
044 Gui Pi Tang Restore the Spleen Decoction L 11682 Lanzhou Tai Bao, China 030520 
01 Xiao Feng Wan  
(Batch: 010904) 
Eliminate Wind Powder  L 67163 Lanzhou Foci, China 010904 
045 Xiao Feng Wan  
(Batch:9903027) 
Eliminate Wind Powder  L 67163 Lanzhou Foci, China 9903027
036 Tao Hong Si Wu Wan Four-Substance Decoction with 
Safflower and Peach Pill 
L 11711 Lanzhou Minshan, China 040410 
048 Tao Hong Si Wu Wan Four-Substance Decoction with 
Safflower and Peach Pit 
L 67284 Lanzhou Foci, China 2004052
3 
025 Tian Wang Bu Xin Dan Emperor of Heaven’s Special Pill to 
Tonify the Heart 
L 55810 Lanzhou Foci, China 2004021
0-2 
028 Tian Wang Bu Xin Wan Emperor of Heaven’s Special Pill to 
Tonify the Heart 
L 11713 Lanzhou Minshan, China  010220 
 
Legend to Table 8.7 above: 
Note: English names are based on Bensky & Barolet: Formulas and Strategies, Eastland Press, 
1990. N /A = not available         
No. 23 and 41 – Produced by same company, same product name but different List numbers.  No.23 
has 9 herbs against 6 herbs in No.41 in the prescription. They are packaged by same manufacturer for 
export to two different companies in Australia, the Shen Neng P/L, NSW, and the Cathay Wholesale 
P/L, NSW. 
No. 15 and 43 – Produced by two different companies. Company that manufactured No.15 was 
formerly related to company that manufactured No.43. The same List number was retained even 
though quality assurance may be entirely different. 
No. 1 and 45 – Same products (from same company), but different batches. Selected to highlight 
possible variations in quality control between batches.  
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8.2.1.3    Chinese medicinal formulae (CMF) – preparation of powder         
 
               From the 100 crude CHM, five popular herbal prescriptions each consisting of 5 to10 
components of crude CHM were packed according to details of the classical Chinese medicinal 
formulae (CMF) in terms of composition and dose. These five CMF or their minor modifications 
are commonly prescribed by practitioners of Chinese medicine to patients for treatment purposes. 
The 5 packs of CMF were then pulverized into fine powder and stored in 50-mL size 
polyethylene tubes until analysis of metal contents. Table 8.8 lists the Chinese and English 
names of these five medicinal formulae, their compositions, doses and brief description of their 
therapeutic functions.  
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Table 8.8   Chinese and English names of the five medicinal formulae under investigation, their 
compositions, doses and brief description of their therapeutic functions.  
Sample 
Code 
Chinese 
Name of 
Formula 
English 
Name of 
Formula 
Herbal Ingredients (Pinyin; English 
Name & Botanical Names) & doses 
Therapeutic 
Functions of 
Herbal Formula 
Weight 
of 
Formula 
Pack 
CMF1 Xiao Yao 
San 
Rambling 
Powder 
1.Chai Hu (Bupleurun root, Radix 
Bupleuri)                                       --- 9g 
2. Dang Gui (Chinese angelica root; 
Radix Angelicae Sinensis)             --- 9g 
3. Bai Shao (White pony root; Radix 
paeoniae Alba)                              --- 9g 
4. Fu Ling (Tuckahoe; Poria)                                                                                                                         
                                                      --- 9g 
5. Zhi Gan Cao (Prepared licorice root; 
Radix Glycyrrhizae Praeparata) 
                                                    --- 4.5g 
Spread liver qi; 
strengthen spleen 
and nourish the 
blood. 
 
 
 
 
 
 
 
 
 
 
40.5g 
CMF2 Si Wu 
Tang 
Four-
Substance 
Decoction 
1.Dang Gui (Chinese angelica root; 
Radix Angelicae Sinensis)           ---12g 
2. Chuan Xiong (Chuanxiong rhizome; 
Rhizoma Ligustici Chuanxiong)  --- 9g 
3. Bai Shao (White peony root; Radix 
paeoniae Alba)                           --- 12g 
4. Shu Di Huang (Prepaed rhizome of 
rehmannia; Radix Rehmanniae 
Praeparata)                                --- 12g 
Tonify the blood 
and regulate the 
liver. 
 
 
 
 
 
 
 
 
 
45g 
CMF3 Tao 
Hong Si 
Wu 
Tang  
Four-
Substance 
Decoction 
with 
Safflower 
& Peach 
Pit 
1. Dang Gui (Chinese angelica root; 
Radix Angelicae Sinensis)           --- 12g                                        
2. Chuan Xiong (Chuanxiong rhizome; 
Rhizoma Ligustici Chuanxiong)   --- 9g                             
3. Bai Shao (White peony root; Radix 
paeoniae Alba)                            --- 12g 
4. Shu Di huang (Prepared rhizome of 
rehmannia; Radix Rehmanniae 
Praeparata)                                --- 12g 
5. Tao Ren (Peach kernel; Semen 
Persicae)                                     --- 12g   
6. Hong Hua (Safflower; Flos 
Carthami)                                     --- 6g                                                                               
Tonify and 
invigorate the blood
and regulate 
menstruation. For 
concurrent blood 
deficiency and 
blood stasis leading 
to a shortened 
menstrual cycle 
with copious 
bleeding of dark-
purple, sticky blood 
with or without 
clots. Also used 
when menstruation 
is accompanied by 
abdominal pain and 
distention due to the 
same mechanism. 
(This formula is 
chosen to determine 
its difference from 
Si Wu Tang as a 
result of addition of 
Tao Ren and Hong 
Hua)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51g 
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Sample 
Code 
Chinese 
Name of 
Formula 
English 
Name of 
Formula 
Herbal Ingredients (Pinyin; English 
Name & Botanical Names) & doses 
Therapeutic 
Functions of 
Herbal Formula 
Weight 
of 
Formula 
Pack 
CMF4 Gui Pi 
Tang 
Restore 
The Spleen 
Decoction 
1. Bai Zhu (Bighead atractylodes 
rhizome; Rhizoma Atractylodis 
Macrocephalae)                        --- 12g 
2. Fu Ling (poria with hostwood; 
Poria cum Ligno Hospite)                        
                                                  --- 12g                           
3. Huang Qi (Astragalus root; Radix 
Astragali seu Hedysari) 
                                                  --- 15g 
4. Long Yan Rou (Longan aril; Arillus 
Longan)      --- 9g                                                                 
5. Suan Zao Ren: (Wild jujube seed; 
Semen Ziziphi Spinosae) - stir-fried, 
shell removed                            --- 12g 
6. Ren Shen: (Ginseng; Radix 
Ginseng)                                      --- 6g                                                                       
7. Mu Xiang (Aucklandia root; Radix 
Aucklandiae)                                ---6g                           
8. Zhi Gan Cao (prepared licorice 
root; Radix Glycyrrhizae Praeparata)-            
                                                     ---5g                               
9. Dang Gui (Chinese angelica root; 
Radix Angelicae Sinensis)         --- 10g                                 
10. Zhi Yuan Zhi (Polygala root; 
Radix Polygalae - honey-parched)              
                                                     --- 6g 
                               
Benefit the spleen 
qi and thereby 
restore its control 
over the blood, 
hence the name. 
Augment the qi, 
tonify the blood, 
strengthen the 
spleen and nourish 
the heart.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93g 
CMF5 Jin Gui 
Shen Qi 
Tang 
Kidney Qi 
Pill from 
the Golden 
Cabinet 
1. Sheng Di Huang (Dried rehmannia 
root; Radix Rehmanniae)          --- 24g                                      
2. Shan Yao (Chinese yam; Rhizoma 
Dioscoreae)                              --- 12g                                                                 
3. Shan Zhu Yu (Dowgood fruit; 
Fructus Corni)                          --- 12g                                                                    
4. Ze Xie (Oriental water plantain; 
Rhizoma Alismatis)                     --- 9g          
5. Fu ling (Poria; Poria)             --- 9g                                                                                                              
6. Mu Dan Pi (Moutan bark; Cortex 
Moutan Radicis)                         --- 9g                                           
7. Gui Zhi (Cinnamon twig; Ramulus 
Cinnamomi)                                --- 3g                                                                  
8. Fu Zi (Prepared aconite root; Radix 
Aconiti Praeparate - stir-baked at 
high temperature)                       --- 3g 
Warm and tonify 
the kidney yang.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81g 
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8.2.2  Determination of Dry Weight 
 
Determination of dry weight of all herbal samples (the CHM, CPM and CMF) were 
analysed in triplicates. This was carried out by transferring 0.5 to 1.5 g of the herbal powder into 
pre-weighed acid-washed Pyrex glass tubes (18 x 90 mm). This gave the wet weight of herbal 
sample. The tube was then placed in oven overnight at ~ 45º C. The tube was weighed again the 
next day to determine the dried weight of the herbal sample. The weight difference between the 
wet and dry weights of the herbal sample was the water content which could be expressed as the 
percentage of the wet weight.                   
 
 
8.2.3  Acid Digestion of CHM, CPM and CMF Samples for Determination of Total    
               Metal Contents 
 
               The accurately weighed dried powder samples (in triplicate) in glass tubes from CHM, 
CPM and CMF were digested in concentrated nitric acid (cHNO3) to dissolve all compounds into 
their atomic form. This was achieved by adding 5.0 mL of concentrated nitric acid into the glass 
tubes and the tubes were allowed to stand in a fume cupboard overnight at room temperature. 
This initial digestion at room temperature avoided spilling due to frothing during subsequent 
heating process. The tubes were then heated in a solid aluminium test tube block placed on a 
heater. The temperature was raised in several stages, i.e., firstly to about 35o C for 0.5 hour, then 
about 60o C for 1 – 2 hours, and finally 85o – 90o C. The acid digestion at this final temperature 
might take between 5 and 24 hours, depending on the nature of the herbal medicines. Care was 
taken not to allow the content to dry up by repeatedly adding 2 - 3 mL of cHNO3 each time when 
the acid solution became low. This process was repeated for as long as the fume observed was 
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brown in colour. For samples that contained high levels of organic compounds, either 0.5 mL 
hydrogen peroxide (H2O2) or 2 mL of concentrated perchloric acid (H2ClO4) might be added to 
assist in the breakdown of organic compounds, thus creating a more complete digestion. When 
the fume evolved turned from brown to white, digestion was regarded as complete, and the 
content was further reduced to a thin wet film of acid on the bottom of the glass tube. At this 
stage 5 mL of 5% HNO3 was added. The tube was then vortexed vigorously to ensure that the 
inner wall was rinsed thoroughly. The digestate was transferred to a 15-mL size polyethylene 
tube. The glass tube was repeatedly rinsed and vortexed (2 – 3 times, each time ~1.5 mL) with 
additional 5% HNO3, to ensure thorough transfer. The pooled polyethylene tubes were 
centrifuged, if necessary, at 5000 rpm for 5 minutes at room temperature to remove any solid 
particles. Each clear digestate was diluted to a final volume of exactly10 mL with 5% HNO3 and 
stored in polyethylene tubes for future metal analysis.    
 
 
8.2.4 Water Extraction of CHM Samples – Dissolution Study of Metal in Aqueous   
               Decoction after Boiling 
 
               Since CHM are administered orally in the form of aqueous decoction of the crude herbal 
materials, the extent of dissolution of different metals in aqueous decoction need to be 
investigated. CHM are derived mainly from any one of the six groups belonging to different parts 
of plants such as (1) root, (2) leaf, (3) seed, (4) bark, (5) flower, and (6) branch/twig, plus marine 
shell. In this project, rather than boiling all the 100 CHM (as in the case of acid digestion for all 
100 CHM), three representative CHM were chosen from each group for dissolution study to 
determine the extent of aqueous metal extraction by the boiling procedure. A total of eighteen (18) 
crude CHM of plant origin, plus the two marine shell or animal bone CHM were chosen for 
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aqueous extraction of metal. Each CHM was prepared in duplicate. This was accomplished by 
weighing exactly 2 g each of the representative crude herbs in the form as purchased (not the 
powder) into glass tubes. Ten mL of milliQ water were added into the tubes. The tubes were then 
placed in heater block and brought to boil to simulate the herbal medicine cooking procedure as 
per instruction from any Chinese medicine practice. After bringing to boil, the tubes were left to 
simmer for about 30 minutes, and then allowed to cool. The aqueous supernatants were 
transferred to polyethylene tubes and then centrifuged at 5000 rpm for 5 minutes. The clear 
decoctions were stored in polyethylene tubes for metal analysis. The herbal residues in the glass 
tubes were extracted a second time with 10 mL milliQ water by repeating the above procedure, 
and the second decoctions were also kept for future metal analysis to evaluate the efficiency of 
extraction between the first and second aqueous decoctions. Table 8.9 is a list of the 
representative herbs used for the study of metal dissolution in aqueous decoction, including the 
volumes of the first and second decoctions after boiling. 
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Table 8.9   List of representative raw Chinese medicines selected from various parts of herbal 
plants for determining efficiency of metal extractions in the boiling process with water (i.e., 
aqueous decoctions), including the weight of medicine and the volumes of first and second 
decoctions. 
 
Volume of Aqueous 
Decoctions (mL) 
 Specimen 
Code 
Chinese Herbal Name 
(Pharmaceutical Name) 
Weight 
of Dried 
Herb 
(g) 
1st 
Decoction 
2nd 
Decoction 
Root     
8 RR8a 2 5 8 
8 RR8b 
Wu Yao 
(Radix Linderae Strychnifoliae) 2 5 8 
11 RR11a 2 10 9 
11 RR11b 
Qian Hu 
(Radix Peucedani)  2 10 9 
83 RR83a 2 8 8 
83 RR83b 
Tian Ma 
(Radix Astrgali Membranaceus) 2 8 8 
Leaf     
34 RL34a 2 10 8 
34 RL34b 
Bo He 
(Herba Menthae Haplocalycis) 2 10 8 
61 RL61a 2 12 10 
61 RL61b 
Zi Su Ye 
(Folium Perillae Frutescentis) 2 12 10 
101 RL101a 2 12 10 
101 RL101b 
Yin Yang Huo 
(Herba Epimedii) 2 12 10 
Seed     
5 RS5a 2 10 10 
5 RS5b 
Lian Zi 
(Semen Nelumbinis) 2 10 10 
18 RS18a 2 12 10 
18 RS18b 
Nu Zhen Zi 
(Fructus Ligustri Lucidi) 2 12 10 
58 RS58a 2 12 10 
58 RS58b 
Wu Wei Zi 
(Fructus Schisandrae) 2 12 10 
Bark      
19 RBa19a 2 12 10 
19 RBa19b 
Huang Bai 
(Cortex Phellodendri) 2 12 10 
28 RBa28a 2 10 10 
28 RBa28b 
Du Zhong  
(Cortex Eucommiae Ulmoidis) 2 10 10 
63 RBa63a 2 10 10 
63 RBa63b 
Rou Gui 
(Cortex Cinnanomi Cassiae) 2 10 10 
Flower     
27 RF27a 2 12 8 
27 RF27b 
Hong Hua 
(Flos CArthami Tinctorii) 2 12 8 
44 RF44a 2 10 8 
44 RF44b  
Xin Yi Hua 
(Flos Magnoliae) 2 10 10 
85 RF85a 2 12 6 
85 RF85b 
Jin Yin Hua 
(Flos Lonicerae Japonicae) 2 12 8 
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 Table 8.9  (Continued). 
 
 
 
 
 
 
Volume of Aqueous 
Decoctions (mL) 
 
 
Specimen 
Code 
Chinese Herbal Name 
(Pharmaceutical Name) 
Weight 
of Dried 
Herb 
(g) 
1st 
Decoction 
2nd 
Decoction 
Branch &Twig     
9 RB9a 2 10 10 
9 RB9b 
Sang Ji Sheng 
(Ramulus Sangjisheng) 2 10 10 
25 RB25a 2 12 10 
25 RB25b 
Gou Teng 
(Ramulus cum Uncis 
Uncariae) 
2 12 10 
51 RB51a 2 12 10 
51 RB51b 
Gui Zhi 
(Ramulus Cinnamomi 
Cassiae) 
2 12 10 
Marine Shell     
57 RBn57a 2 10 10 
57 RBn57b 
Long Gu 
(Os Draconis) 2 10 10 
98 RBn98a 2 10 10 
98 RBn98b 
Mu Li 
(Concha Ostreae) 2 10 10 
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8.2.5  Water Extraction of CMF Samples – Dissolution Study of Metal in Aqueous   
               Decoction after Boiling 
 
 The total metal contents in Chinese medicinal formulae (CMF) can be determined from 
the acid digestions. However, CMF are normally consumed in a fashion similar to the aqueous 
boiling of the CHM described above in 8.2.4. Therefore, these five CMF chosen for acid 
digestion were also investigated for their extent of metal dissolution in aqueous decoction after 
boiling in water. Each CMF was prepared and analysed in duplicate. To accomplish this, the five 
formulae were packed according to their composition and doses as shown in Table 8.8. Then the 
instruction for the preparation of Chinese herbal medicine decoction as provided to patients by 
the Chinese Medicine Teaching Clinic at RMIT University (Bundoora, Victoria) was followed, 
and is described below:    
 
1. Place one pack of herbs in a clay pot or stainless steel pot (non-aluminium). Add 
about 700 – 900 mLs of cold water and soak for approximately 30 minutes. 
Figure 8.1 is a  picture showing the boiling process of Chinese herbal prescription 
in the traditional Chinese claypots to obtain herbal decoctions (Note: for the 
purpose of this investigation, Millipore Q water was used instead) 
2. Bring to boil using household gas stove. Reduce the heat and simmer it down to 
about 400 mLs. This should take approximately 45 minutes. 
3. Drain the liquid into a container. Do not discard the herbs in the pot. (Note: an 
acid-washed glass bottle was used as the container, and the aqueous volume 
was measured; this was the first aqueous decoction) 
4. Add about another 600 mLs of Millipore Q water into the pot and repeat steps 2 
and 3 above, and boil it down to approximately 300 mLs. Then drain the liquid 
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again into another acid-washed glass bottle, and its volume measured. (Note: this 
was the second aqueous decoction) 
5. Mix the two lots of herbal liquid together; then divide into two glasses.  
 
             Normally, either one or two doses (i.e., the two divided glasses referred to in step 5) may 
be drunk per day, depending on instruction from the clinician, half to one hour after dinner. In 
this study, two doses, i.e., the first and second decoctions, would be consumed in one day. 
However, for the purpose of determining the efficiency of sequential extraction, the two 
decoctions would not be mixed. Their volumes were recorded accurately and their metal 
concentrations analysed separately to determine the efficiency of sequential aqueous extraction. 
The final metal concentrations were expressed as µg/g of the herbal formula mixture, taking into 
account of the weight of the formula and the volumes of the aqueous decoction collections in the 
calculation.  
 
Figure 8.1   Picture showing the traditional boiling process of Chinese medicinal prescription of 
raw herbs in claypots 
 
 130 
8.3  Method of Analysis – Metal Determination by Atomic Absorption Spectrometry (AAS)  
 
8.3.1 Introduction 
 
               Metal contents were determined by methods of atomic absorption spectrometry, 
employing graphite furnace technique (GFAAS) for lead (Pb), arsenic (As), cadmium (Cd), and 
chromium (Cr), and cold vapour generation method (CVAAS) for mercury (Hg). The 100 crude 
Chinese herbal medicines (CHM), 50 Chinese proprietary medicines (CPM), and 5 Chinese 
medicinal formulae (CMF) were analysed. Each sample was prepared in triplicates.  During the 
actual AAS determination, each analytical result was the mean of either duplicate or triplicate 
analyses. Therefore, the total number of sample preparation was rather high, and since the final 
volumes of each digestate were only 10 mL, the necessity to use a simple and sensitive analytical 
method became essential. The GFAAS technique was chosen for this project in favour of the 
flame atomic absorption spectrometry technique (FAAS), because (1) it provided a higher 
sensitivity than FAAS, generally 100 times or more; (2) sample volumes used was much less than 
FAAS, typically ~5µg, compared to the 5 mL required for FAAS; and (3) sample preparation 
could be minimized because the method was subject to less interference, and more sensitive.  
 
8.3.2       Summary of Total Number of Herbal Medicines Analysed 
 
               The following quantities of herbal medicines were either digested in acid or extracted 
by boiling in water, followed by analyses for Pb, As, Cd, Cr and Hg. Each sample was prepared 
in triplicate for acid digestion, or in duplicate for extraction by boiling in water. Each acid-
digested or aqueous extracted test sample was analysed twice or three times to produce an 
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averaged analytical result. The following Table 8.10 summarises the number of different herbal 
medicines analysed in this project. 
 
Table 8.10   Total number of different Chinese medicines analysed in the project 
 
  Herbal Medicines Abbreviation Quantity 
analysed 
Acid 
Digestion 
Aqueous 
Extraction 
Crude Chinese Herbal Materials 
(ground into powder) 
CHM 100 All --- 
Crude Chinese Herbal Materials 
(Crude, as purchased) 
CHM 20 --- All 
Chinese Proprietary Medicines 
(as manufactured) 
CPM 50 All --- 
Chinese Medicinal Formulae 
(ground into powder) 
CMF 5 All --- 
Chinese Medicinal Formulae 
(Crude, as purchased) 
CMF 5 --- All 
 
 
 
8.3.3       Sample Dilution Prior to AAS Analysis 
 
              All test samples, both the acid-digested and the water-decocted, were further diluted 
prior to analysis by GFAAS or CVAAS. The analyses were carried out at an acidic medium of 
5% HNO3. Therefore, all digested samples were diluted and adjusted to a final acidic 
concentration of 5% HNO3. Standard solutions were also prepared in 5% HNO3. The following 
sub-sections describe the procedures and extents of dilutions so that the final concentrations of 
the diluted herbal samples lied within the range of the calibration curve of the metal being 
determined.  
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8.3.3.1    Dilutions for the acid-digested samples (i.e.,for  total metal contents) 
 
               Samples included the 100 (each in triplicates) acid-digested crude Chinese herbal 
materials (CHM), the 50 (each in triplicates) acid-digested Chinese proprietary medicines (CPM), 
and the 5 (each in triplicates) acid-digested Chinese medicinal formulae (CMF). They were 
stored frozen in 10mL of 5% HNO3 after acid digestion. Prior to GFAAS analysis, they were 
further diluted with 5% HNO3 solution to a concentration suitable for determination of the metal 
in question. The extents of dilution are specified below under the appropriate sections for the 
metal concerned. 
 
8.3.3.2    Dilutions for the water-decocted samples (i.e., for aqueous metal concentration) 
 
               Samples included the twenty (each in duplicates) aqueous decoctions from the crude 
Chinese herbal materials (CHM), and the five (each in duplicates) aqueous decoctions from the 
Chinese medicinal formulae (CMF) prepared from boiling the CHM or CFM in milliQ water as 
described in Sections 9.2.4 and 9.2.5 above. The metal concentrations were expected to be lower 
than those of the acid-digested total metal content. Therefore, rather than adjusting all the water 
extracted samples to the same volume by adding more water after boiling was complete (as was 
done in the case of the acid-digestate), the water extracts after boiling were transferred to suitable 
graduated polyethylene tubes and their volumes measured, then stored for future analysis. Prior to 
analysis, they were diluted according to the following procedure: a suitable small volume of the 
aqueous extract was initially diluted with an equal volume of 10% HNO3. This step changed the 
aqueous extract to a concentration of 5% HNO3. Any subsequent dilutions were made with 5% 
HNO3, thus keeping the test sample at 5% HNO3 for the final GFAAS analysis.   
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8.3.4   Determination of Lead (Pb) by GFAAS 
 
               After several AAS trial runs, the following dilutions were found to be most appropriate 
for determination of lead in herbal medicines by GFAAS. For acid-digested samples, the CHM 
samples were prepared to a final dilution of 50 times, and both the CPM and CMF samples to 100 
times. To prepare these diluted solutions, a 50-fold solution required a further 1 in 5 dilution of 
the 10-mL digestate with 5% HNO3, (i.e., 100 µL sample + 400 µL 5% HNO3; thus, final dilution 
is 10 x 5 = 50), and a 100-fold dilution required a further 1 in 10 dilution the 10-mL digestates 
with 5% HNO3 (i.e., 50 µL sample + 450 µL 5% HNO3; thus final dilution is 10 x10 = 100), prior 
to analysis by GFAAS. Similarly, for water-extracted samples, the CHM water-extracts were 
prepared to a final dilution of 15 to 20 times for both first and second aqueous decoctions, 
whereas for the CMF water-extracts, they were diluted approximately 300-fold for the first 
collection of aqueous decoction, and approximately 100-fold for the second aqueous decoction. A 
5-point standard curve with concentrations of 0, 5, 10, 20, 40, and 50µg/L was constructed by 
automatic dilutions (by the instrument) using a bulk standard of 50µg/L. Ammonium dihydrogen 
phosphate (NH4H2PO4, 0.5 % in 5% HNO3) was used as modifier, and the make-up solution was 
5% HNO3.  The volumes used in the furnace analysis for the test sample, modifier, and the make-
up solution were 20µL, 5µL and 5µL respectively creating a total volume of 30µL of analytical 
mixture. Nitrogen gas was used as the inert gas instead of argon for economic reason. New 
rational plot was employed for the calibration curve. Each herbal sample was prepared and 
analysed in triplicate, and each AAS result was the average of duplicate or triplicate analyses. 
Details of instrument parameters for lead determination as recorded in the AAS instrument are 
shown in Appendix 8.1, while the main parameters, and furnace temperature program for Pb 
determination are summarised as follows: 
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Parameters: 
     Element                                    Lead (Pb) 
     Wavelength                              283.3 nm 
     Slit width                                 0.5 nm 
     Lamp current                           10.0 mA 
     Calibration mode                     Concentration µg/L        
     Sampling mode                        AutoMix 
     Background correction             BC off 
     Modifier                                   Ammonium dihydrogen phosphate (NH4H2PO4, 0.5 % in   
                                                      5% HNO3) 
 
Step                    Temp (C)      Time (s)     Flow (L/min)    Gas Type   Read    Signal Storage 
 
        
1  Drying        85                  5                3.0    Nitrogen       No            No 
2  Drying                95                  40.0           3.0    Nitrogen       No            No 
3  Drying        120               10.0            3.0    Nitrogen       No             No 
4  Pyrolysis            400                5.0             3.0    Nitrogen       No            No 
5  Pyrolysis        400                1.0             3.0    Nitrogen       No           No 
6  Pyrolysis        400                2.0             0.0    Nitrogen       No            Yes 
7  Atomization       2100              1.0             0.0    Nitrogen       Yes  Yes 
8  Atomization       2100              2.0             0.0    Nitrogen       Yes  Yes 
9  Cleaning        2100              2.0             3.0    Nitrogen       No            Yes 
__________________________________________________________________________ 
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8.3.5       Determination of Arsenic (As) by GFAAS 
 
   After several AAS trial runs, the following dilutions were found to be most appropriate 
for determination of arsenic (As) in herbal medicines by GFAAS. For acid-digested samples, 
the CHM samples were prepared to a final dilution of 50 times, the CPM to 40 times, and the 
CMF samples to 100 times. To prepare these diluted solutions, a 40-fold solution required a  
further 1 in 4 dilution of the 10-mL digestate with 5% HNO3, (i.e., 100 µL sample + 300 µL 5% 
HNO3; thus, final dilution is 10 x 4 = 40), a 50-fold solution required a further 1 in 5 dilution of 
the 10-mL digestate with 5% HNO3, (i.e., 100 µL sample + 400 µL 5% HNO3; thus, final dilution 
is 10 x 5 = 50), and a 100-fold aolution required a further 1 in 10 dilution of the 10-mL digestates 
with 5% HNO3 (i.e., 50 µL sample + 450 µL 5% HNO3; thus final dilution is 10 x10 = 100), prior 
to analysis by GFAAS. Similarly, for water-extracted samples, the CHM samples were 
prepared to a final dilution of 15 to 20 times for both the first and second aqueous decoctions, 
whereas for the CMF water-extracted samples, they were diluted approximately 300-fold for the 
first decoction, and approximately 100-fold for the second collection. A 5-point standard curve 
with concentrations of 0, 5, 10, 20, 30, and 50µg/L was constructed by automatic dilutions (by 
the instrument) using a bulk standard of 50µg/L. Palladium nitrate [Pd(NO3)2, 0.08% in 5% HNO3] 
was used as modifier, and the make-up solution was 5% HNO3.  The volumes used in the furnace 
analysis for the test sample, modifier, and the make-up solution were 20µL, 5µL and 5µL 
respectively creating a total volume of 30µL of analytical mixture. Nitrogen gas was used as the 
inert gas instead of argon for economic reason. A linear plot was employed for the calibration 
curve. Each herbal sample was prepared and analysed in triplicate, and each AAS result was the 
average of duplicate or triplicate analyses. Details of instrument parameters for arsenic 
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determination as recorded in the AAS instrument are shown in Appendix 8.2, while the main 
parameters, and furnace temperature program for As determination are summarised as follows: 
 
Parameters: 
     Element                                    Arsenic (As) 
     Wavelength                              193.7 nm 
     Slit width                                  0.5 nm 
     Lamp current                            10.0 mA 
     Calibration mode                      Concentration µg/L        
     Sampling mode                         AutoMix 
     Background correction              BC off 
     Modifier                                     Palladium nitrate [Pd(NO3)2, 0.08% in 5% HNO3] 
 
Step                    Temp (C)      Time (s)     Flow (L/min)    Gas Type   Read    Signal Storage 
 
        
1  Drying        85                  5                3.0    Nitrogen       No            No 
2  Drying                95                  40.0           3.0    Nitrogen       No            No 
3  Drying        120               10.0            3.0    Nitrogen       No             No 
4  Pyrolysis            1400              5.0             3.0    Nitrogen       No            No 
5  Pyrolysis        1400              1.0             3.0    Nitrogen       No           No 
6  Pyrolysis        1400              2.0             0.0    Nitrogen       No            Yes 
7  Atomization        2600             0.6             0.0    Nitrogen       Yes  Yes 
8  Atomization        2600             2.0             0.0    Nitrogen       Yes  Yes 
9  Cleaning         2600             2.0             3.0    Nitrogen       No            Yes 
_________________________________________________________________________ 
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8.3.6       Determination of Cadmium (Cd) by GFAAS 
 
               After several AAS trial runs, the following dilutions were found to be most appropriate 
for determination of cadmium (Cd) in herbal medicines by GFAAS. For acid-digested samples, 
the CHM samples were prepared to a final dilution of 150 times, the CPM samples to 100 times, 
and the CMF samples to 200 times. To prepare these diluted solutions, a 100-fold solution 
required a further 1 in 10 dilution of the 10-mL digestate with 5% HNO3, (i.e., 50 µL sample + 
450 µL 5% HNO3; thus, final dilution is 10 x 10 = 100), a 150-fold solution required a further 1 in 
15 dilution of the 10-mL digestate with 5% HNO3, (i.e., 25 µL sample + 350 µL 5% HNO3; thus, 
final dilution is 10 x 15 = 150), and a 200-fold dilution required a further 1 in 20 dilution of the 
10-mL digestates with 5% HNO3 (i.e., 25 µL sample + 475 µL 5% HNO3; thus final dilution is 10 
x 20 = 200), prior to analysis by GFAAS. Similarly, for water-extracted samples, the CHM 
aqueous samples were prepared to a final dilution within the range of 30 to 70 times for both the 
first and second aqueous decoctions, whereas for the CMF water-extracted samples, they were 
diluted approximately 300-fold for the first decoction, and approximately 100-fold for the second 
collection. A 5-point standard curve with concentrations of 0, 0.5, 1.0, 2.0, 3.0, and 5.0µg/L was 
constructed by automatic dilutions (by the instrument) using a bulk standard of 5.0µg/L.  
Ammonium dihydrogen phosphate (NH4H2PO4, 2.5 % in 5% HNO3) was used as modifier, and 
the make-up solution was 5% HNO3.  The volumes used in the furnace analysis for the test sample, 
modifier, and the make-up solution were 20µL, 5µL and 5µL respectively creating a total volume 
of 30µL of analytical mixture. Nitrogen gas was used as the inert gas instead of argon for 
economic reason. A new rational plot was employed for the calibration curve. Each herbal sample 
was prepared and analysed in triplicate, and each AAS result was the average of duplicate or 
triplicate analyses. Details of instrument parameters for cadmium determination as recorded 
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in the AAS instrument are shown in Appendix 8.3, while the main parameters, and furnace 
temperature program for Cd determination are summarised as follows: 
Parameters: 
     Element                                     Cadmium (Cd) 
     Wavelength                               228.8 nm 
     Slit width                                   0.5 nm 
     Lamp current                             4.0 mA 
     Calibration mode                      Concentration µg/L        
     Sampling mode                         AutoMix 
     Background correction              BC off 
     Modifier                                    Ammonium dihydrogen phosphate (NH4H2PO4, 2.5 % in  
                                                       5% HNO3) 
 
Step                    Temp (C)      Time (s)     Flow (L/min)    Gas Type   Read    Signal Storage 
 
        
1  Drying        85                  5.0             3.0    Nitrogen       No            No 
2  Drying                95                  40.0           3.0    Nitrogen       No            No 
3  Drying        120               10.0            3.0    Nitrogen       No             No 
4  Pyrolysis            250                5.0             3.0    Nitrogen       No            No 
5  Pyrolysis        250                1.0             3.0    Nitrogen       No           No 
6  Pyrolysis        250                2.0             0.0    Nitrogen       No            Yes 
7  Atomization       1800              0.8             0.0    Nitrogen       Yes  Yes 
8  Atomization       1800              2.0             0.0    Nitrogen       Yes  Yes 
9  Cleaning        1800              2.0             3.0    Nitrogen       No            Yes 
________________________________________________________________________
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8.3.7       Determination of Chromium (Cr) by GFAAS 
  
               After several AAS trial runs, the following dilutions were found to be most appropriate 
for determination of cadmium (Cd) in herbal medicines by GFAAS. For acid-digested samples, 
the CHM samples were prepared to a final dilution of 100 times, the CPM samples to 40 to 500 
times, and the CMF samples to 100 times. To prepare these diluted solutions, a 40-fold solution 
required a further 1 in 4 dilution of the 10-mL digestate with 5% HNO3, (i.e., 100 µL sample + 
300 µL 5% HNO3; thus, final dilution is 10 x 4 = 40), a 100-fold solution required a further 1 in 
10 dilution of the 10-mL digestate with 5% HNO3, (i.e., 40 µL sample + 360 µL 5% HNO3; thus, 
final dilution is 10 x 10 = 100), and a 500-fold dilution required a further 1 in 50 dilution of the 
10-mL digestates with 5% HNO3 (i.e., 25 µL sample + 1225 µL 5% HNO3; thus final dilution is 
10 x 50 = 500), prior to analysis by GFAAS. Similarly, for water-extracted samples, the CHM 
samples were prepared to a final dilution within the range of 15 to 25 times for both the first and 
second aqueous decoctions, whereas for the CMF water-extracted samples, they were diluted 
approximately 300-fold for the first decoction, and approximately 100-fold for the second 
collection. A 4-point standard curve with concentrations of 0, 4, 8, 12, and 24µg/L was 
constructed by automatic dilutions (by the instrument) of a bulk standard of 40µg/L. Palladium 
nitrate [Pd(NO3)2, 0.08% in 5% HNO3] was used as modifier, and the make-up solution was 5% 
HNO3.  The volumes used in the furnace analysis for the test sample, modifier, and the make-up 
solution were 10µL, 5µL and 5µL respectively creating a total volume of 20 µL of analytical 
mixture. Nitrogen gas was used as the inert gas instead of argon for economic reason. A linear 
plot was employed for the calibration curve. Each herbal sample was prepared and analysed in 
triplicate, and each AAS result was the average of duplicate analysis. Details of instrument 
parameters for chromium determination as recorded in the AAS instrument are shown in 
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Appendix 8.4, while the main parameters, and furnace temperature program for Cr determination 
are summarised as follows: 
Parameters: 
     Element                                     Chromium (Cr) 
     Wavelength                               357.9 nm 
     Slit width                                   0.5R nm 
     Lamp current                             7.0 mA 
     Calibration mode                      Concentration µg/L        
     Sampling mode                         AutoMix 
     Background correction              BC off 
     Modifier                                     Palladium nitrate [Pd(NO3)2, 0.08% in 5% HNO3] 
 
Step                    Temp (C)      Time (s)     Flow (L/min)    Gas Type   Read    Signal Storage 
 
        
1  Drying        85                   5.0             3.0    Nitrogen       No            No 
2  Drying                95                  40.0            3.0    Nitrogen       No            No 
3  Drying        120                10.0            3.0    Nitrogen       No             No 
4  Pyrolysis            1000               5.0             3.0    Nitrogen       No            No 
5  Pyrolysis        1000               1.0             3.0    Nitrogen       No           No 
6  Pyrolysis        1000               2.0             0.0    Nitrogen       No            Yes 
7  Atomization       2600               1.2             0.0    Nitrogen      Yes  Yes 
8  Atomization       2600               2.0             0.0    Nitrogen      Yes  Yes 
9  Cleaning        2600               2.0             3.0    Nitrogen       No            Yes 
____________________________________________________________________________ 
 
 
 
 141 
8.3.8       Determination of Mercury (Hg) by Cold Vapour Generation Atomic     
               Absorption Spectrometry (VGAAS) 
 
               For a detailed description of the standard operational procedure of the vapour generation 
accessory unit (VGA-77, Varian) for mercury determination, please refer to Appendix 8.5.  
 
               Figure 8.2 is a schematic diagram of the cold vapour generation system for mercury 
determination. The following is a brief background of the VGAAS technique (Varian VGA-77 
Manual). TheVGA-77 consisted of a peristaltic pump that aspirated a constant and continuous 
flow of test sample and liquid reagents into the mixing coil. In the case of Hg determination, 
MilliQ water was used as mixing reagent prior to chemical reduction. The sample and MilliQ 
water were allowed to mix first before the reductant (25% SnCl2 in 20% HCl) entered the stream. 
Nitrogen gas was then introduced into the stream of liquid mixture. Reduction reaction took place 
while the mixture was flowing through the reaction coil, and hydrogen was vigorously evolved. 
This hydrogen gas helped to strip the mercury vapour from the liquid into the nitrogen. Upon 
reaching the gas/liquid separator, the gas vapour was then separated from the liquid, and the 
liquid drained away to waste, while a second stream of nitrogen was introduced at this point to 
prevent the vapour stream from being saturated with water vapour and condensing in the sample 
introduction system. This stream of cold vapour carrying the mercury element then passed out of 
the separator into the absorption cell where it was analysed by the spectrometer.  
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Figure 8.2   A schematic diagram of the cold vapour generation system for Hg determination 
(adapted from VGA77 handbook of Varian Australia, P/L) 
 
 
 
 
            Since the VGA-77 technology produced a continuous signal for measurement, integration 
mode was applied to analyse the mercury concentration. 
 
           The size of pump tubes used for the reductant and water was black/black, and aspiration 
rates for both reagents were set at 0.8 – 1.2 mL /minute, whereas pump tube for the test sample 
was purple/black and aspiration rate set at 6 – 8 mL /minute. The nitrogen gas pressure was 50 
psi (i.e. 350 kpa). Note: The nitrogen gas pressure must be set between 300 – 400 kpa, i.e. 
between 43 – 57 psi for best result. It is further noted that after a new sample pump tube and/or 
sample line are installed, a solution containing high concentration of mercury (e.g., 100 µg/L) 
should be run for an hour to saturate the lines due to adsorption. This should be run until the 
concentration in the measurement display reaches a plateau. This is to avoid underestimation. 
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             Using the above conditions and as a result of method development, a minimum pre-read 
delay time was found to be 35 seconds, and measurement time 5 seconds. A minimum analytical 
sample volume of 5.5 mL was aspirated in this 40-second period. Therefore, prior to analysis, 6.0 
mL analytical sample was prepared from the 10-mL herbal acid digestate by diluting 3.0 mL 
with 3.0 mL of 5% HNO3 (Thus, total dilution was 10 x 2 = 20). In the case of water-extracted 
samples, 3 mL of the aqueous extracts were diluted with 3 mL of 10% HNO3. To commence Hg 
determination, standard solutions prepared in 5% HNO3 were manually presented via the sample 
line for aspiration and analysis in the order of increasing concentrations. After a 5-point linear 
standard curve with mercury concentrations of 0.5, 1.0, 2.0, 3.0 and 4.0 µg/L was constructed, 
test samples could then be presented for mercury determination. Each herbal sample was 
prepared and analysed in triplicate, and each AAS result was the average of duplicate analysis.   
 
             Some important instrument and analytical parameters are summarized below:  
     Parameters: 
     Element                                     Mercury (Hg) 
     Wavelength                               253.7 nm 
     Slit width                                   0.5 nm 
     Lamp current                             4.0 mA 
     Calibration mode                       Concentration µg/L        
     Measurement mode                   Integration 
     Background correction              BC off 
     Sampling Mode                         AutoMix 
     Calibration algorithm                Linear  
     Measurement time                     5.0 seconds 
     Pre-read delay                            35.0 seconds 
     Reductant container                   25% Stannous chloride in 20% hydrochloric acid (25%  
                                                        SnCl2 in 20% HCl) 
     Acid container                            MilliQ water 
     Aspiration rates: 
              Reductant                          0.8 – 1.2 mL/min 
              MilliQ water                     0.8 – 1.2 mL/min 
              Sample                              6 – 8 mL/min 
     Nitrogen pressure                      50 psi (i.e. 350 kpa)     
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8.4    Accuracy of Determinations of Arsenic (As), Cadmium (Cd) and    
          Chromium (Cr) – Recovery Studies   
           
           As a quality control of the methodology, the accuracy of GFAAS determination of As, Cd 
and Cr was evaluated by recovery studies of the laboratory-spiked samples. This was 
achieved by spiking known amounts of these metals at three different levels representing low, 
medium, and high ranges into accurately weighed (1 gram) herbs respectively. The herb selected 
for this study was Poria (Chinese name: Fu Ling) which had previously been found to be low in 
contents of the metals in question. The spiking procedure involved carefully adding a calculated 
volume of a standard solution (S1a,b,c) of the metal under investigation on top of 1 gram of the 
Poria powder in an acid-washed glass tube. Another non-spiked sample of Poria, also exactly 1 
gram, served as the blank. All levels including the blank were prepared in triplicate. All samples 
were then subjected to the normal procedure of drying, acid digestion with conc HNO3, dilution 
and finally analysis by GFAAS as described previously. 
The amount of the spiked metal recovered was then expressed as a percentage of the quantity 
added. Preparation of the standard solutions used for spiking shown in Table 8.11, and the 
concentrations of the spiked samples are summarized in Table 8.12 below: 
 
             Standard solutions (S1) used for spiking were prepared as described in Section 8.1.4.6. 
They are: 
(S1a)   Arsenic (As): 10 µg/ml 
(S1b)  Cadmium (Cd): 10 µg/ml 
(S1c)  Chromium (Cr): 10 µg/ml 
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Table 8.11   Details of volumes of standard solutions S1a, S1b, and S1c spiked onto1g of Poria 
 
    
* n = 3  
 
 
 
 
 Table 8.12   Metal concentrations of the spiked samples at three different levels 
 
    
* n = 3
  Low level * Moderate level * High level * 
*Blank 
 
Poria (1g)  
(Fu Ling)  
--- --- --- 
*Spiked 
samples  
Poria (1 g) 
(Fu Ling)  
50 µL S1a, S1c 
and 10 µL S1b 
150 µL S1a, S1c 
and 50 µL S1b 
300 µL S1a, S1c 
and 150 µL S1b 
  Low level * Moderate level * High level * 
*Blank 
 
Poria (1g)         
(Fu Ling)  
--- --- --- 
*Spiked 
samples  
 
Poria  (1g)      
(Fu Ling) 
As = 0.5 µg/g 
Cd = 0.1 µg/g  
Cr  = 0.5 µg/g 
As = 1.5 µg/g 
Cd = 0.5 µg/g 
Cr  = 1.5 µg/g 
As = 3.0 µg/g 
Cd = 1.5 µg/g  
Cr  = 3.0 µg/g 
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8.5          Accuracy of Determination of Lead (Pb) and Mercury (Hg) –         
               Recovery Studies 
 
               As a quality control of the methodology, the accuracy of determination of Pb and Hg 
was evaluated by recovery studies using a Polish certified reference material [Mixed Polish Herbs 
(INCT-MPH-2), distributed by Institute of Nuclear Chemistry and Technology, Poland]. The 
certified reference material (CRM) was provided in powder form. Triplicate samples (between 1 
to 2 grams) of the CRM were subjected to the routine drying, acid digestion, dilution and finally 
analysis by GFAAS for Pb, and by cold vapour AAS for Hg, as described in the appropriate 
sections above. These samples were analysed both during the same run (intra-analysis) and in 
different runs (extra-analysis). A total of at least 10 determinations for each metal were carried 
out. The mean results of each metal were compared with, and expressed as the percentage of the 
certified values for Pb and Hg to evaluate the method accuracy.   
 
 
8.6         Precision of Determinations of Pb, As, Cd, Cr, and Hg 
 
              As a second quality control parameter of the methodology, the precision of GFAAS 
determination of Pb, As, Cd and Cr, and of CVAAS determination of Hg was evaluated by 
determining the metal concentration of a selected test sample 8 to 10 times consecutively in the 
same analytical run. Where possible, samples containing low, medium or high levels of the metal 
under investigation were selected for analysed to evaluate the method precision at different 
concentrations. The mean and standard deviation were calculated, and precision of each method 
was expressed as the percentage of the relative standard deviation (%RSD or alternatively as the 
coefficient of variation (CV). 
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8.7         Limit of Detection (LOD) and Limit of Quantitation (LOQ) Determinations 
 
              The LOD and LOQ of the instrument were based on 3 and 10 times, respectively, the 
standard deviation of the method blank. Method blanks were prepared by pipetting 5 mL conc 
HNO3 into acid-washed glass tubes. The tubes were then carried through the whole procedures 
identical to those of the herbal samples, viz., the heating with repeated additions of 5% HNO3, 
followed by dilution of the “digested” sample to a final volume of 10 mL with 5% HNO3, and 
finally determination by either GFAAS for Pb, As, Cd and Cr, or by CVAAS for Hg. 
Determination of these method blanks for each metal was carried out 8 -10 times consecutively in 
the same analytical run. The standard deviation (SD) of the repeated results was then calculated. 
The LOD was equal to 3 times SD, while the LOQ was 10 times SD. 
 
 
8.8        Protocol of Investigation   
 
             The protocol of analyses of metal concentrations in Chinese medicines described in 
sections above is summarised in the flow chart, Figure 8.3 below.
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Figure 8.3         Flow Chart of a Summary of Investigational Protocol 
   
Protocol           Method Development of 5 Heavy Metals 
                                                          
                                                –– Pb –––         (1)  Analytical parameters 
                            –– GFAAS  –– As      –––    (2)  Dilution ranges for different metals 
                                                –– Cd                (3)  Recovery studies – Accuracy evaluation 
                                                –– Cr                (4)  Precision evaluation 
                                                                          (5)  Limit of detection & limit of quantitation 
                            –– VGAAS ––– Hg –– 
 
Purchases of Over-the-counter Herbal Medicines          
 
           Raw Chinese Herbal Materials (CHM): 
           100 samples:- Acid digestion of all 100 samples followed by analyses of 5 metals for  
                     each sample (each prepared in triplicate)  Total metal content 
 
                    20 selected samples:- comprising 3 representative CHM from each of the 7 groups 
                      ––– Flowers                   ––– 3        
                      ––– Roots                      ––– 3      
                      ––– Branches & twigs  ––– 3 
                      ––– Leaves                    ––– 3 
                      ––– Seeds                      ––– 3  
                      ––– Barks                      ––– 3 
                      ––– Marine shell           ––– 2  
                             Water extraction of metals of all 20 samples by boiling followed by  
                     analyses of 5 metals for each sample (in triplicate)  Aqueous metal content  
                              The aqueous metal content as a percentage (%) of the total metal content  
                     of the CHM sample was calculated. The averaged % of the 3 representative   
                     CHM of the group (i.e. the same part of the plant) was used to estimate the 
                     aqueous metal contents of all other CHM belonging to the same group. The   
                     aqueous contents of each CHM of other groups were similarly estimated. Thus, 
                     the estimated values of aqueous metal contents of 98 CHM were obtained. The 
                     remaining 2 belonged to CHM of marine shell origin. 
                    
 
           Chinese Proprietary Medicines (CPM):   
           50 samples:- Acid digestion of all 50 samples followed by analyses of 5 metals for  
                     each sample (prepared in triplicate)  Total metal content 
                                  N.B.   Aqueous metal analysis was not necessary as this form of CPM  
                     was swallowed whole as supplied.  
 
           Chinese Medicinal Formulae (CMF):  
            5 samples:-  Each formula pack was ground into Powder. A quantity of the powder  
                     was digested with acid, followed by analyses of the 5 metals (prepared in  
                     triplicate)  Total metal content 
                     
                     5 CMF samples/packs:-  Water extraction of metals from all 5 packs by boiling  
                   as describe in 9.2.5 followed by analyses of the 5 metals (prepared in duplicate)            
                   Aqueous metal content.  This aqueous metal content allowed calculation of the  
                   actual metal daily intake. 
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                                                                 CHAPTER 9 
RESULTS 
 
9.1      Method Optimisation 
9.1.1   Calibration Curves and UV Absorption Spectra of Standards 
 
            The calibration plots were linear between 0 and 40 µg/L for As, 0 and 24 µg/L for Cr, and 
0 and 6 µg/L for mercury. The coefficient of variations (CV) of these standard curves for As, Cr 
and Hg were 0.9987, 0.9976 and 0.9929 respectively. Some typical calibration curves for each 
metal determination are shown in Figure 9.1 which shows the ranges of standards, the %RSD for 
the duplicate analysis for each standard, and the CVs for the three linear plots. For the 
determination of lead and cadmium the calibration plots chosen were new rational as the linear 
ranges for both metal analysis were so low that it would be impractical and less accurate to make 
very high dilutions. For the determinations of Pb, As, Cd, and Cr using GFAAS methodology the 
UV absorption spectra were recorded during the atomization stage. The absorption peaks were 
clearly sharp and symmetrical. These spectra are shown in Figure 9.2.     
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Figure 9.1    Typical standard curves for Pb, As, Cd, Cr, and Hg showing standard 
concentrations on x-axis and absorbance on y-axis, %RSD and the coefficient of 
variation (R2) for the linear plots    
New Rational - Cal. Set 3
Pb ug/L
Abs
0.00
0.83
0.20
0.40
0.60
0.80
0.0000 60.000020.0000 40.0000
Calibrated
Zoom Overlay
                 
Linear - Cal. Set 1
As ug/L
Abs
0.00
0.56
0.20
0.40
0.0000 45.000010.0000 20.0000 30.0000 40.0000
Calibrated
Zoom Overlay
 
 
Pb Standard Curve: New Rational                              As Standard Curve: Linear         R2 = 0.9987                                                                                         
Std (ug/L)    ABS        Duplicate             %RSD                     Std (ug/L)   ABS      Duplicate           %RSD 
Cal zero        0.0304     0.0311; 0.0296        3.0                          Cal zero      0.0656    0.0727; 0.0585     15.3 
5.0                0.1187     0.1185; 0.1189        0.3                          2.5              0.1168    0.1178; 0.1158       1.2 
10.0              0.2231     0.2260; 0.2201        1.9                          5.0              0.1385    0.1398; 0.1371       1.4 
20.0              0.4102     0.4176; 0.4028        2.6                         10.0             0.1970    0.1978; 0.1962       0.6 
40.0              0.7004     0.7140; 0.6867        2.8                         20.0             0.3235    0.3269; 0.3201       1.5 
50.0              0.8309     0.8330; 0.8288        0.4                         40.0             0.5643    0.5670; 0.5616       0.7 
                                                                                                          
New Rational - Cal. Set 4
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Cd Standard Curve: New Rational                                 Cr Standard Curve: Linear          R2 = 0.9976 
                                                                                         
Std (ug/L)   ABS      Duplicate           %RSD                          ABS (ug/L)   ABS         Duplicates         %RSD 
Cal zero      0.3303    0.3320; 0.3286       0.7                              Cal Zero        0.0755      0.0801; 0.0708       8.7 
0.5              0.1715    0.1698; 0.1731       1.4                              4.0                 0.2269      0.2239; 0.2299       1.9 
1.0              0.3039    0.3085; 0.2993       2.2                              8.0                 0.3834      0.3851; 0.3817       0.6 
2.0              0.5305    0.5336; 0.5274       0.8                              12.0               0.5305      0.5372; 0.5238       1.8 
3.0              0.6884    0.6816; 0.6953       1.4                              24.0               0.9161      0.9155; 0.9167       0.1 
5.0              0.8975    0.8971; 0.8979       0.1   
 
 
          Hg Standard Curve: Linear     
          R2 = 0.9929  
 
          Std (ug/g)    Mean ABS (duplicate)                    
            Cal zero         -0.0003 
            0.5                  0.0125      
            2.0                  0.0458 
            4.0                  0.0818 
            6.0                  0.112
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Figure 9.2   UV absorption spectral traces of standards for Pb, As, Cd and Cr 
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Cd: UV Spectral trace of standards                Cr: UV Spectral trace of standards 
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9.1.2     Accuracy of the Method – as Percentage of Recovery 
 
9.1.2.1  Accuracy of method for lead and mercury 
      
             The accuracy of the method was evaluated by processing 1 to 2 grams of the certified 
reference material (n = 6), Mixed Polish Herbs (INCT-MPH-2) through the whole procedure of 
acid digestion, dilution and analysis. Analysis was carried out in six separate occasions, i.e. 
between runs. The concentrations determined for lead by method of GFAAS, and for mercury by 
VGAAS were then compared with the certified values. The determined concentrations were 
100.5% and 104.0% of the certified values for lead and mercury respectively. Results are shown 
in Table 9.1 below. 
 
Table 9.1   Results of evaluation of accuracy of the analytical methods for lead and mercury 
 
 
 
 
 
 
 
 
 
 
 
 
 
* n = 6 
‡ Polish certified reference material – Mixed Polish Herbs (INCT-MPH-2) 
 ‡Certified 
Reference 
Results. 
(µg/g ± sd) 
Mean 
Determined 
Results 
(µg/g ± sd) 
 
Accuracy as 
% of certified 
values 
 
 
* Lead (Pb) 
 
 
2.16 ± 0.23       
 
2.17 ± 0.08 
 
100.5 
* Mercury (Hg) 17.6 ± 1.6 18.32 ± 3.20 104.0 
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9.1.2.2  Accuracy of method for arsenic, cadmium and chromium 
 
The accuracy of the method for arsenic, cadmium and chromium were evaluated by 
method of recovery after spiking three different levels of these metal standard solutions to 1 gram 
of the crude Chinese herb, Poria (Fu Ling). After being taken through the routine digestion 
procedure, the concentrations of each metal were determined. Results are shown in Tables 9.2, 
9.3, and 9.4 for arsenic, cadmium and chromium respectively. In general, most results were well 
within 5% accuracy. 
 
 
 
Table 9.2   Results of recovery test for arsenic 
 
  
 
* n = 3 for each level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Actual  
concentration. 
(µg/g) 
Mean results 
(µg/g) 
Net As results 
(µg/g) 
As Recovery 
(%) 
 
 
*Fu Ling     (µg/g) 
 
 
0.097 ± 0.013 
   
*As added (0.5 µg/g) 
 
 0.585 ± 0.013 0.488 97.6 
*As added (1.5 µg/g) 
 
 1.517 ± 0.024 1.420 94.7 
*As added (3.0 µg/g) 
 
 2.807 ± 0.012 2.710 90.3 
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Table 9.3   Results of recovery test for cadmium (Cd) 
 
 
 
* n = 3 
 
 
 
 
 
Table 9.4   Results of recovery test for chromium    
 
 
 
* n = 3
 Actual  
concentration. 
(µg/g) 
Mean results 
(µg/g) 
Net Cd results 
(µg/g) 
Cd Recovery 
(%) 
 
 
*Fu Ling     (µg/g) 
 
 
0.027 ± 0.004 
   
*Cd added (0.1 µg/g) 
 
 0.129 ± 0.008 0.102 102.0 
*Cd added (0.5 µg/g) 
 
 0.544 ± 0.010 0.517 103.4 
*Cd added (1.5 µg/g) 
 
 1.652 ± 0.020 1.625 108.3 
 Actual  
concentration. 
(µg/g) 
Mean results 
(µg/g) 
Net CR results 
(µg/g) 
Cr Recovery 
(%) 
 
 
*Fu Ling     (µg/g) 
 
 
0.098 ± 0.023 
   
*Cr added (0.5 µg/g) 
 
 0.576 ± 0.021 0.478 95.6 
*Cr added (1.5 µg/g) 
 
 1.650 ± 0.020 1.552 103.4 
*Cr added (3.0 µg/g) 
 
 3.215 ± 0.052 3.052 101.7 
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9.1.3 Precision of the Method – as Percentage of Relative Standard Deviation   
            (%RSD) 
 
             Representative CHM samples were selected for analysis repetitively up to 8 to 10 times 
for each metal to evaluate the method precision. Results are summarised in Table 9.5 below. The 
table shows that the RSDs for Pb, Cd and As were less than 4%. Chromium was also less than 
4% for both the low and medium levels while at the higher level of about 12 µg/g, the RSD was 
6.9%. These results indicate that the reproducibility of the GFAAS methods was highly 
satisfactory. The precision for the VGAAS method for mercury determination varied somewhat 
from a low RSD of 6.2% for lower concentration to a high RSD of 14.7% for the high 
concentration of  42.7 ng/g. 
 
Table 9.5     Precision of the analytical method for the five metals 
–––––––––––––––––––––––––––––––––––––––––––––––– 
Metal                    Mean ± SD                            RSD (%)                                                                             
–––––––––––––––––––––––––––––––––––––––––––––––– 
Pb  (n = 8)           10.35 ± 0.32 µg/g                   3.1   
 
Cd  (n = 10)         0.322 ± 0.013 µg/g                 3.9     
 
As  (n = 8)           1.12 ± 0.01 µg/g                     0.6 
                            2.49 ± 0.06 µg/g                     2.3 
                            8.36 ± 0.35 µg/g                     4.1 
 
Cr  (n = 8)           0.51 ± 0.02 µg/g                     3.6 
                            3.75 ± 0.08 µg/g                     2.0 
                          11.95 ± 0.83 µg/g                     6.9 
 
Hg  (n = 8)          14.5 ± 0.9 ng/g                        6.2 
                            29.3 ± 3.5 ng/g                      11.9 
                            42.7 ± 6.3 ng/g                      14.7 
 
_________________________________________________
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9.1.4     Limits of Determination – the Limit of Detection (LOD) and Limit of    
               Quantitation (LOQ) 
 
               Method blanks as described in section 9.7 were analysed 8 to 10 consecutively. Results 
are summarised in Table 9.6 below. The LOD and LOQ, based on 3 and 10 times, respectively, 
the standard deviation of the method blank analysis were 0.24 µg/g and 0.8 µg/g respectively for 
Pb, 0.03 µg/g and 0.1 µg/g respectively for arsenic, 1.1 ng/g and 3.5 ng/g respectively for 
cadmium, 2.4 ng/g and 8.0 ng/g respectively for mercury, and 0.06 µg/g and 0.2 µg/g 
respectively for chromium. 
 
Table 9.6   Summary of limits of determination for the five metals 
 
––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Metal                              LOD                                   LOQ 
––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Lead                                0.24 µg/g                           0.8 µg/g 
Arsenic                           0.03 µg/g                           0.1 µg/g 
Cadmium                        1.1 ng/g                             3.5 ng/g 
Mercury                          2.4 ng/g                             8.0 ng/g 
Chromium                      0.06 µg/g                           0.2 µg/g 
––––––––––––––––––––––––––––––––––––––––––––––––––––– 
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9.2     Results of Chinese Herbal Materials (CHM) – Total Metal Contents, Aqueous 
            Metal Concentrations, and Estimated Daily Intakes of Metals  
 
9.2.1    Results of Determination of 5 Metal Contents in Acid-Digested CHM 
 
            Traditionally, metal concentration is measured by its total content in the substance in 
question after acid digestion or microwave extraction. In the present study ninety eight traditional 
Chinese herbal medicines of plant origin, and two marine shells were analyzed for their total (i.e. 
acid-digested) contents of five metals: lead (Pb), arsenic (As), cadmium (Cd), chromium (Cr), 
and mercury (Hg).  The concentrations in terms of µg/g or ng/g of the CHM are summarized in 
Table 9.7. It can be seen that Chinese herbal materials vary greatly in their contents of metals. 
For example, in the case of lead, the contents were as low as 0.10 µg/g for Fu Ling and Qian Shi 
(Sample codes: HDU1 and HAS4 respectively), to as high as 10.27 and 11.97 µg/g for Hong Hua 
and Long Gu respectively (Code: HBS5 and HSD1 respectively), i.e., more than a 100-fold 
difference in concentration. Similarly, Mai Ya (Code: HDG2) contained 0.10 µg of arsenic/g of 
CHM, whereas Long Gu (Code: HSD1) contained 51.54 µg/g, i.e., more than 500-fold difference. 
In the case of cadmium, the lowest content of 34 ng/g was found in Xing Ren (HDC1) while the 
highest level of 1,583 ng/g was found in Wu Wei Zi (HAS1), i.e. approximately 50-fold 
difference. On the other hand, of the 100 CHM analysed for mercury, 28 were below the 
analytical limit of detection of 2.4ng/g, and the highest range of mercury was found to be about 
40 ng/g in Zi Su Ye (HWC2), Long Gu (HSD1) and Yin Yang Huo (HYT5). For chromium 
content, 18 out of 100 CHM were below the analytical limit of detection of 0.06 µg/g, and the 
highest content of 56.47 µg/g was detected in Lu Gen (HEH2).  
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Table 9.7:  Sample number, sample code, and names of the raw Chinese herbs, their pharmacological 
classes and their metal contents (n = 3 for each herb);  LOD: Pb = 0.24 µg/g,  As = 0.03 µg/g,  Cd = 1.1 
ng/g, Hg = 2.4 ng/g,  Cr = 0.06µg/g  
 
 
No. Code 
Chinese 
Name 
Lead 
µg/g ± sd 
Arsenic 
µg/g ± sd 
Cadmium 
ng/g ± sd 
Mercury   
ng/g ± sd 
Chromium 
µg/g ± sd 
Dispel Wind-Cold 
51 HWC1 Gui Zhi 4.84 ± 0.62 0.81 ± 0.04 477.6 ± 82.9 bd 0.92 ± 0.01 
61 HWC2 Zi Su Ye 2.06 ± 0.05 3.35 ± 0.04 464.5 ± 10.5 43.7 ± 0.7 0.11 ± 0.04 
94 HWC3 Jing Jie 3.48 ± 0.14 1.32 ± 0.02 274.0 ± 40.1 9.2 ± 4.0 1.04 ± 0.22 
6 HWC4 Fang Feng 1.50 ± 0.11 2.33 ± 0.19 129.7 ± 22.7 21.3 ± 1.9 0.60 ± 0.04 
17 HWC5 Qiang Huo 0.96 ± 0.12 1.36 ± 0.16 225.8 ± 28.9 14.8 ± 2.2 2.20 ± 0.17 
20 HWC6 Bai Zhi 2.10 ± 0.24 0.81 ± 0.15 133.6 ± 3.8 15.6 ± 4.3 0.44 ± 0.03 
44 HWC7 Xin Ye Hua 1.80 ± 0.12 0.71 ± 0.17 82.3 ± 1.3 31.9 ± 2.2 0.33 ± 0.03 
Dispel Wind-Heat 
34 HWH1 Bo He 1.26 ± 0.03 2.63 ± 0.11 159.2 ± 27.8 10.9 ± 2.0 0.42 ± 0.06 
87 HWH2 Ju Hua 1.39 ± 0.14 0.89 ± 0.11 268.4 ± 23.8 bd 1.80 ± 0.13 
35 HWH3 Chai Hu 1.28 ± 0.21 1.29 ± 0.32 313.6 ± 7.4 11.2 ± 4.5 3.53 ± 1.12 
Eliminate Heat 
23 HEH1 Zhi Mu 1.07 ± 0.14 3.15 ± 0.23 146.9 ± 0.9 21.3 ± 7.4 2.08 ± 0.01 
60 HEH2 Lu Gen 1.59 ± 0.25 0.57 ± 0.03 514.6 ± 70.7 bd 56.47 ±13.4 
52 HEH3 Huang Qin 1.19 ± 0.08 1.23 ± 0.28 181.2 ± 29.6 32.0 ± 3.7 0.41 ± 0.07 
19 HEH4 Huang Bai 0.90 ± 0.10 2.47 ± 0.47 64.5 ± 10.3 13.5  4.9 0.48 ± 0.03 
67 HEH5 Zhi Zi 2.40 ± 0.34 0.73 ± 0.08 338.2 ± 40.6 1.8  0.5 0.14 ± 0.03 
75 HEH6 Ku Shen 0.58 ± 0.01 1.99 ± 0.13 189.1 ± 35.7 bd 3.10 ± 0.48 
95 HEH7 
Long Dan 
Cao 0.91 ± 0.01 2.25 ± 0.17 461.1 ± 73.0 1.8 ± 0.7 13.47±1.36 
Eliminate Heat & Toxins      
85 HHT1 Jin Yin Hua 3.87 ± 0.03 1.12 ± 0.07 237.8 ± 3.8 31.3 ± 3.0 0.33 ± 0.05 
45 HHT2 Lian Qiao 3.09 ± 0.08 1.02 ± 0.12 152.5 ± 4.2 19.4 ± 0.0 0.55 ± 0.03 
90 HHT3 Ban Lan Gen 0.54 ± 0.12 1.48 ± 0.30 213.6 ± 14.1 bd 0.55 ± 0.10 
Eliminate Heat & Cool Blood 
96 HCB1 
Sheng Di 
Huang 2.99 ± 0.29 1.26 ± 0.06 168.2 ± 8.4 9.0 ± 6.5 4.15 ± 1.15 
93 HCB2 Xuan Shen 1.32 ± 0.20 1.01 ± 0.14 238.5 ± 5.9 bd 0.41 ± 0.09 
74 HCB3 Mu Dan Pi 0.62 ± 0.08 0.96 ± 0.21 244.9 ± 44.4 bd 0.11 ± 0.03 
22 HCB4 Chi Shao 0.42 ± 0.01 1.02 ± 0.04 133.8 ± 2.5 16.3 ± 4.4 0.64 ± 0.05 
62 HCB5 Zi Cao 2.62 ± 0.47 2.68 ± 0.38 713.3 ± 15.7 bd 0.71 ± 0.29 
Eliminate Deficiency Heat 
47 HDH1 Di Gu PI 1.10 ± 0.15 2.03 ± 0.10 173.6 ± 21.6 11.3 ± 4.7 1.39 ± 0.11 
Purgatives      
32 HPU1 Da Huang 0.51 ± 0.04 3.32 ± 0.09 198.1 ± 23.7 10.7 ± 1.4 0.30 ± 0.01 
Eliminate Wind-Damp 
38 HWD1 Du Huo 1.61 ± 0.50 0.88 ± 0.09 197.1 ± 8.2 8.9 ± 1.3 1.01 ± 0.03 
70 HWD2 Qin Jiao 1.21 ± 0.05 1.42 ± 0.07 318.5 ± 57.6 8.7 ± 4.0 4.67 ± 0.09 
9 HWD3 Sang Ji Sheng 1.44 ± 0.19 1.33 ± 0.13 155.5 ± 21.1 16.8 ± 2.5 1.46 ± 0.22 
Aromatic for Dispelling Damp  
30 HAD1 Cang Zhu 0.53 ± 0.07 3.51 ± 0.08 170.7 ± 9.5 5.9 ± 4.3 0.38 ± 0.04 
79 HAD2 Huo Po 1.29 ± 0.15 0.68 ± 0.07 99.9 ± 3.4 18.0 ± 0.8 5.12 ± 0.80 
49 HAD3 Huo Xiang 0.98 ± 0.05 2.14 ± 0.06 158.4 ± 30.0 20.2 ± 1.4 0.33 ± 0.05 
69 HAD4 Sha Ren 2.59 ± 0.16 0.70 ± 0.04 302.9 ± 22.9 11.7 ± 3.9 0.38 ± 0.04 
 
Key for Table 9.7  Hg: 23 of 100 were < LOD; Cr: 3 of 100 were < LOD; bd = below detection limit; 
ug/g = microgram per gram dried weight of raw herb; ng/g = nanogram per gram dried weight of raw herb. 
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Table 9.7 continued:  Sample number, sample code, and names of the raw Chinese herbs, their 
pharmacological classes and their metal contents (n = 3 for each herb) 
 
 
No. Code Chinese Name 
Lead 
µg/g ± sd 
Arsenic 
µg/g ± sd 
Cadmium 
ng/g ± sd 
Mercury   
ng/g ± sd 
Chromium 
µg/g ± sd 
Diuretics 
97 HDU1 Fu Ling 0.11 ± 0.01 0.28 ± 0.04 55.2 ± 2.8 bd 0.09 ± 0.01 
36 HDU2 Ze Xie 1.30 ± 0.04 0.40 ± 0.02 319.3 ± 18.6 5.1 ± 1.7 0.04 ± 0.00 
68 HDU3 Yi Yi Ren 0.45 ± 0.03 0.43 ± 0.06 108.8 ± 14.3 bd 0.32 ± 0.04 
Warming Interior  
54 HWI1 Gan Jiang 1.27 ± 0.20 0.49 ± 0.05 305.2 ± 24.9 bd 0.72 ± 0.07 
63 HWI2 Rou Gui 1.43 ± 0.04 2.41 ± 0.16 439.6 ± 28.9 8.4 ± 7.7 0.08 ± 0.02 
1 HWI3 Wu Zhu Yu 2.78 ± 0.16 0.86 ± 0.06 205.9 ± 31.7 22.1 ± 4.4 0.34 ± 0.04 
Regulate Qi 
64      HRQ1 Ju Pi  1.68 ± 0.15 1.59 ± 0.11 211.3 ± 14.1 4.1 ± 1.5 0.37 ± 0.10 
72 HRQ2 Qing Pi 0.98 ± 0.01 0.75 ± 0.18 189.6 ± 59.9 3.46 ± 2.4 1.01 ± 0.23 
41 HRQ3 Zhi Ke 1.20 ± 0.05 1.29 ± 0.15 118.6 ± 4.2 10.0 ± 0.7 0.25 ± 0.03 
59 HRQ4 Mu Xiang 1.37 ± 0.14 1.27 ± 0.24 1030.3 ±10.2 7.5 ± 2.2 1.52 ± 0.32 
3 HRQ5 Xiang Fu 0.68 ± 0.02 0.14 ± 0.01 118.9 ± 4.2 15.5 ± 1.6 1.40 ± 0.08 
8 HRQ6 Wu Yao 1.50 ± 0.13 0.74 ± 0.03 781.8 ± 51.5 17.7 ± 4.7 0.93 ± 0.11 
7 HRQ7 Yan Hu Suo 1.02 ± 0.03 0.20 ± 0.06 171.1 ± 2.5 15.4 ± 2.5 0.15 ± 0.01 
Digestives 
55 HDG1 Shan Zha  1.3 ± 0.14 0.74 ± 0.06 92.2 ± 23.8 13.8 ± 7.2 2.23 ± 0.99 
16 HDG2 Mai Ya 0.74 ± 0.27 0.10 ± 0.15 71.2 ± 15.3 10.8 ± 0.0 3.98 ± 0.81 
Anthelmintics 
33 HAN1 Da Fu Pi 1.07 ± 0.05 0.30 ± 0.03 157.6 ± 7.2 2.2 ± 0.9 0.54 ± 0.01 
Hemostatics 
48 HHM1 Ce Bai Ye 0.37 ± 0.04 18.61±1.11 39.0 ± 12.8 22.9 ± 1.5 0.77 ± 0.10 
91 HHM2 Bai Mao Gen 1.66 ± 0.2 1.23 ± 0.04 240.5 ± 8.5 4.1 ± 0.2 3.55 ± 0.51 
Activate Blood Circulation & Remove Blood Stasis 
92 HBS1 Chuan Xiong 0.73 ± 0.02 0.95 ± 0.04 326.7 ± 11.5 15.9 ± 2.1 3.05 ± 1.75 
66 HBS2 Yu Jin 3.40 ± 0.01 1.05 ± 0.01 335.8 ± 12.4 bd 0.66 ± 0.14 
2 HBS3 Dan Shen 1.42 ± 0.50 1.28 ± 0.09 116.0 ± 7.4 18.2 ± 2.3 2.35 ± 0.05 
80 HBS4 Ye Mu Cao 2.69 ± 0.04 2.21 ± 0.42 950.8 ±203.1 15.7 ± 6.5 0.61 ± 0.16 
27 HBS5 Hong Hua 10.27 0.59 5.99 ± 1.26 166.7 ± 3.7 11.0 ± 2.1 0.92 ± 0.01 
71 HBS6 Chuan Niu Xi 0.85 ± 0.06 4.15 ± 0.50 320.2 ± 2.2 12.9 ± 2.2 8.57 ± 1.21 
89 HBS7 Huai Niu Xi 1.56 ± 0.27 1.06 ± 0.07 242.8 ± 24.2 8.9 ± 0.8 2.82 ± 0.36 
98 HBS8 Mo Yao 2.50 ± 0.24 2.08 ± 1.31 75.9 ± 14.8 2.3 ± 0.7 11.02±1.40 
Expectorants, Anti-tussives & Dysnea- relieving Drugs 
40 HRP1 Ban Xia 0.67 ± 0.13 2.97 ± 0.04 94.5 ± 13.3 7.8 ± 0.91 15.3 ± 0.41 
76 HRP2 Jie Geng 1.81 ± 0.06 0.52 ± 0.04 259.3 ± 39.2 bd 0.21 ± 0.05 
11 HRP3 Qian Hu  2.44 ± 0.27 0.71 ± 0.04 674.3 ± 95.3 11.6 ± 0.1 2.12 ± 0.47 
65 HRP4 Gua Lou 5.10 ± 0.30 0.93 ± 0.13 580.1 ±  91.1 bd 3.57 ± 0.86 
77 HRP5 Chuan Bei Mu 1.52 ± 0.04 0.26 ± 0.01 319.1 ± 14.9 bd 0.16 ± 0.03 
 
Key for Table 9.7 
sd = standard deviation of the mean 
bd = below detection limit 
ug/g = microgram per gram dried weight of raw herb 
ng/g = nanogram per gram dried weight of raw herb 
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Table 9.7 continued:  Sample number, sample code, and names of the raw Chinese herbs, their 
pharmacological classes and their metal contents (n = 3 for each herb) 
 
 
No. Code Chinese Name 
Lead 
µg/g ± sd 
Arsenic 
µg/g ± sd 
Cadmium 
ng/g ± sd 
Mercury   
ng/g ± sd 
Chromium 
µg/g ± sd 
Relieve Cough & Dyspnea      
37 HDC1 Xing Ren  0.51 ± 0.02 0.31 ± 0.01 34.5 ± 0.3 7.6 ± 2.0 0.03 ± 0.01 
39 HDC2 Bai Bu 1.22 ± 0.06 0.80 ± 0.04 146.5 ± 13.2 9.6 ± 3.5 2.97 ± 0.16 
99 HDC3 Zi Wan 0.69 ± 0.07 2.25 ± 0.19 629.0 ± 10.4 1.3 ± 0.6 5.32 ± 0.61 
81 HDC4 Su Zi 0.73 ± 0.07 0.60 ± 0.04 64.8 ± 3.5 bd bd 
82 HDC5 Sang Bai Pi 0.90 ± 0.05 1.16 ± 0.24 100.2 ± 4.3 bd 0.98 ± 0.11 
Sedatives      
57 HSD1 Long Gu 11.97 ±1.04 51.54 ±6.19 1053.5 ± 225 42.7 ± 6.3 19.52 ±1.67 
31 HSD2 Suan Zao Ren 0.94 ± 0.05 0.86 ± 0.18 52.4 ± 7.5 8.6 ± 1.3 0.13 ± 0.00 
73 HSD3 Bai Zi Ren 0.86 ± 0.08 0.54 ± 0.19 223.4 ± 14.6 11.3 ± 2.0 0.13 ± 0.02 
14 HSD4 Yuan Zhi 0.66 ± 0.04 0.96 ± 0.16 72.7 ± 4.7 19.6±12.6 2.21 ± 0.27 
Calm Liver & Suppress Wind      
83 HCL1 Tian Ma 1.19 ± 0.15 1.80 ± 0.03 170.2 ± 24.5 29.3 ± 3.5 2.28 ± 0.24 
25 HCL2 Gou Teng 1.31 ± 0.32 1.12 ± 0.06 165.9 ± 4.5 13.5 ± 1.8 2.99 ± 0.12 
103 HCL3 Mu Li 8.68 ± 0.44 31.56 ±1.46 232.9 ± 18.1 bd 5.48 ± 0.33 
Qi Tonics      
53 HQT1 Huang Qi 1.08 ± 0.02 0.44 ± 0.08 115.4 ± 7.8 8.0 ± 2.5 0.77 ± 0.11 
56 HQT2 Bai Zhu 1.77 ± 0.21 1.76 ± 0.20 201.4 ± 3.8 bd 3.09 ± 0.44 
4 HQT3 Shan yao 1.59 ± 0.34 0.39 ± 0.01 74.6 ± 2.2 23.8 ± 5.8 0.11 ± 0.00 
24 HQT4 Gan Cao 0.74 ± 0.04 0.74 ± 0.16 61.3 ± 4.0 13.3 ± 2.9 0.47 ± 0.08 
42 HQT5 Zhi Gan Cao 0.28 ± 0.09 1.62 ± 0.20 
   81.8 ± 3.5  14.9 ±1.0 1.93 ± 0.18 
Yang Tonics      
28 HYT1 Du Zhong 1.16 ± 0.10 2.10 ± 0.30 164.4 ± 7.6 14.2 ± 4.1 5.09 ± 0.46 
43 HYT2 Xu Duan 0.59 ± 0.10 4.12 ± 0.49 267.5 ± 2.0 7.3 ± 0.4 3.67 ± 0.31 
46 HYT3 Bu Gu Zhi 1.67 ± 0.11 0.81 ± 0.02 104.2 ± 20.8 15.8 ± 0.0 0.68 ± 0.08 
100 HYT4 Rou Cong Rong 2.04 ± 0.16 1.17 ± 0.07 198.1 ± 7.3 0.6 ± 0.3 14.96 ±1.47 
101 HYT5 Yin Yang Huo 1.25 ± 0.04 2.31 ± 0.30 62.7 ± 11.1 43.4 ± 7.0 3.42 ± 0.60 
Blood Tonics      
10 HBT1 Dang Gui 1.49 ± 0.02 0.56 ± 0.09 113.0 ± 9.2 15.4 ± 3.8 0.59 ± 0.01 
78 HBT2 He Shou Wu 1.32 ± 0.10 1.34 ± 0.14 149.2 ± 7.8 bd 2.14 ± 0.20 
50 HBT3 Shu Di Huang 1.83 ± 0.06 1.93 ± 0.28 185.8 ± 0.0 16.3 ± 0.9 18.53±0.52 
12 HBT4 Bai Shao 0.72 ± 0.07 1.22 ± 0.03 104.8 ± 2.3 23.4 ± 1.1 0.10 ± 0.03 
Yin Tonics      
13 HYN1 Bei Sha Shen 1.03 ± 0.05 0.46 ± 0.13 88.4 ± 7.3 12.7 ± 4.9 0.11 ± 0.02 
88 HYN2 Mai Men Dong 0.78 ± 0.19 0.73 ± 0.10 254.0 ± 8.1 bd 2.64 ± 0.06 
15 HYN3 Yu Zhu 0.53 ± 0.09 0.38 ± 0.06 260.4 ± 95.8 18.1 ± 9.4 0.25 ± 0.03 
29 HYN4 Shan Zhu Yu 1.60 ± 0.02 1.26 ± 0.25 178.3 ± 19.8 8.1 ± 2.3 0.14 ± 0.01 
21 HYN5 Gou Qi Zi 1.87 ± 0.11 0.44 ± 0.10 212.1 ± 6.1 16.8 ± 2.5 0.89 ± 0.14 
86 HYN6 Han Lian Cao 1.69 ± 0.28 2.56 ± 0.27 1123.9 ±62.4 bd 2.63 ± 0.12 
18 HYN7 Nu Zhen Zi 2.09 ± 0.32 2.69 ± 0.19 216.7 ± 28.8 22.8 ±10.9 0.82 ± 0.00 
Astringents      
58 HAS1 Wu Wei Zi 1.92 ± 0.18 0.55 ± 0.03 1582.7 ± 324 19.3 ± 0.7 1.78 ± 0.34 
26 HAS2 Fu Ziao Mai 0.75 ± 0.10 0.49 ± 0.16 61.9 ± 1.8 2.5 ± 1.4 bd 
5 HAS3 Lian Zi 1.44 ± 0.02 0.18 ± 0.00 228.4 ± 4.1 17.5 ± 2.0 0.07 ± 0.02 
84 HAS4 Qian Shi 0.10 ± 0.01 0.40 ± 0.02 74.4 ± 8.5 bd 0.13 ± 0.01 
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9.2.1.1  Difference inTotal Metal Contents inAcid-digested CHM 
 
            The contents of the 5 metals in the herbal samples were generally low for the great 
majority of the Chinese herbal materials analysed. Figure 9.3 is a scatter plot of the distribution 
of lead (Pb) contents among the 100 CHMs. It shows that about 80% of the CHM samples 
contained less than 2 µg of lead /g, and 18% had lead contents of between 2 and 5 µg/g, while the 
remaining three samples were higher than the rest with concentrations between 8 and 12 µg/g. 
The two samples with by far the highest contents were the marine shell, Long Gu, and Mu Li. 
 
   The arsenic contents among the 100 CHMs were even more heavily distributed on the 
very low levels with almost all lying below 4 µg/g (Figure 9.4). Two samples were especially 
high. They were the two marine shells, Long Gu and Mu Li.  
 
   The distribution of cadmium contents among the 100 CHM samples was more dispersed 
although the majority were less than 0.4 µg/g as shown in Figure 9.5. For mercury, 33 samples 
were below the analytical limit of detection of 2.4 ng/g, while the remaining samples had a much 
wider spread of distributions than arsenic, as seen in Figure 9.6. Three CHM samples had 
mercury contents of above 40 ng/g. Again, Long Gu was one of them. On the other hand, 
chromium contents in CHM tended to cluster at low concentrations, at less than 5 µg/g. Lu Gen, 
at 56.5 µg/g was the only outlier (Figure 9.7). 
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Figure 9.3 – 9.7: Distributions of the five mertals among the 100 Chinese herbal materials 
showing heavy preponderance at the low concentrations 
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9.2.2     Results of Metal Concentrations in Aqueous Decoctions of CHM  
 
             Crude CHM are not consumed raw as purchased. They are boiled in water either 
individually or as part of a prescription (a formula) as described in section 8.2.5, and the aqueous 
solution (i.e., decoction) thus obtained, is drunk for its medicinal property. Hence, the metal 
content in the water extraction after boiling represents the real fraction of metal intake. Therefore, 
in this project, the water-soluble fraction of metals in the herbs obtained through the process of 
boiling in water was also investigated. The 100 CHMs in this project came from one of the 6 
different parts of plants, namely, roots, leaves, seeds, barks, flowers, and branches/twigs. Rather 
than repeating the processes of aqueous extraction and analysis for all 100 CHM, three 
representative CHM were selected from each group of the 6 different parts of plants. This 
amounted to 18 herbal plants plus the two marine shell and bone (Long Gu, and Mu Li). They 
were then taken through the processes of two consecutive boiling steps with water, resulting in 
first decoction and second decoction (Column 2 of Table 9.8), and finally their metal contents 
analysed. In addition, the only two CHM of marine shell origin, were also included for analysis. 
Take Wu Yao as an example. Its total acid-digested Pb content (determined earlier) is shown in 
column 3. The metal contents determined in the first and second aqueous decoctions for Wu Yao 
were then calculated as a percentage of the total acid-digested metal content (Column 4). 
Similarly, columns 5 and 6 represent aqueous metal results obtained for the two decoctions of 
Qin Hu while columns 7 and 8 are results for Tian Ma. These three CHM came from roots of 
plants. The percentages of these three CHM from the first decoctions or second decoctions were 
then averaged (Column 9). The two averaged percentages represent the efficiencies (expressed as 
% of the total metal concentration) of aqueous extraction of lead in the first and second 
decoctions. The difference in % efficiencies between the two aqueous decoctions is indicated by 
their ratio (Column 11). On the other hand, the sum of these two efficiencies gave the total % of 
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extraction from the two combined decoctions. This combined % is important as it represents the 
daily intake from drinking the two decoctions per day (drunk in two separate occasions: usually 
morning and evening before or after meals). Further, the individual combined % of aqueous 
extraction (first and second decoctions) of a specific metal (in this case, Pb) from the three 
representative root CHM, namely, the Wu Yao, Qin Hu, and Tian Ma, were then averaged, and 
the averaged value was used to calculate the aqueous Pb metal contents for all other CHM of root 
origin.  
 
               The above procedure and calculations for Pb were also applied to the other four aqueous 
metal determinations for CHM from Leaves, Seeds, Barks, Flowers, Branches, and Marine Shells. 
Results are similarly summarised (as in Table 9.8 for lead) in Table 9.9 for arsenic, in Table 
9.10 for cadmium, in Table 9.11 for mercury, and in Table 9.12 for chromium. The averaged 
percentages of the combined aqueous extractions (i.e. sum of the first and second decoctions) of 
each metal and for each group of CHM are summarised in Table 9.13. 
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Table 9.8   Lead (Pb) concentration in the aqueous decoctions of the 20 representative Chinese herbal materials 
 
1 2 3 4 5 6 7 8 9 10 11 
Aqueous 
Extraction of 
Herb # 1 (n =2) 
Aqueous 
Extraction of 
Herb # 2 (n =2) 
Aqueous 
Extraction of 
Herb # 3 (n =2) 
Part of 
Herb 
Sequence 
of Boiling 
(each 
boiling: 
n = 2)  
Total 
Lead 
(Acid-
digested) 
µg/g 
Aqeous 
Pb 
µg/g 
% of 
Total 
Lead 
Total 
Lead 
(Acid-
digested) 
µg/g 
Aqeous 
Pb 
µg/g 
% of 
Total 
Lead 
Total 
Lead 
(Acid-
digested) 
µg/g 
Aqeous 
Pb 
µg/g 
% of 
Total 
Lead 
Average 
Aqueous 
% (of 3 
herbs)  of 
the Total 
Pb 
% of  Pb 
Distribu-
tion 
between 
1st & 2nd 
Decoctions 
Extraction  
Efficiency 
between 
1st & 2nd 
Decoctions 
1st : 2nd 
Root 1st Boiling 0.0166 1.1 0.2831 11.6 0.1736 14.6 9.1 47.6 
 2nd Boiling 0.0088 0.6 0.1614 6.6 0.2707 22.8 10.0 52.4 
 1st + 2nd  
Wu Yao  
= 1.50 ± 
0.13 
 1.7 
Qin Hu = 
2.44 ± 
0.27 
 18.2 
Tian Ma 
=1.19 ± 
0.15 
 37.4 19.1%  
 
≅ 1 : 1 
 
Leaf 1st Boiling 0.3206 25.4 0.4464 21.7 0.1660 13.3 20.1 68.9 
 2nd Boiling 0.1136 9.0 0.2106 10.2 0.1005 8.0 9.1 31.1 
 1st + 2nd  
Bo Hu = 
1.26 ±  
0.03 
 34.4 
Zi Su Ye 
2.06 ± 
0.05 
 31.9 
Yin Yan 
Huo = 
1.25±0.04 
 21.3 29.2%  
 
≅ 2.2 : 1 
 
Seed 1st Boiling 0.4296 29.8 0.6005 28.7 0.2063 10.7 23.1 59.1 
 2nd Boiling 0.3124 21.7 0.5258 25.2 0.0194 1.0 16.0 40.9 
 1st + 2nd  
Lian Zi = 
1.44 ± 
0.02 
 51.5 
Nu Zhen 
Zi = 2.09 
± 0.32 
 53.9 
Wu Wei 
Zi = 1.92 
± 0.18 
 11.7 39.1%  
 
≅ 1.4 : 1 
 
Bark 1st Boiling 0.1427 15.9 0.2233 19.3 0.1777 12.4 15.9 55.2 
 2nd Boiling 0.0934 10.4 0.1864 16.1 0.1752 12.3 12.9 44.8 
 1st + 2nd  
Huang 
Bai = 0.90 
±  0.10 
 26.3 
Du 
Zhong = 
1.16±0.10 
 35.4 
Rou Gui 
= 1.43 ± 
0.04 
 24.7 28.8%  
 
≅ 1.2 : 1 
 
Flower 1st Boiling 0.2215 2.2 0.1769 9.8 0.1901 4.9 5.6 65.1 
 2nd Boiling 0.1581 1.5 0.0754 4.2 0.1268 3.3 3.0 34.9 
 1st + 2nd  
Hong Hua 
= 10.27 
±  0.59 
 3.7 
Xin Yi 
Hua = 
1.80±0.12  
 14.0 
Jin Yin 
Hua = 
3.87±0.03 
 8.2 8.6%  
 
≅ 2 : 1 
 
Branch 1st Boiling 0.1746 12.1 0.4024 30.7 0.2505 5.3 16.1 63.0 
 2nd Boiling 0.1258 8.7 0.2231 17.0 0.1175 2.5 9.4 37.0 
 1st + 2nd  
Sang Ji 
Sheng = 
1.44± 0.19 
 20.8 
Gou 
Teng =  
1.31±0.32 
 47.7 
Gui Zhi  
= 4.69 ± 
0.07 
 7.8 25.5%  
 
≅ 1.7 : 1 
 
Shell 1st Boiling 0.0727 0.6 0.0790 0.9   0.8 61.5 
 2nd Boiling 0.0569 0.6 0.0514 0.4   0.5 38.5 
 1st + 2nd  
Long Gu 
= 11.97 ± 
1.04 
 1.2 
Mu Li 
= 8.68 ± 
0.44 
 1.3 
 
  1.3%  
 
≅ 1.6 : 1 
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Table 9.9   Arsenic (As) concentration in the aqueous decoctions of the 20 representative Chinese herbal materials 
 
1 2 3 4 5 6 7 8 9 10 11 
Aqueous 
Extraction of 
Herb # 1 (n = 2) 
Aqueous 
Extraction of 
Herb # 2 (n = 2) 
Aqueous 
Extraction of 
Herb # 3 (n = 2) 
Part of 
Herb 
Sequence 
of Boiling 
(each 
boiling: 
n = 2) 
Total 
Arsenic 
(Acid-
digested) 
µg/g 
Aqeous 
As 
µg/g 
% of 
Total 
Arsenic 
Total 
Arsenic 
(Acid-
digested) 
µg/g 
Aqeous 
As 
µg/g 
% of 
Total 
Arsenic 
Total 
Arsenic 
(Acid-
digested) 
µg/g 
Aqeous 
As 
µg/g 
% of 
Total 
Arsenic 
Average 
Aqueous 
% (of 3 
herbs)  
of the 
Total As 
% of  As 
Distribu-
tion 
between 
1st & 2nd 
Boiling 
Extraction 
Efficiency 
between 
1st & 2nd 
Decoctions 
1st : 2nd 
Root 1st Boiling 01471 18.8 0.2814 39.8 0.3112 17.3 25.3 50.0 
 2nd Boiling 0.1568 20.1 0.2695 38.1 0.3165 17.6 25.3 50.0 
 1st + 2nd  
Wu Yao  
= 0.74 ±  
0..30 
 39.0 
Qin Hu = 
0.71 ± 
0.04 
 77.9 
Tian Ma 
=1.80 ± 
0.03 
 34.9 50.6%  
 
≅ 1 : 1 
 
Leaf 1st Boiling 0.5817 22.1 0.4256 12.7 0.4387 18.9 17.9 67.0 
 2nd Boiling 0.2305 8.8 0.1997 5.9 0.2717 11.7 8.8 33.0 
 1st + 2nd  
Bo Hu = 
2.63 ±  
0.11 
 30.9 
Zi Su Ye 
3.35 ± 
0.04 
 18.6 
Yin Yan 
Huo = 
2.31±0.30 
 30.6 26.7%  
 
≅ 2 : 1 
 
Seed 1st Boiling 0.0899 49.5 0.2328 8.7 0.3778 68.4 42.2 76.2 
 2nd Boiling 0.0567 31.2 0.1222 4.5 0.0225 4.0 13.2 23.8 
 1st + 2nd  
Lian Zi = 
0.18 ± 
0.00 
 80.7 
Nu Zhen 
Zi = 2.69 
± 0.19 
 13.2 
Wu Wei 
Zi = 0.55 
± 0.03 
 72.4 55.4%  
 
≅ 3.2 : 1 
 
Bark 1st Boiling 0.2045 8.3 0.0537 2.6 0.0933 3.9 14.8 67.0 
 2nd Boiling 0.0654 2.6 0.0237 1.1 0.0880 3.6 7.3 33.0 
 1st + 2nd  
Huang 
Bai = 
2.47±0.47 
 10.9 
Du  
Zhong  = 
2.10±0.30 
 3.7 
Rou Gui 
= 2.41 ± 
0.16 
 7.5 22.1%  
 
≅ 2 : 1 
 
Flower 1st Boiling 0.4779 7.9 0.1910 26.9 0.2872 25.6 20.2 63.7 
 2nd Boiling 0.0999 1.6 0.1438 20.3 0.1429 12.7 11.5 36.3 
 1st + 2nd  
Hong 
Hua = 
5.99±1.26 
 9.6 
Xin Yi 
Hua = 
0.71±0.17  
 47.3 
Jin Yin 
Hua = 
1.12±0.07 
 38.4 31.7%  
 
≅ 1.8 : 1 
 
Branch 1st Boiling 0.1797 13.5 0.1257 10.7 0.1877 22.3 15.7 66.8 
 2nd Boiling 0.0996 7.5 0.0720 6.1 0.0802 9.8 7.8 33.2 
 1st + 2nd  
Sang Ji 
Sheng = 
1.33±0.13 
 21.0 
Gou 
Teng =  
1.12±0.06 
 16.8 
Gui Zhi  
= 0.81 ± 
0.04 
 32.9 23.5%  
 
≅ 2 : 1 
 
Shell 1st Boiling 0.0050 < 0.1 0.1506 0.4   < 0.3 < 50 
 2nd Boiling bd / bd 0.0 0.1968 0.6   0.3 ~ 50 
 1st + 2nd  
Long Gu 
= 51.54 ± 
6.19 
 < 0.1 
Mu Li 
= 31.56 ±  
1.46 
 1.0 
 
  ~ 0.6%  
 
≅ 1 : 1 
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Table 9.10    Cadmium (Cd) concentration in the aqueous decoctions of the 20 representative Chinese herbal materials 
1 2 3 4 5 6 7 8 9 10 11 
Aqueous 
Extraction of 
Herb # 1 (n =2) 
Aqueous 
Extraction of 
Herb # 2 (n = 2) 
Aqueous 
Extraction of 
Herb # 3 (n = 2) 
Part of 
Herb 
Sequence 
of Boiling 
(each 
boiling: 
n = 2) 
Total Cd 
(Acid-
digested) 
ng/g Aqeous 
Cd 
ng/g 
% of 
Total 
Cd 
Total Cd 
(Acid-
digested) 
ng/g Aqeou
s Cd 
ng/g 
% of 
Total 
Cd 
Total Cd 
(Acid-
digested) 
ng/g Aqeous 
Cd 
ng/g 
% of 
Total 
Cd 
Average 
Aqueous 
% (of 3 
herbs)  of 
the Total 
Cd 
% of  
Cd 
Distrib
u-tion 
between 
1st & 2nd 
Boiling 
Extraction 
Efficiency 
between 
1st & 2nd 
Decoction
s 
1st : 2nd 
Root 1st Boiling 117.3 15.0 72.5 10.8 49.6 29.1 18.3 52.7 
 2nd Boiling 92.5 11.8 66.5 9.9 47.0 27.6 16.4 47.3 
 1st + 2nd  
Wu Yao  
= 781.8 ±  
51.5 
 26.8 
Qin Hu = 
674.3 ± 
95.3 
 20.7 
Tian Ma 
= 170.2   
±  24.5 
 56.7 34.7%  
 
≅ 1 : 1 
 
Leaf 1st Boiling 84.6 53.1 127.3 27.4 59.9 48.5 43.0 71.9 
 2nd Boiling 15.2 9.5 37.9 8.1 40.7 33.0 16.8 28.1 
 1st + 2nd  
Bo Hu = 
159.2 ±  
17.8 
 62.6 
Zi Su Ye 
464.5 ± 
10.5 
 35.5 
Yin Yan 
Huo = 
123.4± 61 
 81.5 59.8%  
 
≅ 2.5 : 1 
 
Seed 1st Boiling 49.9 21.8 68.9 31.8 137.9 8.7 20.8 78.5 
 2nd Boiling 34.3 15.0 2 0.9 19.9 1.3 5.7 21.5 
 1st + 2nd  
Lian Zi = 
228.4 ± 
4.1 
 36.8 
Nu Zhen 
Zi =216.7 
±  28.8 
 32.7 
Wu Wei 
Zi 1582.7  
±  324.6 
 10.0 26.5%  
 
≅ 3.7 : 1 
 
Bark 1st Boiling 22.0 34.1 28.4 17.2 10.4 2.4 17.9 66.1 
 2nd Boiling 10.1 15.6 16.3 9.9 8.9 2.0 9.2 33.9 
 1st + 2nd  
Huang 
Bai = 
64.5±10.3 
 49.7 
Du 
Zhong  =  
164.4±7.6 
 27.1 
Rou Gui 
= 439.6 ±  
28.9 
 4.4 27.1%  
 
≅ 2 : 1 
 
Flower 1st Boiling 127.6 76.5 116.4 77.8 18.9 7.9 54.1 83.0 
 2nd Boiling 9.9 5.9 25.5 17.0 24.6 10.3 11.1 17.0 
 1st + 2nd  
Hong Hua 
= 
166.7±3.7 
 82.4 
Xin Yi 
Hua149.
5 ±. 23.4  
 94.8 
Jin Yin 
Hua237.
8  ±  3.8 
 18.2 65.2%  
 
≅ 5 : 1 
 
Branc
h 
1st Boiling 24.5 15.7 12.9 7.8 24.3 5.1 9.5 49.0 
 2nd Boiling 36.2 23.3 9.4 5.6 4.5 1.0 9.9 51.0 
 1st + 2nd  
Sang Ji 
Sheng = 
155..5 ± 
21.1 
 39.0 
Gou 
Teng =  
165.9 ±  
4.5 
 13.4 
Gui Zhi  
= 477.6  
±  82.9 
 6.1 19.4%  
 
≅ 1 : 1 
 
Shell 1st Boiling 0.75 ~ 0.1 9.0 3.9   2.0 80.0 
 2nd Boiling bd 0.0 2.4 1.0   0.5 20.0 
 1st + 2nd  
Long Gu 
= 1053.4 ±  
224.9 
 ~0.1 
Mu Li 
= 232.9  
± 18.1 
 4.9 
 
  2.5%  
 
≅ 4 : 1 
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Table 9.11   Mercury (Hg) concentration in the aqueous decoctions of the 20 representative Chinese herbal materials 
1 2 3 4 5 6 7 8 9 10 11 
Aqueous  
Extraction  
of Herb # 1 (n =2) 
Aqueous  
Extraction of 
Herb # 2 (n = 2) 
Aqueous  
Extraction of 
Herb # 3 (n = 2) 
Part of 
Herb 
Sequence 
of Boiling 
(each 
boiling: 
n = 2) 
Total Hg 
(Acid-
digested) 
ng/g Aqeous 
Hg 
ng/g 
% of 
Total 
Hg 
Total Hg 
(Acid-
digested) 
ng/g Aqeous 
Hg 
ng/g 
% of 
Total 
Hg 
Total Hg 
(Acid-
digested) 
ng/g Aqeous 
Hg 
ng/g 
% of 
Total 
Hg 
Average 
Aqueous 
% (of 3 
herbs)  of 
the Total 
Hg 
% of 
Hg  
Distribu 
-tion 
Between 
1st & 2nd 
Boiling 
Extraction 
Efficiency 
between 
1st & 2nd 
Decoctions 
1st : 2nd 
Root 1st Boiling bd bd 1.35 11.6 1.45 4.9 5.5 40.1 
 2nd Boiling bd bd 1.15 9.9 4.35 14.8 8.2 59.9 
 1st + 2nd  
Wu Yao  
= 17.7 ±  
4.7 
 bd 
Qin Hu 
=11.6  
± 0.1 
 21.5 
Tian Ma 
= 29.3 ± 
3.5 
 19.7 13.7%  
 
≅ 0.7 : 1 
 
Leaf 1st Boiling 8.2 51.5 8.15 18.5 bd Bd 23.3 55.2 
 2nd Boiling 6.7 41.7 6.6 15.1 bd Bd 18.9 44.8 
 1st + 2nd  
Bo Hu = 
15.8 ±  
6.2 
 93.2 
Zi Su Ye 
43.7 ± 
0.7 
 33.6 
Yin Yan 
Huo = 
43.4 ±7.0 
 Bd 42.2%  
 
≅ 1.2 : 1 
 
Seed 1st Boiling bd bd 1.2 5.2 1.5 8.0 4.4 53.7 
 2nd Boiling bd bd 1.1 4.8 1.3 6.7 3.8 46.3 
 1st + 2nd  
Lian Zi 
= 
17.4 ± 
2.0 
 bd 
Nu Zhen 
Zi = 22.7 
±  6.9 
 10.0 
Wu Wei 
Zi = 19.3 
±  0.7 
 14.7 8.2%  
 
≅ 1.2 : 1 
 
Bark 1st Boiling bd bd 0.6 4.2 3.2 38.1 14.1 42.9 
 2nd Boiling bd bd 0.6 4.2 4.4 52.3 18.8 57.1 
 1st + 2nd  
Huang 
Bai = 
13.5 ± 
4.9 
 bd 
Du  
Zhong  = 
14.2 ± 
4.1 
 8.4 
Rou Gui 
= 8.4 ±  
7.7 
 90.4 32.9%  
 
≅ 0.8 : 1 
 
Flower 1st Boiling 0.4 3.6 4.4 13.8 1.4 4.4 7.2 50.3 
 2nd Boiling 0.6 5.4 1.1 12.5 1.1 3.5 7.1 49.7 
 1st + 2nd  
Hong 
Hua = 
11.0 ± 
2.1 
 9.0 
Xin Yi  
Hua = 
31.9±. 
2.2  
 26.3 
Jin Yin 
Hua = 
31.3 ± 
3.0 
 7.9 14.3%  
 
≅ 1 : 1 
 
Branch 1st Boiling 1.2 7.1 1.5 11.1 1.7 8.1 8.8 41.1 
 2nd Boiling 1.3 7.7 1.1 11.1 4.1 18.9 12.6 58.9 
 1st + 2nd  
Sang Ji 
Sheng = 
16.8 ±2.5 
 14.8 
Gou 
Teng = 
13.5± 1.8 
 22.2 
Gui Zhi  
= 21.6 ±  
2.4 
 27.0 21.4%  
 
≅ 0.7 : 1 
 
Shell 1st Boiling 6.9 16.1 bd bd   0.2 < 50 
 2nd Boiling 7.1 16.6 bd bd   ~ 0.2 50 
 1st + 2nd  
Long Gu 
= 42.7 ±  
6.3 
 32.7 
Mu Li 
= bd  
 bd 
 
  ≅ 0.4%  
 
≅ 1 : 1 
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Table 9.12   Chromium (Cr) concentration in the aqueous decoctions of the 20 representative Chinese herbal materials 
 
1 2 3 4 5 6 7 8 9 10 11 
Aqueous 
Extraction of 
Herb # 1  
(n = 2) 
Aqueous 
Extraction of 
Herb # 2 
 (n = 2) 
Aqueous 
Extraction of 
Herb # 3  
(n = 2) 
Part of 
Herb 
Sequence 
of Boiling 
(each 
boiling: 
n = 2)  
Total 
Chromium 
(Acid-
digested) 
µg/g Aqeous 
Cr 
µg/g 
% of 
Total 
Cr 
Total 
Chromium 
(Acid-
digested) 
µg/g Aqeous 
Cd 
µg/g 
% of 
Total 
Cr 
Total 
Chromium 
(Acid-
digested) 
µg/g Aqeous 
Cr 
µg/g 
% of 
Total 
Cr 
Average 
Aqueous 
% (of 3 
herbs)  of 
the Total 
Cr 
% of  Cr 
Distribu-
tion 
between 
1st & 2nd 
Boiling 
Extraction  
Efficiency 
between 
1st & 2nd 
Decoctions 
1st : 2nd 
Root 1st Boiling 0.0817 8.8 0.0803 3.8 0.3072 13.5 8.7 51.5 
 2nd Boiling 0.0757 8.1 0.0804 3.8 0.2905 12.8 8.2 48.5 
 1st + 2nd  
Wu Yao  
= 0.93 ± 
0.11 
 16.9 
Qin Hu = 
2.44 ± 
0.27 
 7.6 
Tian Ma 
=1.19 ± 
0.15 
 26.3 16.9%  
 
≅ 1 : 1 
 
Leaf 1st Boiling 0.1361 32.3 0.1039 44.4 0.0249 0.7 25.8 61.7 
 2nd Boiling 0.0765 18.1 0.0696 29.7 0.0079 0.2 16.0 38.3 
 1st + 2nd  
Bo Hu = 
0.42 ±  
0.06 
 50.4 
Zi Su Ye 
2.06 ± 
0.05 
 74.1 
Yin Yan 
Huo = 
1.25±0.04 
 0.9 41.8%  
 
≅ 1.6 : 1 
 
Seed 1st Boiling 0.0007 1.0 0.0412 5.0 0.2593 14.6 6.9 83.1 
 2nd Boiling 0.0003 0.4 0.0044 0.5 0.0578 3.2 1.4 16.9 
 1st + 2nd  
Lian Zi = 
0.068 ± 
0.02 
 1.4 
Nu Zhen Zi 
= 2.09 ± 
0.32 
 5.5 
Wu Wei Zi 
= 1.92 ± 
0.18 
 17.8 8.3%  
 
≅ 5 : 1 
 
Bark 1st Boiling 0.0131 2.7 0.0312 0.6 0.0049 6.2 3.1 96.9 
 2nd Boiling bd < 0.1 0.0017 < 0.1 0.0002 0.3 0.1 3.1 
 1st + 2nd  
Huang Bai 
= 0.489 ±  
0.04 
 2.7 
Du Zhong 
= 
1.16±0.10 
 0.6 
Rou Gui = 
1.43 ± 0.04 
 6.5 3.2%  
 
≅ 30 : 1 
 
Flower 1st Boiling 0.0629 6.8 0.1362 40.6 0.0446 13.5 20.3 66.1 
 2nd Boiling 0.0151 1.6 0.0642 19.1 0.0347 10.5 10.4 33.9 
 1st + 2nd  
Hong Hua 
= 0.924 
±  0.02 
 8.4 
Xin Yi Hua 
= 1.80±0.12  
 59.8 
Jin Yin 
Hua = 
3.87±0.03 
 24.0 30.7%  
 
≅ 2 : 1 
 
Branch 1st Boiling 0.1016 6.9 0.0912 3.0 0.1395 15.1 8.3 53.9 
 2nd Boiling 0.0929 6.3 0.0752 2.5 0.1143 12.4 7.1 46.1 
 1st + 2nd  
Sang Ji 
Sheng = 
1.46 ± 0.22 
 13.3 
Gou Teng 
=  
1.31±0.32 
 5.5 
Gui Zhi  
= 4.69 ± 
0.07 
 27.5 15.4%  
 
≅ 1.2 : 1 
 
Shell 1st Boiling 0.0388 0.2 0.0106 0.2   0.2 50.0 
 2nd Boiling 0.0573 0.3 bd 0.0   ~ 0.2 50.0 
 1st + 2nd  
Long Gu 
= 19.52 ± 
1.67 
 0.5 
Mu Li 
= 8.68 ± 
0.44 
 0.2 
 
  ~ 0.4%  
 
≅ 1 : 1 
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Key for Table 9.8 to Table 9.12: 
 
1.   Total Lead (Acid-digested), in µg/g = Results obtained from triplicate samples (n = 3), and 
each sample analysed 2 – 3 times 
2.   Aqueous Pb, in µg/g = Concentration of Pb in the aqueous solution after either 1st-time 
boiling or 2nd-time boiling or the sum of the two boiled solution, in µg/g of the herb. 
3. % of Total Lead = The lead concentration in the aqueous solution as a % of the total lead 
concentration in the acid-digested herb as determined by AAS.  
4. Average Aqueous % (of 3 herbs) of the Total (acid-digested) PB = The averaged % value of 
the three individual herbs from either the 1st aqueous decoction, or the 2nd or the sum of the 
two decoctions. For example, for average % of the1st decoction = sum of the 3 individual % 
of total Lead obtained in their 1st boiled solutions ÷ 3. 
5. % of Pb Distribution between 1st and 2nd Boiled Solutions，for example, for the distribution 
of the 1st boiled solution = Average aqueous % (of 3 herbs) of the total Pb ÷ the average 
aqueous % of the sum of the 3 herbs. 
6. Average Ratio between 1st and 2nd boiling =  % of Pb distribution of the 1st (refer to 5 above) 
÷ % of Pb distribution in the combined (sum of the 1st and 2nd) boiled solutions. 
7.   bd = below detection limit.                                                                                               
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Table 9.13   Summary of metal contents in combined aqueous decoctions (first and second) for 
different metals and different types of CHMs 
 
           Part of Herb 
 
Averaged 
% Extraction 
 
Metal 
 
Root 
 
Leaf 
 
Seed 
 
Bark 
 
Flower 
 
Branch
& 
Twig 
 
Marine 
Shell 
& 
Bone 
Average % 
of Extrac-
tion for  
Each Metal 
for All 
CHMs 
Lead                  Pb 19 29 39 29 9 26 1.3 25% 
Arsenic             As 51 27 55 22 32 24 0.6 35% 
Mercury           Hg 14 42 8 33 14 21 0.4 22% 
Cadmium         Cd 35 60 27 27 65 19 2.5 39% 
Chromium       Cr 17 42 8 3 31 15 0.4 19% 
% of extraction for 
all metals together 
 
28% 
 
40% 
 
28% 
 
23% 
 
30% 
 
    21% 
 
1% 
 
 
 
Comparison of efficiency of extraction between different groups of herbal materials, according to 
table above: 
           Leaf  > Flower  > Root / Seed  > Bark  > Branch (twig)  >>> Marine Shell / Bone 
 
Comparison of efficiency of extraction between different metals, according to table above:           
           Cadmium > Arsenic > Lead > Mercury > Chromium 
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          In general, upon comparing the ratios of metal extraction between the first and second 
decoctions (see columns 11 in Tables 9.8 to 9.12) for all metals except mercury, the efficiency of 
metal extraction for the first decoction was generally higher than that for the second decoction, 
irrespective of the part of plant. This difference in extraction efficiency could be up to 5 times 
higher. For example, the average Pb contents in the first decoctions for both the leaf and flower 
CHM were about 2-fold greater than their second decoctions (see column 11, Table 9.8). Similar 
differences, about 2-fold, were also obtained in As contents for the leaf, bark, flower and branch 
CHM (Column 11, Table 9.9).  This difference could be as high as 5 times as in the case of Cd 
for the flower CHM (column 11, Table 9.10), and in the case of Cr for the seed CHMs (column 
11, Table 9.12). The greatest difference in extraction efficiency was seen in Cr contents for the 
bark CHM where the Cr content in the first decoction was about 30 times higher than in the 
second (column 11, Table 9.12). However, this was because the first boiling extracted almost all 
the water-soluble fraction of Cr, leaving little behind for the second decoction. This general trend 
of efficiency of extraction suggests that the potency of the first decoction might be much higher 
than the second for most types of CHM. However, for root CHM, there was little difference in 
the efficiency of extraction between the first and second boiling processes for the five metals, 
suggesting possible similar potencies between the two decoctions as far as root CHMs are 
concerned. On the other hand, for mercury contents, the average efficiency of extraction, at least 
for the five metals, was equal between the first and second decoctions, for all types (i.e., plant 
parts) of CHM with ratios of approximately 1:1 for all groups (see column 11, Table 9.11).   
 
          Interestingly, the two marine shell CHMs, Long Gu (HSD1) and Mu Li (HCL3) contained 
very high total (acid-digested) metal contents for all the 5 metals studied (see Table 9.8). For 
example, among the 100 CHMs, the highest contents of Pb, As and Hg were found in Long Gu, 
while Cd and Cr contents were also among the highest determined. Yet, the average aggregate 
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water extraction (i.e. first and second decoctions) of each of the 5 metals from the two marine 
shells was insignificantly low, only about 1% of the absolute total amount, indicating an 
extremely inefficient extraction from marine shells, at least for metals, by the aqueous boiling 
process.  
             
          Clearly, different parts of a plant led to widely different efficiencies of aqueous extraction, 
expressed as % of the acid-digested total metal content. These average aqueous extractions of 
each of the 5 metals from the 6 groups of CHMs plus the two marine shell CHMs are summarised 
in Table 9.13 above.  For a particular part of the plant, e.g. the root CHMs, the average % of 
extraction of all 5 metals combined was 28%, shown in the bottom row of Table 10.13. The 
highest average % was from leaves (~ 40%), and by far the lowest was the marine shell CHMs (~ 
1%). These aqueous extraction efficiencies for the various groups of CHM, in decreasing order, 
are listed below:  
 
              Leaves > Flowers > Roots ≅ Seeds > Barks > Branches & Twigs >>>> Marine Shells 
 
          For a particular metal, e.g., Pb, the average % of extraction of all 6 groups of CHMs 
combined was ~ 25%, shown in the last column of Table 9.13. The highest average % of 
extraction was for Cd (~ 39%), and the remaining 3 metals were around 20%. These average 
aqueous extraction efficiencies for the various metals, in decreasing order, was thus: 
 
              Cadmium > Arsenic > Lead > Mercury > Chromium 
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9.2.3    Estimated Daily Oral Exposure to Metals After Consuming the Combined 
            Aqueous Decoctions – as Estimated Daily Intake, or Estimated Weekly Intake     
             
           Using the average combined % efficiency of aqueous extraction (sum of 1st and 2nd 
decoctions) for a specific metal and specific group of plant as determined in section 9.2.2 above, 
and tabulated in Table 9.13, the daily intake of each metal for the individual CHM by way of 
drinking the combined aqueous decoctions (i.e. the first and second decoctions) was then 
calculated from the total (acid-digested) metal contents (in µg/g or ng/g) (see Table 9.8), based 
on the assumption that 10g of each herb were prescribed to be boiled in water twice and the two 
aqueous decoctions consumed daily. For example, for sample No. 51 (Gui Zhi) (see Table 9.14, 
1st row) the aqueous Pb content is 26% of the total Pb content of 4.84 µg/g (i.e. 4.84 x 0.26 = 
1.258 µg/g). For the average prescribed quantity of 10g of CHM per day, the estimated daily 
intake becomes 12.58 µg/day/person (i.e.,1.258 µg/g x 10). From this estimated daily intake, the 
estimated weekly intake of Pb in terms of µg/kg bw/week (estimated WI) might also be 
calculated by dividing estimated daily intake per person by the average adult body weight of 60 
kg (JECFA, 1991) and then multiplied by 7 (i.e. days per week). The resultant estimated WI of 
Pb of 1.47 µg/kg bw/week from consuming 10 g of Gui Zhi daily was then compared to the 
official tolerable limit, i.e. the tolerable daily intake (TDI) for the particular metal (in this case, 
the PTWI for Pb = 25 µg/kg bw/week), and was expressed as 5.9 % of PTWI [i.e., (1.47 / 25) x 
100% = 5.9%] to evaluate the risk or otherwise of adult exposure to this elemental contaminant in 
Gui Zhi. Thus, adopting this mathematical procedure, estimated DI, estimated WI, and the % of 
PTWI of adult exposure for the 100 CHM for each of the 5 heavy metals are summarised in 
Table 9.14 for Pb, Table 9.15 for As, Table 9.16 for Cd, Table 9.17 for Hg, and Table 9.18 for 
Cr.    
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Table 9.14.   Estimated daily intake (DI) of Lead (Pb) from consumption of aqueous decoctions of an 
individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to be 
decocted twice. WHO: PTWI = 25 µg/kg bw/week; PTDI = 3.6 µg/kg bw/day.  
 
No. 
 
 
 
Sample 
Code 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Average 
% of 
Aqueous 
Extrac-
tion 
Total  
Lead 
(Pb) 
µg/g ± sd 
 
Estimated 
Daily 
intake 
(µg/day/ 
person) 
Estimated 
Weekly 
Intake 
(µg/kg 
bw/week) 
Adult 
weekly 
Exposure 
(25µg/kg/w
k) 
% PTWI 
Dispel Wind-Cold 
51 HWC1 Gui Zhi Branch 26 4.84 ± 0.62 12.58 1.47 5.9 
61 HWC2 Zi Su Ye Leaf 29 2.06 ± 0.05 5.97 0.70 2.8 
94 HWC3 Jing Jie Leaf 29 3.48 ± 0.14 10.09 1.18 4.7 
6 HWC4 Fang Feng Root  19 1.50 ± 0.11 2.85 0.33 1.3 
17 HWC5 Qiang Huo Root 19 0.96 ± 0.12 1.82 0.21 0.8 
20 HWC6 Bai Zhi Root 19 2.10 ± 0.24 3.99 0.47 1.9 
44 HWC7 Xin Ye Hua Flower 9 1.80 ± 0.12 1.62 0.19 0.8 
Dispel Wind-Heat 
34 HWH1 Bo He Leaf 29 1.26 ± 0.03 3.65 0.43 1.7 
87 HWH2 Ju Hua Flower 9 1.39 ± 0.14 1.25 0.15 0.6 
35 HWH3 Chai Hu Root 19 1.28 ± 0.21 2.43 0.28 1.1 
Eliminate Heat 
23 HEH1 Zhi Mu Root 19 1.07 ± 0.14 2.03 0.24 0.1 
60 HEH2 Lu Gen Root 19 1.59 ± 0.25 3.02 0.35 1.4 
52 HEH3 Huang Qin Root 19 1.19 ± 0.08 2.26 0.26 1.0 
19 HEH4 Huang Bai Bark 29 0.90 ± 0.10 2.61 0.30 1.2 
67 HEH5 Zhi Zi Seed 39 2.40 ± 0.34 9.36 1.09 4.4 
75 HEH6 Ku Shen Root 19 0.58 ± 0.01 1.10 0.13 0.5 
95 HEH7 
Long Dan 
Cao Root 19 0.91 ± 0.01 1.73 0.20 
0.8 
Eliminate Heat & Toxins 
85 HHT1 Jin Yin Hua Flower  9 3.87 ± 0.03 3.48 0.41 1.6 
45 HHT2 Lian Qiao Seed  39 3.09 ± 0.08 12.05 1.41 5.6 
90 HHT3 Ban Lan Gen Root 19 0.54 ± 0.12 1.03 0.12 0.5 
Eliminate Heat & Cool Blood 
96 HCB1 
Sheng Di 
Huang Root 19 2.99 ± 0.29 5.68 0.66 
2.6 
93 HCB2 Xuan Shen Root 19 1.32 ± 0.20 2.51 0.29 1.2 
74 HCB3 Mu Dan Pi Bark 29 0.62 ± 0.08 1.80 0.21 0.8 
22 HCB4 Chi Shao Root 19 0.42 ± 0.01 0.80 0.09 0.4 
62 HCB5 Zi Cao Leaf 29 2.62 ± 0.47 7.60 0.89 3.6 
Eliminate Deficiency Heat 
47 HDH1 Di Gu PI Bark 29 1.10 ± 0.15 3.19 0.37 1.5 
Purgatives       
32 HPU1 Da Huang Root 19 0.51 ± 0.04 0.97 0.11 0.4 
Eliminate Wind-Damp 
38 HWD1 Du Huo Root 19 1.61 ± 0.50 3.06 0.36 1.4 
70 HWD2 Qin Jiao Root 19 1.21 ± 0.05 2.30 0.27 1.1 
9 HWD3 
Sang Ji 
Sheng Branch 26 1.44 ± 0.19 3.74 0.44 
1.8 
Aromatic for Dispelling Damp  
30 HAD1 Cang Zhu Root 19 0.53 ± 0.07 1.01 0.12 0.5 
79 HAD2 Huo Po Root 19 1.29 ± 0.15 2.45 0.29 1.2 
49 HAD3 Huo Xiang Leaf  29 0.98 ± 0.05 2.84 0.33 1.3 
69 HAD4 Sha Ren Seed 39 2.59 ± 0.16 10.10 1.18 4.7 
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Table 9.14 Continued. Estimated daily intake (DI) of Lead (Pb) from consumption of aqueous decoctions 
of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to 
be decocted twice. 
   
No. 
 
 
 
Sample 
Code 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Average 
% of 
Aqueous 
Extrac-
tion 
Total  
Lead 
(Pb) 
µg/g ± sd 
 
Estimated 
Daily 
intake 
(µg/day/ 
person) 
Estimated 
Weekly 
Intake 
(µg/kg 
bw/week) 
Adult 
weekly 
Exposure 
(25µg/kg/wk) 
%  PTWI 
Diuretics 
97 HDU1 Fu Ling Root 19 0.11 ± 0.01 0.21 0.02 0.1 
36 HDU2 Ze Xie Root 19 1.30 ± 0.04 2.47 0.29 1.2 
68 HDU3 Yi Yi Ren Seed 39 0.45 ± 0.03 1.76 0.20 0.8 
Warming Interior  
54 HWI1 Gan Jiang Root  19 1.27 ± 0.20 2.41 0.28 1.1 
63 HWI2 Rou Gui Bark  29 1.43 ± 0.04 4.15 0.48 1.9 
1 HWI3 Wu Zhu Yu Seed 39 2.78 ± 0.16 10.84 1.26 5.0 
Regulate Qi 
64     HRQ1 Ju Pi  Bark  29 1.68 ± 0.15 4.87 0.57 2.3 
72 HRQ2 Qing Pi Bark  29 0.98 ± 0.01 2.84 0.33 1.3 
41 HRQ3 Zhi Ke Bark 29 1.20 ± 0.05 3.48 0.41 1.6 
59 HRQ4 Mu Xiang Root 19 1.37 ± 0.14 2.60 0.30 1.2 
3 HRQ5 Xiang Fu Root 19 0.68 ± 0.02 1.29 0.15 0.6 
8 HRQ6 Wu Yao Root 19 1.50 ± 0.13 2.85 0.33 1.3 
7 HRQ7 Yan Hu Suo Root 19 1.02 ± 0.03 1.94 0.23 0.9 
Digestives 
55 HDG1 Shan Zha  Seed 39 1.3 ± 0.14 5.07 0.59 2.4 
16 HDG2 Mai Ya Seed 39 0.74 ± 0.27 2.89 0.34 1.4 
Anthelmintics 
33 HAN1 Da Fu Pi Bark 29 1.07 ± 0.05 3.10 0.36 1.4 
Hemostatics       
48 HHM1 Ce Bai Ye Leaf 29 0.37 ± 0.04 1.07 0.13 0.5 
91 HHM2 Bai Mao Gen Root 19 1.66 ± 0.2 3.15 0.37 1.5 
Activate Blood Circulation & Remove Blood Stasis 
92 HBS1 Chuan Xiong Root 19 0.73 ± 0.02 1.39 0.16 0.6 
66 HBS2 Yu Jin Root 19 3.40 ± 0.01 6.46 0.75 3.0 
2 HBS3 Dan Shen Root 19 1.42 ± 0.50 2.70 0.31 1.2 
80 HBS4 Ye Mu Cao Leaf  29 2.69 ± 0.04 7.80 0.91 3.6 
27 HBS5 Hong Hua Flower 9 10.27± 0.59 9.24 1.08 4.3 
71 HBS6 Chuan Niu Xi Root 19 0.85 ± 0.06 1.62 0.19 0.8 
89 HBS7 Huai Niu Xi Root 19 1.56 ± 0.27 2.96 0.35 1.4 
Expectorants, Anti-tussives & Dysnea- relieving Drugs 
40 HRP1 Ban Xia Root 19 0.67 ± 0.13 1.27 0.15 0.6 
76 HRP2 Jie Geng Root 19 1.81 ± 0.06 3.44 0.40 1.6 
11 HRP3 Qian Hu  Root 19 2.44 ± 0.27 4.64 0.54 2.2 
65 HRP4 Gua Lou Bark 29 5.10 ± 0.30 14.79 1.73 6.9 
77 HRP5 
Chuan Bei 
Mu 
Root 19 1.52 ± 0.04 
2.89 0.34 
1.4 
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Table 9.14 Continued.  Estimated daily intake (DI) of Lead (Pb) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a 
prescription to be decocted twice. 
No. 
 
 
 
Sample 
Code 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Average 
% of 
Aqueous 
Extrac-
tion 
Total  
Lead 
(Pb) 
µg/g ± sd 
 
Estimated 
Daily 
intake 
(µg/day/ 
person) 
Estimated 
Weekly 
Intake 
(µg/kg 
bw/week) 
Adult 
weekly 
Exposure 
(25µg/kg/wk) 
%  PTWI 
Relieve Cough & Dyspnea 
37 HDC1 Xing Ren  Seed 39 0.51 ± 0.02 1.99 0.23 0.9 
39 HDC2 Bai Bu Root 19 1.22 ± 0.06 2.32 0.27 1.1 
99 HDC3 Zi Wan Root 19 0.69 ± 0.07 1.31 0.15 0.6 
81 HDC4 Su Zi Seed 39 0.73 ± 0.07 2.85 0.33 1.3 
82 HDC5 Sang Bai Pi Bark 29 0.90 ± 0.05 2.61 0.30 1.2 
Sedatives / Calm the Spirit 
57 HSD1 Long Gu Shell 1.3 11.97 ±1.04 1.56 0.18 0.7 
31 HSD2 Suan Zao Ren Seed 39 0.94 ± 0.05 3.67 0.43 1.7 
73 HSD3 Bai Zi Ren Seed 39 0.86 ± 0.08 3.35 0.39 1.6 
14 HSD4 Yuan Zhi Root 19 0.66 ± 0.04 1.25 0.15 0.6 
98 HCL3 Mu Li Shell 1.3 8.68 ± 0.44 1.13 0.13 0.5 
Calm Liver & Suppress Wind 
83 HCL1 Tian Ma Root 19 1.19 ± 0.15 2.26 0.26 1.0 
25 HCL2 Gou Teng Branch 29 1.31 ± 0.32 3.80 0.44 1.8 
Qi Tonics 
53 HQT1 Huang Qi Root 19 1.08 ± 0.02 2.05 0.24 1.0 
56 HQT2 Bai Zhu Root 19 1.77 ± 0.21 3.36 0.39 1.6 
4 HQT3 Shan yao Root 19 1.59 ± 0.34 3.02 0.35 1.4 
24 HQT4 Gan Cao Root 19 0.74 ± 0.04 1.41 0.16 0.6 
42 HQT5 Zhi Gan Cao Root 19 0.28  0.09 0.53 0.06 0.2 
Yang Tonics 
28 HYT1 Du Zhong Bark 29 1.16 ± 0.10 3.36 0.39 1.6 
43 HYT2 Xu Duan Root 19 0.59 ± 0.10 1.12 0.13 0.5 
46 HYT3 Bu Gu Zhi Seed 39 1.67 ± 0.11 6.51 0.76 3.0 
100 HYT4 
Rou Cong 
Rong 
Branch 26 2.04 ± 0.16 
5.30 0.62 
2.5 
101 HYT5 Yin Yang Huo Branch 26 1.25 ± 0.04 3.25 0.38 1.5 
Blood Tonics 
10 HBT1 Dang Gui Root 19 1.49 ± 0.02 2.83 0.33 1.3 
78 HBT2 He Shou Wu Root 19 1.32 ± 0.10 2.51 0.29 1.2 
50 HBT3 Shu Di Huang Root 19 1.83 ± 0.06 3.48 0.41 1.6 
12 HBT4 Bai Shao Root 19 0.72 ± 0.07 1.37 0.16 0.6 
Yin Tonics 
13 HYN1 Bei Sha Shen Root 19 1.03 ± 0.05 1.96 0.23 0.9 
88 HYN2 
Mai Men 
Dong 
Root       19 0.78 ± 0.19 
1.48 0.17 
0.7 
15 HYN3 Yu Zhu Root 19 0.53 ± 0.09 1.01 0.12 0.5 
29 HYN4 Shan Zhu Yu Seed 39 1.60 ± 0.02 6.24 0.73 2.9 
21 HYN5 Gou Qi Zi Seed 39 1.87 ± 0.11 7.29 0.85 3.4 
86 HYN6 Han Lian Cao Branch 26 1.69 ± 0.28 4.39 0.51 2.0 
18 HYN7 Nu Zhen Zi Seed 39 2.09 ± 0.32 8.15 0.95 3.8 
Astringents 
58 HAS1 Wu Wei Zi Seed 39 1.92 ± 0.18 7.49 0.87 3.5 
26 HAS2 Fu Ziao Mai Seed 39 0.75 ± 0.10 2.93 0.34 1.4 
5 HAS3 Lian Zi Seed 39 1.44 ± 0.02 5.62 0.66 2.6 
84 HAS4 Qian Shi Seed 39 0.10 ± 0.01 0.39 0.05 0.2 
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Table 9.15.  Estimated Daily Intake of arsenic (As) from consumption of aqueous decoctions of an 
individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to be 
decocted twice. WHO: PTWI = 15 µg/kg bw/week; PTDI = 2.1 µg/kg bw/day (Values are for inorganic 
arsenic) ANZFA: PTWI = 21 µg/kg bw/week; PTDI = 3 µg/kg bw/day (Values are for inorganic arsenic) 
– ANZFA PTWI was used for calculation here.  Standard body weight = 60 kg 
No. 
 
 
 
Sample 
Code 
 
 
Chinese 
Name 
 
 
 
Part  
of Plant 
 
Average 
% of  
Aqueous 
Extrac-
tion 
Total 
Arsenic 
(As) 
µg/g ± sd 
 
Estimated 
Daily 
intake 
µg/day/ 
person 
Estimated 
Weekly 
Intake 
(µg/kg 
bw/week) 
Adult 
weekly 
Exposure 
(21µg/kg/wk) 
%  PTWI 
Dispel Wind-Cold 
51 HWC1 Gui Zhi Branch 24 0.81 ± 0.04 1.94 0.23 1.1 
61 HWC2 Zi Su Ye Leaf 27 3.35 ± 0.04 9.05 1.06 5.0 
94 HWC3 Jing Jie Leaf 27 1.32 ± 0.02 3.56 0.42 2.0 
6 HWC4 Fang Feng Root  51 2.33 ± 0.19 11.88 1.39 6.6 
17 HWC5 Qiang Huo Root 51 1.36 ± 0.16 6.94 0.81 3.9 
20 HWC6 Bai Zhi Root 51 0.81 ± 0.15 4.13 0.48 2.3 
44 HWC7 Xin Ye Hua Flower 32 0.71 ± 0.17 2.27 0.27 1.3 
Dispel Wind-Heat 
34 HWH1 Bo He Leaf 27 2.63 ± 0.11 7.10 0.83 4.0 
87 HWH2 Ju Hua Flower 32 0.89 ± 0.11 2.85 0.33 1.6 
35 HWH3 Chai Hu Root 51 1.29 ± 0.32 6.58 0.77 3.7 
Eliminate Heat 
23 HEH1 Zhi Mu Root 51 3.15 ± 0.23 16.07 1.87 8.9 
60 HEH2 Lu Gen Root 51 0.57 ± 0.03 2.91 0.34 1.6 
52 HEH3 Huang Qin Root 51 1.23 ± 0.28 6.27 0.73 3.5 
19 HEH4 Huang Bai Bark 22 2.47 ± 0.47 5.43 0.63 3.0 
67 HEH5 Zhi Zi Seed 55 0.73 ± 0.08 4.02 0.47 2.2 
75 HEH6 Ku Shen Root 51 1.99 ± 0.13 10.15 1.18 5.6 
95 HEH7 Long Dan Cao Root 51 2.25 ± 0.17 11.48 1.34 6.4 
Eliminate Heat & Toxins 
85 HHT1 Jin Yin Hua Flower  32 1.12 ± 0.07 3.58 0.42 2.0 
45 HHT2 Lian Qiao Seed  55 1.02 ± 0.12 5.61 0.65 3.1 
90 HHT3 Ban Lan Gen Root 51 1.48 ± 0.30 7.55 0.88 4.2 
Eliminate Heat & Cool Blood 
96 HCB1 
Sheng Di 
Huang Root 51 1.26 ± 0.06 6.43 0.75 
3.6 
93 HCB2 Xuan Shen Root 51 1.01 ± 0.14 5.15 0.60 2.9 
74 HCB3 Mu Dan Pi Bark 22 0.96 ± 0.21 2.11 0.25 1.2 
22 HCB4 Chi Shao Root 51 1.02 ± 0.04 5.20 0.61 2.9 
62 HCB5 Zi Cao Leaf 27 2.68 ± 0.38 7.24 0.84 4.0 
Eliminate Deficiency Heat 
47 HDH1 Di Gu PI Bark 22 2.03 ± 0.10 4.47 0.52 2.5 
Purgatives       
32 HPU1 Da Huang Root 51 3.32 ± 0.09 16.93 1.98 9.4 
Eliminate Wind-Damp 
38 HWD1 Du Huo Root 51 0.88 ± 0.09 4.49 0.52 2.5 
70 HWD2 Qin Jiao Root 51 1.42 ± 0.07 7.24 0.84 4.0 
9 HWD3 
Sang Ji 
Sheng Branch 24 1.33 ± 0.13 3.19 0.37 
1.8 
Aromatic for Dispelling Damp  
30 HAD1 Cang Zhu Root 51 3.51 ± 0.08 17.90 2.09 10.0 
79 HAD2 Huo Po Root 51 0.68 ± 0.07 3.47 0.40 1.9 
49 HAD3 Huo Xiang Leaf  27 2.14 ± 0.06 5.78 0.67 3.2 
69 HAD4 Sha Ren Seed 55 0.70 ± 0.04 3.85 0.45 2.1 
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Table 9.15. Continued  Estimated Daily Intake of arsenic (As) from consumption of aqueous decoctions 
of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to 
be decocted twice. 
 
No. 
 
 
 
Sample 
Code 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
Average 
% of  
Aqueous 
Extrac-
tion 
Total 
Arsenic 
(As) 
µg/g ± sd 
 
Estimated 
Daily 
intake 
µg/day/ 
person 
Estimated 
Weekly 
Intake 
(µg/kg 
bw/week) 
Adult 
weekly 
Exposure 
(21µg/kg/wk) 
%  PTWI 
Diuretics 
97 HDU1 Fu Ling Root 51 0.28 ± 0.04 1.43 0.17 0.8 
36 HDU2 Ze Xie Root 51 0.40 ± 0.02 2.04 0.24 1.1 
68 HDU3 Yi Yi Ren Seed 55 0.43 ± 0.06 2.37 0.28 1.3 
Warming Interior  
54 HWI1 Gan Jiang Root  51 0.49 ± 0.05 2.50 0.29 1.3 
63 HWI2 Rou Gui Bark  22 2.41 ± 0.16 5.30 0.62 3.0 
1 HWI3 Wu Zhu Yu Seed 55 0.86 ± 0.06 4.73 0.55 2.6 
Regulate Qi 
64     HRQ1 Ju Pi  Bark  22 1.59 ± 0.11 3.50 0.41 2.6 
72 HRQ2 Qing Pi Bark  22 0.75 ± 0.18 1.65 0.19 0.9 
41 HRQ3 Zhi Ke Bark 22 1.29 ± 0.15 2.84 0.33 1.6 
59 HRQ4 Mu Xiang Root 51 1.27 ± 0.24 6.48 0.76 3.6 
3 HRQ5 Xiang Fu Root 51 0.14 ± 0.01 0.71 0.08 0.4 
8 HRQ6 Wu Yao Root 51 0.74 ± 0.03 3.77 0.44 2.1 
7 HRQ7 Yan Hu Suo Root 51 0.20 ± 0.06 1.02 0.12 0.6 
Digestives 
55 HDG1 Shan Zha  Seed 55 0.74 ± 0.06 4.07 0.47 2.2 
16 HDG2 Mai Ya Seed 55 0.10 ± 0.15 0.55 0.06 0.3 
Anthelmintics 
33 HAN1 Da Fu Pi Bark 22 0.30 ± 0.03 0.66 0.08 0.4 
Hemostatics 
48 HHM1 Ce Bai Ye Leaf 27 18.61 ±1.11 50.25 5.86 27.9 
91 HHM2 Bai Mao Gen Root 51 1.23 ± 0.04 6.27 0.73 3.5 
Activate Blood Circulation & Remove Blood Stasis 
92 HBS1 Chuan Xiong Root 51 0.95 ± 0.04 4.85 0.57 2.7 
66 HBS2 Yu Jin Root 51 1.05 ± 0.01 5.36 0.62 3.0 
2 HBS3 Dan Shen Root 51 1.28 ± 0.09 6.53 0.76 3.6 
80 HBS4 Ye Mu Cao Leaf  27 2.21 ± 0.42 5.97 0.70 3.3 
27 HBS5 Hong Hua Flower 32 5.99 ± 1.26 19.17 2.24 10.7 
71 HBS6 Chuan Niu Xi Root 51 4.15 ± 0.50 21.17 2.47 11.8 
89 HBS7 Huai Niu Xi Root 51 1.06 ± 0.07 5.41 0.63 3.0 
Expectorants, Anti-tussives & Dysnea- relieving Drugs 
40 HRP1 Ban Xia Root 51 2.97 ± 0.04 15.15 1.77 8.4 
76 HRP2 Jie Geng Root 51 0.52 ± 0.04 2.65 0.31 1.5 
11 HRP3 Qian Hu  Root 51 0.71 ± 0.04 3.62 0.42 2.0 
65 HRP4 Gua Lou Bark 22 0.93 ± 0.13 2.05 0.24 1.1 
77 HRP5 Chuan Bei Mu Root 51 0.26 ± 0.01 1.33 0.15 0.7 
Relieve Cough & Dyspnea 
37 HDC1 Xing Ren  Seed 55 0.31 ± 0.01 1.71 0.20 1.0 
39 HDC2 Bai Bu Root 51 0.80 ± 0.04 4.08 0.48 2.3 
99 HDC3 Zi Wan Root 51 2.25 ± 0.19 11.48 1.34 6.4 
81 HDC4 Su Zi Seed 55 0.60 ± 0.04 3.30 0.39 1.9 
82 HDC5 Sang Bai Pi Bark 22 1.16 ± 0.24 2.55 0.30 1.4 
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Table 9.15. Continued   Estimated Daily Intake of arsenic (As) from consumption of aqueous decoctions 
of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to 
be decocted twice. 
 
No. 
 
 
 
Sample 
Code 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
Average 
% of  
Aqueous 
Extrac-
tion 
Total 
Arsenic 
(As) 
µg/g ± sd 
 
Estimated 
Daily 
intake 
µg/day/ 
person 
Estimated 
Weekly 
Intake 
(µg/kg 
bw/week) 
Adult 
weekly 
Exposure 
(21µg/kg/wk) 
%  PTWI 
Sedatives / Calm the Spirit 
57 HSD1 Long Gu Shell 0.6 51.54 ±6.19 3.09 0.36 1.7 
31 HSD2 
Suan Zao 
Ren 
Seed 55 0.86 ± 0.18 
4.73 0.55 
2.6 
73 HSD3 Bai Zi Ren Seed 55 0.54 ± 0.19 2.97 0.35 1.7 
14 HSD4 Yuan Zhi Root 51 0.96 ± 0.16 4.90 0.57 2.7 
98 HCL3 Mu Li Shell 0.6 31.56 ±1.46 1.89 0.22 1.0 
Calm Liver & Suppress Wind 
83 HCL1 Tian Ma Root 51 1.80 ± 0.03 9.18 1.07 5.1 
25 HCL2 Gou Teng Branch 24 1.12 ± 0.06 2.69 0.31 1.5 
Qi Tonics 
53 HQT1 Huang Qi Root 51 0.44 ± 0.08 2.24 0.26 1.2 
56 HQT2 Bai Zhu Root 51 1.76 ± 0.20 8.98 1.05 5.0 
4 HQT3 Shan yao Root 51 0.39 ± 0.01 1.99 0.23 1.1 
24 HQT4 Gan Cao Root 51 0.74 ± 0.16 3.77 0.44 2.1 
42 HQT5 Zhi Gan Cao Root 51 1.62  0.20 8.26 0.96 4.6 
Yang Tonics 
28 HYT1 Du Zhong Bark 22 2.10 ± 0.30 4.62 0.54 2.6 
43 HYT2 Xu Duan Root 51 4.12 ± 0.49 21.01 2.45 11.7 
46 HYT3 Bu Gu Zhi Seed 55 0.81 ± 0.02 4.46 0.52 2.5 
100 HYT4 
Rou Cong 
Rong 
Branch 24 1.17 ± 0.07 
2.81 0.33 1.6 
101 HYT5 Yin Yang Huo Branch 24 2.31 ± 0.30 5.54 0.65 3.1 
Blood Tonics 
10 HBT1 Dang Gui Root 51 0.56 ± 0.09 2.86 0.33 1.6 
78 HBT2 He Shou Wu Root 51 1.34 ± 0.14 6.83 0.80 3.8 
50 HBT3 Shu Di Huang Root 51 1.93 ± 0.28 9.84 1.15 5.5 
12 HBT4 Bai Shao Root 51 1.22 ± 0.03 6.22 0.73 3.5 
Yin Tonics 
13 HYN1 Bei Sha Shen Root 51 0.46 ± 0.13 2.35 0.27 1.3 
88 HYN2 Mai Men Dong Root 51 0.73 ± 0.10 3.72 0.43 2.0 
15 HYN3 Yu Zhu Root 51 0.38 ± 0.06 1.94 0.23 1.1 
29 HYN4 Shan Zhu Yu Seed 55 1.26 ± 0.25 6.93 0.81 3.9 
21 HYN5 Gou Qi Zi Seed 55 0.44 ± 0.10 2.42 0.28 1.3 
86 HYN6 Han Lian Cao Branch 24 2.56 ± 0.27 6.14 0.72 3.4 
18 HYN7 Nu Zhen Zi Seed 55 2.69 ± 0.19 14.80 1.73 8.2 
Astringents 
58 HAS1 Wu Wei Zi Seed 55 0.55 ± 0.03 3.03 0.35 1.7 
26 HAS2 Fu Ziao Mai Seed 55 0.49 ± 0.16 2.70 0.31 1.5 
5 HAS3 Lian Zi Seed 55 0.18 ± 0.00 0.99 0.12 0.6 
84 HAS4 Qian Shi Seed 55 0.40 ± 0.02 2.20 0.26 1.2 
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Table 9.16.  Estimated weekly Intake of cadmium (Cd) from consumption of aqueous decoctions of an 
individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to be 
decocted twice. WHO: PTWI = 7 µg/kg bw (i.e., 7000 ng/kg bw) 
 
No. 
 
 
Code 
 
 
Chinese 
Name 
Part of 
Plant 
 
Av % of 
Aq Ext 
Total 
Cadmium 
(Cd) 
ng/g ± sd 
Estimated 
DI 
ng/day/ 
person 
Estimated 
Weekly 
Intake 
ng/kg bw 
WHO: 
(7ug/kg 
/wk)  
as 
% PTWI 
Dispel Wind-Cold 
51 HWC1 Gui Zhi Branch 19 478 ± 83 908.2 106.0 1.5 
61 HWC2 Zi Su Ye Leaf 60 464 ± 11 2784 324.8 4.6 
94 HWC3 Jing Jie Leaf 60 274 ± 40 1644 191.8 2.7 
6 HWC4 Fang Feng Root  35 130 ± 23 455 53.1 0.8 
17 HWC5 Qiang Huo Root 35 226 ± 29 791 92.3 1.3 
20 HWC6 Bai Zhi Root 35 134 ± 4 469 54.7 0.8 
44 HWC7 Xin Ye Hua Flower 65 82 ± 1 533 62.2 0.9 
Dispel Wind-Heat 
34 HWH1 Bo He Leaf 60 159 ± 28 954 111.3 1.6 
87 HWH2 Ju Hua Flower 65 268 ± 24 1742 203.2 2.9 
35 HWH3 Chai Hu Root 35 314 ± 7 1099 128.2 1.8 
Eliminate Heat 
23 HEH1 Zhi Mu Root 35 147 ± 1 514.5 60.0 0.9 
60 HEH2 Lu Gen Root 35 515 ± 71 1802.5 210.3 3.0 
52 HEH3 Huang Qin Root 35 181 ± 30 633.5 73.9 1.1 
19 HEH4 Huang Bai Bark 27 64 ± 10 172.8 20.2 0.3 
67 HEH5 Zhi Zi Seed 27 338 ± 41 912.6 106.5 1.5 
75 HEH6 Ku Shen Root 35 189 ± 36 661.5 77.2 1.1 
95 HEH7 
Long Dan 
Cao Root 35 461 ± 73 1613.5 188.2 2.7 
Eliminate Heat & Toxins 
85 HHT1 Jin Yin Hua Flower  65 238 ± 4 1547 180.5 2.6 
45 HHT2 Lian Qiao Seed  27 152 ± 4 410.4 47.9 0.7 
90 HHT3 Ban Lan Gen Root 35 214 ±14 749 87.4 1.2 
Eliminate Heat & Cool Blood 
96 HCB1 
Sheng Di 
Huang Root 14 168 ± 8 235.2 27.4 0.4 
93 HCB2 Xuan Shen Root 14 238 ± 6 333.2 38.9 0.6 
74 HCB3 Mu Dan Pi Bark 27 245 ± 44 661.5 77.2 1.1 
22 HCB4 Chi Shao Root 35 134 ± 2 469 54.7 0.8 
62 HCB5 Zi Cao Leaf 60 713 ± 16 4278 499.1 7.1 
Eliminate Deficiency Heat 
47 HDH1 Di Gu PI Bark 27 174 ± 22 469.8 54.8 0.8 
Purgatives 
32 HPU1 Da Huang Root 35 198 ± 24 693 80.9 1.2 
Eliminate Wind-Damp 
38 HWD1 Du Huo Root 35 197 ± 8 689.5 80.4 1.1 
70 HWD2 Qin Jiao Root 35 318 ± 58 1113 129.9 1.9 
9 HWD3 Sang Ji Sheng Branch 19 155 ± 21 294.5 34.4 0.5 
Aromatic for Dispelling Damp  
30 HAD1 Cang Zhu Root 35 171 ± 9 598.5 69.8 10 
79 HAD2 Huo Po Root 35 100 ± 3 350 40.8 0.6 
49 HAD3 Huo Xiang Leaf  60 158 ± 30 948 110.6 1.6 
69 HAD4 Sha Ren Seed 27 303 ± 23 818.1 95.4 1.4 
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Table 9.16.Continued   Estimated weekly Intake of cadmium (Cd) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a 
prescription to be decocted twice. WHO: PTWI = 7 µg/kg bw (i.e., 7000 ng/kg bw) 
WHO: PTWI = 7 µg/kg bw (i.e., 7000 ng/kg bw) 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total 
Cadmium 
(Cd) 
ng/g ± sd 
Estimated 
DI  
ng/day/ 
person 
Estimated 
Weekly 
Intake 
ng/kg bw 
WHO: 
(7ug/kg /wk) 
as 
% PTWI 
Diuretics 
97 HDU1 Fu Ling Root 35 55 ± 3 192.5 22.5 0.3 
36 HDU2 Ze Xie Root 35 319 ± 19 1116.5 130.3 1.9 
68 HDU3 Yi Yi Ren Seed 27 109 ± 14 294.3 34.3 0.5 
Warming Interior  
54 HWI1 Gan Jiang Root  35 305 ± 25 1067.5 124.5 1.8 
63 HWI2 Rou Gui Bark  19 440 ± 29 836 97.5 1.4 
1 HWI3 Wu Zhu Yu Seed 27 206 ± 32 556.2 64.9 0.9 
Regulate Qi 
64     HRQ1 Ju Pi  Bark  27 211 ± 14 569.7 66.5 1.0 
72 HRQ2 Qing Pi Bark  27 190 ± 60 513 59.9 0.9 
41 HRQ3 Zhi Ke Bark 27 119 ± 4 321.3 37.5 0.5 
59 HRQ4 Mu Xiang Root 35 1030 ±10 3605 420.6 6.0 
3 HRQ5 Xiang Fu Root 35 119 ± 4 416.5 48.6 0.7 
8 HRQ6 Wu Yao Root 35 782 ± 51 2737 319.3 4.6 
7 HRQ7 Yan Hu Suo Root 35 171 ± 2 598.5 69.8 1.0 
Digestives 
55 HDG1 Shan Zha  Seed 27 92 ± 24 248.4 29.0 0.4 
16 HDG2 Mai Ya Seed 27 71 ± 15 191.7 22.4 0.3 
Anthelmintics 
33 HAN1 Da Fu Pi Bark 27 158 ± 7 426.6 49.8 0.7 
Hemostatics 
48 HHM1 Ce Bai Ye Leaf 60 39 ± 13 234 27.3 0.4 
91 HHM2 Bai Mao Gen Root 35 240 ± 8 840 98.0 1.4 
Activate Blood Circulation & Remove Blood Stasis 
92 HBS1 
Chuan 
Xiong 
Root 35 
327 ± 11 1144.5 133.5 1.9 
66 HBS2 Yu Jin Root 35 336 ± 12 1176 137.2 2.0 
2 HBS3 Dan Shen Root 35 116 ± 7 406 47.4 0.7 
80 HBS4 Ye Mu Cao Leaf  60 951 ±203 5706 665.7 9.5 
27 HBS5 Hong Hua Flower 65 167 ± 4 1085.5 126.6 1.8 
71 HBS6 Chuan Niu Xi Root 35 320 ± 2 1120 130.7 1.9 
89 HBS7 Huai Niu Xi Root 35 243 ± 24 850.5 99.2 1.4 
Expectorants, Anti-tussives & Dysnea - relieving Drugs 
40 HRP1 Ban Xia Root 35 94 ± 13 329 38.4 0.5 
76 HRP2 Jie Geng Root 35 259 ± 39 906.5 105.8 1.5 
11 HRP3 Qian Hu  Root 35 674 ± 95 2359 275.2 3.9 
65 HRP4 Gua Lou Bark 27 580 ± 91 1566 182.7 2.6 
77 HRP5 Chuan Bei Mu Root 35 319 ± 15 1116.5 130.3 1.9 
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Table 9.16. Continued  Estimated weekly Intake of cadmium (Cd) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a 
prescription to be decocted twice. WHO: PTWI = 7 µg/kg bw (i.e., 7000 ng/kg bw) 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total 
Cadmium 
(Cd) 
ng/g ± sd 
Estimated 
DI  
ng/day/ 
person 
Estimated 
Weekly 
Intake 
ng/kg bw 
WHO: 
(7ug/kg/wk)  
as 
% PTWI 
Relieve Cough & Dyspnea 
37 HDC1 Xing Ren  Seed 27 34 ± 0 91.8 10.7 0.2 
39 HDC2 Bai Bu Root 35 146 ± 13 511 59.6 0.9 
99 HDC3 Zi Wan Root 35 629 ± 10 2201.5 256.8 3.7 
81 HDC4 Su Zi Seed 27 65 ± 3 175.5 20.5 0.3 
82 HDC5 Sang Bai Pi Bark 27 100 ± 4 270 31.5 0.5 
Sedatives / Calm the Spirit 
57 HSD1 Long Gu Shell 3 1053 ± 225 315.9 36.9 0.5 
31 HSD2 Suan Zao Ren Seed 27 52 ± 7 140.4 16.4 0.2 
73 HSD3 Bai Zi Ren Seed 27 223 ± 15 602.1 70.2 1.0 
14 HSD4 Yuan Zhi Root 35 73 ± 5 255.5 29.8 0.4 
98 HCL3 Mu Li  Shell 3 233 ± 18 69.9 8.2 0.1 
Calm Liver & Suppress Wind 
83 HCL1 Tian Ma Root 35 170 ± 24 595 69.4 1.0 
25 HCL2 Gou Teng Branch 19 166 ± 4 315.4 36.8 0.5 
Qi Tonics 
53 HQT1 Huang Qi Root 35 115 ± 8 402.5 47.0 0.7 
56 HQT2 Bai Zhu Root 35 201 ± 4 703.5 82.1 1.2 
4 HQT3 Shan yao Root 35 75 ± 2 262.5 30.6 0.4 
24 HQT4 Gan Cao Root 35 61 ± 4 213.5 24.9 0.4 
42 HQT5 Zhi Gan Cao Root 35 82 ± 3 287.0 33.5 0.5 
Yang Tonics 
28 HYT1 Du Zhong Bark 27 164 ± 8 442.8 51.7 0.7 
43 HYT2 Xu Duan Root 35 267 ± 2 934.5 109.0 1.6 
46 HYT3 Bu Gu Zhi Seed 27 104 ± 21 280.8 32.8 0.5 
100 HYT4 
Rou Cong 
Rong 
Branch 19 
198 ± 7 376.2 43.9 0.6 
101 HYT5 Yin Yang Huo Branch 19 63 ± 11 119.7 14.0 0.2 
Blood Tonics 
10 HBT1 Dang Gui Root 35 113 ± 9 395.5 46.1 0.7 
78 HBT2 He Shou Wu Root 35 149 ± 8 521.5 60.8 0.9 
50 HBT3 Shu Di Huang Root 35 186 ± 0.0 651 76.0 1.1 
12 HBT4 Bai Shao Root 35 105 ± 2 367.5 42.9 0.6 
Yin Tonics 
13 HYN1 Bei Sha Shen Root 35 88 ± 7 308 35.9 0.5 
88 HYN2 Mai Men Dong Root 35 254 ± 8 889 103.7 1.5 
15 HYN3 Yu Zhu Root 35 260 ± 96 910 106.2 1.5 
29 HYN4 Shan Zhu Yu Seed 27 178 ± 20 480.6 56.1 0.8 
21 HYN5 Gou Qi Zi Seed 27 212 ± 6 572.4 66.8 1.0 
86 HYN6 Han Lian Cao Branch 19 1124 ±62 2135.6 249.2 3.6 
18 HYN7 Nu Zhen Zi Seed 27 217 ± 29 585.9 68.4 1.0 
Astringents 
58 HAS1 Wu Wei Zi Seed 27 1583 ±324 4274.1 498.6 7.1 
26 HAS2 Fu Ziao Mai Seed 27 62 ± 2 167.4 19.5 0.3 
5 HAS3 Lian Zi Seed 27 228 ± 4 615.6 71.8 1.0 
84 HAS4 Qian Shi Seed 27 74 ± 8 199.8 23.3 0.3 
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Table 9.17. Estimated Daily Intake of mercury (Hg) from consumption of aqueous decoctions of an 
individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to be 
decocted twice. Provisional Tolerable Weekly Intake (PTWI) = 5 µg/kg bw/week (i.e., 5,000 ng/kg 
bw/week) for total mercury (WHO, 2000); and 3.3 µg/kg bw/week for the toxic methymercury. WHO: 
PTWI for Total Hg = 300 ug/person (60kg) of which no more than 200 ug is present as methylmercury 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total 
Mercury 
(Hg) 
ng/g ± sd 
Estimated 
DI  
ng/day/ 
person 
Estimated 
Weekly 
Intake 
ng/kg bw 
Adult 
Exposure 
(Total Hg) 
% of PTWI 
Dispel Wind-Cold 
51 HWC1 Gui Zhi Branch 21 bd bd bd bd 
61 HWC2 Zi Su Ye Leaf 42 43.7 ± 0.7 183.5 21.4 0.43 
94 HWC3 Jing Jie Leaf 42 9.2 ± 4.0 38.6 4.5 0.09 
6 HWC4 Fang Feng Root  14 21.3 ± 1.9 29.8 3.5 0.07 
17 HWC5 Qiang Huo Root 14 14.8 ± 2.2 20.7 2.4 0.05 
20 HWC6 Bai Zhi Root 14 15.6 ± 4.3 21.8 2.5 0.05 
44 HWC7 Xin Ye Hua Flower 14 31.9 ± 2.2 44.7 5.2 0.10 
Dispel Wind-Heat 
34 HWH1 Bo He Leaf 42 10.9 ± 2.0 45.8 5.3 0.11 
87 HWH2 Ju Hua Flower 14 bd bd 0.0 bd 
35 HWH3 Chai Hu Root 14 11.2 ± 4.5 15.7 1.8 0.04 
Eliminate Heat 
23 HEH1 Zhi Mu Root 14 21.3 ± 7.4 29.8 3.5 0.07 
60 HEH2 Lu Gen Root 14 bd bd 0.0 bd 
52 HEH3 Huang Qin Root 14 32.0 ± 3.7 44.8 5.2 0.10 
19 HEH4 Huang Bai Bark 33 13.5 ± 4.9 44.6 5.2 0.10 
67 HEH5 Zhi Zi Seed 8 1.8 ± 0.5 1.4 0.2 <0.01 
75 HEH6 Ku Shen Root 14 bd bd 0.0 bd 
95 HEH7 Long Dan Cao Root 14 1.8 ± 0.7 2.5 0.3 0.01 
Eliminate Heat & Toxins 
85 HHT1 Jin Yin Hua Flower  14 31.3 ± 3.0 43.8 5.1 0.10 
45 HHT2 Lian Qiao Seed  8 19.4 ± 0.0 15.5 1.8 0.04 
90 HHT3 Ban Lan Gen Root 14 bd bd 0.0 bd 
Eliminate Heat & Cool Blood 
96 HCB1 
Sheng Di 
Huang Root 14 9.0 ± 6.5 12.6 1.5 0.03 
93 HCB2 Xuan Shen Root 14 bd bd 0.0 bd 
74 HCB3 Mu Dan Pi Bark 33 bd bd 0.0 bd 
22 HCB4 Chi Shao Root 14 16.3 ± 4.4 22.8 2.7 0.05 
62 HCB5 Zi Cao Leaf 42 bd bd 0.0 bd 
Eliminate Deficiency Heat 
47 HDH1 Di Gu PI Bark 33 11.3 ± 4.7 37.3 4.4 0.09 
Purgatives       
32 HPU1 Da Huang Root 14 10.7 ± 1.4 15.0 1.7 0.03 
Eliminate Wind-Damp 
38 HWD1 Du Huo Root 14 8.9 ± 1.3 12.5 1.5 0.03 
70 HWD2 Qin Jiao Root 14 8.7 ± 4.0 12.2 1.4 0.03 
9 HWD3 Sang Ji Sheng Branch 21 16.8 ± 2.5 35.3 4.1 0.08 
Aromatic for Dispelling Damp  
30 HAD1 Cang Zhu Root 14 5.9 ± 4.3 8.3 1.0 0.02 
79 HAD2 Huo Po Root 14 18.0 ± 0.8 25.2 2.9 0.06 
49 HAD3 Huo Xiang Leaf  42 20.2 ± 1.4 84.8 9.9 0.20 
69 HAD4 Sha Ren Seed 8 11.7 ± 3.9 9.4 1.1 0.02 
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Table 9.17.Continued  Estimated Daily Intake of mercury (Hg) from consumption of aqueous decoctions 
of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to 
be decocted twice. 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total 
Mercury 
(Hg) 
ng/g ± sd 
Estimated 
DI 
ng/day/ 
person 
Estimated 
Weekly 
Intake  
ng/kg bw 
Adult 
Exposure 
(Total Hg) 
%  PTWI 
Diuretics 
97 HDU1 Fu Ling Root 14 bd bd bd bd 
36 HDU2 Ze Xie Root 14 5.1 ± 1.7 7.1 0.8 0.02 
68 HDU3 Yi Yi Ren Seed 8 bd bd bd bd 
Warming Interior  
54 HWI1 Gan Jiang Root  14 bd bd bd bd 
63 HWI2 Rou Gui Bark  33 8.4 ± 7.7 27.7 3.2 0.06 
1 HWI3 Wu Zhu Yu Seed 8 22.1 ± 4.4 17.7 2.1 0.04 
Regulate Qi 
64     HRQ1 Ju Pi  Bark  33 4.1 ± 1.5 13.5 1.6 0.03 
72 HRQ2 Qing Pi Bark  33 3.46 ± 2.4 11.4 1.3 0.03 
41 HRQ3 Zhi Ke Bark 33 10.0 ± 0.7 33.0 3.9 0.08 
59 HRQ4 Mu Xiang Root 14 7.5 ± 2.2 10.5 1.2 0.02 
3 HRQ5 Xiang Fu Root 14 15.5 ± 1.6 21.7 2.5 0.05 
8 HRQ6 Wu Yao Root 14 17.7 ± 4.7 24.8 2.9 0.06 
7 HRQ7 Yan Hu Suo Root 14 15.4 ± 2.5 21.6 2.5 0.05 
Digestives 
55 HDG1 Shan Zha  Seed 8 13.8 ± 7.2 11.0 1.3 0.03 
16 HDG2 Mai Ya Seed 8 10.8 ± 0.0 8.6 1.0 0.02 
Anthelmintics 
33 HAN1 Da Fu Pi Bark 33 2.2 ± 0.9 7.3 0.8 0.02 
Hemostatics 
48 HHM1 Ce Bai Ye Leaf 42 22.9 ± 1.5 96.2 11.2 0.22 
91 HHM2 Bai Mao Gen Root 14 4.1 ± 0.2 5.7 0.7 0.01 
Activate Blood Circulation & Remove Blood Stasis 
92 HBS1 Chuan Xiong Root 14 15.9 ± 2.1 22.3 2.6 0.05 
66 HBS2 Yu Jin Root 14 bd bd bd bd 
2 HBS3 Dan Shen Root 14 18.2 ± 2.3 25.5 3.0 0.06 
80 HBS4 Ye Mu Cao Leaf  42 15.7 ± 6.5 65.9 7.7 0.15 
27 HBS5 Hong Hua Flower 14 11.0 ± 2.1 15.4 1.8 0.04 
71 HBS6 Chuan Niu Xi Root 14 12.9 ± 2.2 18.1 2.1 0.04 
89 HBS7 Huai Niu Xi Root 14 8.9 ± 0.8 12.5 1.5 0.03 
Expectorants, Anti-tussives & Dysnea- relieving Drugs 
40 HRP1 Ban Xia Root 14 7.8 ± 0.91 10.9 1.3 0.03 
76 HRP2 Jie Geng Root 14 bd bd bd bd 
11 HRP3 Qian Hu  Root 14 11.6 ± 0.1 16.2 1.9 0.04 
65 HRP4 Gua Lou Bark 33 bd bd bd bd 
77 HRP5 Chuan Bei Mu Root 14 bd bd bd bd 
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Table 9.17.Continued  Estimated Daily Intake of mercury (Hg) from consumption of aqueous decoctions 
of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a prescription to 
be decocted twice. (N.B.  23 of 100 CHMs were < LOD of 2.4 ng/g) 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total 
Mercury 
(Hg) 
ng/g ± sd 
Estimated 
DI 
ng/day/ 
person 
Estimated 
Weekly 
Intake 
ng/kg bw 
Adult 
Exposure 
(Total Hg) 
%  PTWI 
Relieve Cough & Dyspnea 
37 HDC1 Xing Ren  Seed 8 7.6 ± 2.0 6.1 0.7 0.01 
39 HDC2 Bai Bu Root 14 9.6 ± 3.5 13.4 1.6 0.03 
99 HDC3 Zi Wan Root 14 1.3 ± 0.6 1.8 0.2 bd 
81 HDC4 Su Zi Seed 8 bd bd bd bd 
82 HDC5 Sang Bai Pi Bark 33 bd bd bd bd 
Sedatives / Calm the Spirit 
57 HSD1 Long Gu Shell 0.4 42.7 ± 6.3 1.7 0.2 bd 
31 HSD2 Suan Zao Ren Seed 8 8.6 ± 1.3 6.9 0.8 0.02 
73 HSD3 Bai Zi Ren Seed 8 11.3 ± 2.0 9.0 1.1 0.02 
14 HSD4 Yuan Zhi Root 14 19.6 ±12.6 27.4 3.2 0.06 
98 HCL3 Mu Li  Shell 0.4 bd bd bd bd 
Calm Liver & Suppress Wind 
83 HCL1 Tian Ma Root 14 29.3 ± 3.5 41.0 4.8 0.10 
25 HCL2 Gou Teng Branch 21 13.5 ± 1.8 28.4 3.3 0.07 
Qi Tonics 
53 HQT1 Huang Qi Root 14 8.0 ± 2.5 11.2 1.3 0.03 
56 HQT2 Bai Zhu Root 14 bd bd bd bd 
4 HQT3 Shan yao Root 14 23.8 ± 5.8 33.3 3.9 0.08 
24 HQT4 Gan Cao Root 14 13.3 ± 2.9 18.6 2.2 0.04 
42 HQT5 Zhi Gan Cao Root 14   14.9  1.0 20.9 2.4 0.05 
Yang Tonics 
28 HYT1 Du Zhong Bark 14 14.2 ± 4.1 19.9 2.3 0.05 
43 HYT2 Xu Duan Root 14 7.3 ± 0.4 10.2 1.2 0.02 
46 HYT3 Bu Gu Zhi Seed 18 15.8 ± 0.0 28.4 3.3 0.07 
100 HYT4 
Rou Cong 
Rong 
Branch 21 
0.6 ± 0.3 1.3 0.1 <0.01 
101 HYT5 Yin Yang Huo Branch 21 43.4 ± 7.0 91.1 10.6 0.21 
Blood Tonics 
10 HBT1 Dang Gui Root 14 15.4 ± 3.8 21.6 2.5 0.05 
78 HBT2 He Shou Wu Root 14 bd bd bd bd 
50 HBT3 Shu Di Huang Root 14 16.3 ± 0.9 22.8 2.7 0.05 
12 HBT4 Bai Shao Root 14 23.4 ± 1.1 32.8 3.8 0.08 
Yin Tonics 
13 HYN1 Bei Sha Shen Root 14 12.7 ± 4.9 17.8 2.1 0.04 
88 HYN2 Mai Men Dong Root 14 bd bd bd bd 
15 HYN3 Yu Zhu Root 14 18.1 ± 9.4 25.3 3.0 0.06 
29 HYN4 Shan Zhu Yu Seed 8 8.1 ± 2.3 6.5 0.8 0.02 
21 HYN5 Gou Qi Zi Seed 8 16.8 ± 2.5 13.4 1.6 0.03 
86 HYN6 Han Lian Cao Branch 21 bd bd bd bd 
18 HYN7 Nu Zhen Zi Seed 8 22.8 ±10.9 18.2 2.1 0.04 
Astringents 
58 HAS1 Wu Wei Zi Seed 8 19.3 ± 0.7 15.4 1.8 0.04 
26 HAS2 Fu Ziao Mai Seed 8 2.5 ± 1.4 2.0 0.2 <0.01 
5 HAS3 Lian Zi Seed 8 17.5 ± 2.0 14.0 1.6 0.03 
84 HAS4 Qian Shi Seed 8 bd bd bd bd 
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Table 9.18. Estimated Daily Intake of Cr from consumption of aqueous decoctions of an individual raw 
herb based on an averaged weight of 10 g prescribed for each herb in a prescription to be decocted twice.   
Adequate intake (AI) of Chromium (Cr) is 35 µg/day, and 25 µg/day for young men and women respectively.  
Recommended daily intake (RDI) is 120 µg/day. LOD = 0.06 µg/g. 
No. 
 
 
 
Sample 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total (acid-
digested) 
Chromium 
(Cr) 
µg/g ± sd 
Estimated     
Daily 
Intake 
µg/day 
  Adult 
Exposure 
(35µg/day)  
% of  AI 
Adult 
Exposure  
(120µg/day) 
% of  RDI  
Dispel Wind-Cold 
51 HWC1 Gui Zhi Branch 15 0.92 ± 0.01 1.38 4.0 1.2 
61 HWC2 Zi Su Ye Leaf 52 0.11 ± 0.04 0.57 1.7 0.5 
94 HWC3 Jing Jie Leaf 52 1.04 ± 0.22 5.41 15.4 4.5 
6 HWC4 Fang Feng Root  17 0.60 ± 0.04 1.02 2.9 0.9 
17 HWC5 Qiang Huo Root 17 2.20 ± 0.17 3.74 10.6 3.1 
20 HWC6 Bai Zhi Root 17 0.44 ± 0.03 0.75 2.0 0.6 
44 HWC7 Xin Ye Hua Flower 31 0.33 ± 0.03 1.02 2.9 0.9 
Dispel Wind-Heat 
34 HWH1 Bo He Leaf 42 0.42 ± 0.06 1.76 5.1 1.5 
87 HWH2 Ju Hua Flower 31 1.80 ± 0.13 5.58 16.0 4.7 
35 HWH3 Chai Hu Root 17 3.53 ± 1.12 6.00 17.1 5.0 
Eliminate Heat 
23 HEH1 Zhi Mu Root 17 2.08 ± 0.01 3.54 10.0 3.0 
60 HEH2 Lu Gen Root 17 56.47 ±13.4 96.00     274.3 80.0 
52 HEH3 Huang Qin Root 17 0.41 ± 0.07 0.70 2.0 0.6 
19 HEH4 Huang Bai Bark 3 0.48 ± 0.03 0.14 0.3 0.1 
67 HEH5 Zhi Zi Seed 8 0.14 ± 0.03 0.11 0.3 < 0.1 
75 HEH6 Ku Shen Root 17 3.10 ± 0.48 5.27 15.1 4.4 
95 HEH7 Long Dan Cao Root 17 13.47 ±1.36 22.90 65.4 19.1 
Eliminate Heat & Toxins 
85 HHT1 Jin Yin Hua Flower  31 0.33 ± 0.05 1.02 2.9 0.9 
45 HHT2 Lian Qiao Seed  8 0.55 ± 0.03 0.44 1.1 0.4 
90 HHT3 Ban Lan Gen Root 17 0.55 ± 0.10 0.94 2.6 0.8 
Eliminate Heat & Cool Blood 
96 HCB1 
Sheng Di 
Huang Root 17 4.15 ± 1.15 7.06 20.3 5.9 
93 HCB2 Xuan Shen Root 17 0.41 ± 0.09 0.70 2.0 0.6 
74 HCB3 Mu Dan Pi Bark 3 0.11 ± 0.03 0.03 < 0.1 < 0.1 
22 HCB4 Chi Shao Root 17 0.64 ± 0.05 1.09 3.1 0.9 
62 HCB5 Zi Cao Leaf 42 0.71 ± 0.29 2.98 8.5 2.5 
Eliminate Deficiency Heat 
47 HDH1 Di Gu PI Bark 3 1.39 ± 0.11 0.42 1.2 0.4 
Purgatives       
32 HPU1 Da Huang Root 17 0.30 ± 0.01 0.51 1.5 0.4 
Eliminate Wind-Damp 
38 HWD1 Du Huo Root 17 1.01 ± 0.03 1.72 4.9 1.4 
70 HWD2 Qin Jiao Root 17 4.67 ± 0.09 7.94 22.7 6.6 
9 HWD3 
Sang Ji 
Sheng Branch 15 1.46 ± 0.22 2.19 6.3 1.8 
Aromatic for Dispelling Damp  
30 HAD1 Cang Zhu Root 17 0.38 ± 0.04 0.65 1.9 1.6 
79 HAD2 Huo Po Root 17 5.12 ± 0.80 8.70 24.9 7.3 
49 HAD3 Huo Xiang Leaf  42 0.33 ± 0.05 1.39 4.0 1.2 
69 HAD4 Sha Ren Seed 8 0.38 ± 0.04 0.30 0.9 0.3 
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Table 9.18 Continued  Estimated Daily Intake of chromium (Cr) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a 
prescription to be decocted twice 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total (acid-
digested) 
Chromium 
(Cr) 
µg/g ± sd 
Estimated     
Daily 
Intake 
µg/day 
  Adult 
Exposure 
(35µg/day)  
% of  AI 
Adult 
Exposure  
(120µg/day) 
% of  RDI  
Diuretics 
97 HDU1 Fu Ling Root 17 0.09 ± 0.01 0.15 0.4 0.1 
36 HDU2 Ze Xie Root 17 bd bd bd bd 
68 HDU3 Yi Yi Ren Seed 8 0.32 ± 0.04 0.26 0.7 2.2 
Warming Interior  
54 HWI1 Gan Jiang Root  17 0.72 ± 0.07 1.22 3.5  
63 HWI2 Rou Gui Bark  3 0.08 ± 0.02 0.02 < 0.1 < 0.1 
1 HWI3 Wu Zhu Yu Seed 8 0.34 ± 0.04 0.27 0.80 0.2 
Regulate Qi 
64     HRQ1 Ju Pi  Bark  3 0.37 ± 0.10 0.11 0.3 < 0.1 
72 HRQ2 Qing Pi Bark  3 1.01 ± 0.23 0.30 0.9 0.3 
41 HRQ3 Zhi Ke Bark 3 0.25 ± 0.03 0.08 0.2 < 0.1 
59 HRQ4 Mu Xiang Root 17 1.52 ± 0.32 2.58 7.4 2.2 
3 HRQ5 Xiang Fu Root 17 1.40 ± 0.08 2.38 6.8 2.0 
8 HRQ6 Wu Yao Root 17 0.93 ± 0.11 1.58 4.5 1.3 
7 HRQ7 Yan Hu Suo Root 17 0.15 ± 0.01 0.26 0.7 0.2 
Digestives 
55 HDG1 Shan Zha  Seed 8 2.23 ± 0.99 1.78 5.1 1.5 
16 HDG2 Mai Ya Seed 8 3.98 ± 0.81 3.18 9.1 2.7 
Anthelmintics 
33 HAN1 Da Fu Pi Bark 3 0.54 ± 0.01 0.16 0.5 0.1 
Hemostatics 
48 HHM1 Ce Bai Ye Leaf 42 0.77 ± 0.10 3.23 9.2 2.7 
91 HHM2 Bai Mao Gen Root 17 3.55 ± 0.51 6.04 17.2 5.0 
Activate Blood Circulation & Remove Blood Stasis 
92 HBS1 Chuan Xiong Root 17 3.05 ± 1.75 5.19 14.8 4.3 
66 HBS2 Yu Jin Root 17 0.66 ± 0.14 1.12 3.2 0.9 
2 HBS3 Dan Shen Root 17 2.35 ± 0.05 4.0 11.4 3.3 
80 HBS4 Ye Mu Cao Leaf  42 0.61 ± 0.16 2.56 7.3 2.1 
27 HBS5 Hong Hua Flower 31 0.92 ± 0.01 2.85 8.1 2.4 
71 HBS6 Chuan Niu Xi Root 17 8.57 ± 1.21 14.57 41.6 12.1 
89 HBS7 Huai Niu Xi Root 17 2.82 ± 0.36 4.79 13.7 4.0 
Expectorants, Anti-tussives & Dysnea- relieving Drugs 
40 HRP1 Ban Xia Root 17 15.3 ± 0.41 26.00 74.3 21.7 
76 HRP2 Jie Geng Root 17 0.21 ± 0.05 0.36 1.0 0.3 
11 HRP3 Qian Hu  Root 17 2.12 ± 0.47 3.60 10.3 3.0 
65 HRP4 Gua Lou Bark 3 3.57 ± 0.86 1.07 3.1 0.9 
77 HRP5 Chuan Bei Mu Root 17 0.16 ± 0.03 0.27 0.8 0.2 
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Table 9.18 Continuued Estimated Daily Intake of chromium (Cr) from consumption of aqueous 
decoctions of an individual raw herb based on an averaged weight of 10 g prescribed for each herb in a 
prescription to be decocted twice. 
 
No. 
 
 
 
Code 
 
 
 
Chinese 
Name 
 
 
 
Part of 
Plant 
 
 
Av % of 
Aq Ext 
 
Total (acid-
digested) 
Chromium 
(Cr) 
µg/g ± sd 
Estimated     
Daily 
Intake  
µg/day 
  Adult 
Exposure 
(35µg/day) 
% of  AI 
Adult 
Exposure  
(120µg/day) 
% of  RDI  
Relieve Cough & Dyspnea 
37 HDC1 Xing Ren  Seed 8 bd bd bd bd 
39 HDC2 Bai Bu Root 17 2.97 ± 0.16 5.05 14.4 4.2 
99 HDC3 Zi Wan Root 17 5.32 ± 0.61 9.04 25.8 7.5 
81 HDC4 Su Zi Seed 17 bd bd bd bd 
82 HDC5 Sang Bai Pi Bark 3 0.98 ± 0.11 0.29 0.8 0.2 
Sedatives / Calm the Spirit 
57 HSD1 Long Gu Shell 0.4 19.52 ±1.67 0.78 2.2 0.7 
31 HSD2 Suan Zao Ren Seed 8 0.13 ± 0.00 0.10 0.3 < 0.1 
73 HSD3 Bai Zi Ren Seed 9 0.13 ± 0.02 0.12 0.3 0.1 
14 HSD4 Yuan Zhi Root 17 2.21 ± 0.27 3.76 10.7 1.8 
98 HCL3 Mu Li  Shell 0.4 5.48 ±0.33 0.22 0.6 0.2 
Calm Liver & Suppress Wind 
83 HCL1 Tian Ma Root 17 2.28 ± 0.24 3.88 11.1 3.2 
25 HCL2 Gou Teng Branch 15 2.99 ± 0.12 4.49 12.8 3.7 
Qi Tonics 
53 HQT1 Huang Qi Root 17 0.77 ± 0.11 1.31 3.7 1.1 
56 HQT2 Bai Zhu Root 17 3.09 ± 0.44 5.25 15.0 4.4 
4 HQT3 Shan yao Root 17 0.11 ± 0.00 0.19 0.5 0.2 
24 HQT4 Gan Cao Root 17 0.47 ± 0.08 0.80 2.3 0.7 
42 HQT5 Zhi Gan Cao Root 17 1.93 ± 0.18 3.28 9.4 2.7 
Yang Tonics 
28 HYT1 Du Zhong Bark 3 5.09 ± 0.46 1.53 4.4 1.2 
43 HYT2 Xu Duan Root 17 3.67 ± 0.31 6.24 17.8 5.2 
46 HYT3 Bu Gu Zhi Seed 8 0.68 ± 0.08 0.54 1.6 0.5 
100 HYT4 
Rou Cong 
Rong 
Branch 15 14.96 ±1.47 
22.44 64.1 18.7 
101 HYT5 Yin Yang Huo Branch 15 3.42 ± 0.60 5.13 14.7 4.3 
Blood Tonics 
10 HBT1 Dang Gui Root 17 0.59 ± 0.01 1.00 2.8 0.8 
78 HBT2 He Shou Wu Root 17 2.14 ± 0.20 3.64 10.4 3.0 
50 HBT3 Shu Di Huang Root 17 18.53 ±0.52 31.50 90.0 26.3 
12 HBT4 Bai Shao Root 17 0.10 ± 0.03 0.17 0.5 0.1 
Yin Tonics 
13 HYN1 Bei Sha Shen Root 17 0.11 ± 0.02 0.19 0.5 0.2 
88 HYN2 Mai Men Dong Root 17 2.64 ± 0.06 4.49 12.8 3.7 
15 HYN3 Yu Zhu Root 17 0.25 ± 0.03 0.43 1.2 0.4 
29 HYN4 Shan Zhu Yu Seed 8 0.14 ± 0.01 0.11 0.3 <0.1 
21 HYN5 Gou Qi Zi Seed 8 0.89 ± 0.14 0.71 2.0 0.6 
86 HYN6 Han Lian Cao Branch 15 2.63 ± 0.12 3.95 11.3 3.3 
18 HYN7 Nu Zhen Zi Seed 17 0.82 ± 0.00 1.39 4.0 1.1 
Astringents 
58 HAS1 Wu Wei Zi Seed 8 1.78 ± 0.34 1.42 4.1 1.2 
26 HAS2 Fu Ziao Mai Seed 8 bd bd bd bd 
5 HAS3 Lian Zi Seed 8 0.07 ± 0.02 0.06 0.2 < 0.1 
84 HAS4 Qian Shi Seed 8 0.13 ± 0.01 0.10 0.3 < 0.1 
Key to Table 9.14 to Table 9.18: 
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• LOD,  Limit of detection  
• sd = standard deviation of the mean 
• bd = below detection limit 
• ug/g = microgram per gram dried weight of raw herb 
• ng/g = nanogram per gram dried weight of raw herb 
 
• To calculate Estimated Daily Intake = Total metal content x % of Extraction x 10 (g) 
 
• To convert “Estimated Daily intake (a)” to “Estimated Weekly Intake (b)” = (a) divided 
by 60 kg, and multiplied by 7 (days) 
 
• For Cr: To calculate % of AI or % of RDI from Estimated Daily Intake (DI)  
 
             = (DI / AI or DI / RDI) x 100
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9.2.4   Interpretation of Estimated Oral Exposure With Respect To Regulatory   
           Standards – as Percentage of Provisional Tolerable Daily or Weekly Intake  
           (% PTDI or % PTWI)  
 
           Tolerable daily Intakes (TDI) are tolerable limits set at levels below which toxic effects 
should not occur as a result of daily ingestion over a lifetime . Of the five metals in this study, 
namely, Pb, Cd, Hg, As, and Cr, the Provisional Tolerable Weekly Intake (PTWI) for Pb, Cd and 
Hg were established by WHO (WHO, 2000, 2001), while the Provisional Tolerable Daily Intake 
(PTDI), and hence the Provisional Tolerable Weekly Intake (PTWI) was set for As by WHO in 
1999 (WHO, 1999). No provisional tolerable limit is available for chromium. Therefore, the safe 
level for consumption referred to as the reference dose, RfD for Cr was employed in the present 
study. These health standards for heavy metals, i.e. the PTWI, PTDI and RfD (alternatively 
referred to as TDI), were used as the maximum safety levels for oral ingestion. The estimated 
weekly intakes or estimated daily intakes of each metal for each CHM listed in Tables 9.14 – 
9.18, were then expressed as % of their PTWI (or RfD for Cr) to give an indication of the degree 
of safety from ingesting the aqueous decoctions of these CHM. These % of PTWI are shown in 
the last column of each table. The results of each metal exposure are discussed in separate 
sections below.  
 
 
9.2.4.1  Estimates of Daily Lead (Pb) Intake from the Combined Aqueous Decoctions 
             of CHM – as % of PTWI 
               
             It can be seen that the daily oral exposure of lead, expressed as % PTWI, of all 100 CHM 
when ingested as a 10g and twice-decocted aqueous solutions on their own were well under the 
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tolerable limits. For example, the last column of Table 10.14 shows that the majority of the 100 
CHM would expose an adult to less than 1.5% PTWI, with the lowest being a mere 0.1% from Fu 
Ling (specimen code: HDU1) and the highest 6.9% from Gua Lou (HRP4). Assuming the worst 
case scenario in which six CHM that contained some of the highest aqueous Pb concentrations 
were put together in one herbal prescription which consisted of Gua Lou (HRP4), Gui Zhi 
(HWC1), Zhi Zi (HEH5), Lian Qiao (HHT2), Wu Zhu Yu (HWI3) and Hong Hua (HBS5), their 
respective % PTWI being 6.9, 5.9, 5.6, 5.0, and 4.3, the total exposure from drinking such 
combined decoctions was still only 32 % PTWI. However, such a hypothetical herbal 
composition would be highly unlikely indeed. 
 
 
9.2.4.2  Estimates of Daily Arsenic (As) Intake from the Combined Aqueous Decoctions 
               of CHM – as % of PTWI  
 
             Similarly, the highest daily exposure to As came from the consumption of aqueous 
decoctions of 10 grams of Ce Bai Ye (HHN1) which amounted to 27.9% PTWI, while the lowest 
came from Mai Ya (HDG2), a mere 0.3% (see Table 9.15, last column). The 27.9% PTWI of Ce 
Bai Ye appeared to be the only CHM high at that level. Another 4 CHM gave % PTWI of around 
10%. Again, assuming the hypothetical worst case scenario of ingesting the combined aqueous 
decoctions of the six CHM containing the highest As concentration, namely, Ce Bai Ye (HHM1), 
Cang Zhu (HAD1), Hong Hua (HBS5), Chuan Niu Xi (HBS6), Ban Xia (HRP1), and Xu Duan 
(HYT2), their respective % of PTWI being 27.9, 10.0, 10.7, 11.8, 8.4, and 11.7, the total daily 
exposure to As would have been 79.5%. This is still within the tolerable limit of daily intake. 
Again, such a hypothetical scenario would be highly improbable. 
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9.2.4.3   Estimates of Daily Cadmium (Cd) Intake from the Combined Aqueous      
               Decoctions of CHM – as % of PTWI 
                
          With respect to Cd (see Table 8.16, last column), 91% of the CHM would result in an adult 
exposure of 3% of PTWI or less. Among these, 55% CHM accounted for oral exposure of 1% 
PTWI or less. The remaining 9 CHM among the higher Cd medicines had % of PTWI well below 
10%.  Overall, the 100 CHM studied contained low Cd contents, and would not present 
significant health risk even if the above worst-case scenario were to occur. 
 
 
9.2.4.4  Estimates of Daily Mercury (Hg) Intake from the Combined Aqueous    
             Decoctions of CHM – as % of PTWI            
                
          The mercury contents in aqueous decoctions of CHM were extremely low (see Table 9.17). 
Thirty-seven out of the 100 CHMs had Hg contents below the analytical limit of quantitation of 8 
ng/g. The highest estimated daily intake was less than 185 ng/day/person in Zi Su Ye (HWC2), 
which would have produced an insignificant adult exposure of 0.43% of PTWI. The great 
majority of CHMs gave less than 0.1 % PTWI. Chinese herbal materials, therefore, are well 
within the safe exposure levels for this heavy metal. 
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9.2.4.5  Estimates of Daily Chromium (Cr) Intake from the Combined Aqueous 
             Decoctions of CHM – as % of PTWI       
               
           A tolerable limit, such as PTWI, has not been established for Cr. Instead, reference doses 
(RfD) in the way of adequate intake (AI) levels of 35 µg/day for males aged between 14 and 50, 
or 25 µg/day for females aged between 19 and 50 (Institue of Medicine, 2001), and a maximum 
recommended daily intake (RDI) level of 120 µg/day (Lerntech, 2006) have been set for adults 
based on estimated mean intakes. Thus, AI for men is about 1.38 times higher than that for 
women while the RDI level is same for both men and women. A safety dose of 200 µg/day has 
also been suggested (Lerntech, 2006). For purpose of discussion, this safety level will be used in 
this project as the provisional tolerable daily intake for evaluation of safety, for lack of 
established regulatory standards. Table 9.18 shows the estimated daily intakes of Cr from 
consuming the combined aqueous decoctions of the 10g CHM, and their respective % of 
adequate daily intakes (as % AI) for adult males (the second last column), and as % of maximum 
recommended daily intakes (as % RDI) (last column). Chromium levels of 18 of the 100 CHM 
were below the limit of quantitation of 0.2 µg/g. For the majority of the remaining 82 CHMs, the 
estimated daily intake of Cr was less than 6 µg /day. Lu Gen (HEH2), by comparison, was the 
only one CHM that was exceptionally high in Cr content, providing an estimated daily intake of 
96 µg/day, which would exceed the adequate intake (AI) by 274 % for men, or by 384 % for 
women. They were, however, less than 50 % of RDI of 120 µg/day, or only about 25% of the 
safety dose of 200 µg/day. Three other CHM, Long Dan Cao (HEH7), Ban Xia (HRP1) and Rou 
Cong Rong (HYT4), each provided between approximately 65 to 75 % AI for men, and between 
90 to 100 % AI for women. 
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9.2.5  Total Daily Exposure of Metals From the Combined CHM Aqueous Decoctions      
          in Addition to a Normal Australian Daily Diet  
 
          In reality, total metal exposure in a patient taking CHM should also take into consideration 
of his/her normal daily diet characteristic of the Australian context. The 20th Australian Total 
Diet Survey (ATDS) published by the Food Standards Australia New Zealand in 2003 (FSANZ, 
2003a) – Appendix 1] reported the following percentage range of mean estimated daily dietary 
exposures for adult males aged between 25 and 34 years: Lead (1.8 – 11 % PTWI), Arsenic (18.6 
– 29.2 % PTWI), Cadmium (7.6 – 24 % PTWI), and Mercury (1.9 – 13 % PTWI). No TDI 
standard value has been set for chromium. However, adult men in the United States have been 
estimated to consume 39 to 54 µg of chromium per day from food. In contrast, adult women 
average 23 to 29 µg/day (Institue of Medicine, 2001).  When the ranges of estimated daily 
exposures to a particular metal determined for the Chinese herbal materials were added to these 
dietary exposures, a more realistic range of total daily exposure to the metal would be obtained.  
 
          It should be pointed out here that there is no data of mean estimated daily dietary exposures 
for the elderly cohort in the ANZFS document. The data for the young age-group (25-34 years) 
were deliberately chosen in this study for interpretation because they represent the highest 
exposure values compared to all other younger, and the female cohorts. This choice would 
demonstrate the worse-case scenario when their mean estimated daily dietary exposures are 
added to the daily exposure of metals from the Chinese herbal preparations. It is reasonable to 
assume that elderly people would consume less daily food than the young adults, and 
consequently expose to lower amount of metals. This would mean the elderly people who are 
taking Chinese herbal medicines would be exposed to a lower total combined metal content than 
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the younger cohorts. However, this lower exposure needs to be considered against their 
compromised metabolism especially their liver and renal functions. Since the liver and kidney are 
two major organs that are involved in the catabolism and excretion respectively. Reduction in the 
efficiency of breakdown and excretion processes may lead to increase of metal accumulation in 
the bodily fluids. 
 
         Results for As, Cd, Pb, and Hg from the total exposures to both daily diet and aqueous 
decoctions of CHM are shown in Table 9.19 below.  
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Table 9.19   Summary of daily metal exposure expressed as % PTWI, from normal Australian 
dieta (ATDS; from consuming combined aqueous decoctions of a 10g CHMb; and from the total 
exposure to both Diet and CHM.    
Metal Adult male daily 
exposure from 
Australian diet 
(ATDS),  
as % PTWIa 
 
PTWI based on 
WHO & ANZFS 
standards 
respectively 
Adult daily 
exposure from the 
2 aqueous 
decoctions of a 
single 10g CHM, 
as % PTWIb    
 
(Results from this 
project) 
Total daily 
exposure from 
sum of the daily 
diet and aqueous 
decoctions, as  
% PTWI 
 
(=  % PTWIa +  
% PTWIb) 
 
Arsenic 
(WHO: 15 µg/kg bw/wk) 
 
Arsenic 
(ANZFS: 21 µg/kg bw/wk) 
 
 
26.1 – 41.1 
 
 
18.6 – 29.2 
 
0.3 – 27.9* 
 
 
0.3 – 27.9* 
 
26.4 – 69.0 
 
 
18.9 – 57.1 
Cadmium 
 
7.6 – 24 0.1 – 9.5* 7.7 – 33.5 
Lead 
 
1.8 – 11 1.1 – 6.9* 1.9 – 17.9 
Mercury 1.9 – 13 0 – 4.3* 1.9 – 17.3 
 
*  The lower values of the ranges are from CHM with the lowest % PTWI, and higher values of 
the range are from the CHM with the highest % PTWI. 
 
          This table shows the lowest and highest combined exposure (Diet and CHM) as % of 
PTWI (Provisional Tolerable Weekly Intake) after a patient had consumed a 10 grams of CHM 
with the lowest aqueous metal content, or 10 grams of CHM with the highest aqueous metal 
content. This approach uses the two most extreme values to highlight the best and worse case 
scenarios of diet and CHM combinations. Since majority of the CHM were low in metal contents, 
it is clear that metal exposures from most CHM were rather insignificant (refer to the lower 
values of the ranges in the last column). Even with the worse case scenarios, the highest 
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combined exposures reached only around 18 % PTWI for lead and mercury, and 34 % PTWI for 
cadmium respectively. Measured against the Australian regulatory standard for As, the combined 
exposure reached 57.1 % of PTWI after Ce Bai Ye containing the highest As content was 
consumed in addition to a normal diet. And, when compared against the lower WHO regulatory 
standard for As, the combined exposure became 69 %.  
 
          Similarly, the two extreme values of daily intakes of Cr (i.e. the lowest and highest) were 
added to the normal dietary exposure to give a range of combined exposure (Diet  + CHM). 
These combined dietary and CHM intakes of Cr were then calculated as % of adequate intake (as 
%AI) to show the effect of CHM ingestion on adequacy of daily intake for this metal. The 
combined intakes were also expressed as % of the recommended daily exposure (as %RDI), as 
well as % of the tolerable daily intake level (as % TDI) to evaluate the extent of health risk. 
Because the mean daily dietary exposure to Cr differs between men and women, and the standard 
values of adequate intake (AI) for men are higher than those for women, the above percentage 
expressions were carried out separately for men and women, and the results are shown in Table 
9.20 below. 
 
          Table 10.20 shows the best and worse case scenarios of ingesting the CHM having the 
lowest Cr (0.11µg/day), and ingesting the CHM having the highest Cr (96.0 µg/day), in addition 
to a normal diet. The total daily exposure far exceeded the daily adequate intake levels (% AI) for 
both male and female, and just above the recommended daily levels (% RDI). Nevertheless, they 
were still below the maximum tolerable level of 200 µg/day, reaching 75 % and 63 % of the 
tolerable limit (i.e. as % TDI) for men and women respectively (see last column of Table 10.21), 
when the CHM having the highest Cr content was considered.    
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Table 9.20   Range of combined estimated daily exposures to Cr as a percentage of the AIa, RDIb, 
and TDIc after the lowest and highest estimated daily intakes of Cr from combined aqueous 
decoctions of a single CHM are added to the range of the mean daily dietary exposures to Cr  
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
                 Adult range           Adult daily           Range of         Adult            Adult             Combined     
                 of mean daily        intake of              combined       daily             daily              mean daily  
                 dietary exposure    lowest &              exposure         combined      combined      exposure                                                                                        
                 to Cr (µg/day)       highest CHM        Diet +CHM    exposure       exposure        compared to 
                 (Ref: Institute       (µg/day)                                        (M=35; F=25)   (120µg/day)       maximum 
                 of Medicine,         (Result from                                 (as                 (as                 daily level                                                      
                 2001)                    present project)     (µg/day)          % AI)          % RDI)         (as % TDI)  
                                                               
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
                      
 
Male         39 – 54               0.11 – 96.0*           39 – 150          112 – 429      33 – 125        20 – 75  
 
 
Female      23 – 29               0.11 – 96.0*           23 – 125          92 – 500        19 – 104        12 – 63 
 
a
 AI (adequate intake) = 35 µg/day for men, and 25 µg/day for women;   b RDI (Recommended 
daily intake) = 120 µg/day;    c TDI (Tolerable daily intake) = 200 µg/day;     * First value was 
the lowest daily intake from CHM, and second value was highest daily intake from CHM 
 
 
9.3    RESULTS OF THE 50 CHINESE PROPRIETARY MEDICINES (CPM) – Total    
           Metal Contents in Acid-digested Samples 
 
           Fifty patent Chinese proprietary medicines were analysed for their total acid-digested 
contents of the five metals. The proprietary names of these patent products were listed in Table 
9.21. Of the 50 patent medicines, there were 7 pairs that bore the same Chinese formula names. 
This implied that the Chinese herbal components for each pair were same. However, they were 
different to each other in one respect or the other, such as different manufacturers, or same 
manufacturer but different batch numbers. They were included to highlight the potential 
variations in manufacturing quality, if any. Results of the 5 acid-digested metal (i.e. total) 
contents for each CPM are also shown in Table 9.21.
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Table 9.21   Total metal contents in Chinese proprietary medicines showing proprietary name 
and manufacturer LOD, Pb =0.24 µg/g; As = 0.03 µg/g; Cr = 0.06 µg/g;  Hg = 2.4 ng/g;  Cd = 1.1 
ng/g 
 
No. Chinese Name Manufacturer Lead 
(Pb) 
µg/g 
Arsenic 
(As) 
µg/g 
Chromium 
(Cr) µg/g 
Mercury 
(Hg) 
ng/g 
Cadmium 
(Cd) 
ng/g 
02 Ba Zheng San  Lanzhou Foci, China 0.52 ± 0.05 1.74 ± 0.08 4.51 ± 0.09 21.6 ± 1.5 95.8 ± 0.8 
03 Xiao Qing Long Tang Lanzhou Minshan, China 1.32 ± 0.29 1.54 ± 0.03 2.42 ± 0.34 5.0 ± 4.6 71.5 ± 2.1 
04 Long Dan Xie Gan Tang Lanzhou Tai Bao, China 0.79 ± 0.06 1.51 ± 0.07 5.49 ± 0.47 4.5 ± 1.2 156.8 ± 8.6 
05 Xin Yi Wan Lanzhou Minshan, China 1.40 ± 0.04 1.87 ± 0.03 2.87 ± 0.13 5.6 ± 3.0 190.4 ± 3.3 
06 Tao Chih Pien  Tianjin Drug Co., China 0.43 ± 0.01 4.52 ± 0.16 1.60 ± 0.14 17.7 ± 13.1 101.4 ± 11.3 
07 Chuan Xiong Cha Tiao Wan Lanzhou Foci, China 1.33 ± 0.16 1.96 ± 0.09 11.9 ± 0.84 25.3 ± 6.3 195.7 ± 7.7 
08 Ba Zhen Tang Lanzhou Tai Bao, China 1.71 ± 0.07 1.55 ± 0.11 0.72 ± 0.10 3.3 ± 0.3 158.2 ± 12.2 
09 Liu Wei Di Huang Wan Lanzhou Foci, China 1.50 ± 0.10 0.91 ± 0.02 0.32 ± 0.07 13.2 ± 2.0 144.2 ± 6.7 
010 Po Chai Pills Li Chung Shing Tong, 
Hong Kong 
1.79 ± 0.15 1.37 ± 0.06 6.06 ± 0.36 13.5 ± 6.5 194.7 ± 30.1 
011 Duo Huo Ji Sheng Tang Lanzhou Foci, China 2.12 ± 0.23 1.87 ± 0.11 2.66 ± 0.25 14.5 ± 0.9 181.3 ± 14.0 
012 Jian Pi Wan Lanzhou Foci, China 1.64 ± 0.07 1.12 ± 0.06 0.72 ± 0.04 10.9 ± 6.2 60.7 ± 10.4 
014 Er Chen Tang Lanzhou Tai Bao, China 0.80 ± 0.07 1.15 ± 0.02 2.29 ± 0.01 19.9 ± 2.8 41.7 ± 9.7 
016 Shen Ling Bai Zhu San Lanzhou Minshan, China 1.88 ± 0.18 1.11 ± 0.03 2.18 ± 0.17 10.4 ± 2.1 144.5 ± 15.3 
017 Yu Ping Feng San Lanzhou Minshan, China 1.93 ± 0.10 1.54 ± 0.05 1.02 ± 0.09 15.3 ± 7.4 329.8 ± 20.7 
018 Chai Hu Shu Gan San Lanzhou Foci, China 2.12 ± 0.05 1.40 ± 0.02 1.51 ± 0.12 229.4 ± 47.9 205.3 ± 11.3 
019 Huo Xiang Zheng Qi San Lanzhou Tai Bao, China 1.95 ± 0.02 2.22 ± 0.06 0.56 ± 0.08 31.4 ± 7.9 197.5 ± 40.3 
020 Xiao Chai Hu Tang Lanzhou Minshan, China 1.90 ± 0.01 1.33 ± 0.01 0.43 ± 0.05 19.8 ± 4.3 140.2 ± 0.06 
021 Qing Qi Hua Tan Wan Lanzhou Foci, China 1.38 ± 0.10 1.03 ± 0.04 3.80 ± 0.35 17.6 ± 10.4 184.5 ± 6.3 
022 Xiao Yao San Lanzhou Foci, China 0.95 ± 0.24 1.35 ± 0.00 1.28 ± 0.04 11.5 ± 3.2 158.7 ± 23.0 
024 Yin Qiao Wan Lanzhou Minshan, China 1.59 ± 0.30 1.48 ± 0.10 3.25 ± 0.26 45.1 ± 30.1 149.9 ± 33.3 
026 Fang Feng Tong Sheng San Lanzhou Foci, China 2.34 ± 0.08 2.20 ± 0.01 0.50 ± 0.19 12.2 ± 6.4 216.1 ± 4.3 
027 Niu Huang Qing Xin Wan Beijing Tong Ren Tang 2.65 ± 0.16 0.71 ± 0.07 7.04 ± 0.42 18.6 ±7.7 109.3 ± 8.4 
029 An Shen Ding Zhi Wan Lanzhou Foci, China 8.11 ± 0.31 1.89 ± 0.18 2.25 ± 0.12 6.8 ± 3.9 205.3 ± 21.9 
031 Huang Lian Jie Du Tang Lanzhou Mian San, China 1.37 ± 0.07 1.09 ± 0.12 1.05 ± 0.30 10.1 ± 3.9 161.1 ± 2.2 
032 Xue Fu Zhu Yu Tang Lanzhou Tai Bao, China 1.06 ± 0.07 0.79 ± 0.01 0.46 ± 0.03 bd 176.7 ± 5.9 
033 Sang Ju Wan Lanzhou Foci, China 1.63 ± 0.05 0.79 ± 0.02 7.53 ± 1.50 152.5 ± 26.7 129.4 ± 4.2 
034 Mai Wei Di Huang Wan Lanzhou Foci, China 1.14 ± 0.11 0.65 ± 0.07 0.51 ± 0.02 23.7 ± 4.2 192.1 ± 10.8 
035 Shen Qi Da Bu Wan Lanzhou Minshan, China 1.00 ± 0.18 1.06 ± 0.10 0.68 ± 0.25 172.6 ± 29.0 168.9 ± 11.1 
037 Tian Ma Gou Teng Wan Lanzhou Tai Bao, China 1.42 ± 0.15 0.48 ± 0.03 0.41 ± 0.05 43.5 ± 33.3 151.6 ± 24.6 
038 Qian Bai Bi Yan Pian Guangzhou Qixing, China 2.01 ± 0.16 4.28 ± 0.53 0.60 ± 0.08 258.9 ±108.1 667.4 ± 17.9 
039 Zuo Gui Wan Lanzhou Minshan, China 1.41± 0.23 1.05 ± 0.16 1.64 ± 0.16 78.0 ± 25.2 108.1 ± 7.8 
040 You Gui Wan Lanzhou Foci, China 1.39 ± 0.42 0.84 ± 0.24 0.44 ± 0.13 62.4 ± 4.0 155.9 ± 32.2 
046 Wen Dan Tang Lanzhou Tai Bao, China 1.11 ± 0.12 1.36 ± 0.05 0.75 ± 0.09 29.2 ± 15.6 152.1 ± 11.2 
047 Zhi Bai Ba Wei Wan Lanzhou Minshan, China 1.46 ± 0.06 1.29 ± 0.08 0.74 ± 0.21 bd 105.1 ± 12.7 
049 Bi Min Gan Pian King Tim Internatl., Aust. 2.98 ± 0.07 2.90 ± 0.09 2.87 ± 0.28 bd 388.7 ± 12.1 
050 Kun Bao Wan Tong Ren Tong, Aust. 2.43 ± 0.45 1.40 ± 0.54 3.56 ± 0.89 bd 76.8 ± 11.2 
023 Bao He Wan (Sheng Neng 
P/L) 
Lanzhou Foci, China 1.68 ± 0.08 1.26 ± 0.03 1.10 ± 0.15 51.9 ± 29.4 126.6 ± 8.6 
041 Bao He Wan (Cathay P/L) Lanzhou Foci, China 1.71 ± 0.17 1.60 ± 0.01 0.38 ± 0.05 501.7 ± 34.0 126.3 ± 21.2 
013 Bu Zhong Yi Qi Wan Lanzhou Minshan, China 1.28 ± 0.23 1.95 ± 0.06 0.71 ± 0.09 12.6 ± 2.9 111.6 ± 14.1 
042 Bu Zhong Yi Qi Wan Lanzhou Foci, China 1.41 ± 0.28 1.19 ± 0.31 0.63 ± 0.16 48.8 ± 30.1 166.3 ± 22.7 
015 Zhi Sou San & Addition Lanzhou Tai Bao, China 1.87 ± 0.20 1.26 ± 0.05 1.83 ± 0.23 12.8 ± 5.5 65.8 ± 18.5 
043 Zhi Sou Wan & Addition Lanzhou Foci, China 1.43 ± 0.04 2.20 ± 0.18 1.75 ± 0.12 33.0 ± 9.3 238.2 ± 28.5 
030 Gui Pi Wan  Lanzhou Foci. China 2.34 ± 0.28 1.44 ± 0.08 0.68 ± 0.04 bd 173.4 ± 37.7 
044 Gui Pi Wan Lanzhou Tai Bao, Chins 2.38 ± 0.26 1.38 ± 0.04 3.79 ± 0.08 15.0 ± 2.5 166.4 ± 9.5 
01 Xiao Feng Wan (Batch 
010904) 
Lanzhou Foci, China 0.72 ± 0.03 1.37 ± 0.08 4.51 ± 0.09 21.6 ± 1.5 94.8 ± 0.8 
045 Xiao Feng Wan (Batch 
9903027) 
Lanzhou Foci, China 1.26 ± 0.03 1.54 ± 0.07 0.89 ± 0.02 35.5 ± 10.2 39.5 ± 0.4 
036 Tao Hong Si Wu Wan Lanzhou Minshan, China 1.68 ± 0.10 0.71 ± 0.02 0.70 ± 0.27 26.7 ± 2.9 168.4 ± 5.6 
048 Tao Hong Si Wu Wan Lanzhou Foci, China 2.45 ± 0.38 1.22 ± 0.04 3.01 ± 0.33 bd 151.8 ± 8.0 
025 Tian Wang Bu Xin Dan Lanzhou Foci, China 1.09 ± 0.03 1.34 ± 0.03 4.30 ± 0.31 20.8 ± 7.1 158.1 ± 5.6 
028 Tian Wang Bu Xin Wan Lanzhou Minshan, China  1.57 ± 0.11 1.44 ± 0.14 1.10 ± 0.03 10.8 ± 7.8 105.2 ± 5.7 
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Key to Table 9.21: 
 
23 and 41 – Produced by same company, same product name but different List numbers.  #23 has 9 
herbs against 6 herbs in #41 in the prescription. They are packaged by same manufacturer for export to 
two different companies in Australia, the Shen Neng P/L, NSW, and the Cathay Wholesale P/L, NSW. 
15 and 43 – Produced by two different companies. Company that manufactured #15 was formerly 
related to company that manufactured #43. The same List number was retained even though quality 
assurance may be entirely different. 
1 and 45 – Same products (from same company), but different batches. Selected to highlight 
possible variations in quality control between batches. 13 and 42 – Different companies, (and 
different List numbers). nd = not detected
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9.3.1   Results of Total Lead (Pb) Contents in Acid-digested CPM  
 
          Two out of 50 CPMs had no Pb, or had Pb contents below the analytical limit of                                                          
quantitation of 0.8 µg/g. They were the Ba Zheng San (No. 02) and Xiao Feng Wan (No. 1, Batch 
010904). Surprisingly, a second pack of Xiao Feng Wan (No. 045), produced by the same 
company (Lanzhou Foci, China), but belonging to a different batch, contained 1.26 µg of Pb/g. 
Significant Pb difference were also detected in the two Tao Hong Si Wu Wan that were 
manufactured by two different companies (No. 036 from Lanzhou Minshan Co., and No. 048 
from Lanzhou Foci Co.). The former product contained 1.68 µg Pb/g, and the latter 2.45 µg/g. An 
Shen Ding Zhi Wan, on the other hand, contained the highest content of Pb among the 50 CPMs, 
at 8.11 µg/g of the pills. 
 
 
9.3.2   Results of Total Arsenic (As) Contents in Acid-digested CPM  
 
          With respect to As content (see Table 9.21), majority of the 50 CPM had levels between 
1.0 and 2.0 µg/g of the pills, 8 were less than 1.0 µg/g, 4 were between 2.0 and 3.0 µg/g, while 
only 2 were about 4.5 µg/g. There was not much difference in As contents between most pairs of 
CPMs, except between Zhi Sou San & Addition (No. 015) and Zhi Sou Wan & Addition (No. 
043), produced by different pharmaceutical companies. The former had an As content of 1.26 
µg/g and the latter 2.20 µg/g. Overall, arsenic contents in Chinese proprietary medicines were 
low. 
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9.3.3   Results of Total Chromium (Cr) Contents in Acid-digested CPM 
 
          Similarly, Cr contents in CPMs were also low (see Table 9.21), especially when taking 
into consideration of the very high standard value of acceptable daily intake. The proprietary 
medicine with the highest Cr content was Chuan Xiong Cha Tiao Wan (No. 07), containing 11.9 
µg/g, and the lowest product, the well known Liu Wei Di Huang Wan (No. 09), contained only 
0.32 µg/g. However, there were more marked differences in Cr between paired products. For 
example, the Xiao Feng Wan contained Cr contents of 4.51 µg/g and 0.89 µg/g for the two 
different batches (No. 01, and No. 045) even though they were manufactured by the same 
pharmaceutical company, Lanzhou Foci. The same company also manufactured Bao He Wan for 
two different herbal wholesalers in Australia. Again, the CPM for Sheng Neng P/L, Australia (No. 
023) consisted of 1.10 µg Cr/g of the pills, whereas the CPM for Cathay P/L, Australia (No. 041) 
consisted of only 0.38 µg/g. These discrepancies indicated the variation in quality control during 
manufacturing processes. A four-fold difference was also observed in the paired Tian Wang Bu 
Xin Dan/Wan as a result of two different manufacturers. The product by Lanzhou Foci Co. (No. 
025) had 4.30 µg of Cr/g, while that by Lanzhou Minshan Co. had 1.10 µg/g. 
 
 
 
9.3.4   Results of Total Mercury (Hg) and Cadmium (Cd) Contents in  
           Acid-digested CPM  
 
          By comparison, the Hg and Cd contents in CPM (see Table 9.21) were even lower than the 
other three metals in absolute quantities. Mercury was below the analytical limit of quantitation  
of 8 ng/g, for 11 of the 50 CPM. Others were mostly less than 50 ng/g (i.e. < 0.05 µg/g). Four 
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were found to contain Hg of between 200 and 500 ng/g. Again, some manufacturing quality 
difference (10-fold) also occurred in the two Bao He Wan (No. 023 & No. 041), both produced 
by same company Lanzhou Foci, one being 51.9 ng/g and the other 501.7 ng/g in terms of Hg 
content. Chinese proprietary medicines were also low in Cd levels. All but four contained 200 
ng/g or less (i.e. ≤ 0.2 µg/g). An approximately 4-fold difference in Cd level, 65.8 ng/g and 238.2 
ng/g, was observed between the paired Zhi Sou San & Addition manufactured by Lanzhou Tai 
Bao, and Lanzhou Foci respectively. 
 
 
9.3.5     Difference in Total Metal Contents Among 50CPM 
 
           The contents of the 5 metals were generally low for the great majority of the Chinese 
proprietary medicines analysed. Figure 9.8 is a scatter plot of the distribution of lead contents 
among the 50 CPM. It shows that all, except one, of the 50 CPMs had lead contents of less than 3 
µg/g of the tablet. Of these, 39 CPMs contained less than 2 µg/g. The one sample that was high in 
Pb content at 8.11 µg/g belonged to An Shen Ding Zhi Wan (No. 029).    
 
          The arsenic contents in the 50 CPM were more evenly scattered between about 0.5 µg/g 
and 2.2 µg/g (Figure 9.9). Two CPM contained about twice as much arsenic contents as the rest. 
They were the Qian Bai Bi Yan Pian (No. 038), and Tao Chih Pien (No. 06), with arsenic 
concentrations of 4.28 µg/g and 4.52 µg/g respectively. 
 
          Similarly, all but 3 samples of the 50 CPM had less than 240 ng of cadmium per gram of 
tablet (i.e., < 0.24 µg/g) (Figure 9.10). Two patent products had cadmium between 300 ng/g and 
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400 ng/g. Again, the Qian Bai Bi Yan Pian (No. 038), at 667.7 ng/g, contained the highest 
concentration of chromium in this study.  
 
          Mercury contents in CPM were generally very low (Figure 9.11). They tended to cluster at 
less than 100 ng/g levels (i.e., < 0.1 µg/g). The highest product belonged to Bao He Wan (No. 
041) containing 501.7 ng/g. This amount was about 10 times more mercury than most other 
products. 
  
          Of the 5 metals studied, chromium contents were the most scattered among the 50 
proprietary products (Figure 9.12). Their concentration spread between about 0.5 µg/g and 7.5 
µg/g, apart from one product, Chuan Xiong Cha Tiao Wan (No. 07), which consisted of 11.9 
µg/g.     
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Figure 9.8 – 9.12: Distributions of the five metals among the 50 Chinese proprietary medicines 
showing heavy preponderance at the low concentrations 
 
 
Figure 10.9 Distribution of Lead (Pb) Content Among 
50 CPM
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Figure 10.10 Distribution of Arsenic (As) Content 
Among 50 CPM
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Figure 10.11 Distribution of Cadmium (Cd) Content 
Among 50 CPM
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Figure 10.12 Distribution of Mercury (Hg) Content 
Among 50 CPM
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Figure 10.13 Distribution of Chromium (Cr) Content 
Among 50 CPM
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9.3.6 Estimated Oral Exposure to Metals After Consuming Recommended Dose of   
            CPM – as Estimated Daily Intake  
 
          Estimation of exposure of metals due to ingestion of CPM differed from that for the crude 
Chinese herbal medicines (CHM). Crude CHM required boiling in water to prepare for the 
ingestible aqueous decoction. Chinese proprietary medicines, on the other hand, are generally 
manufactured ready for ingestion in the form of pills or tablets or capsules, and are swallowed 
whole as purchased. Therefore, no conversion from the acid-digested content into the boiling 
aqueous fraction is necessary. The estimated daily or weekly intake of each metal was calculated 
directly by multiplying the acid-digested metal content (as µg/g or ng/g) by the weight (in gram) 
of the recommended dose per day. Where a range of doses was given, then the lower and upper 
levels of estimated intake were also calculated. Assessment of risk of exposure was then made by 
comparing the estimated daily or weekly intake to the tolerable limits for adult exposure, as a % 
of the PTWI. Such procedure of safety assessments for the 50 CPM are presented metal by metal 
and listed in Tables 9.22 to 9.26.  
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Table 9.22:   Estimated daily exposure to Lead (Pb) from ingestion of CPM, and interpreted as % of 
maximum weekly allowable Intake (%PTWI) for Pb which is 25 µg/kg bw per week (WHO guideline 2000)        
  
No. Chinese Name Recom- 
mended  
Dose 
No. of 
Pills 
Ingested 
Daily 
Total 
Weight  
of  Pills 
Ingested 
(g/day) 
Total  
Lead/g  
of Pills 
Found 
(µg/g) 
Estimated 
Daily Pb 
Ingested 
(µg/day) 
Estimated 
Weekly 
Pb Intake 
µg/kg bw 
Adult 
Exposure 
(25µg/kg 
bw/week) 
as %PTWI 
02 Ba Zheng San  8 Pills; 3 times / d 24 4.422 0.52 ± 0.05 2.299 0.27       1.1 
03 Xiao Qing Long Tang 8 Pills; 3 times / d 24 3.818 1.32 ± 0.29 5.040 0.59 2.4 
04 Long Dan Xie Gan Tang 8 Pills; 3 times / d 24 3.817 0.79 ± 0.06 3.015 0.35 1.4 
05 Xin Yi Wan 8 Pills; 3 times / d 24 3.758 1.40 ± 0.04 5.261 0.61 2.4 
06 Tao Chih Pien  2-4 Tab; 2 times / d 4 – 8 1.184 –  
2.368 
0.43 ± 0.01 0.509 –  
1.018 
0.06 – 
 0.12 
0.2 – 0.5 
07 Chuan Xiong Cha Tiao Wan 15 Pills; 3 times / d 45 7.967 1.33 ± 0.16 10.596 1.24 5.0 
08 Ba Zhen Tang 8 Pills;  3 times / d 24 4.107 1.71 ± 0.07 7.023 0.82 3.3 
09 Liu Wei Di Huang Wan 8 Pills; 3 times / d 24 4.364 1.50 ± 0.10 6.546 0.76 3.0 
010 Po Chai Pills 1-2 bottles; 4x / d 4 – 8  
Bottles 
8.438 –  
16.876 
1.79 ± 0.15 15.104 – 
30.208 
1.76 – 
 3.52 
7.0 – 14.1 
011 Duo Huo Ji Sheng Tang 8 Pills; 3 times / d 24 4.509 2.12 ± 0.23 9.559 1.12 4.5 
012 Jian Pi Wan 8 Pills; 3 times / d 24 4.522 1.64 ± 0.07 7.416 0.87 3.5 
014 Er Chen Tang 8 Pills; 3 times / d 24 4.039 0.80 ± 0.07 3.231 0.38 1.5 
016 Shen Ling Bai Zhu San 8 Pills; 3 times / d 24 3.988 1.88 ± 0.18 7.497 0.87 3.5 
017 Yu Ping Feng San 8 Pills; 3 times / d 24 4.150 1.93 ± 0.10 8.010 0.93 3.7 
018 Chai Hu Shu Gan San 8 Pills; 3 times / d 24 4.206 2.12 ± 0.05 8.917 1.04 4.2 
019 Huo Xiang Zheng Qi San 8 Pills; 3 times / d 24 3.834 1.95 ± 0.02 7.476 0.87 3.5 
020 Xiao Chai Hu Tang 8 Pills; 3 times / d 24 4.103 1.90 ± 0.01 7.796 0.91 3.6 
021 Qing Qi Hua Tan Wan 6 Pills; 3 times / d 24 4.305 1.38 ± 0.10 5.941 0.69 2.8 
022 Xiao Yao San 8 Pills; 3 times / d 24 4.245 0.95 ± 0.24 4.033 0.47 1.9 
024 Yin Qiao Wan 8 Pills; 3 times / d 24 3.812 1.59 ± 0.30 6.061 0.71 2.8 
026 Fang Feng Tong Sheng San 8 Pills; 3 times / d 24 3.870 2.34 ± 0.08 9.056 1.06  4.2 
027 Niu Huang Qing Xin Wan 1-2 Pills; 2 times / d 2 – 4 5.992 –  
11.984 
2.65 ± 0.16 15.879 – 
31.758 
1.85 –  
3.71 
7.4 – 14.8 
029 An Shen Ding Zhi Wan 15 Pills; 3 times / d 45 7.750 8.10 ± 0.31 62.775 7.32 29.3 
031 Huang Lian Jie Du Tang 8 Pills; 3 times / d 24 3.693 1.37 ± 0.07 5.059 0.59 2.4 
032 Xue Fu Zhu Yu Tang 8 Pills; 3 times / d 24 3.820 1.06 ± 0.07 4.049 0.47 1.9 
033 Sang Ju Wan 8 Pills; 3 times / d 24 4.488 1.63 ± 0.05 7.315 0.85 3.4 
034 Mai Wei Di Huang Wan 8 Pills; 3 times / d 24 4.030 1.14 ± 0.11 4.594 0.58 2.3 
035 Shen Qi Da Bu Wan 8 Pills; 3 times / d 24 4.106 1.00 ± 0.18 4.106 0.48 1.9 
037 Tian Ma Gou Teng Wan 8 Pills; 3 times / d 24 3.710 1.42 ± 0.15 5.268 0.61 2.4 
038 Qian Bai Bi Yan Pian 4 Tab; 3 times /d for 
1 month; then 1 / d   
12 6.051 2.01 ± 0.16 12.163 1.42 5.7 
039 Zuo Gui Wan 8 Pills; 3 times / d 24 4.343 1.41± 0.23 6.124 0.71 2.8 
040 You Gui Wan 8 Pills; 3 times / d 24 4.457 1.39 ± 0.42 6.195 0.72 2.9 
046 Wen Dan Tang 8 Pills; 3 times / d 24 4.045 1.11 ± 0.12 4.490 0.52 2.1 
047 Zhi Bai Ba Wei Wan 8 Pills; 3 times / d 24 4.052 1.46 ± 0.06 5.916 0.69 2.8 
049 Bi Min Gan Pian 3-5 Pills; 3 times / d 9 – 15 5.277 –  
8.795 
2.98 ± 0.07 15.725 – 
26.209 
1.83 – 
3.06 
7.3 – 12.2 
050 Kun Bao Wan 25-50 Pills; 2 / d for 
1month, then by ½ 
for 2-3 months 
50 –  
100 
4.660 –  
9.320 
2.43 ± 0.45 11.324 – 
22.648 
1.32 –  
2.64 
5.3 – 10.6 
023 Bao He Wan (Sheng Neng P/L) 8 Pills; 3 times / d 24 3.933 1.68 ± 0.08 6.607 0.77 3.1 
041 Bao He Wan (Cathay P/L) 8 Pills; 3 times / d 24 3.817 1.71 ± 0.17 6.527 0.76 3.0 
013 Bu Zhong Yi Qi Wan  (MS) 8 Pills; 3 times / d 24 3.889 1.28 ± 0.23 4.978 0.58 2.3 
042 Bu Zhong Yi Qi Wan  (FC) 8 Pills; 3 times / d 24 4.078 1.41 ± 0.28 5.750 0.67 2.7 
015 Zhi Sou San & Addition (TB) 8 Pills; 3 times / d 24 3.925 1.87 ± 0.20 7.340 0.86 3.4 
043 Zhi Sou Wan & Addition (FC) 10 Pills; 3 times / d 30 5.025 1.43 ± 0.04 7.186 0.84 3.4 
030 Gui Pi Wan  8 Pills; 3 times / d 24 3.914 2.34 ± 0.28 9.159 1.07 4.3 
044 Gui Pi Wan 8 Pills; 3 times/d 24 3.726 2.38 ± 0.26 8.868 1.03 4.1 
01 Xiao Feng Wan  (Batch: 010904) 15 Pills; 3 times / d 45 8.022 0.72 ± 0.03 5.776 0.67 2.7 
045 Xiao Feng Wan  (Batch: 9903027) 15 Pills; 3 times / d 45 7.667 1.26 ± 0.03 9.660 1.13 4.5 
036 Tao Hong Si Wu Wan 8 Pills; 3 times / d 24 4.016 1.68 ± 0.10 6.747 0.79 3.2 
048 Tao Hong Si Wu Wan 12 Pills; 3 times / d 36 6.041 2.45 ± 0.38 14.800 1.73 6.9 
025 Tian Wang Bu Xin Dan 8 Pills; 3 times / d 24 4.081 1.09 ± 0.03 4.448 0.52 2.1 
028 Tian Wang Bu Xin Wan 8 Pills, 3 times / d 24 3.839 1.57 ± 0.11 6.027 0.70 2.8 
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Key for Tables 9.22 to 9.26: 
23 and 41 – Produced by same company, same product name but different List numbers.  #23 has 9 
herbs  
against 6 herbs in #41 in the prescription. They are packaged by same manufacturer for export to two 
different companies in Australia, the Shen Neng P/L, NSW, and the Cathay Wholesale P/L, NSW. 
15 and 43 – Produced by two different companies. Company that manufactured #15 was formerly 
related to company that manufactured #43. The same List number was retained even though quality 
assurance may be entirely different. 
1 and 45 – Same products (from same company), but different batches. Selected to highlight 
possible variations in quality control between batches. 
 
Calculations: 
(a) Total Weight of Pills Ingested, in ug/day 
(b) Total Lead (Pb), in µg/g of pill = as measured by AAS  
(c) Total Lead ingested, in ug/day = (a) x (b) 
(d) Estimated Weekly Intake (EWI) ug/kg bw = © x 7days ÷ 60 kg 
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Table 9.23:   Estimated weekly exposure to arsenic (As) from ingestion of CPM, and interpreted as 
% of maximum weekly allowable intake (%PTWI) for As which is 21 µg/kg bw/week (ANZFA, 1999); 
Also 15 µg/kg bw per week (WHO, 1999 recommendation). See Key in Table 9.22 for further explanation.  
      Adult 
Exposure 
% of PTWI 
 
No. 
 
Chinese Name 
 
Recom- 
mended  
Dose 
 
No. of 
Pills 
Ingest
ed 
Daily 
 
Total 
Weight  
of  Pills 
Ingested 
(g/day) 
 
Total  
Arsenic 
/g of Pills 
Found 
(µg/g) 
 
Total  
Daily As 
Ingested 
 
(µg/day) 
 
Estimated 
Weekly 
As Intake  
 
µg/kg bw W H 
O 
AN
ZFA 
02 Ba Zheng San  8 Pills; 3 times / d 24 4.422 1.74 ± 0.08 7.694 0.90    6.0    4.3 
03 Xiao Qing Long Tang 8 Pills; 3 times / d 24 3.818 1.54 ± 0.03 5.880 0.69 4.6 3.3 
04 Long Dan Xie Gan Tang 8 Pills; 3 times / d 24 3.817 1.51 ± 0.07 5.764 0.67 4.5 3.2 
05 Xin Yi Wan 8 Pills; 3 times / d 24 3.758 1.87 ± 0.03 7.027 0.82 5.5 3.9 
06 Tao Chih Pien  2-4 Tab; 2 times/d 4 – 8 1.184 –  
2.368 
4.52 ± 0.16 5.352 – 
10.703 
0.62 –  
3.12 
4.1– 
20.8 
3.0 – 
14.9 
07 Chuan Xiong Cha Tiao Wan 15 Pills; 3 times / d 45 7.967 1.96 ± 0.09 15.615 1.82 12.1 9.7 
08 Ba Zhen Tang 8 Pills;  3 times / d 24 4.107 1.55 ± 0.11 6.366 0.74 4.9 3.5 
09 Liu Wei Di Huang Wan 8 Pills; 3 times / d 24 4.364 0.91 ± 0.02 3.971 0.46 3.1 2.2 
010 Po Chai Pills 1-2 bottles; 4x / d 4 – 8 
Bottles 
8.438 –  
16.876 
1.37 ± 0.06 11.560 – 
23.120 
1.35 –  
2.70 
9.0– 
18.0 
6.4 – 
12.9 
011 Duo Huo Ji Sheng Tang 8 Pills; 3 times / d 24 4.509 1.87 ± 0.11 8.432 0.98 6.5 4.7 
012 Jian Pi Wan 8 Pills; 3 times / d 24 4.522 1.12 ± 0.06 5.065 0.59 3.9 2.8 
014 Er Chen Tang 8 Pills; 3 times / d 24 4.039 1.15 ± 0.02 4.645 0.54 3.6 2.6 
016 Shen Ling Bai Zhu San 8 Pills; 3 times / d 24 3.988 1.11 ± 0.03 4.427 0.52 3.5 2.5 
017 Yu Ping Feng San 8 Pills; 3 times / d 24 4.150 1.54 ± 0.05 6.391 0.75 5.0 3.6 
018 Chai Hu Shu Gan San 8 Pills; 3 times / d 24 4.206 1.40 ± 0.02 5.888 0.69 4.6 3.3 
019 Huo Xiang Zheng Qi San 8 Pills; 3 times / d 24 3.834 2.22 ± 0.06 8.511 0.99 6.6 4.7 
020 Xiao Chai Hu Tang 8 Pills; 3 times / d 24 4.103 1.33 ± 0.01 5.457 0.64 4.3 3.0 
021 Qing Qi Hua Tan Wan 6 Pills; 3 times / d 24 4.305 1.03 ± 0.04 4.434 0.52 3.5 2.4 
022 Xiao Yao San 8 Pills; 3 times / d 24 4.245 1.35 ± 0.00 5.731 0.67 4.5 3.2 
024 Yin Qiao Wan 8 Pills; 3 times / d 24 3.812 1.48 ± 0.10 5.642 0.66 4.4 3.1 
026 Fang Feng Tong Sheng San 8 Pills; 3 times / d 24 3.870 2.20 ± 0.01 8.514 0.99 6.6 4.7 
027 Niu Huang Qing Xin Wan 1-2 Pills;  
2 times/d 
2 – 4 5.992 –  
11.984 
0.71 ± 0.07 4.254 – 
8.509 
0.50 –  
1.00 
3.3– 
6.7 
2.4 – 
4.8 
029 An Shen Ding Zhi Wan 15 Pills; 3 times / d 45 7.750 1.89 ± 0.18 14.648 1.71 11.4 8.1 
031 Huang Lian Jie Du Tang 8 Pills; 3 times / d 24 3.693 1.09 ± 0.12 4.025 0.47 3.1 2.2 
032 Xue Fu Zhu Yu Tang 8 Pills; 3 times / d 24 3.820 0.79 ± 0.01 3.018 0.35 2.3 1.7 
033 Sang Ju Wan 8 Pills; 3 times / d 24 4.488 0.79 ± 0.02 3.546 0.28 1.9 1.3 
034 Mai Wei Di Huang Wan 8 Pills; 3 times / d 24 4.030 0.65 ± 0.07 2.620 0.31 2.1 1.5 
035 Shen Qi Da Bu Wan 8 Pills; 3 times / d 24 4.106 1.06 ± 0.10 4.352 0.51 3.4 2.4 
037 Tian Ma Gou Teng Wan 8 Pills; 3 times / d 24 3.710 0.48 ± 0.03 1.781 0.21 1.4 1.0 
038 Qian Bai Bi Yan Pian 4 Tab; 3 times/d for 
1 month; then 1/ d    
12 6.051 4.28 ± 0.53 25.900 3.02 20.1 14.4 
039 Zuo Gui Wan 8 Pills; 3 times / d 24 4.343 1.05 ± 0.16 4.560 0.53 3.5 2.5 
040 You Gui Wan 8 Pills; 3 times / d 24 4.457 0.84 ± 0.24 3.744 0.44 2.9 2.1 
046 Wen Dan Tang 8 Pills; 3 times / d 24 4.045 1.36 ± 0.05 5.501 0.64 4.3 3.1 
047 Zhi Bai Ba Wei Wan 8 Pills; 3 times / d 24 4.052 1.29 ± 0.08 5.227 0.61 4.1 2.9 
049 Bi Min Gan Pian 3-5 Pills; 3 times/d 9 – 15 5.277 –  
8.795 
2.90 ± 0.09 15.303 – 
25.506 
1.79 –  
2.98 
11.–
19.9 
8.5 – 
14.2 
050 Kun Bao Wan 25-50 Pills;  
2 / d for 1month, 
then by ½  
for 2-3 months 
50 –  
100 
4.660 –  
9.320 
1.40 ± 0.54 6.524 – 
13.048 
0.76 –  
1.52 
5.1– 
10.1 
3.6 – 
7.2 
023 Bao He Wan (Sheng Neng P/L) 8 Pills; 3 times / d 24 3.933 1.26 ± 0.03 4.956 0.58 3.9 2.8 
041 Bao He Wan (Cathay P/L) 8 Pills; 3 times / d 24 3.817 1.60 ± 0.01 6.107 0.71 4.7 3.4 
013 Bu Zhong Yi Qi Wan  (MS) 8 Pills; 3 times / d 24 3.889 1.95 ± 0.06 7.584 0.88 5.9 4.2 
042 Bu Zhong Yi Qi Wan  (FC) 8 Pills; 3 times / d 24 4.078 1.19 ± 0.31 4.853 0.57 3.8 2.7 
015 Zhi Sou San & Addition (TB) 8 Pills; 3 times / d 24 3.925 1.26 ± 0.05 4.946 0.58 3.9 2.8 
043 Zhi Sou Wan & Addition (FC) 10 Pills; 3 times/d 30 5.025 2.20 ± 0.18 11.055 1.29 8.6 6.1 
030 Gui Pi Wan  8 Pills; 3 times / d 24 3.914 1.44 ± 0.08 5.636 0.66 4.4 3.1 
044 Gui Pi Wan 8 Pills; 3 times/d 24 3.726 1.38 ± 0.04 5.142 0.60 4.0 2.9 
01 Xiao Feng Wan  (Batch: 010904) 15 Pills; 3 times/d 45 8.022 1.37 ± 0.08 10.990 1.28 8.5 6.1 
045 Xiao Feng Wan  (Batch: 9903027) 15 Pills; 3 times / d 45 7.667 1.54 ± 0.07 11.807 1.40 9.3 6.7 
036 Tao Hong Si Wu Wan 8 Pills; 3 times / d 24 4.016 0.71 ± 0.02 2.851 0.33 2.2 1.6 
048 Tao Hong Si Wu Wan 12 Pills; 3 times/d 36 6.041 1.22 ± 0.04 7.370 0.86 5.7 4.1 
025 Tian Wang Bu Xin Dan 8 Pills; 3 times / d 24 4.081 1.34 ± 0.03 5.469 0.64 4.3 3.0 
028 Tian Wang Bu Xin Wan 8 Pills, 3 times / d 24 3.839 1.44 ± 0.14 5.528 0.64 4.3 3.0 
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Table 9.24:  Estimated weekly exposure to cadmium (Cd) from ingestion of CPM, and interpreted 
as % of maximum weekly allowable intake (%PTWI) for Cd which is 7 µg/kg bw/week(or 7,000 
ng/kg bw /week (WHO, 2001)    
      
No. Chinese Name Recom- 
mended  
Dose 
No. of 
Pills 
Inges
ted 
Daily 
Total 
Weight  
of  Pills 
Ingested 
(g/day) 
Total  
Cd/g of Pills
Found 
(ng/g) 
Total  
Daily Cd 
Ingested 
(ng/day) 
Estimated 
Weekly 
Cd Intake 
 
ng/kg bw 
Adult 
Exposure 
(7,000 ng/ 
kg/week) 
%  PTWI 
02 Ba Zheng San  8 Pills; 3 times / d 24 4.422 95.8 ± 0.8 423.63 49.4      0.71 
03 Xiao Qing Long Tang 8 Pills; 3 times / d 24 3.818 71.5 ± 2.1 272.99 31.8 0.45 
04 Long Dan Xie Gan Tang 8 Pills; 3 times / d 24 3.817 156.8 ± 8.6 598.50 69.8 1.00 
05 Xin Yi Wan 8 Pills; 3 times / d 24 3.758 190.4 ± 3.3 715.52 83.5 1.19 
06 Tao Chih Pien  2-4 Tab; 2 times / d 4 – 8 1.184 –  
2.368 
101.4 ± 11.3 120.06 – 
240.12 
14.0 – 
28.0 
0.2 – 0.4 
07 Chuan Xiong Cha Tiao Wan 15 Pills; 3 times / d 45 7.967 195.7 ± 7.7 1559.14 181.9 2.60 
08 Ba Zhen Tang 8 Pills;  3 times / d 24 4.107 158.2 ± 12.2 649.73 75.8 1.08 
09 Liu Wei Di Huang Wan 8 Pills; 3 times / d 24 4.364 144.2 ± 6.7 629.29 73.4 1.05 
010 Po Chai Pills 1-2 bottles; 4x / d 4 – 8  
bottles 
8.438 –  
16.876 
194.7 ± 30.1 1642.88 – 
3285.76 
191.7 – 
383.3 
2.74 – 5.48 
011 Duo Huo Ji Sheng Tang 8 Pills; 3 times / d 24 4.509 181.3 ± 14.0 817.48 95.4 1.36 
012 Jian Pi Wan 8 Pills; 3 times / d 24 4.522 60.7 ± 10.4 274.48 32.0 0.46 
014 Er Chen Tang 8 Pills; 3 times / d 24 4.039 41.7 ± 9.7 168.43 19.7 0.28 
016 Shen Ling Bai Zhu San 8 Pills; 3 times / d 24 3.988 144.5 ± 15.3 576.27 67.2 0.96 
017 Yu Ping Feng San 8 Pills; 3 times / d 24 4.150 329.8 ± 20.7 1368.67 159.7 2.28 
018 Chai Hu Shu Gan San 8 Pills; 3 times / d 24 4.206 205.3 ± 11.3 863.49 100.9 1.44 
019 Huo Xiang Zheng Qi San 8 Pills; 3 times / d 24 3.834 197.5 ± 40.3 757.21 88.3 1.26 
020 Xiao Chai Hu Tang 8 Pills; 3 times / d 24 4.103 140.2 ± 0.06 575.24 67.1 0.96 
021 Qing Qi Hua Tan Wan 6 Pills; 3 times / d 24 4.305 184.5 ± 6.3 794.27 92.7 1.32 
022 Xiao Yao San 8 Pills; 3 times / d 24 4.245 158.7 ± 23.0 673.68 78.6 1.12 
024 Yin Qiao Wan 8 Pills; 3 times / d 24 3.812 149.9 ± 33.3 571.42 66.7 0.95 
026 Fang Feng Tong Sheng San 8 Pills; 3 times / d 24 3.870 216.1 ± 4.3 836.31 97.6 1.39 
027 Niu Huang Qing Xin Wan 1-2 Pills;  
2 times / d 
2 – 4 5.992 –  
11.984 
109.3 ± 8.4 654.92 – 
1309.85 
76.4 – 
152.8 
1.09 – 2.18 
029 An Shen Ding Zhi Wan 15 Pills; 3 times / d 45 7.750 205.3 ± 21.9 1591.07 185.6 2.65 
031 Huang Lian Jie Du Tang 8 Pills; 3 times / d 24 3.693 161.1 ± 2.2 594.94 69.4 0.99 
032 Xue Fu Zhu Yu Tang 8 Pills; 3 times / d 24 3.820 176.7 ± 5.9 674.99 78.7 1.12 
033 Sang Ju Wan 8 Pills; 3 times / d 24 4.488 129.4 ± 4.2 580.75 67.8 0.97 
034 Mai Wei Di Huang Wan 8 Pills; 3 times / d 24 4.030 192.1 ± 10.8 774.16 90.3 1.29 
035 Shen Qi Da Bu Wan 8 Pills; 3 times / d 24 4.106 168.9 ± 11.1 693.50 80.9 1.16 
037 Tian Ma Gou Teng Wan 8 Pills; 3 times / d 24 3.710 151.6 ± 24.6 562.44 65.6 0.94 
038 Qian Bai Bi Yan Pian 4 Tab; 3 times / d  
for 1 mo; then 1/d 
12 6.051 667.4 ± 17.9 4038.44 471.2 6.73 
039 Zuo Gui Wan 8 Pills; 3 times / d 24 4.343 108.1 ± 7.8 469.48 54.8 0.78 
040 You Gui Wan 8 Pills; 3 times / d 24 4.457 155.9 ± 32.2 694.85 81.1 1.16 
046 Wen Dan Tang 8 Pills; 3 times / d 24 4.045 152.1 ± 11.2 615.24 71.8 1.03 
047 Zhi Bai Ba Wei Wan 8 Pills; 3 times / d 24 4.052 105.1 ± 12.7 425.86 49.7 0.71 
049 Bi Min Gan Pian 3-5 Pills; 3 times/d 9 – 15 5.277 –  
8.795 
388.7 ± 12.1 2051.17 – 
3418.62 
239.3 – 
398.8 
3.42 – 5.70 
050 Kun Bao Wan 25-50 Pills; 2 / d for 
1month, then by ½  
for 2-3 months 
50 –  
100 
4.660 –  
9.320 
76.8 ± 11.2 357.89 – 
715.78 
41.8 – 
83.5 
0.60 – 1.20 
023 Bao He Wan (Sheng Neng P/L) 8 Pills; 3 times / d 24 3.933 126.6 ± 8.6 497.92 58.1 0.83 
041 Bao He Wan (Cathay P/L) 8 Pills; 3 times / d 24 3.817 126.3 ± 21.2 482.09 56.2 0.80 
013 Bu Zhong Yi Qi Wan  (MS) 8 Pills; 3 times / d 24 3.889 111.6 ± 14.1 434.01 50.6 0.72 
042 Bu Zhong Yi Qi Wan  (FC) 8 Pills; 3 times / d 24 4.078 166.3 ± 22.7 678.17 79.1 1.13 
015 Zhi Sou San & Addition (TB) 8 Pills; 3 times / d 24 3.925 65.8 ± 18.5 258.26 30.1 0.43 
043 Zhi Sou Wan & Addition (FC) 10 Pills; 3 times/d 30 5.025 238.2 ± 28.5 1196.95 139.6 1.99 
030 Gui Pi Wan  8 Pills; 3 times / d 24 3.914 173.4 ± 37.7 678.69 79.2 1.13 
044 Gui Pi Wan 8 Pills; 3 times/d 24 3.726 166.4 ± 9.5 620.00 72.3 1.03 
01 Xiao Feng Wan  (Batch: 010904) 15 Pills; 3 times / d 45 8.022 94.8 ± 0.8 760.48 88.7 1.27 
045 Xiao Feng Wan  (Batch: 9903027) 15 Pills; 3 times / d 45 7.667 39.5 ± 0.4 302.85 35.3 0.50 
036 Tao Hong Si Wu Wan 8 Pills; 3 times / d 24 4.016 168.4 ± 5.6 676.29 78.9 1.13 
048 Tao Hong Si Wu Wan 12 Pills; 3 times/d 36 6.041 151.8 ± 8.0 917.02 107.0 1.53 
025 Tian Wang Bu Xin Dan 8 Pills; 3 times / d 24 4.081 158.1 ± 5.6 645.21 75.3 1.08 
028 Tian Wang Bu Xin Wan 8 Pills, 3 times / d 24 3.839 105.2 ± 5.7 403.86 47.1 0.67 
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Table 9.25: Estimated weekly exposure to mercury (Hg) from ingestion of CPM, and interpreted as  
% of maximum weekly allowable intake (%PTWI) for total Hg which is 5 µg/kg bw per week(WHO, 2000);  
[Hg (methyl mercury) is 3.3 µg/kg bw per week (WHO, 1999)]      
   
 
No. Chinese Name Recom- 
mended  
Dose 
No. of 
Pills 
Ingest
ed 
Daily 
Total 
Weight  
of  Pills 
Ingested 
(g/day) 
Total  
Mercury 
/g of Pills 
Found 
(ng/g) 
Total  
Daily Hg 
Ingested 
 
(ng/day) 
Estimated 
Weekly 
Hg Intake 
 
ng/kg bw 
Adult 
Exposure 
 
%  PTWI 
02 Ba Zheng San  8 Pills; 3 times / d 24 4.422 21.6 ± 1.5 95.51 11.1 0.2 
03 Xiao Qing Long Tang 8 Pills; 3 times / d 24 3.818 5.0 ± 4.6 19.09 2.2 0.04 
04 Long Dan Xie Gan Tang 8 Pills; 3 times / d 24 3.817 4.5 ± 1.2 17.18 2.0 0.04 
05 Xin Yi Wan 8 Pills; 3 times / d 24 3.758 5.6 ± 3.0 21.04 2.5 0.05 
06 Tao Chih Pien  2-4 Tab; 2 times / d 4 – 8 1.184 – 
2.368 
17.7 ± 13.1 20.96 – 41.91 2.4 – 
 4.9 
0.05 – 
 0.10 
07 Chuan Xiong Cha Tiao Wan 15 Pills; 3 times / d 45 7.967 25.3 ± 6.3 201.56 23.5 0.47 
08 Ba Zhen Tang 8 Pills;  3 times / d 24 4.107 3.3 ± 0.3 13.55 1.6 0.03 
09 Liu Wei Di Huang Wan 8 Pills; 3 times / d 24 4.364 13.2 ± 2.0 57.60 6.7 0.13 
010 Po Chai Pills 1-2 bottles; 4x / d 4 – 8  
bottles 
8.438 –  
16.876 
13.5 ± 6.5 113.91 – 
227.83 
13.3 –  
26.6 
0.27 –  
0.53 
011 Duo Huo Ji Sheng Tang 8 Pills; 3 times / d 24 4.509 14.5 ± 0.9 65.38 7.6 0.15 
012 Jian Pi Wan 8 Pills; 3 times / d 24 4.522 10.9 ± 6.2 49.29 5.8 0.12 
014 Er Chen Tang 8 Pills; 3 times / d 24 4.039 19.9 ± 2.8 80.38 9.4 0.19 
016 Shen Ling Bai Zhu San 8 Pills; 3 times / d 24 3.988 10.4 ± 2.1 41.47 4.8 0.10 
017 Yu Ping Feng San 8 Pills; 3 times / d 24 4.150 15.3 ± 7.4 63.49 7.4 0.15 
018 Chai Hu Shu Gan San 8 Pills; 3 times / d 24 4.206 229.4 ± 47.9 964.86 112.6 2.25 
019 Huo Xiang Zheng Qi San 8 Pills; 3 times / d 24 3.834 31.4 ± 7.9 120.39 14.0 0.28 
020 Xiao Chai Hu Tang 8 Pills; 3 times / d 24 4.103 19.8 ± 4.3 81.24 9.5 0.19 
021 Qing Qi Hua Tan Wan 6 Pills; 3 times / d 24 4.305 17.6 ± 10.4 75.77 8.8 0.18 
022 Xiao Yao San 8 Pills; 3 times / d 24 4.245 11.5 ± 3.2 48.82 5.7 0.11 
024 Yin Qiao Wan 8 Pills; 3 times / d 24 3.812 45.1 ± 30.1 171.92 20.1 0.40 
026 Fang Feng Tong Sheng San 8 Pills; 3 times / d 24 3.870 12.2 ± 6.4 47.21 5.5 0.11 
027 Niu Huang Qing Xin Wan 1-2 Pills; 2 times / d 2 – 4 5.992 –  
11.984 
18.6 ±7.7 111.45 – 
222.90 
13.0 –  
26.0 
0.26 –  
0.52 
029 An Shen Ding Zhi Wan 15 Pills; 3 times / d 45 7.750 6.8 ± 3.4 52.70 6.1 0.12 
031 Huang Lian Jie Du Tang 8 Pills; 3 times / d 24 3.693 10.1 ± 3.9 37.30 4.4 0.09 
032 Xue Fu Zhu Yu Tang 8 Pills; 3 times / d 24 3.820 bd bd bd bd 
033 Sang Ju Wan 8 Pills; 3 times / d 24 4.488 152.5 ± 26.7 684.42 79.8 1.60 
034 Mai Wei Di Huang Wan 8 Pills; 3 times / d 24 4.030 23.7 ± 4.2 95.51 11.1 0.22 
035 Shen Qi Da Bu Wan 8 Pills; 3 times / d 24 4.106 172.6 ± 29.0 708.69 82.7 1.65 
037 Tian Ma Gou Teng Wan 8 Pills; 3 times / d 24 3.710 43.5 ± 33.3 161.38 18.8 0.38 
038 Qian Bai Bi Yan Pian 4 Tab; 3 x /d for 1 
month; then1 / d  
12 6.051 258.9 ±108.1 1566.60 182.8 3.66 
039 Zuo Gui Wan 8 Pills; 3 times / d 24 4.343 78.0 ± 25.2 338.75 39.5 0.79 
040 You Gui Wan 8 Pills; 3 times / d 24 4.457 62.4 ± 4.0 278.12 32.5 0.65 
046 Wen Dan Tang 8 Pills; 3 times / d 24 4.045 29.2 ± 15.6 118.11 13.8 0.28 
047 Zhi Bai Ba Wei Wan 8 Pills; 3 times / d 24 4.052 bd bd bd bd 
049 Bi Min Gan Pian 3-5 Pills;  
3 times / d 
9 – 15 5.277 – 
8.795 
bd bd bd bd 
050 Kun Bao Wan 25-50 Pills; 2 / d 
for 1month, then 
by ½ for 2-3 months 
50 –  
100 
4.660 –  
9.320 
bd bd bd bd 
023 Bao He Wan (Sheng Neng P/L) 8 Pills; 3 times / d 24 3.933 51.9 ± 29.4 204.12 23.8 0.48 
041 Bao He Wan (Cathay P/L) 8 Pills; 3 times / d 24 3.817 501.7 ± 34.0 1915.10 223.4 4.47 
013 Bu Zhong Yi Qi Wan  (MS) 8 Pills; 3 times / d 24 3.889 12.6 ± 2.9 49.00 5.7 0.11 
042 Bu Zhong Yi Qi Wan  (FC) 8 Pills; 3 times / d 24 4.078 48.8 ± 30.1 199.01 23.2 0.46 
015 Zhi Sou San & Addition (TB) 8 Pills; 3 times / d 24 3.925 12.8 ± 5.5 50.24 5.9 0.12 
043 Zhi Sou Wan & Addition (FC) 10 Pills; 3 times /d 30 5.025 33.0 ± 9.3 165.82 19.3 0.39 
030 Gui Pi Wan  8 Pills; 3 times / d 24 3.914 bd bd bd bd 
044 Gui Pi Wan 8 Pills; 3 times/d 24 3.726 15.0 ± 2.5 55.89 6.5 0.13 
01 Xiao Feng Wan  (Batch: 010904) 15 Pills; 3 times /d 45 8.022 21.6 ± 1.5 173.27 20.5 0.41 
045 Xiao Feng Wan  (Batch: 9903027) 15 Pills; 3 times /d 45 7.667 35.5 ± 10.2 272.18 31.8 0.64 
036 Tao Hong Si Wu Wan 8 Pills; 3 times / d 24 4.016 26.7 ± 2.9 107.23 12.5 0.25 
048 Tao Hong Si Wu Wan 12 Pills; 3 times /d 36 6.041 bd bd bd bd 
025 Tian Wang Bu Xin Dan 8 Pills; 3 times / d 24 4.081 20.8 ± 7.1 84.88 9.9 0.12 
028 Tian Wang Bu Xin Wan 8 Pills, 3 times / d 24 3.839 10.8 ± 7.8 41.46 4.8 0.10 
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Table 9.26:  Estimated total daily exposure to chromium (Cr) from ingestion of CPM, and  
interpretedas % of Adequate Intake (%AI) of Cr which are 35 µg/day, and 25 µg/day for young  
men and women respectively.Recommended daily intake (RDI) is 120 µg/day, and maximum  
tolerable level has been suggested to be 200 µg/day 
 
No. Chinese Name Recom- 
mended  
Dose 
No. of 
Pills 
Ingest
ed 
Daily 
Total 
Weight  
Of  Pills 
Ingested 
(g/day) 
Total  
Chromium 
/g of Pills 
Found 
(µg/g) 
Estimated 
Total  
Daily Cr 
Ingested 
(µg/day) 
Adult male 
Exposure 
(AI = 35 
µg/day) 
% of AI 
Adult 
Exposure 
(RDI =120 
µg/day) 
% of RDI 
02 Ba Zheng San  8 Pills; 3 times / d 24 4.422 4.51 ± 0.09 19.94 57.0     16.6 
03 Xiao Qing Long Tang 8 Pills; 3 times / d 24 3.818 2.42 ± 0.34 9.24 26.4 7.7 
04 Long Dan Xie Gan Tang 8 Pills; 3 times / d 24 3.817 5.49 ± 0.47 20.94 59.8 17.5 
05 Xin Yi Wan 8 Pills; 3 times / d 24 3.758 2.87 ± 0.13 10.79 30.8 9.0 
06 Tao Chih Pien  2-4 Tab; 2 times / d 4 – 8 1.184 –  
2.368 
1.60 ± 0.14 1.89 –  
3.79 
5.4 – 10.8 1.6 – 
3.2  
07 Chuan Xiong Cha Tiao Wan 15 Pills; 3 times / d 45 7.967 11.9 ± 0.84 94.81 270.9 79.0 
08 Ba Zhen Tang 8 Pills;  3 times / d 24 4.107 0.72 ± 0.10 2.96 8.5 2.5 
09 Liu Wei Di Huang Wan 8 Pills; 3 times / d 24 4.364 0.32 ± 0.07 1.40 4.0 1.2 
010 Po Chai Pills 1-2 bottles; 4x / d 4 – 8  
bottles 
8.438 –  
16.876 
6.06 ± 0.36 51.13 – 
102.27 
146.1 – 292.2 42.6 – 85.2 
011 Duo Huo Ji Sheng Tang 8 Pills; 3 times / d 24 4.509 2.66 ± 0.25 11.99 34.3 10.0 
012 Jian Pi Wan 8 Pills; 3 times / d 24 4.522 0.72 ± 0.04 3.26 9.3 2.7 
014 Er Chen Tang 8 Pills; 3 times / d 24 4.039 2.29 ± 0.01 9.25 26.4 7.7 
016 Shen Ling Bai Zhu San 8 Pills; 3 times / d 24 3.988 2.18 ± 0.17 8.69 24.8 7.2 
017 Yu Ping Feng San 8 Pills; 3 times / d 24 4.150 1.02 ± 0.09 4.23 12.1 3.5 
018 Chai Hu Shu Gan San 8 Pills; 3 times / d 24 4.206 1.51 ± 0.12 6.35 18.1 5.3 
019 Huo Xiang Zheng Qi San 8 Pills; 3 times / d 24 3.834 0.56 ± 0.08 2.15 6.1 1.8 
020 Xiao Chai Hu Tang 8 Pills; 3 times / d 24 4.103 0.43 ± 0.05 1.76 5.0 1.5 
021 Qing Qi Hua Tan Wan 6 Pills; 3 times / d 24 4.305 3.80 ± 0.35 16.36 46.7 13.6 
022 Xiao Yao San 8 Pills; 3 times / d 24 4.245 1.28 ± 0.04 5.43 15.5 4.5 
024 Yin Qiao Wan 8 Pills; 3 times / d 24 3.812 3.25 ± 0.26 12.36 35.3 10.3 
026 Fang Feng Tong Sheng San 8 Pills; 3 times / d 24 3.870 0.50 ± 0.19 1.94 5.5 1.6 
027 Niu Huang Qing Xin Wan 1-2 Pills; 2 times / d 2 – 4 5.992 –  
11.984 
7.04 ± 0.42 42.18 – 84.37 120.5 – 241.0 35.2 – 70.3 
029 An Shen Ding Zhi Wan 15 Pills; 3 times / d 45 7.750 2.25 ± 0.12 17.44 49.8 14.5 
031 Huang Lian Jie Du Tang 8 Pills; 3 times / d 24 3.693 1.05 ± 0.30 3.88 11.1 3.2 
032 Xue Fu Zhu Yu Tang 8 Pills; 3 times / d 24 3.820 0.46 ± 0.03 1.76 5.0 1.5 
033 Sang Ju Wan 8 Pills; 3 times / d 24 4.488 7.53 ± 1.50 33.80 96.6 28.2 
034 Mai Wei Di Huang Wan 8 Pills; 3 times / d 24 4.030 0.51 ± 0.02 2.06 5.9 1.7 
035 Shen Qi Da Bu Wan 8 Pills; 3 times / d 24 4.106 0.68 ± 0.25 2.79 8.0 2.3 
037 Tian Ma Gou Teng Wan 8 Pills; 3 times / d 24 3.710 0.41 ± 0.05 1.52 4.3 1.3 
038 Qian Bai Bi Yan Pian 4 Tab; 3 times/d for  
1 month; then 1 / d    
12 6.051 0.60 ± 0.08 3.63 10.4 3.0 
039 Zuo Gui Wan 8 Pills; 3 times / d 24 4.343 1.64 ± 0.16 7.12 20.3 5.9 
040 You Gui Wan 8 Pills; 3 times / d 24 4.457 0.44 ± 0.13 1.96 5.6 1.6 
046 Wen Dan Tang 8 Pills; 3 times / d 24 4.045 0.75 ± 0.09 3.03 8.7 2.5 
047 Zhi Bai Ba Wei Wan 8 Pills; 3 times / d 24 4.052 0.74 ± 0.21 3.00 8.6 2.5 
049 Bi Min Gan Pian 3-5 Pills; 3 times / d 9 – 15 5.277 –  
8.795 
2.87 ± 0.28 15.15 – 25.24 43.3 –  
72.1 
12.6 – 21.0 
050 Kun Bao Wan 25-50 Pills; 2 / d for 
1month, then by ½  
for 2-3 months 
50 –  
100 
4.660 –  
9.320 
3.56 ± 0.89 16.29 – 33.18 46.5 –  
94.8 
13.6 – 27.7 
023 Bao He Wan (Sheng Neng P/L) 8 Pills; 3 times / d 24 3.933 1.10 ± 0.15 4.33 12.4 3.6 
041 Bao He Wan (Cathay P/L) 8 Pills; 3 times / d 24 3.817 0.38 ± 0.05 1.45 4.1 1.2 
013 Bu Zhong Yi Qi Wan  (MS) 8 Pills; 3 times / d 24 3.889 0.71 ± 0.09 2.76 7.9  2.3 
042 Bu Zhong Yi Qi Wan  (FC) 8 Pills; 3 times / d 24 4.078 0.63 ± 0.16 2.57 7.3 2.1 
015 Zhi Sou San & Addition (TB) 8 Pills; 3 times / d 24 3.925 1.83 ± 0.23 7.18 20.5 6.0 
043 Zhi Sou Wan & Addition (FC) 10 Pills; 3 times / d 30 5.025 1.75 ± 0.12 8.79 25.1 7.3 
030 Gui Pi Wan  8 Pills; 3 times / d 24 3.914 0.68 ± 0.04 2.66 7.6 2.2 
044 Gui Pi Wan 8 Pills; 3 times/d 24 3.726 3.79 ± 0.08 14.12 40.3 11.8 
01 Xiao Feng Wan  (Batch: 010904) 15 Pills; 3 times / d 45 8.022 4.51 ± 0.09 36.18 103.4 30.2 
045 Xiao Feng Wan  (Batch: 9903027) 15 Pills; 3 times / d 45 7.667 0.89 ± 0.02 6.82 19.5 5.7 
036 Tao Hong Si Wu Wan 8 Pills; 3 times / d 24 4.016 0.70 ± 0.27 2.81 8.0 2.3 
048 Tao Hong Si Wu Wan 12 Pills; 3 times / d 36 6.041 3.01 ± 0.33 18.18 51.9 15.2 
025 Tian Wang Bu Xin Dan 8 Pills; 3 times / d 24 4.081 4.30 ± 0.31 17.55 50.1 14.6 
028 Tian Wang Bu Xin Wan 8 Pills, 3 times / d 24 3.839 1.10 ± 0.03 4.22 12.0 3.5 
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9.3.6.1 Estimates of Daily Lead (Pb) Intakes from CPM Compared With    
            Regulatory Standard – as % of PTDI 
 
           Table 9.22 outlines the Chinese names of the 50 CPM (For the corresponding English 
names, please refer to Table 10.22), recommended dose per day (in g/day), and the total Pb 
contents (in µg/g of the CPM) determined in the acid-digested samples. The product of these two 
values (i.e., dose x µg/g) gave the total daily intake. For purpose of comparison with the safety 
guideline of Provisional Tolerable Weekly Intake (PTWI), the daily intake per person was then 
converted to weekly intake per kg body weight (bw) per week by being divided by an average bw 
of 60 kg, and multiplied by 7 days. Finally, these weekly intakes were expressed as the % PTWI 
using the WHO regulatory standard of PTWI level of 25 µg/kg bw/week for Pb. Results are 
shown in the last column of Table 10.23. It can be seen that of the 50 CPM only 4 would produce 
up 10 – 15 % of PTWI for Pb, if the maximum recommended doses were taken. They were Po 
Chai Pills (No. 010), Niu Huang Qing Xin Wan (No. 027), Bi Min Gan Pian (No. 049), and Kun 
Bao Wan (No. 050). One CPM, An Shen Ding Zhi Wan (No. 029) contained exceptionally high 
Pb content. A normal recommended dose of this patent medicine would provide 29.3 % of the 
PTWI. All the other CPM would constitute insignificant amount of adult exposure of about 5% or 
less of PTWI. Among the paired CPM, all were less than 5 %, except Tao Hong Si Wu Wan (No. 
048), which contributed 6.9 %. A second Tao Hong Si Wu Wan (No. 036) produced by a 
different company, contributed about half the amount at 3.2 %. 
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9.3.6.2 Estimates of Daily Arsenic (As) Intakes from CPM Compared With      
            Regulatory Standard – as % of PTDI    
 
           Table 9.23 shows the estimated weekly arsenic intakes from each CPM if administered 
according to the recommended doses. They were compared with two regulatory tolerable levels 
for intake of As, one recommended by the FAO/WHO Expert Committee on Food Additives 
(WHO, 1999), the other by the Australia new Zealand Food Authority (ANZFA, 1999). The 
WHO guideline was lower than the ANZFA. The adult exposure as a result of consuming these 
CPM expressed as a % of these two PTWI guidelines are shown in the last two columns of Table 
10.24. Using the lower WHO limit of 15 µg/kg bw/week as reference standard, 4 of the 50 CPM 
would produce about 20 % of the weekly tolerable limits. They were the Tao Chih Pien (No. 06), 
Po Chai Pills (No. 010), Qian Bai Bi Yan Pian (No. 038), and Bi Min Gan Pian (No. 049).  Four 
CPMs gave around 10% of PTWI, while the rest, more than 40 CPM, would contribute around 
5% or less of PTWI. Again, nearly 3-fold difference in % PTWI, 2.2 and 5.7 % respectively, was 
found in the two Tao Hong Si Wu Wan, which were manufactured by two different 
pharmaceutical companies. On the other hand, if the higher ANZFS tolerable level of 21 µg/kg 
bw/week was used as the reference standard, then the % PTWI of oral exposure to As would be 
reduced by approximately 28% for every CPM compared to those calculated for WHO reference, 
thus making CPM even safer. 
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9.3.6.3 Estimates of Daily and Weekly Cadmium (Cd) Intake from CPM Compared   
            With Regulatory Standard, as % of PTWI 
  
           Table 9.24 presents the estimated weekly Cd intakes from each CPM if administered 
according to the recommended doses. They were compared with the PTWI level for Cd of 7,000 
ng/kg bw/week (i.e. 7 µg/kg bw/week) recommended by the FAO/WHO Expert Committee on 
Food Additives (WHO, 2001), expressed as % of  PTWI. The estimated weekly intakes for the 
majority of CPM were generally very low, around 100 or less ng/kg bw/week. Three were 
particularly higher, between 400 and 500 ng/kg bw/week. They were the two patent medicines 
for treating allergic rhinitis, namely, the Qian Bai Bi Yan Pian (No. 038), and the Bi Min Gan 
Pian (No. 049). The third one was Po Chai Pills (No.010). Even at such higher levels, their 
contributions to Cd exposure were still rather insignificant, less than 7 % of PTWI.  
 
 
9.3.6.4 Estimates of Daily and Weekly Mercury (Hg) Ingestion in CPM Compared  
            With Regulatory Standard, as % of PTWI 
 
          Table 9.25 presents similar picture of the estimated weekly intakes of Hg, and their % of 
PTWI. The PTWI levels recommended by WHO were 3,300 ng/kg bw/week (i.e. 3.3 µg/kg 
bw/week) for methyl mercury (WHO, 1999), and 5,000 ng/kg bw/week (i.e. 5 µg/kg bw/week) 
for total mercury (WHO, 2000). Using the total mercury standard level as the reference 
maximum tolerable exposure, the highest estimated weekly Hg intake came from Bao He Wan 
(No. 041, manufactured for Cathy P/L, Australia), and amounted to an oral exposure of 4.5 % of 
PTWI as a result of ingesting the recommended dose. On the other hand, the other Bao He Wan 
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(No. 023, manufactured for Sheng Neng P/L, Australia, by the same pharmaceutical company) 
had significantly lower Hg content, and would contribute a mere 0.5 % of PTWI, i.e. nearly one-
tenth of the other product No. 041. This highlights the inconsistency of quality control in the 
manufacturing processes. Three other CPM had Hg contents that would result in % of PTWI 
between 1.5 and 3.7, while the rest, 46 out of 50 CPM would result in less than 1 % of PTWI. 
Thus, Hg contents in CPM did not appear to pose any safety problem.  
 
 
9.3.6.5 Estimates of daily Chromium (Cr) intakes from CPM compared  
            with recommended reference doses – as % AI, %RDI, and %TDI 
 
           A tolerable limit, such as PTWI, has not been established for Cr. Instead, an adequate 
intake (AI) level of 35 µg/day for males aged between 14 and 50, or AI of 25 µg/day for females 
aged between 19 and 50 (Institue of Medicine, 2001), and a maximum recommended daily intake 
(RDI) level of 120 µg/day for both adult genders (Lerntech, 2006) have been set based on 
estimated mean intakes. Thus, AI for men is about 1.38 times higher than that for women while 
the RDI level is same for both men and women. A safety dose of 200 µg/day has also been 
reported (Lerntech, 2006). For purpose of discussion, this safety level will be used in this project 
as the tolerable maximum daily intake, for lack of established reference standards. Table 9.26 
shows estimated daily intakes of Cr from taking the CPM, and their respective exposure 
expressed as % of AI for adult males (the second last column), and as % of RDI (last column). It 
can be seen that the amount of oral intake of Cr spread widely among the CPM ranging from a 
few % of AI up to about 100 % or more. In particular, three patent medicines, Chuang Xiong Cha 
Tiao Wan (No. 07), Po Chai Pills (No. 010) and Niu Haung Qing Xin Wan (No. 027), when 
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administered at the recommended doses, would provide between 250 to 300 % of daily AI 
requirement. Note that because the AI established for adult males is 1.38 times higher than that 
for females (i.e.35/25), all adult female exposure due to consumption of these CPM would be 
expected to be proportionally 1.38 times higher than the male percentages of AI listed in the 
Table 10.27. This would make the Kun Bao Wan (No. 050) significantly exceeding 100 % of AI, 
from the 46.5 – 94.8 % range to 64.2 – 130.0 %.  However, despite such high intake, all CPM 
were still significantly below the maximum recommended daily intake of 120 µg/day, giving 
approximately 79 %, 85 % and 70 % respectively of RDI for the three high-Cr patent medicines 
mentioned above. Nevertheless, at such high levels caution should be exercised. 
 
          Three pairs of CPM showed large difference in Cr levels. Of particular concern are the two 
different batches of Xiao Feng Wan, which were manufactured by the same company, Lanzhou, 
Foci. They contained vastly different contents of Cr, 4.51 µg/g and 0.89 µg/g for No. 01 and No. 
045 respectively. This discrepancy in concentrations resulted in a large difference in adult male 
exposure of 103.4 % and 19.5 % of AI respectively, or 142.7 % and 26.9 % respectively for 
female exposure. This highlights problems that may arise as a result of inconsistency in quality 
control.  Nevertheless, when expressed as the % of the safety dose of 200 µg/day, they are still 
below this maximum level. Similarly, the two Gui Pi Wan (No. 030 and No. 044) produced by 
different companies, would expose a male patient to highly different estimated daily ingestion of 
2.66 µg/day and 14.12 µg/day respectively, which in turn, supplied 7.6 % and 40.3 % if AI. 
Difference of similar magnitude was also observed in a third pair of CPM, namely, the Tao Hong 
Si Wu Wan, No. 036 and No. 048.   
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9.3.7 Total Daily Exposure of Metals from CPM in Addition to a Normal  
            Australian Daily Diet       
 
          As described in Section 9.2.5 above concerning interpretation of metal exposure from 
crude Chinese herbal medicines (CHM) and from daily dietary intake, in order to obtain a 
realistic total metal exposure, the same procedure is also carried out here for metal intake from 
Chinese proprietary medicines (CPM). When the estimated daily intake values of CPM were 
added to the normal dietary exposures, a more realistic range of total daily exposure to the metal 
could be obtained. The dietary metal exposure data were obtained from the 20th Australian Total 
Dietary Survey (ATDS). The calculated composite CPM-diet exposure results are shown in 
Table 9.27 below. This table shows the lowest and highest combined exposures (Daily diet plus 
CPM), as % of PTDI after a patient had consumed recommended doses of CPM and a normal 
daily diet. Thus, in the worse case scenario of combining highest range of diet exposure with the 
CPM containing the highest content of either Pb or Cd or Hg, the total exposures were still less 
than a third of the acceptable tolerable daily intakes. Therefore, none of the CPM was likely to 
present any significant risk for these 3 metals. In the case of arsenic, the recommended maximum 
dose of Tao Chih Pien gave the highest daily % of PTDI at 20.8 % based on the WHO standard. 
When this was added to the highest As level of Australian daily dietary intake, the maximum 
total daily exposure amounted to 61.9 % PTDI. And, if the higher regulatory tolerable daily 
intake standard adopted by ANZFS (Australia and New Zealand) in Australia was used for 
calculation in place of the lower WHO standard, it would decrease the estimated total exposure to 
44.1 %, i.e. less than half of the tolerable limit. 
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Table 9.27.   Range of total (Diet + CPM) daily exposures to metals as a percentage of the 
tolerable limits after the CPM containing the lowest or highest levels of metals detected in the 
present projecta are added to the corresponding lower and higher percentage range of mean 
estimated PTDIb of the same metals reported in The 20th Australian Total Diet Survey (ATDS) 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Metal                    Adult males daily                            Adult daily                    Combined daily  
                      exposure from ATDS                        exposure from                      exposure from  
                                    (25-34 years)                        a single CPM                ATDS and a single  
                                            % TDIb                                  %TDIa                             CPM    % TDI    
                      (Ref: The 20th ATDS)     (Results from this project)         (i.e. % TDIb + %TDIa) 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
                      
 
Arsenic                           26.1 – 41.1                             1.4 – 20.8*                        27.5  – 61.9 
(WHO=15) 
 
Arsenic                           18.7 – 29.3                             1.0 – 14.9*                        19.6  – 44.1 
(ANZFS=21) 
 
Cadmium                         7.6 – 24                                 0.3  – 6.7*                           7.9 – 30.7 
 
Lead                                 1.8 – 11                                0.5 – 29.3*                           2.3 – 32.0 
 
Mercury (Total Hg)         1.9 – 13                                   0 – 4.5*                             1.9 – 17.5 
 
*  The lower values of the ranges are from the CPM with the lowest % PTDI, and higher values 
of the range are from the CPM with the highest % PTDI. 
           Similarly, the two most extreme values of Cr daily intakes from CPM were also added to 
the normal dietary exposure to highlight the potential extremes of exposure. Because the average 
exposure to Cr, and the standard of adequate intake (AI) for men are higher than those for women, 
calculations for AI, and for recommended daily exposure (RDI) are considered separately, and 
results are shown in Table 9.28 below. 
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Table 9.28   Range of combined estimated daily exposures to Cr as a percentage of the AIa, RDIb, 
and PTDIc  after the lowest and highest estimated daily intakes of Cr in Chinese proprietary 
medicine (CPM) are added to the range of the mean daily dietary exposures to Cr reported by 
Institute of Medicine, 2001 
 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
                 Adult range           Adult daily           Combined       Adult            Adult             Combined     
                 of mean daily        intake of              range of          daily             daily              daily  
                 dietary exposure    lowest &              exposure:        exposure       exposure        exposure                                                                                        
                 to Cr (µg/day)       highest CPM                                                                           compared to 
                 (Ref: Institute       (µg/day)                Diet +CPM     (M=35; F=25)   (120µg/day)       maximum 
                 of Medicine,         (Result from                                 (as                 (as                 daily level                                                      
                 2001)                    present project)     (µg/day)          % AI)            % RDI)         (as %PTDI)                                                               
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
                      
 
Male         39 – 54               1.4 – 102.3*          40 – 156         115 – 447      33 – 130        20 – 78  
 
Female      23 – 29               1.4 – 102.3*          24 – 131         96 – 524        20 – 109        12 – 66 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
a
 AI = 35 µg/day for men, and 25 µg/day for women;   b RDI = 120 µg/day;    c PTDI = 200 
µg/day;    * First value was the lowest daily intake from CPM, and second value was highest 
daily intake from CPM 
 
          Table 9.28 shows the best and worse case scenarios of ingesting the CPM having the 
lowest Cr (1.4 µg/day), and ingesting the CPM having the highest Cr (102.3 µg/day), in addition 
to a normal diet. For the CPM having the highest Cr level, the total daily exposure far exceeded 
the daily adequate intake levels (AI) by 4- and 5-fold respectively for men (447 %AI) and women 
(524 %AI), and just above the recommended daily levels (130 and 109% RDI respectively). 
Nevertheless, they were below the maximum tolerable level of 200 µg/day, reaching 78 % and 66 
% of the toxic limit for men and women respectively (see last column of Table 10.29).  
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9.4 Results of Chinese Medicinal Formulae (CMF)  
 
           Five popular Chinese herbal medicinal formulae were investigated for total metal contents 
after acid digestion, as well as for water-soluble fraction of metals after boiling in water (i.e., the 
aqueous decoction). From these two analytical results, the water extraction of metals as a 
percentage of the total (acid-digested) metal content can then be calculated to assess the 
efficiency of the aqueous boiling process. Finally, the contribution to daily intake of metal as a 
result of regularly consuming aqueous CMF decoctions by a patient will be considered by 
assessing its % of tolerable daily limit of intake, in addition to a normal Australian dietary intake. 
Details of the five formulae are in Table 8.8. The procedure of preparing herbal powder, acid 
digestion, the aqueous decoction, and finally analysis of the 5 herbal formulae were described 
under Method, Chapter 8. The formulae were CMF1: Xiao Yao San (Rambling Powder), CMF2: 
Si Wu Tang (Four-Substance Decoction), CMF3: Tao Hong Si Wu Tang (Four-Substance 
Decoction with Safflower & Peach Pit), CMF4: Gui Pi Tang (Restore The Spleen Decoction), 
and CMF5: Jin Gui Shen Qi Tang (Kidney Qi Pill from The Golden Cabinet). 
 
 
9.4.1   Results of the 5 Metal Contents in Acid-digested CMF Samples 
 
           The analytical results of total (acid-digested) metal concentration for each formula were 
recorded in Table 9.29. The concentration of each metal was the mean of triplicate samples, 
expressed as either µg or ng of the metal per gram of the herbal powder (designated by (a) value 
in the table). This value was used to calculate the total amount of the metal in the whole formula 
(designated by (b) in the table) by multiplying this value with the weight of the formula. These 
results are also displayed in histograms in Figure 9.13, which shows that in terms of metal per 
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gram of the formula, Jin Gui Shen Wi Tang (CMF 5) contained the highest content of lead, at 
2.18 µg/g whereas Tao Hong Si Wu Tang (CMF3) had the highest concentration of mercury, at 
8.8 ng/g, and Si Wu Tang (CMF2) was the highest in chromium content, at 5.5 µg/g. The total 
amount of metal present in the whole formula are also expressed in histogram Figure 9.14, which 
clearly shows that overall CMF5, Jin Gui Shen Qi Tang, because of its heavier formula weight, 
ended up being top in lead, arsenic and chromium contents, and was second in cadmium and 
mercury, among the 5 formulae under investigation. Tao Hong Si Wu Tang (CMF3) was by far 
the highest in mercury content.  
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Table 9.29     Total concentrations (acid-digested) of 5 different metals in five Chinese medicinal formulae  
(3 duplicate samples for each formula, i.e., n = 3)  
 
Concentrations of Each Metal in Different Formulae 
  (a) µg/g (or ng/g) ± sd (n = 3) of the herbal mixture 
  (b) µg / whole herbal pack = weight of metal/g x weight of herbal pack in g 
Sample 
Code of 
Each 
Formula  
Chinese Name 
of Formula 
Total 
Weight of 
Each 
Herbal 
Pack 
g/pack 
Lead  
Pb 
(a) µg/g  
(b) µg/pack 
Arsenic  
As 
(a) µg/g  
(b) µg/pack 
Mercury  
Hg 
(a) ng/g  
(b) µg/pack 
Cadmium  
Cd 
(a) ng/g  
(b) µg/pack 
Chromium 
Cr 
(a) µg/g  
(b) µg/pack 
CMF1 Xiao Yao San 40.5 (a) 1.41 ± 0.23 
(b) 57.21 
(a) 0.93 ± 0.20 
(b) 37.83 
(a) 2.6 ± 1.6 
(b) 0.105 
(a) 148 ± 21.9 
(b) 5.99 
(a) 2.35 ± 0.25 
(b) 95.06 
CMF2 Si Wu Tang 45.0 (a) 1.28 ± 0.23 
(b) 57.57 
(a) 1.53 ± 0.20 
(b) 68.72 
(a) 4.2 ± 0.6 
(b) 0.189  
(a) 95.9 ± 2.1 
(b) 4.32 
(a) 5.48 ± 0.33 
(b) 246.80 
CMF3 Tao Hong Si 
Wu Tang 
51.0 (a) 1.15 ± 0.19 
(b) 58.84 
(a) 1.16 ± 015 
(b) 58.86 
(a) 8.8 ± 1.4 
(b) 0.449 
(a) 122.7±29.7 
(b) 6.258  
(a) 1.54 ± 0.16 
(b) 78.40 
CMF4 Gui Pi Tang 93.0 (a) 0.85 ± 0.11 
(b) 67.31 
(a) 0.72 ± 0.03 
(b) 67.31 
(a) 2.9 ± 0.4 
(b) 0.269  
(a) 115.7 ± 9.6 
(b) 10.760 
(a) 1.83 ± 0.21 
(b) 170.07 
CMF5 Jin Gui Shen 
Qi Tang 
81.0 (a) 2.18 ± 0.31 
(b) 176.33 
(a) 1.04 ± 0.02 
(b) 83.85 
(a) 3.3 ± 0.4 
(b) 0.267 
(a) 94.7 ± 3.3 
(b) 7.671 
(a) 3.49 ± 0.42 
(b) 282.83 
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Figure 9.13   Histograms showing oncentrations of five different metals in each gram of the 
formula 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 Key: 
1. CMF1: Xiao Yao San –   
                       (Rambling Powder) 
2. CMF2: Si Wu Tang –  
                       (Four-Substance Decoction) 
3. CMF3: Tao Hong Si Wu Tang –  
                       (Dour-Substance Decoction    
                       with Safflower & Peach Pit) 
4. CMF4: Gui Pi Tang –  
                       (Restore The Spleen  
                        Decoction) 
5. CMF5: Jin Gui Shen Qi Tang –  
                       (Kidney Qi Pill from the   
                       Golden Cabinet) 
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Figure 9.14   Histograms showing concentrations of five different metals in µg per whole pack of 
formula 
 
 
 
 
 
 
                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                             
                                                                                    Key: 
6. CMF1: Xiao Yao San                                       1.   CMF1: Xiao Yao San –    
7.                                                                                             (Rambling Powder) 
8.                                                                           2.   CMF2: Si Wu Tang –  
9.                                                                                             (Four-Substance Decoction)  
10.                                                                           3.   CMF3: Tao Hong Si Wu Tang – 
11.                                                                                             (Dour-Substance Decoction   
12.                                                                                              with Safflower & Peach Pit) 
13.                                                                           4.   CMF4: Gui Pi Tang –  
14.                                                                                             (Restore The Spleen  
15.                                                                                              Decoction)   
16.                                                                           5.   CMF5: Jin Gui Shen Qi Tang – 
17.                                                                                             (Kidney Qi Pill from the    
                                                                                                       Golden Cabinet) 
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 9.4.2    Results of the 5 Metal Contents in Aqueous Decoctions of CMF 
 
           The CMF were boiled in water as would be carried out in real clinical practice of Chinese 
medicine, to extract metals in order to determine the metal contents in the aqueous decoctions 
that could be consumed. Each formula was prepared in duplicate, and each pack was boiled twice 
to produce first and second decoctions. Results of lead (Pb) concentrations determined for the 
first and second decoctions are shown in Table 9.30, columns d and e. Similarly, results for 
arsenic, mercury, cadmium, and chromium are shown respectively in the columns of d and e of 
Tables 9.31, 9.32, 9.33, and 9.34. These tables include information of total weight of the herbal 
formula (column a), the total acid-digested content of metals for each formula, in µg/g (column 
b), and in µg/whole pack of herbs (column c), the metal concentrations in the first and second 
aqueous decoctions (columns d & e respectively), the summed amount of metal of the 2 
decoctions (column f), the sum of the 2 decoctions as a % of the total acid-digested amount 
(column g), each decoction as a percentage of the total acid-digested amount (column h), a 
comparison of aqueous extraction efficiency between the first and second decoctions (column i), 
and finally, the quantity of metal consumed per day as a result of following the herbal treatment 
regime (column j). The results of the individual metal in aqueous decoctions are explained in 
details in the following sub-sections.
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     Table 9.30      Raw data for the extraction of Lead (Pb) in the aqueous decoctions of five Chinese herbal formulae – including weight of  
     herbal pack, total Pb content in acid digestion, Pb content in the 1st and 2nd aqueous decoctions, and the estimated daily intake of lead from    
     herbal administration 
 
Aqueous Decoction 
(n = 2) 
Sample 
Code &  
Name of 
Formulae 
 
a. Total 
weight of 
pack  
 
 
(gram) 
b. Total 
(acid-
digested) 
Pb µg/g ± 
sd 
(n =3) 
c.Total 
Pb per 
Pack 
(µg) = 
 
a x b 
d. First 
decoction 
Mean µg/g ± 
sd of Pb   
e. Second 
decoction 
Mean µg/g ± 
sd of Pb   
f. Sum of Pb 
in the 2 
aqueous 
decoctions: 
µg/g = 
 d + e 
g.  Sum of Pb 
in the 2 
decoctions as 
% of total Pb 
= 
f ÷ b x 100 
h. Efficiency of 
extraction for 
1st & 2nd  
decoctions   
1st = d ÷bx100 
2nd= e ÷bx100 
i. Efficiency 
of extraction 
between  
1st :  2nd 
decoctions = 
d ÷ f : e ÷ f 
j. Total Pb 
ingested per 
day 
(1st + 2nd) 
µg/day = 
g x c ÷ 100 
CMF1  
Xiao Yao 
San 
40.5 1.413  
± 0.228  
CV=16% 
57.21 
 
0.395 
± 0.092 
CV=23% 
0.088 
± 0.022 
CV=25% 
0.483 34.2% 1st   = 27.9% 
2nd  = 6.3% 
1st : 2nd = 
~ 4.5 : 1 
19.57 
 
CMF2 
Si Wu Tang 
45.0 1.279 
± 0.229 
CV=18% 
57.57 0.342 
±0.054 
CV=16% 
0.090 
± 0.026 
CV=29% 
0.432 33.8% 1st   = 26.7% 
2nd  = 7.0% 
1st : 2nd = 
~ 2.8 : 1 
19.44 
 
CMF3 
Tao Hong 
Si Wu Tang 
51.0 1.154 
± 0.192 
CV=17% 
58.84 0.349 
± 0.056 
CV=16% 
0.174 
± 0.064 
CV=37% 
0.523 45.3% 1st   = 30.2% 
2nd  = 15.1% 
1st : 2nd = 
~ 2 : 1 
26.65 
 
CMF4 
Gui Pi Tang 
93.0 0.854 
± 0.109 
CV=13% 
79.41 0.166 
± 0.032 
CV=19% 
0.113 
± 0.001 
CV=1% 
0.279 32.7% 1st   = 19.4% 
2nd  = 13.3% 
1st : 2nd = 
~ 1.5 : 1 
25.96 
 
CMF5 
Jin Gui 
Shen Qi 
Tang 
81.0 2.177   
±0.305 
CV=14% 
176.33 0.097  
± 0.008 
CV=9% 
0.020   
± 0.005 
CV=25% 
0.117 5.3% 1st   = 4.4% 
2nd  = 0.9% 
1st : 2nd = 
~ 4.9 : 1 
9.45 
 
    Av. CV for total (acid) Pb = 16%;     Av. CV for 1st aqueous decoction = 17%;      Av. CV for 2nd Aqueous decoction = 23%;     CV = sd x100/mean
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      Table 9.31      Raw data for the extraction of Arsenic (As) in the aqueous decoctions of five Chinese herbal formulae – including weight  
      of herbal pack, total As content in acid digestion, As content in the 1st and 2nd aqueous decoctions, and the estimated daily intake of lead  
      from herbal administration 
 
Aqueous Decoction 
(n = 2) 
Sample 
Code &  
Name of 
Formulae 
 
 
a. Total 
weight 
of pack  
 
 
(gram) 
b. Total 
(acid-
digested) 
As µg/g ± 
sd 
(n =3) 
c.Total 
As per 
Pack 
(µg) = 
 
a x b 
d. First 
decoction 
Mean µg/g 
± sd of As 
e. Second 
decoction 
Mean µg/g 
± sd of As 
f.Sum of As 
in the 2 
aqueous 
decoctions: 
µg/g = 
 
 d + e 
g. Sum of 
As in the 2 
decoctions 
as % of 
total As = 
 
f ÷ b x 100 
h. Efficiency 
of extraction 
for 1st  & 2nd 
decoctions   
1st = d ÷bx100 
2nd= e ÷bx100 
i. 
Efficiency 
of 
extraction 
between  
1st :  2nd 
decoctions 
= 
d ÷ f : e ÷ f 
j. Total As 
ingested 
per day 
(1st + 2nd) 
 
µg/day = 
g x c ÷ 100 
CMF1  
Xiao Yao 
San 
40.5 0.934  
± 0.201  
CV=21% 
37.83 
 
0.207 
± 0.0.092 
CV=21% 
0.037 
± 0.005 
CV=14% 
0.243 26.0% 1st   = 22.1% 
2nd  = 3.9% 
1st : 2nd = 
~ 5.6 : 1 
9.85 
 
CMF2 
Si Wu Tang 
45.0 1.527 
± 0.202 
CV=13% 
68.72 0.241 
±0.021 
CV=9% 
0.070 
± 0.023 
CV=33% 
0.312 20.4% 1st   = 15.8% 
2nd  = 4.6% 
1st : 2nd = 
~ 3.4 : 1 
14.03 
 
CMF3 
Tao Hong Si 
Wu Tang 
51.0 1.156 
± 0.145 
CV=12% 
58.96 0.336 
± 0.030 
CV=9% 
0.139 
± 0.012 
CV=8% 
0.475 41.1% 1st   = 29.0% 
2nd  = 12.0% 
1st : 2nd = 
~ 2.4 : 1 
24.21 
 
CMF4 
Gui Pi Tang 
93 0.724 
± 0.028 
CV=4% 
67.31 0.099 
± 0.026 
CV=26% 
0.060 
± 0.011 
CV=19% 
0.159 22.0% 1st   = 13.6% 
2nd  = 8.4% 
1st : 2nd = 
~ 1.6 : 1 
14.82 
 
CMF5 
Jin Gui 
Shen Qi 
Tang 
81.0 1.035   
±0.018 
CV=2% 
83.85 0.139  
± 0.047 
CV=33% 
0.026   
± 0.012 
CV=46% 
0.165 16.0% 1st   = 13.4% 
2nd  = 2.5% 
1st : 2nd = 
~ 5.3 : 1 
13.40 
     
   Av. CV for total (acid) As = 10%;       Av. CV for 1st aqueous decoction = 20%;        Av. CV for 2nd Aqueous decoction = 24%
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     Table 9.32      Raw data for the extraction of Mercury (Hg) in the aqueous decoctions of five Chinese herbal formulae – including weight of  
     herbal pack, total Hg content in acid digestion, Hg content in the 1st and 2nd aqueous decoctions, and the estimated daily intake of mercury  
     from herbal administration 
 
Aqueous Decoction 
(n = 2) 
 
 
 
a. Total 
weight 
of pack  
 
 
(gram) 
b. Total 
(acid-
digested) 
Hg ng/g ± 
sd 
(n =3) 
c.Total 
Hg per 
Pack 
 
µg = 
a x b 
d. First 
decoction 
Mean µg/g 
± sd of Hg 
e. Second 
decoction 
Mean µg/g 
± sd of Hg 
f.Sum of Hg 
in the 2 
aqueous 
decoctions: 
µg/g = 
 d + e 
g. Sum of  
Hg in the 2  
decoctions  
as % of  
total Hg = 
f ÷ b x 100 
h. Efficiency  
of extraction  
for 1st & 2nd  
decoctions   
1st = d ÷bx100 
2nd= e ÷bx100 
i. Efficiency  
of 
extraction 
between  
1st :  2nd  
decoctions 
= 
d ÷ f : e ÷ f 
j. Total Hg  
ingested  
per day 
(1st + 2nd) 
µg/day = 
g x c ÷ 100 
CMF1  
Xiao Yao 
San 
40.5 2.6  
± 1.6 
CV=61% 
0.11 
 
bd bd bd bd 1st   = bd 
2nd  = bd 
1st : 2nd = 
bd 
bd 
 
CMF2 
Si Wu Tang 
45.0 4.2 
± 0.6 
CV=14% 
0.19 bd bd bd bd 1st   = bd 
2nd  = bd 
1st : 2nd = 
bd 
bd 
 
CMF3 
Tao Hong 
Si Wu Tang 
51.0 8.8 
± 1.4 
CV=16% 
0.45 bd bd bd bd 1st   = bd 
2nd  = bd 
1st : 2nd = 
bd 
bd 
 
CMF4 
Gui Pi Tang 
93.0 2.9 
± 0.4 
CV=14% 
0.27 bd bd bd bd 1st   = bd 
2nd  = bd 
1st : 2nd = 
bd 
bd 
 
CMF5 
Jin Gui 
Shen Qi 
Tang 
81.0 3.3  
± 0.4 
CV=12% 
0.27 bd bd bd bd 1st   = bd 
2nd  = bd 
1st : 2nd = 
bd 
bd 
     
    Av. CV for total (acid) Hg = 23%;        bd = below detection limit                                                                                                                                           
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       Table 9.33     Raw data for the extraction of Cadmium (Cd) in the aqueous decoctions of five Chinese herbal formulae – including weight of        
       herbal pack, total Cd content in acid digestion, Cd content in the 1st and 2nd aqueous decoctions, and the estimated daily intake of cadmium 
       from herbal administration  
 
Aqueous Decoction 
(n = 2) 
Sample 
Code &  
Name of 
Formulae 
 
a. Total 
weight 
of pack  
 
 
(gram) 
b. Total 
(acid-
digested) 
Cd ng/g ±  
sd 
(n =3) 
c.Total 
Cd per 
Pack 
 
µg = 
a x b 
d. First 
decoction 
Mean µg/g 
± sd of Cd 
e. Second 
decoction 
Mean µg/g 
± sd of Cd 
f.Sum of 
Cd in the 2 
aqueous 
decoctions: 
ng/g = 
 d + e 
g. Sum of 
Cd in the 2 
decoctions 
as % of 
total Cd = 
f ÷ b x 100 
h. Efficiency  
of extraction  
for 1st & 2nd  
decoctions   
1st = d 
÷bx100 
2nd= e 
÷bx100 
i. Efficiency 
of extraction 
between  
1st :  2nd 
decoctions = 
d ÷ f : e ÷ f 
j. Total Cd 
ingested 
per day 
(1st + 2nd) 
µg/day = 
g x c ÷ 100 
CMF1  
Xiao Yao 
San 
40.5 148.0  
± 21.8  
CV=15% 
5.99 
 
53.5 
± 3.3 
CV=6% 
5.1 
± 3.3 
CV=64% 
58.6 39.6% 1st   = 36.2% 
2nd  = 3.4% 
1st : 2nd = 
~ 10.6 : 1 
2.37 
 
CMF2 
Si Wu 
Tang 
45.0 95.9 
± 2.1 
CV=2% 
4.32 52.2 
(n = 1) 
 
11.2 
(n = 1) 
 
62.4 66.1% 1st   = 54.4% 
2nd  = 11.7% 
1st : 2nd = 
~ 4.6 : 1 
2.85 
 
CMF3 
Tao Hong 
Si Wu 
Tang 
51.0 122.7 
± 29.7 
CV=24% 
6.26 35.2 
± 0.7 
CV=2% 
32.5 
± 0.7 
CV=2% 
67.7 55.2% 1st   = 28.7% 
2nd  = 26.5% 
1st : 2nd = 
~ 1 : 1 
3.45 
 
CMF4 
Gui Pi 
Tang 
93.0 115.7 
± 9.6 
CV=8% 
10.76 7.6 
± 0.8 
CV=11% 
15.7 
± 0.8 
CV=5% 
23.3 20.1% 1st   = 6.6% 
2nd  = 13.6% 
1st : 2nd = 
~ 0.5 : 1 
2.17 
 
CMF5 
Jin Gui 
Shen Qi 
Tang 
81.0 94.7   
± 1.9 
CV=2% 
7.67 27.7 
± 2.8 
CV=2% 
2.2   
± 0.8 
CV=36% 
29.9 31.5% 1st   = 29.2% 
2nd  = 2.3% 
1st : 2nd = 
~ 12.7 : 1 
2.42 
         
        Av. CV for total (acid) Cd = 10%;       Av. CV for 1st aqueous decoction = 5%;        Av. CV for 2nd Aqueous decoction = 27%                                       
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       Table 9.34      Raw data for the extraction of Chromium (Cr) in the aqueous decoctions of five Chinese herbal formulae – including weight  
       of herbal pack, total Cr content in acid digestion, Cr content in the 1st and 2nd aqueous decoctions, and the estimated daily intake of chromium      
       from herbal administration 
 
Aqueous Decoction 
(n = 2) 
Sample 
Code &  
Name of 
Formulae 
 
a. Total 
weight of 
pack  
 
 
(gram) 
b. Total 
(acid-
digested) 
Cr µg/g ± 
sd 
(n =3) 
c.Total 
Cr per 
Pack 
(µg) = 
 
a x b 
d. First 
decoction 
Mean µg/g 
± sd of Cr 
e. Second 
decoction 
Mean µg/g 
± sd of Cr 
f. Sum of 
Cr in the 2 
aqueous 
decoctions: 
µg/g = 
 d + e 
g. Sum of 
Cr in the 2 
decoctions 
as % of 
total Cr = 
f ÷ b x 100 
h. Efficiency 
of extraction 
for 1st & 2nd  
decoctions   
1st = d 
÷bx100 
2nd= e 
÷bx100 
i. Efficiency 
of extraction 
between  
1st :  2nd 
decoctions = 
d ÷ f : e ÷ f 
j. Total Cr 
ingested 
per day  
(1st + 2nd) 
µg/day = 
g x c ÷ 100 
CMF1  
Xiao Yao 
San 
40.5 2.347  
± 0.255  
CV=11% 
95.06 
 
0.048 
± 0.009 
CV=19% 
0.023 
± 0.024 
CV=105% 
0.071 3.0% 1st   = 2.0% 
2nd  = 1.0% 
1st : 2nd = 
~ 2 : 1 
2.85 
 
CMF2 
Si Wu 
Tang 
45.0 5.484 
± 0.331 
CV=6% 
246.80 0.097 
±0.012 
CV=13% 
0.021 
± 0.006 
CV=30% 
0.117 2.1% 1st   = 1.8% 
2nd  = 0.4% 
1st : 2nd = 
~ 4.5 : 1 
5.18 
 
CMF3 
Tao Hong 
Si Wu 
Tang 
51.0 1.537 
± 0.158 
CV=10% 
78.40 0.091 
± 0.011 
CV=12% 
0.028 
± 0.000 
CV=0% 
0.119 7.7% 1st   = 5.9% 
2nd  = 1.8% 
1st : 2nd = 
~ 3.3 : 1 
6.04 
 
CMF4 
Gui Pi 
Tang 
93.0 1.829 
± 0.211 
CV=11% 
170.07 0.010 
± 0.003 
CV=30% 
0.009 
± 0.001 
CV=12% 
0.019 1.0% 1st   = 0.5% 
2nd  = 0.5% 
1st : 2nd = 
~ 1 : 1 
1.75 
 
CMF5 
Jin Gui 
Shen Qi 
Tang 
81.0 3.492    
± 0.424 
CV=12% 
282.83 0.018 
± 0.003 
CV=14% 
0.003 
± 0.001 
CV=49% 
0.021 0.6% 1st   = 0.5% 
2nd  = 0.1% 
1st : 2nd = 
~ 5 : 1 
1.70 
  
           Av. CV for total (acid) Cr = 10%;     Av. CV for 1st aqueous decoction = 18%;      Av. CV for 2nd Aqueous decoction = 39%;     CV = sd x10
  
 233 
9.4.2.1  Results of lead concentrations in aqueous decoctions of the 5 CMF 
 
           In Table 9.30, it can be seen that lead concentrations in the first decoctions of all 5 
Chinese medicinal formulae were much higher than in the second decoctions, ranging from 1.5 
times for Gui Pi Tang to 5 times for Jin Gui Shen Qi Tang (see column i). This suggested that the 
efficiency of aqueous extraction was much higher for the first decoction than for the second. 
When the two decoctions were combined together, the total amounts of metal were quite variable 
depending on the formula. For example, the combined quantity of aqueous Pb in Jin Gui Shen Qi 
Tang amounted to only 5.3 % of the acid Pb available in the herbal pack whereas in Tao Hong Si 
Wu Tang, nearly 50 % of the acid-available Pb were extracted into water for consumption (see 
column g). The aqueous lead concentrations in the other 3 formulae resulted in about 33 % to 34 
% of the acid available Pb contents. From these results the total daily ingestions of Pb were 
estimated to be ranging from about 9.5 µg per day for Jin Gui Shen Qi Tang to about 20 µg per 
day for Xiao Yao San and Si Wu Tang, to about 26 µg per day for Gui Pi Tang, to 27 µg per day 
for Tao Hong Si Wu Tang. These daily intakes from Chinese medicinal formulae (CMF) 
appeared to be higher than those from Chinese proprietary medicines (CPM), and not 
unexpectedly much higher than those from the single CHM herbs. 
 
 
9.4.2.2 Results of arsenic concentrations in aqueous decoctions of the 5 CMF     
 
           A similar picture was also obtained for aqueous arsenic contents in the 5 CMF (Table 9.31) 
demonstrating similar percentage of aqueous extraction of metal compared to the total available 
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in acid, the more superior efficiency of extraction in the first decoction, and again, higher daily 
exposure to the metal from consuming CMF than from CPM and even higher 
than a single herbal CHM. However, the aggregate amount of arsenic from the two aqueous 
decoctions of Jin Gui Shen Qi Tang at 16 % of total acid-digested metal content was a lot higher 
than lead at 5.3 % suggesting that arsenic might be better extracted into water than lead was.  
 
 
9.4.2.3 Results of mercury concentrations in aqueous decoctions of the 5 CMF 
 
          Interestingly, mercury concentrations in the aqueous decoctions of the 5 CMF were all 
below the limit of detection of 2.4 ng/g (Table 9.32). This finding indicates that mercury was not 
well extracted into water. Thus, the daily exposure to Hg from consuming CMF decoctions was 
negligible. 
 
 
9.4.2.4 Results of cadmium contents in aqueous decoctions of the 5 CMF 
 
           Table 9.33 shows the cadmium results in the aqueous decoctions of the 5 CMF. On 
average Cd was more efficiently extracted into water than the other metals, with the Si Wu Tang 
releasing 54.4 % of Cd into water from the first boiling process. A second boiling step released a 
further 11.7 %, making a total of 66 % of total Cd available. Tao Hong Si Wu Tang, a formula 
with two more herbs additional to Si Wu Tang, also released a total of 55.2 %, with both the first 
and second decoctions contributing approximately equal amounts. For the first time, it was 
observed that the first decoction actually contained less metal than the second, in the case of Gui 
Pi Tang. The ratio between the first and second decoctions was ~ 0.5 : 1.0, the total metal content 
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in the two decoctions being about 20 % of what was available . On the other hand, the first 
decoctions of the other two CMF, Xaio Yao San, and Jin Gui Shen Qi Tang respectively 
contained nearly 11 and 13 times more Cd than the second decoctions. Overall, the daily 
exposure to Cd ranged from about 2.4 µg per day to about 2.9 µg per day. 
 
 
9.4.2.5 Results of chromium contents in aqueous decoctions of the 5 CMF                
 
           Table 9.34 shows that aqueous chromium concentrations in the 5 CMF were low, despite 
the fact that chromium was by far the most abundant residual element among the 5 metals studied 
in these herbal formulae. Thus, the combined metal concentrations in the decoctions represented 
from as low as 0.6 % to a maximum of 7.7 % of the total metal available (column g), and 
amounted to a daily exposure of only 1.70 µg per day and 6.04 µg per day respectively (column 
j). The metal extraction efficiency was also higher in the first than in the second decoctions. 
 
 
9.4.3    Estimates of Daily Metal Intakes from CMF Compared With Regulatory  
            Standard 
           
           From the results of daily exposures to the 5 metals discussed above, the potential risk of 
these metals in CMF was then evaluated by expressing these daily exposures as a percentage of 
the regulatory standards. For Pb, As, Cd and Hg, the regulatory standard was the tolerable daily 
intake, i.e., as % of PTDI or % of PTWI (Table 9.35). For Cr (Table 9.36), the risks were
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compared with the adequate intake (AI), the recommended daily intake (RDI), and the 
recommended maximum daily intake % TDI. Method of calculation is detailed in Table 9.35. 
 
Table 9.35    Adult daily exposure to different metals in the aqueous decoctions of CMF (µg/day), 
and as a percentage of the tolerable daily intake (% TDI)   TDI for Pb = 3.6 µg/kg bw/day (WHO, 
2000), TDI for As = 3 µg/kg bw/day (ANZFA, 1999), TDI for As = 2.1 µg/kg bw/day (WHO, 1999), 
TDI for Cd = 1 µg/kg bw/day (WHO, 2001). 
 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
                                                Adult daily exposure to metals in CMF, as % of TDI 
         –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
                   CMF1                 CMF2                  CMF3                   CMF4                  CMF5 
         –––––––––––––       –––––––––––––     –––––––––––––       –––––––––––––       –––––––––––– 
         Daily intake    %TDI      Daily intake   %TDI      Daily intake   %TDI       Daily intake   %TDI       Daily intake   %TDI 
            (µg/day)                  (µg/day)                 (µg/day)                   (µg/day)                   (µg/day) 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Pb         9.57    9.1%        19.44    9.0%        26.65   12.3%        25.96    12.0%         9.45    4.4% 
 
Asa       9.85    5.5%        14.03    7.8%        24.21   13.4%       14.82       8.2%       13.40     7.4% 
 
Asb           9.85    7.8%        14.03   11.1%       24.21   19.2%       14.82     11.8%       13.40    10.6% 
 
Cd        2.37    4.0%         2.85     4.8%         3.45     5.8%         2.17       3.6%         2.42     4.0% 
____________________________________________________________________________ 
 
For calculation of daily intake into %TDI, convert the daily intake of µg/day to µg/kg bw/day by 
dividing the intake by a standard sdult weight of 60kg, and then divided by the regulatory TDI 
standard for the metal and multiplied by 100. For example, for the daily intake of Pb from CMF1, 
the %TDI = (9.57/60)x(100/3.6). 
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Table 9.36   Adult daily exposure to chromium in the aqueous decoctions of CMF (µg/day), and 
as a percentage of the daily adequate intake (% AI) where AI = 35 µg/day for mana and 25 
µg/day for womenb, as a percentage of the recommended daily intake (% RDIc) where RDI = 
120 µg/day for all adults, as well as percentage of the exposure limit, the maximum tolerable 
daily intake (% TDId) where TDI = 200 µg/day. These reference intake values are from Institute 
of Medicine (Institue of Medicine, 2001). 
 
Adult daily exposure to chromium in CMF, as % of AI, RDI, TDI 
    CMF1 CMF2 CMF3 CMF4 CMF5 
 
 
Daily exposure (µg/day) 
     2.852            5.183              6.037            1.752              1.697 
% AI        Men 
                Women 
8.1% 
11.4% 
14.8% 
20.7% 
17.2% 
24.1% 
5.0% 
7.0% 
4.8% 
6.8% 
 
% RDI All adults 2.4% 4.3% 5.0% 1.5% 1.4% 
% TDI All adults 1.4% 2.6% 3.0% 0.9% 0.8% 
 
 Note: For conversion of daily exposure to Cr as % AI, % RDI and % TDI, divide the value of 
daily intake by the reference RI, or reference RDI, or reference TDI respectively and then 
multiplied by 100.  
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9.4.3.1  Estimates of Daily Pb, As, Cd, and Hg Intakes from CMF Compared With  
            Regulatory Standard, as % of PTDI 
 
           Table 9.35 outlines the exposures to Pb, As, Cd and Hg as % of PTDI for each CMF after 
consumption of the aqueous decoctions of these CMF. The PTDI values were based on WHO 
regulatory standards. For arsenic, an additional standard reference value established by the 
Australian and New Zealand Food Authority (ANZFA, 1999) was also used for risk 
interpretation, as this value was adopted by Food Standards Australia New Zealand (FSANZ, 
2003a) to analyse metal exposure in the Australian Total Diet Survey (ATDS). The ANZFA 
PTDI value was higher than that of WHO. Thus, % PTDI of arsenic was approximately 30 % 
lower based on the ANZFA reference standard value than on the WHO values. Results of metal 
exposure indicated that none of the 5 CMF posed any risk of metal toxicity as a result of 
ingestion of the aqueous decoctions, since the highest % PTDI reached was arsenic from Tao 
Hong Si Wu Tang (CMF3), and it was only 19.2 % PTDI. This estimation was based on the more 
stringent WHO tolerable limit of 2.1 µg/kg bw/day. If the ANZFA standard of 3 µg/kg bw/day 
was used, the % PTDI would have been even lower, a mere 13.4 %. Overall, most CMF 
contributed Pb, As and Cd levels of between 4 – 12 % of PTDI. In the case of mercury, the 
aqueous content was below the limit of detection. Therefore, the CMF contribution of exposure 
to this metal was negligible.  
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9.4.3.2 Estimates of Daily Cr Intake from CMF Compared With Reference Values,  
            as % of AI, % of RDI, and % of TDI 
 
          For the evaluation of chromium in CMF, the daily exposure due to these 5 CMF was 
compared to three reference values. They were the adequate intake (AI), the recommended daily 
intake (RDI), and finally the maximum level, i.e., the tolerable daily intake (TDI) beyond which 
adverse effects might occur. Further, the dietary requirement for Cr regarded as adequate was 
higher for men than for women. Thus, the % of AI achieved as a result of ingesting the same 
CMF decoctions were also different between the two gender groups. These results are shown in 
Table 9.36. It can be seen that among the 5 formulae, Tao Hong Si Wu Tang (CMF3), produced 
higher percentages of the three reference values, reaching 24.1 % of AI in women, or 17.2 % in 
men. However, in terms of recommended daily level and the tolerable limit, it amounted to a 
mere 5.0 % and 3.0 % respectively. The other 4 medicinal formulae were even less significant. 
 
9.4.4   Interpretation of Daily Exposure to Metals From Aqueous CMF Decoctions in  
            Addition to a Normal Australian Daily Diet  
 
          As with the CHM and CPM, the CMF metal exposure (as % TDI) was also added to the 
range of mean Australian total dietary survey (ATDS) values (also expressed as % TDI) to obtain 
a more realistic combined percentage value of daily exposure (i.e., % TDI for diet + % TDI for 
CMF) to each metal for each CMF. This mathematical assessment was carried out for Pb, As, Cd 
and Cr, but not for Hg as there was practicably no mercury found in the aqueous decoctions of 
the CMF. The results of each metal are considered in the sub-sections below. 
 
9.4.4.1 Total Daily Exposure to Pb from Aqueous CMF Decoctions in Addition to  
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            a Normal Australian Daily Diet 
     
         Table 9.37 shows the range of mean % TDI of adult exposure to Pb obtained from the 
Australian 20th ATDS report (2nd column), the daily exposure to Pb in aqueous CMF decoctions 
(% PTDI) obtained from this study (refer to 3rd column; and as calculated in Table 9.30), and the 
combined daily  exposure (ATDS + CMF) in the last column. Results showed that the highest % 
of PTDI reached had a range of 14.1 to 23.3 % PTDI. This belonged to Tao Hong Si Wu Tang 
(CMF3). The other 4 combined values were slightest lower.  
 
Table 9.37   Range of total (combined) daily exposures to lead (Pb) as a percentage of the 
tolerable limit after the daily exposures to Pb as % of TDI in the aqueous decoctions of CMF 
determined in the present studya are added to the percentage range of mean estimated daily 
dietary exposuresb to Pb, reported in The 20th Australian Total Diet Survey (FSANZ, 2003b) 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Chinese                        Adult male                           Adult daily                    Combined daily  
Medicinal               daily exposure                          exposure to              exposure to Pb from  
Formula            to Pb from ATDS                      Pb in aqueous                 ATDS & aqueous  
(CMF)                      (25-34 years)                decoction of CMF                decoction of CMF 
                                         % TDIb                                 %TDIa                                          % TDI    
                   (Ref: The 20th ATDS)      (Results from this study)         (i.e. % TDIb + %TDIa) 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
                      
 
CMF1                           1.8 – 11                                    9.1 %                           10.9 – 20.1 % 
 
CMF2                           1.8 – 11                                    9.0 %                           10.8 – 20.0 % 
 
CMF3                           1.8 – 11                                  12.3 %                           14.1 – 23.3 % 
                        
CMF4                           1.8 – 11                                  12.0 %                           13.8 – 23.0 %         
 
CMF5                           1.8 – 11                                   4.4 %                              6.2 – 15.4 % 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
 
Key: CMF1, Xiao Yao San; CMF2, Si Wu Tang; CMF3, Tao Hong Si Wu Tang; CMF4, Gui Pi 
Tang; CMF5, Jin Gui Shen Qi Tang.               
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9.4.4.2  Total daily Cadmium exposure from combined CMF aqueous decoctions in addition                  
             to a Normal Australian Daily Diet 
 
          Table 9.38 summarises results for cadmium exposure from normal diet and CMF. The total 
values of exposure were slightly higher than those reached by Cd, up to a range of 13.4 – 29.8 % 
PTDI in the case of Tao Hong Si Wu Tang (CMF3). The remaining four formulae were similar, 
i.e., less than one-third of the tolerable level. 
 
Table 9.38   Range of total (combined) daily exposures to cadmium (Cd) as a percentage of the 
tolerable limit after the daily exposures to Cd, as % of TDI in the aqueous decoctions of CMF, 
determined in the present studya are added to the percentage range of mean estimated daily 
dietary exposuresb to Cd, reported in The 20th Australian Total Diet Survey (FSANZ, 2003b) 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Chinese                        Adult male                           Adult daily                    Combined daily  
Medicinal               daily exposure                          exposure to              exposure to Cd from  
Formula            to Cd from ATDS                      Cd in aqueous                 ATDS & aqueous  
(CMF)                      (25-34 years)                decoction of CMF                decoction of CMF 
                                         % TDIb                                 %TDIa                                          % TDI    
                   (Ref: The 20th ATDS)      (Results from this study)         (i.e. % TDIb + %TDIa) 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
                      
 
CMF1                           7.6 – 24                                    4.0 %                           11.6 – 28.0 % 
 
CMF2                           7.6 – 24                                    4.8 %                           12.8 – 28.8 % 
 
CMF3                           7.6 – 24                                    5.8 %                           13.4 – 29.8 % 
                        
CMF4                           7.6 – 24                                    3.6 %                           11.2 – 27.6 %         
 
CMF5                           7.6 – 24                                    4.0 %                           11.6 – 28.0 % 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Key: CMF1, Xiao Yao San; CMF2, Si Wu Tang; CMF3, Tao Hong Si Wu Tang; CMF4, Gui Pi 
Tang; CMF5, Jin Gui Shen Qi Tang.                
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9.4.4.3  Total daily Arsenic Exposure from combined CMF aqueous decoctions in Addition to  
             a normal Australian daily diet 
 
          Table 9.39 lists two % PTDI of arsenic for each CMF, calculated using the ANZFA 
(ANZFA, 1999)c, and WHO (WHO, 1999)d guidelines respectively. Combined arsenic exposures 
were quite high reaching almost 50 % (37.8 – 48.4 %) of the tolerable limit according to WHO 
guideline, for Tao Hong Si Wu Tang (CMF3). The rest were only a little lower, between 35 and 
40 % of PTDI in total. If the less stringent ANZFA guideline were used as reference standard, 
then the percentages of exposure reached would be approximately 10 % lower, making it 
theoretically safer. 
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Table 9.39   Range of total (combined) daily exposures to cadmium (As) as a percentage of the 
tolerable limit after the daily exposures to As in the aqueous decoctions of CMF, determined in 
the present studya are added to the percentage range of mean estimated daily dietary exposuresb 
to As, reported in The 20th Australian Total Diet Survey (FSANZ, 2003b) 
 
Daily exposures to As in CMF were calculated using regulatory standards from ANZFA 
(ANZFA, 1999)c, and WHO (WHO, 1999)d. 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Chinese                        Adult male                           Adult daily                    Combined daily  
Medicinal               daily exposure                          exposure to              exposure to As from  
Formula            to As from ATDS                      As in aqueous                 ATDS & aqueous  
(CMF)                      (25-34 years)                decoction of CMF                decoction of CMF 
                                         % TDIb                                 %TDIa                                          % TDI    
                   (Ref: The 20th ATDS)      (Results from this study)         (i.e. % TDIb + %TDIa) 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
                      
 
CMF1                      18.6 – 29.2                                 5.5 %c                           24.1 – 34.7 %c 
                                                                                   7.8 %d                           26.4 – 37.0 %d 
 
CMF2                      18.6 – 29.2                                 7.8 %c                           26.4 – 37.0 %c 
                                                                                 11.1 %d                           29.7 – 40.3 %d 
 
CMF3                      18.6 – 29.2                               13.4 %c                           32.0 – 42.6 %c 
                                                                                 19.2 %d                           37.8 – 48.4 %d 
 
CMF4                      18.6 – 29.2                                 8.2 %c                           26.8 – 34.4 %c    
                                                                                 11.8 %d                           30.4 – 41.0 %d 
 
CMF5                      18.6 – 29.2                                 7.4 %c                           26.0 – 36.6 %c 
                                                                                 10.6 %d                           29.2 – 39.8 %d 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Key: CMF1, Xiao Yao San; CMF2, Si Wu Tang; CMF3, Tao Hong Si Wu Tang; CMF4, Gui Pi 
Tang; CMF5, Jin Gui Shen Qi Tang.                
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9.4.4.4  Total daily chromium exposure from CMF aqueous decoctions in addition to a normal     
             Australian daily diet 
 
          Table 9.40 compares the combined Cr exposures (Daily diet plus CMF decoctions) 
between men and women, and expressed the total exposures in terms of daily adequate intake 
(AI). It is clear that a normal diet alone would provide adequately in excess of the daily intake 
requirement of Cr. The small additional contribution of Cr from the CMF medication increased 
the percentage of intake by 3 to 10 % depending on the Chinese medicinal formula. However, in 
terms of the percentage of the higher level of recommended daily intake (% RDI), the highest 
%RDI reached was again from Tao Hong Si Wu Tang (CMF 3) at 50% of the recommended 
daily intake of 120 µg/day for men and 29 % for women. Further, when the tolerable daily intake 
(% TDI) was considered, the combined levels were far below the safety limit of 200 µg/day, 
reaching a maximum of 30 % in the male adults, and 18 % in the female adults.   
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Table 9.40   Range of combined daily exposures to Cr as a percentage of the AIa, RDIb, and 
PTDIc after the estimated daily intakes of Cr in aqueous Chinese medicinal formulae (CMF) were 
added to the range of the mean daily dietary exposures to Cr adapted from Institute of Medicine, 
(Institue of Medicine, 2001) 
               
         
 
 
 
 
 
          CMF 
 
Adult 
rangeof 
mean daily 
dietary 
exposure to 
Cr  
(µg/day)      
(Ref:Institute 
of Medicine, 
2001) 
 
 
Adult daily 
Cr exposure 
(µg/day) in 
aqueous 
CMF 
decoction 
(Result 
from this 
study) 
 
Combined 
range of 
exposure: 
Diet + CMF 
(µg/day) 
 
 
 
Adult daily 
exposure vs 
Adequate 
Intake 
(M=35; 
F=25)  
(as % AI) 
 
Adulta daily 
exposure vs 
Recommended 
Daily Intake 
(120 µg/day) 
(as %RDI) 
 
Combined 
daily 
exposure vs 
Provisional 
Tolerable 
Daily Limit 
(as % TDI) 
     
 
M   CMF1           39 – 54              2.85           41.9 – 56.9         120 – 163           35 – 47              21 – 28  
       CMF2           39 – 54              5.18           44.2 – 59.2         126 – 169           37 – 49              22 – 30  
E    CMF3           39 – 54              6.04           45.0 – 60.0         129 – 171           38 – 50              23 – 30  
       CMF4           39 – 54              1.75           40.8 – 55.8         117 – 159           34 – 47              20 – 28  
N    CMF5           39 – 54              1.70           40.7 – 55.7         116 – 159           34 – 46              20 – 28  
 
W   CMF1            23 – 29             2.85          25.9 – 31.9          103 – 127           22 – 27              13 – 16  
O    CMF2            23 – 29             5.18          28.2 – 34.2           13 – 137            24 – 29              14 – 17  
M   CMF3            23 – 29             6.04          29.0 – 35.0          116 – 140            24 – 29             15 – 18  
E    CMF4            23 – 29             1.75          24.8 – 30.8            99 – 123            21 – 26             12 – 15  
N    CMF5            23 – 29             1.70          24.7 – 30.7            99 – 123            21 – 26             12 – 15  
 
 
a
 AI = 35 µg/day for men, and 25 µg/day for women;   b RDI = 120 µg/day;   c PTDI = 200 
µg/day;     
 
Note; Men and women have different range of mean daily dietary exposure to Cr, and also 
different levels of adequate intake (AI). 
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CHAPTER 10 
DISCUSSION AND CONCLUSION 
 
10.1     Introduction 
 
            This research was designed to systematically and comprehensively analyse a large 
number of crude Chinese herbal materials (CHM), Chinese proprietary medicines (CPM), and 
Chinese herbal formulae (CMF) in order to evaluate the general risk of TCM posed to consumers, 
specifically in the State of Victoria, Australia. To this end, reliable and sensitive methods of 
analysis need to be established so that results and conclusion drawn are valid. Then, a large-scale 
systematic screening of metal contents in TCM purchased locally in Victoria needs to be carried 
out. The herbal materials analysed also need to be representative of the TCM consumed by the 
public in Victoria. Finally, analytical results should be interpreted in a realistic manner based on 
total daily consumption which includes not only the metal content from the herbal medicines but 
also exposures from daily dietary intake, and with reference to universally recognised regulatory 
standards of safety. The following discussion, therefore, will follow the steps of the research 
approaches laid out above, and highlighted with some graphs and tables. 
 
             Before further discussion, the nature of representativeness of the herbal samples should 
be explained since they were sourced from only two suppliers and therefore these herbs might 
come from a similar region. In fact an examination of the 50 Chinese proprietary medicines 
(CPM) shows that they were manufactured by at least 6 different pharmaceutical companies 
located in different parts of China. This implies that the raw herbal ingredients of each company 
would most likely have originated from different regional sources as well. With regard to the 100 
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raw herbs, they were purchased from two major wholesalers in Victoria, namely, Hong An Phat 
Acupuncture and Herbal Company in Richmond, and Winner Herbal Supplies, in Kensington. 
There are approximately 5 wholesalers in Victoria, and these two are among the three largest. 
Together they would probably be supplying more than 50% of herbal materials to retailers and 
Chinese medicine clinics in the whole of Victoria. Furthermore, an inspection of their product 
packaging reveals that these two companies imported their goods from various sources 
(companies) not only from China but also from Hong Kong. Thus, while 100 herbal items may 
not be totally representative to all products in the market, they nevertheless represent a good 
proportion of the spectrum of what are being marketed in Victoria. The current findings therefore 
provide a reasonable representation and understanding of the state of metal contaminants in both 
raw and Chinese patent medicines. The significance of the results is not lost because of the 
factors of sourcing and supply. That being said, it is acknowledged that to be 100% certain, 
ideally random samples from every batch of imports of all raw herbs and patent medicines should 
be analysed. 
            
 
10.2     Analytical Methods Are Reliable 
 
            In this project the method of graphite furnace atomic absorption spectrometry (GFAAS) 
was chosen in favour of the simpler and less time-consuming method such as flame atomic 
absorption spectrometry (FAAS), because of its higher sensitivity, precision and accuracy as 
discussed in “Methods” in Chapter 9. For example, Saper and co-workers reported only 20% of 
the 70 Ayurvedic herbal products contained Pb, Hg, and/or As (Saper et al., 2004), whereas in 
this study over 90% of the CHM were found to contain Pb, As, Cd, and Cr, and more than 60% 
contained Hg. Their low number of positive finding was undoubtedly due to the low sensitivities 
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of the method of x-ray fluorescence spectroscopy which had a minimum detection limits of 5 
µg/g for Pb, 20 µg/g for Hg, and 10 µg/g for As. These limits are at least 20 to few hundred times 
less sensitive compared to the GFAAS established in the present project. The GFAAS, and the 
cold vapour atomic absorption spectrometry methodologies (CVAAS) established in this project 
for the measurement of Lead, Arsenic, Cadmium, Chromium, and Mercury were highly 
satisfactory. The methods were extremely sensitive, as indicated by the very low levels of limits 
of detection, and limits of quantitation (refer to Table 10.6). They were also highly precise with 
percentages of relative standard deviation (%RSD) being within 5% or less for most metals (see 
Table 10.5). Furthermore, the accuracy of all the methods were confirmed either by analysing a 
commercial certified reference material, the Mixed Polish Herbs (INCT-MPH-2) for Lead and 
Mercury, or by spiking herbs with known quantities of the metals, in the case of Arsenic, 
Cadmium and Chromium. All accuracies were generally within the 95 – 105% (refer to Tables 
10.1 – 10.4). In this project, every crude herbal material (CHM), and proprietary products (CPM) 
were analysed in triplicates (CMF in duplicates) by being carried through the whole process of 
digestion and analysis. Furthermore, each final result was usually the average of triplicate 
analyses by the instrument of each sample. Hence, final results were reliable. Because of the high 
analytical sensitivity, a much higher percentage of the medicinal samples in the present study 
than many other reports (Au et al., 2000; Ko, 1998; Saper et al., 2004) was found to contain all 
four metals, Pb, As, Cd, and Cr, even though some concentrations were insignificantly low. 
However, 37 out of 100 crude Chinese herbal materials, and 12 out of 50 Chinese proprietary 
medicines either did not contain Hg or had Hg at a concentration lower than the limit of method’s 
quantitation (LOQ), the LOQ being very low at 0.008 µg/g (or 8 ng/g). That such a high 
proportion of medicinal materials having undetectable Hg is not surprising since the main source 
of mercury tends to come from the marine environment (FSANZ, 2003b) rather than from soil. 
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Further, Hg is highly volatile, and is unstable even under the normal temperature unless it is 
absorbed into the food chain. 
 
                 Metal contaminants in CHM and CPM may be divided into two stages, namely, (1) 
from the growth of raw herbal plants to final processed products, and (2) from the purchases of 
these retail products to the final laboratory analysis of their metal contents. Contamination of 
metals that occur in stage 1 is beyond the scope of this study. Current scientific studies related to 
safety issues of metal contamination in herbal medicines focus on stage 2, that is, the 
measurement of elemental concentrations in the retail products in order to assess their risks and 
safety to consumers. Therefore, contamination due to investigator’s handling and analysis is a 
real and important issue.  In this study utmost care has been taken in each step, from storage 
immediately after purchase to preparation of herbal medicines into powder, to acid digestion 
steps, preparation of aqueous decoctions, to final instrumental measurement. Precautionary and 
quality control steps are clearly described in the thesis. These include, for example, nitric acid 
wash of all containers, grinding in stainless steel grinder, use of metal-free polyethene tubes that 
have been further washed with nitric acid, inclusion of method blanks (i.e., negative blank 
controls that contain trace-metal grade nitric acid only, and that are carried through all the 
preparative and analytical steps). Also, only the best trace-metal grade of nitric acid available was 
used in this entire study. Metal-free Milli-Q grade water was used throughout the entire study, 
including its use for washing and rinsing. Further, positive controls – an internationally certified 
commercial herbal product – are also included throughout the entire preparative and analytical 
steps. Should any negative control produce any positive measurable value, i.e., above limit of 
detection, the entire analytical run would need to be discarded and repeated. Similarly, if the 
results of certified material were greater or less than 10% of the certified values, the entire 
analytical batch of the herbal samples would need to be repeated. At no stage throughout this 
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project did any negative control produce results above limit of detection. The positive control 
results were generally within ± 5% of the certified values.   
 
 
10.3     Total Acid-digested Metal Content in CHM Is Not Relevant for Safety  
            Interpretation  
  
           Although almost all100 CHM contain heavy metals, it is important to point out that the 
great majority of them had very low total (acid-digested) contents in any of the 5 metals (see 
Table 10.7; Figures 10.4 – 10.8). Many of these CHM would have been found to be negative or 
below detection limits, had the flame atomic absorption spectrometry (FAAS) method been used 
for determination, since GFAAS technique is at least 10 to100 times more sensitive than FAAS. 
However, for any one metal, between 1 and 4 CHM of the 100 CHM (i.e., 1 to 4 %) (See Figures 
10.4 – 10.8) had exceptionally higher metal content than the rest. The ones that were consistently 
high in total metal contents were typically the marine shells, namely, Long Gu (No. 57, Os 
Draconis), and Mu Li (No. 98, Concha Ostreae). Both were among the highest in Pb, As, and Hg. 
These findings confirm the well known ability of marine animals to incorporate heavy metals into 
their physiological system. Surprisingly, Hong Hua (No. 27, Flos Carthami Tinctonii), a very 
commonly used Chinese herb for invigorating blood circulation, and removing blood stasis, was 
found to contain very high contents of Pb and As. Wu Wei Zi (No. 58, Fructus Schisandrae 
chinensis), and Lu Gen (No. 60, Rhizoma Phragmitis) also contained rather high contents of Cd 
and Cr respectively. Therefore, based on these findings, up to 96 - 99% of CHM should not 
present any health concern, even if the total metal contents were used to assess risk. On the other 
hand, whether the few CHM containing higher metal contents, pose any real risk to consumers 
would depend on method of interpretation. Traditionally, the total (acid-digested) contents would 
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have been used to extrapolate/infer risk and provide justification for warning of potential 
poisoning. However, such method of extrapolation ignores the fact that CHM are not consumed 
whole. Therefore, to use the total metal content for risk interpretation is to ignore the procedure 
of boiling in water in clinical practice. It also assumes that the water-soluble fraction of metals is 
necessarily equal to the acid-digested content which had been demonstrated not to be the case in 
the present study.   
 
10.4   Low Metal Concentrations in Aqueous Decoctions of CHM Result in Safety of   
          TCM 
  
          The present study demonstrated that metal concentrations in aqueous decoctions were 
much lower than the total (acid-digested) metal contents present in the CHM. The water-soluble 
fraction of metal as a percentage of the total metal varied from as low as 3 % to as high as 65 % 
for CHM of plant origin, depending on the particular metal and particular part of the plant being 
boiled/decocted (see Table 10.14). On the other hand, for the two marine shells in this study, 
Long Gu (No. 57, Os Draconis) and Mu Li (No. 98, Concha Ostreae), the percentages of water-
soluble fraction were surprisingly and extremely low, an average of 1% only.  To highlight the 
differences in metal concentrations between the acid-digested and the corresponding water-
extracted solutions, their results are plotted in Figures 10.1 - 10.5 below.  
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Figure 10.1 Aqueous lead concentrations and their corresponding acid-digested metal contents in 
the 100 CHM 
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Figure 10.2 Aqueous arsenic concentrations and their corresponding acid-digested metal 
 
contents in the 100 CHM 
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Figure 10.3 Aqueous cadmium concentrations and their corresponding acid-digested metal 
contents in the 100 CHM 
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Figure 10.4 Aqueous lead concentrations and their corresponding acid-digested metal  
contents in the 100 CHM 
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Figure 10.5  Aqueous lead concentrations and their corresponding acid-digested metal  
contents in the 100 CHM 
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            These figures show that the aqueous concentrations were much lower than the total 
contents. Therefore, it is clear that it would be inappropriate to interpret CHM safety in terms of 
the total content, since crude CHM are not consumed whole. In Chinese medicine clinical 
practice, a certain quantity of the CHM, usually about 10 g each on average, is boiled in a certain 
quantity of water until the aqueous volume is reduced to about half. The aqueous decoction is 
then consumed for medicinal purpose.  The CHM are either boiled singly or as part of a Chinese 
herbal formula (CMF). The present finding that boiling in water greatly reduced the metal 
concentrations confirms that it would be erroneous to assume water-soluble and acid-digested 
metal concentrations were same. Therefore, when we take into account of the Chinese medicine 
practice of ingesting the aqueous decoction, it becomes apparent that even the few CHM 
containing higher metal contents would no longer become a safety issue. It is also interesting to 
point out here that traditionally for many centuries in China, boiling of Chinese herbs in metal 
utensils has always been disallowed. It has to be carried out in a porcelain pot, as though the 
Chinese forebears in ancient times knew about the leaching of toxic metals from metal utensils! 
 
            A standard protocol for interpreting safety of TCM is generally lacking in the literature. 
All published reports except one (Saper et al., 2004) did not estimate daily intake by comparing 
with regulatory standards. Saper’s metal intake report, however, was not on Chinese herbal 
medicines, but on Indian herbal remedies. These researchers analysed 70 Ayurvedic herbal 
products and compared the estimated daily intakes with the US Pharmacopeia (USP) 
specifications, i.e., the recommended reference dose (RfD) for maximum allowable lead, arsenic 
and mercury. Based on these RfD, they concluded that each of the 14 heavy metal-containing 
Ayurvedic samples might result in heavy metal intake above regulatory standards. It should be 
pointed out here that these researchers did not use the WHO regulatory standards as guidelines. 
In this study, estimates of daily intake of each metal for the 100 CHM were calculated from the 
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aqueous metal concentrations rather than the acid-digested contents (i.e., from the actual 
ingestible fraction as in clinical practice), and then compared with the WHO and Australian new 
Zealand Food Standards (ANZFS) specifications for Provisional Tolerable Daily or Weekly 
Intakes (PTDI or PTWI) (refer to Tables 10.14 – 10.18). These regulatory standards are thought 
to be more relevant in the Australian context as well as more universally adopted. These tables 
also show that individually none of the 100 CHM analysed when administered in the form of 
aqueous decoction on an averaged 10 g daily dose, would result in any significant contribution to 
the daily intake. However, one could argue that CHM are seldom used singly. They are usually 
combined in herbal prescription to make a decoction. Therefore, for sake of argument, if we 
consider the worse case scenario of combining the 6 highest metal-containing CHM for any one 
particular metal as mentioned in Chapter 10, sections 10.2.4.1 to 10.2.4.5, we will obtain 
significantly higher total percentages of the provisional tolerable daily intakes (% of PTDI) as 
shown in the last column of Table 10.1 below.  
 
Table 10.1  Hypothetical worse case scenario of consuming combined aqueous decoctions of six 
CHM containing the highest metal contents 
 
Metal CHM1 CHM2 CHM3 CHM4 CHM5 CHM6 Total  
% 
PTDI 
Pb Gua Lou 
(No.65) 
Gui Zhi 
(No.51) 
Zhi Zi 
(No.67) 
Lian Qiao 
(No.45) 
Wu Zhu 
(No.1) 
Hong Hua 
(No.27) 
33.3% 
As Ce Bai Ye 
(No.48) 
Cang Zhu 
(No.30) 
Xu Duan 
(No.43) 
Chuan Niu 
Xi 
(No.71) 
Ban Xia 
(No.40) 
Hong Hua 
(No.27) 
79.5% 
Cd Zi Su Ye 
(No.61) 
Zi Cao 
(No.62) 
Mu Xiang 
(No.59) 
Wu Yao 
(No.8) 
Ye Mu 
(No.80) 
Wu Wei Zi 
(No.58) 
38.9% 
Cr Lu Gen 
(No.60) 
Zi Wan 
(No.99) 
Rou Cong 
Rong 
(No.100) 
Chuan Niu 
Xi 
(No.71) 
Ban Xia 
(No.40) 
Shu Di 
Huang 
(No.50) 
99.8% 
Hg < 0.5% < 0.5% < 0.5% < 0.5% < 0.5% < 0.5% < 3% 
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In other words, even in such an unlikely situation, they are still below the limits of regulatory 
standards (see last column). Nevertheless, such a hypothetical situation would be highly unlikely 
to ever occur. Further, in real life situation, a patient taking Chinese herbal medicines would also 
be consuming a normal diet of foods. The daily dietary food consumption would also contribute 
to metal intake. Therefore, to evaluate risk of a patient’s total metal daily exposure it is necessary 
to take into account of the two metal sources, diet and CHM. The metal intakes from daily dietary 
foods by way of Total Dietary Study (TDS) are regularly analysed and reported by most western 
and European countries, including Australia (FSANZ, 2003b) The latest Australian Total Dietary 
Survey (ATDS), formerly known as Australian Market Basket Survey (AMBS), undertaken 
jointly by Australia and New Zealand (FSANZ, 2003b) listed the daily metal intakes of Pb, As, 
Cd, and Hg from normal dietary foods for both adult male and female and interpreted in terms of 
% of TDI. In this study, the metal contributions from CHM (analysed in this study) and normal 
diet (reported in (FSANZ, 2003b) were added together to evaluate the potential risk of metal 
exposure. These total exposures are shown in Table 9.19. It can be seen that the CHM generally 
contributed lower daily intake than did food. The combined exposures were well below the 
maximum tolerable limits. The highest combined exposures were 69.0% and 57.1% of PTDI 
respectively for As depending on which regulatory guidelines, WHO or ANZFS were used, and 
33.5% PTDI for Cd, and around 17% PTDI for Pb and Hg when the individual CHM with the 
highest aqueous metal concentration was ingested along with a normal diet. Since the majority of 
CHM lied on the very low ranges of % PTDI, the combined diet and CHM would be low for the 
majority of CHM. This approach demonstrates the worse and best case scenario of consuming a 
diet in addition to a CHM containing the highest or the lowest metal concentrations. Similarly, 
Table 9.20 also shows this combined diet and CHM approach for Cr. Since there is no 
recommended WHO provisional guideline for Cr, other reference values (Lerntech, 2006) were 
adopted to provide several tiers of evaluation. Chromium is an essential nutrient required to 
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potentiate the action of insulin so that the body can use sugars, proteins, and fats (Shrivastava, 
Upreti, Seth, & Chaturvedi, 2002). Deficiency of the element may lead to impaired glucose 
utilization (Brown et al., 1986), and today Cr is routinely incorporated in patients receiving total 
parenteral nutrition (TPN). Hence, the combined diet and CHM Cr intakes were interpreted in 
terms of percentage of adequate intake (% AI) for nutrition requirement, and percentage of 
recommended dietary intake (% RDI), both set based on estimated mean intakes (Institue of 
Medicine, 2001). Since few serious adverse effects have been associated with excess Cr intake 
from food, therefore, no Provisional Tolerable Daily Intake (PTDI) level has been established. 
Nevertheless, a maximum dose of 200 µg/day has been referred to as being a safety limit above 
which adverse effects might occur after chronic intake (Lerntech, 2006). For purpose of risk 
evaluation, this safety limit of 200 µg/day will also be included here as a tolerable dietary intake 
(TDI). From Table 9.20 it is apparent that a person can usually achieve adequate intake and the 
recommended daily intake of Cr from a normal diet. Therefore, when CHM with the highest level 
of Cr was consumed, the total exposure would be well in excess of AI and RDI, but still within 
the TDI. In reality very large majority of the CHM contained very low Cr, and consequently most 
of the combined exposures lied in the low range of the % RDI and % TDI for adults of either 
genders (see last 2 columns in Table 9.20). Thus, these results demonstrate that for the five 
metals studied, the 100 crude Chinese herbal materials are safe in terms of metal contamination. 
The fact that the two major herbal wholesalers from which these herbal materials were purchased 
supplied probably 50% of the consumer market is also reassuring.    
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10.5   Total Acid-digested Metal Contents and Aqueous Metal Concentrations in the   
          Five Chinese Herbal Formulae (CMF) 
 
          The five herbal formulae chosen for this study were some of the most common 
prescriptions in Chinese medicine clinical practice. They are often adopted with or without 
modifications. They represent prescriptions for common syndromes such as Qi Stagnation, Blood 
Deficiency, Blood Deficiency and Blood Stagnation, Spleen Qi Deficiency, and Kidney Yang 
Deficiency. Details of their therapeutic functions and herbal compositions are listed in Table 8.8. 
In most TCM practice, patients are instructed to boil the pack of herbs in water twice and pool the 
two decoctions together and then divide it into two equal volumes (i.e., two doses) to be 
consumed in two separate occasions either in one day (i.e., two doses daily), or in two days (i.e., 
one dose per day). Therefore, the aqueous metal concentrations in this study are the relevant 
values for safety interpretation. As with CHM, the 5 CMF were analysed for total (acid-digested) 
metal contents (see Table 9.29) and also for their water-soluble fraction of metals (aqueous 
results in Tables 9.30 – 9.34). Table 10.2 below summarises the total acid-digested contents of 
each metal for the 5 herbal formulae, both in µg/g of the formula, and in µg per whole formula 
pack. Table 10.3 summarises the corresponding metal concentrations in the aqueous decoctions 
of these formulae, also in µg/g, and in µg consumed per day. For purpose of safety evaluation, 
the higher dosage, i.e., two doses of the aqueous decoctions per day were used.  Like CHM, the 
aqueous metal concentrations from these herbal formulae represented only small percentages of 
the total metal present. Obviously, the final quantity of metal varies depending on the weight of 
the herbal prescription. For example, for CMF 4 (Gui Pi Tang) the lead concentration in terms of 
µg of Pb/g of formula was 0.279, ranking 4th in decreasing order of concentration as follows: 
              CMF 3 > CMF 1 > CMF 2 > CMF 4 > CMF 5 
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But, because the formula, Gui Pi Tang, was the heaviest having the highest number of herbal 
ingredients, the total amount of water-soluble Pb in the whole prescription became higher (= 
0.279 µg x 93g where 93 being weight of the formula) at 25.956 µg. This changed the order of 
Gui Pi Tang into the 2nd highest in Pb consumed in aqueous decoctions per day, as follows:              
 
             CMF 3 > CMF 4 > CMF 1 > CMF 2 > CMF 5 
 
 
          The above observation has implication for clinical practice. Therefore, it is worthwhile to 
bear in mind that the heavier the herbal pack (e.g., bigger number of herbal ingredients, and/or 
larger quantity of each herbal ingredient), the more likely the final amount of metals consumed 
per day will also be higher.                  
 
Table 10.2   Summary of total acid-digested content of each metal of the 5 herbal formulae, in 
µg/g (or ng/g) of the formula, and in µg per whole formula pack 
 
Metal 
Total (acid-
digested) 
content 
CMF 1  
 
(Xiao Yao 
San) 
CMF 2  
 
(Si Wu Tang) 
CMF 3  
 
(Tao Hong Si 
Wu Tang) 
CMF 4  
 
(Gui Pi Tang) 
CMF 5  
 
(Jin Gui Shen 
Qi Tang) 
Pb       (µg/g) 1.41 1.28 1.15 0.85 2.18 
As       (µg/g) 0.93 1.53 1.16 0.72 10.40 
Cr       (µg/g) 2.35 5.48 1.54 1.83 3.49 
Cd       (ng/g) 148 95.9 122.7 115.7 94.7 
Hg       (ng/g)  2.6 4.2 8.8 2.9 3.3 
 
Pb (µg/pack) 57.21 57.57 58.65 79.05 176.33 
As (µg/pack) 37.83 68.72 59.16 66.96 83.85 
Cr (µg/pack) 95.06 246.8 78.4 170.19 282.83 
Cd (µg/pack) 5.99 4.32 6.26 10.76 7.67 
Hg (µg/pack) 0.11 0.19 0.45 0.27 0.27 
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Table 10.3   Summary of concentrations of each metal in aqueous decoctions of the 5 herbal 
formulae, in µg/g (or ng/g) of the formula, and in µg consumed per day 
 
Metal 
Total (acid-
digested) 
content 
CMF 1  
 
(Xiao Yao 
San) 
CMF 2  
 
(Si Wu Tang) 
CMF 3  
 
(Tao Hong Si 
Wu Tang) 
CMF 4  
 
(Gui Pi Tang) 
CMF 5  
 
(Jin Gui Shen 
Qi Tang) 
Pb       (µg/g) 0.48 0.43 0.52 0.28 0.12 
As       (µg/g) 0.24 0.31 0.48 0.16 0.17 
Cr       (µg/g) 0.07 0.12 0.12 0.02 0.02 
Cd       (ng/g) 58.6 62.4 67.7 23.3 29.9 
Hg       (ng/g)  bd bd bd bd bd 
 
Pb   (µg/day) 19.57 19.44 26.65 25.96 9.45 
As   (µg/day) 9.85 14.03 24.21 14.82 13.40 
Cr   (µg/day) 2.85 5.18 6.04 1.75 1.70 
Cd  (µg/day) 2.37 2.85 3.45 2.17 2.42 
Hg  (µg/day) bd bd bd bd bd 
             
 
          Another observation is that the quantity of different metals also varies depending on the 
composition of the formulae. The following examples show the orders of each CMF for each 
metal in terms of total quantity of the metal consumed in aqueous decoctions per day. 
 
For As:    CMF 3 > CMF 4 > CMF 2 > CMF 5 > CMF 1 
For Cd:    CMF 3 > CMF 2 > CMF 5 > CMF 1 > CMF 4 
For Cr:    CMF 3 > CMF2 > CMF 1 > CMF 4 > CMF 5   
 
          While the concentration order of most CMF changes for different metals, it is interesting to 
note that CMF 3 (Tao Hong Si Wu Tang) consistently contained the highest quantity for most the 
four metals. This formula contained two additional crude Chinese herbs compared to the formula, 
Si Wu Tang (CMF 2). They are Hong Hua (No. 27 in Table 8.6) and Tao Ren. It is, therefore, not 
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surprising to find that Hong Hua as an individual CHM was also found to be consistently high in 
most heavy metals as discussed previously.   
 
          As with the CHM, the aqueous concentrations of Cd and Hg in CMF were also extremely 
low. They were expressed in nanogram per gram as against the microgram per gram scale for Pb, 
As and Cr. In particular, mercury was virtually not detectable in the aqueous decoctions of all 5 
herbal formulae. It suggests that mercury is not extracted efficiently into water. This is an 
encouraging and significant finding, and should be regarded as a positive sign in the practice of 
herbal medicine.  
 
10.6     Estimates of Daily Metal Intakes from Aqueous Decoctions of CMF Demonstrate 
            Relative Safety of Crude CMF Administered in Aqueous Form  
             
            To evaluate risk of consuming aqueous decoctions, which is one of the most common 
forms of therapeutic administration in TCM practice, the daily exposures to the 5 metals in the 5 
Chinese herbal formulae determined in the present study (as µg/day, summarised and highlighted 
in the lower half of Table 10.3 above) were expressed as % of PTDI for Pb, As, Cd and Hg in 
Table 9.35, and in Table 9.36 for Cr. This study has clearly demonstrated that the practice of 
boiling in water definitely resulted in reducing the metal concentrations to well below the upper 
tolerable limits of daily intake. For Pb, As and Cd, the daily intakes of µg/kg bw/day for any 
CMF were all below 20% PTDI. For arsenic, according to the WHO regulatory standard of PTDI 
of 2.1 µg/kg bw/day (WHO, 1999), the CMF3, Tao Hong Si Wu Tang, would provide the highest 
arsenic intake of 19.2% of PTDI, and CMF1, Xiao Yao San, would provide the lowest 7.8% of 
PTDI. However, in Australia a less stringent PTDI guideline of 3 µg/kg bw/day (FSANZ, 2003a) 
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has been adopted. Based on this guideline, their exposures would then be reduced to even safer 
levels of 13.4% PTDI and 5.5% PTDI  respectively for Tao Hong Si Wu Tang and Xiao Yao San 
respectively (see Table 9.35).  
 
          In the case of chromium, as expected, CMF3, Tao Hong Si Wu Tang, provided the highest 
percentage of daily adequate intake (AI), up to 24.1% for women, and 17.2% for men. In terms of 
recommended daily intake (RDI), and the safety limit (TDI), all five CMF were rather 
insignificant contributors (see Table 10.36). In reality, for a patient taking Chinese medicinal 
decoctions, the total daily metal exposure should be estimated by combining the two major 
sources, that is diet and CMF. Thus, this study shows that % PTDI exposures to Pb from the 
CMF were fairly similar to that of diet (see Table 9.37), and the daily combined exposures (diet 
and CMF) were up to about 23% PTDI, a level well under the maximum regulatory standard. On 
the other hand, the contribution of As from CMF decoctions, are generally lower than the low 
range of the mean estimated daily dietary exposures reported in the 20th Australian Total Diet 
Survey (ATDS) (FSANZ, 2003a) (see Table 10.39). Therefore, taking daily doses of aqueous 
Chinese medicinal formula would add only marginally and safely to the combined As exposure. 
Similarly, CMF decoctions, having only low concentrations of Cd and Cr, contributed only a few 
% of PTDI to the daily dietary exposures.  
 
          In summary, although a few crude herbs were found to contain metals in exceptionally high 
absolute total contents which were only available after digestion in strong nitric acid, this study 
has demonstrated relative safety of crude Chinese herbal materials (CHM) and Chinese herbal 
formulae (CMF) when used in the traditional method of boiling in water for a specified period of 
time, and then administering the aqueous decoctions.  After exhaustive literature review, there 
does not appear to be any previous report of comprehensive studies of water dissolution of CHM  
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and/or CMF published in the English language. The present study appears to be the first of its 
kind. 
 
10.7      Efficiency of Water Extraction and its Implication              
               
         Another finding of interest in this study is the difference of efficiency in water extraction 
between the first and second decoctions. In general, the first extraction was up to 6 times more 
efficient than the second (refer to Tables 9.30 – 9.34 for CMF; and Tables 9.8 – 9.12 for CHM). 
Based on these results it may be reasonable to infer that other active ingredients in the CHM and 
CMF might also be present in vastly different quantities between the two consecutive decoctions. 
An important clinical implication of this finding is that the first aqueous decoction would have 
higher potency than the second. Consequently, if the two decoctions were not pooled and mixed 
well, and were taken in two separate occasions daily (i.e., bds; e.g, AM and PM), as often is the 
case, it would result in rather different potencies and efficacies between the two doses. Often, 
patients might also be taking the herbal decoction only once daily.  In this case, if they were to 
boil the herbal pack in day 1, and consumed the decoction, and then on the following day 2, boil 
the herbal pack the second time and consumed the second decoction, then the efficacy of the 
second dose would be much reduced. This might not be a good therapeutic practice. Fortuitously, 
most practitioners would instruct patients to boil the prescription herbal pack twice, and pool and 
mix well the first and second decoctions, then divide the pooled aqueous fluid into two equal 
portions for oral administration in two separate doses per day or in 2 days. This procedure as 
described in detail in Chapter 8, section 8.2.5, would eliminate the large discrepancy between the 
two doses. However, not all practitioners advise their patients to pool the two samples. Some 
patients are instructed to boil each herbal pack only once a day for one intake per day and then 
the pack will be either discarded or be boiled second time the next day for the second daily intake, 
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before being discarded. These variations in decoction administration undoubtedly are likely to 
lead to variations in therapeutic effectiveness.  
 
          Apart from the difference between two successive decoctions, this study also found that the 
efficiency of water extraction was related to the nature of the plant materials. Thus, for a 
particular part of the plant, e.g., the root CHM, the average % of extraction of all 5 metals 
combined was 28%, shown in the bottom row of Table 9.13. The highest average % was from 
leaves (~ 40%), and by far the lowest was the marine shell CHM (~ 1%). These extraction 
efficiencies in decreasing order for the various groups of CHM, are listed below:  
 
Leaves  > Flowers  > Roots  ≅  Seeds  > Barks  > Branches/Twigs  >>> Marine Shells / Bone 
 (~ 40%)   (~ 30%)    (~ 28%)    (~28%)   (~23%)            (~21%)                        (~1%) 
 
          Further, for a particular metal, e.g., Pb, the average % of extraction of all 6 groups of CHM 
combined was ~ 25%, shown in the last column of Table 9.13. The highest extraction average 
was ~ 39% for Cd, followed by As at ~35%. These extraction efficiencies in decreasing order for 
the various metals are shown below: 
 
              Cadmium  >  Arsenic  >  Lead   >   Mercury  >  Chromium 
              (~ 39%)         (~ 35%)     (~ 25%)    (~ 22%)       (~19%) 
 
           These findings suggest that possibly the harder and/or drier the herbs were, such as the 
roots and branches of a plant, the less efficient the water extraction would be, whereas soft parts,
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such as leaves and flowers provided more efficient water extraction of the metals. In addition, 
water dissolubility (i.e., efficiency of water extraction) might also be metal-dependent. Thus, 
overall Cd was more soluble or extractable in water than As which, inturn, was more soluble than 
Pb under the current conditions. Therefore, by reference, active ingredients in CHM and CMF 
might also be expected to have varying extractability, and consequently varying potencies.   
 
          While CHM and CMF were found not to pose any significant level of health risk to 
consumers based on their low % PTDI, the difference in water extraction efficiency between the 
two successive decoctions, might be a cause for therapeutic/potency concern, particularly for the 
CMF. Both CHM and CMF were boiled in the original crude state, not powder.  To minimize this 
dosage discrepancy, the common practice of pooling, mixing and dividing should be mandatory. 
Also, it might be useful to render the harder and drier types of herbal materials like hard seeds, 
roots, barks and branches by crushing them to smaller and softer pieces before dispensing to 
patients for boiling. Whether this procedure would help to improve the overall aqueous extraction 
and therefore, potency of the combined decoction will need to be investigated.  
 
10.8    Estimates of Daily Metal Intakes from Chinese Proprietary Medicines (CPM) 
           and Issue of Safety 
 
          The CPM are actually Chinese medicinal formulae manufactured and packaged into final 
consumable commercial products in the form of pills, tablets, or capsules. Commercially, they are 
often marketed by the name of the Chinese medicinal formula followed by one of the following 
suffixes, Pills, Wan, San, Pian/Pien, or Tang (see Table 8.7). Generally and theoretically, CPM 
with same medicinal formula name, but ending with different suffixes are made of the same and 
similarly weighed Chinese herbal medicinal components (i.e., same CHM). Of the 50 popular 
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CPM under investigation here, there were 7 pairs of CPM products. Each pair was manufactured 
either by different pharmaceutical companies, or same company but different batches (listed in 
pairs as the bottom last 14 products in Table 8.7). These pairs were deliberately included in the 
study to assess quality assurance of manufacturing process. 
 
           This study showed that in terms of total metal contents per gram of the CPM, the Pb, As, 
Cd, Hg, and Cr concentrations of almost all 50 CPMs clustered at the low or very low levels (see 
Table 9.21 and Figures 9.8 – 9.12). For each metal, there was one or two CPM that had 
exceptionally higher level. However, whether these high CPMs contributed to high daily intake 
would depend on the recommended daily dose. Unlike CHM and CMF, CPM do not have to be 
decocted in water. They are ingested whole as purchased. Therefore, these total (acid-digested) 
contents were directly relevant to the daily or weekly intake. Based on the 
manufacturers’ recommended daily dose, the weekly oral exposures per kg body weight 
(µg/kg bw/week) of each metal are shown in Tables 9.22 – 9.26. Upon comparing these results 
with the WHO and ANZFS regulatory standards expressed as % PTDI, the study found that for 
Pb, 43 out of 50 (86%) CPM contributed less than 5% PTDI, 6 out of 50 (12%) contributed 
between 5 –15% PTDI, while one, An Shen Ding Zhi Wan (No. 29) was exceptionally high at 
29.3% PTDI. When a patient taking this spirit-calming CPM at the recommended dose while 
maintaining normal diet, his/her maximum combined daily exposure to Pb would become 40.3% 
PTDI (see Table 9.27). If doubled dose were taken for some reason, then it would have been 
69.6% PTDI. In other words, it was still well within the safety margin.  
 
             For Cd exposure from CPM, the three high outliers as shown in Figure 9.10 achieved 
only less than 7% PTDI, and a maximum of about 30% PTDI when combining with a normal diet 
(Table 9.27).  
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             On the other hand, 4 out of 50 (8%) CPMs produced As up to approximately 20% PTDI 
based on WHO regulatory standard (Table 9.23). They would have boosted the combined daily 
exposure (diet and CPM) to a maximum of around 62% PTDI (Table 9.27). If an overdose, say 
twice the recommended dose, was administered, the maximum daily As exposure would have 
been around 83% PTDI, thus nearing the limit of safety of 100%. However, if the less stringent 
safety guideline of Australia and New Zealand was used, then an overdose of these CPM would 
still be ~ 59% PTDI. Otherwise, a recommended dose in addition to an Australian daily diet, 
would have resulted in less than 50% of the safety limit.  
 
          Overall, Hg exposure due to CPM was insignificant.  
 
          Chromium (Cr), on the other hand, existed in fairly high levels in three of 50 CPM. They 
were Po Chai Pills (No. 10), Chuan Xiong Cha Tiao Wan (No. 7) and Niu Huang Qing Xin Wan 
(No. 27) (Table 9.26, Figure 9.12). The ingestion at recommended dose would expose a person 
to 42 – 51% TDI. When combining with daily food intake, it would amount to a maximum of 
78% TDI for an adult male, and 66% TDI for an adult female (Table 9.28), because the average 
female daily dietary intake was estimated to be lower than the male counterpart in Australia 
(ANZFS, 2003). Obviously, if a patient ingested twice the recommended maximum daily dose, 
then the combined daily exposure (food and CPM) would have been well in excess of the 
recommended upper limit of reference dose (RfD = 200 µg/day), and reached ~ 150% TDI, that 
is, above the recommended safe limit.  
 
           It can be concluded from these findings and discussions that up to ~ 95% of the 50 CPM 
were extremely low in all 5 metals. Two to three CPM contained higher amounts, but were still 
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safe when ingested according to the daily dose recommended by the manufacturers. Risk might 
arise in the case of Cr for three CPM described above, only if the proprietary products were taken 
well in excess of the manufacturers’ recommended doses. 
 
           It is noteworthy to point out that of the eight over-the-counter patent CPM with high metal 
contents, several consistently contained high contents of different heavy metals. For example, 
Qian Bai Bi Yan Pian (No. 38), Bi Min Gan Pian (No. 49), both indicated for allergic rhinitis, 
were among the high Cd and As products. Qian Bai Bi Yan Pian was also high in Hg. Po Chai 
Pills (No. 10) was high in 3 of the 5 metals measured, Cd, As, and Cr. It is interesting to note that 
44 out of 50 (88%) CPM were manufactured by three large pharmaceutical companies in China. 
They are Lanzhou Foci, Lanzhou Minshan, and Lanzhou Tai Bao. Of the eight high-metal CPM, 
five were manufactured by companies other than these three. One was manufactured by Lanzhou 
Foci for an Australian company. Two were produced outside mainland China, one of which in 
Hong Kong (Po Chai Pills), the other in Australia (Bi Min Gan Pian). This finding highlights the 
variations in manufacturing quality control between different companies. Surprisingly, lack of 
control is not necessarily confined to mainland China, contrary to popular perception. 
 
          Another interesting finding is the quality of products of the same formula (see Table 9.21). 
It appeared that quality controls were not consistent, even within the same company. For example, 
Bao He Wan (No. 23) produced by Lanzhou Foci for a distributor in Australia, Sheng Neng P/L, 
and Bao He Wan (No 41) produced by the same company for another distributor in Australia, 
Cathay P/L, had vastly different contents of Hg. The former products contained ~ 52 ng/g, while 
the latter contained ~ 502 ng/g. Furthermore, the same Chinese manufacturer produced two 
different batches of Xiao Feng Wan. While most of the metal contents were roughly similar, 
batch 010904 (No. 01) contained about 5 times higher Cr content in µg/g than batch 9903027 (No. 
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45). Different pharmaceutical companies would also produce same formulated products with 
varying degrees of metal contaminants. For example, Tao Hong Si Wu Wan (No 36) from 
Lanzhou Minshan, contained Hg at ~ 27 ng/g whereas Hg in Tao Hong Si Wu Wan (No. 48) 
from Lanzhou Foci, was below detectable limit. Yet, product No. 48 had more than 4 times of Cr 
than Product No. 36. Other pairs also demonstrated differences.  
 
          As pointed by a number of researchers (Schilcher 1983; Kabelitz 1998; Koh & Woo 2000), 
contamination could come form several sources, (1) the region of supply of the herbal material 
for manufacture, being affected by the agronomical conditions, (2) the manufacturing  processes, 
such as the containers used during production, and (3) deliberate addition for purported medicinal 
benefit. In Australia, products known to have deliberate addition of metals are prohibited for 
import and sale. Hence, the question of quality control during production, that is GMP, needs to 
be addressed.  
 
          Results in the present study confirm the findings of many reports in that metal 
contamination do exist in CHM (Khan et al., 2001), and in CPM (Au et al., 2000; Garvey et al., 
2001; Ko, 1998; Koh & Woo, 2000). However, contrary to their claims of metals in toxic 
concentrations, this study did not find evidence of excessive metal contamination, especially in 
regards to dangerous level that requires public warning. A few CHM and CPM might be high in 
certain metals, but they were not high enough to cause health problem based on the universally 
recognised WHO regulatory standards, and the ANZFS guidelines for safety. In this study the 
safety of TCM was assessed based not only on the contents of  CHM, CMF and CPM as % PTDI, 
they were also assessed by being added onto the % PTDI exposures from the Australian daily 
dietary intakes. These would produce a realistic total exposure of each metal. Yet, all results 
clearly showed that total combined exposures were all below the regulatory standard of 100% 
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PTDI, an indicator of the safe maximum tolerable level for chronic intake of the metal. The 
discrepancies between the present findings and reports in literature are most likely due to the fact 
that legal Acts and Regulations exist in Australia since 2002 to control and regulate the qualities 
of the import and sales of TCM products, and TGA has the role of enforcing them. Consequently, 
products of doubtful quality are prohibited for sale. On the other hand, Singapore government 
was led to introduce new legislations to enforce quality of CPM after the publication by Koh & 
Woo reporting the numerous Chinese proprietary medicines having metals in excess of the legal 
limits (Koh & Woo, 2000). In the USA, herbal and complementary medicines are still regarded 
as health products which are exempt from FDA regulation. The situation in which Garvey and 
co-workers found excessive concentrations in some Asian herbal products (Garvey et al., 2001) 
was different from this study because their samples were unsystematically purchased from 
various Asian countries, a collection approach that was open to criticism.   
 
          Another feature of this study is the measurement of metal concentrations in aqueous 
decoctions to reflect the true and realistic exposure, as it would have occurred in real TCM 
clinical practice. This is a rational approach of safety evaluation, and avoids claims of potential 
risk based on extrapolation and conjecture. 
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10.9     Conclusion 
 
            The 100 crude Chinese herbal matrials, 5 Chinese herbal formulae, and 50 Chinese 
proprietary medicines investigated in this study were within the safety health limits when 
ingested according to the normal clinical practice of TCM, and according to the manufacturers’ 
recommended dosage. For a definitive conclusion, a comprehensive screening of all medicinal 
products available to consumers is necessary. However, the screening of relatively large number 
of medicinal samples, and the method of sample collection in the present study render the 
findings being representative of a very high percentage of the Chinese medicines used by 
practitioners of TCM and hence, the consumers in Victoria, Australia. Although the intakes of the 
four heavy metals, Pb, As, Hg and Cd from Chinese medicines were well below their respective 
PTDI or PTWI, when added to the daily dietary intake, some of the total exposures amounted to 
relatively high percentages, and therefore calls for a more detailed future risk assessment and 
continuing monitor. 
 
          An important finding of large difference between the first and second decoctions in terms 
of metal concentrations warrants further research, as it may infer that the active ingredients in 
these decoctions might also be vastly different, thereby resulting in large variations in potency. 
One approach to determine if crushing of the herbs of hard nature, such as roots and barks, will 
improve solubility is to identify several active components of the particular herb from the 
Pharmacopoeia of the People’s Republic of China (PRC, 1997), and compare their concentrations 
in aqueous decoctions between those obtained from crude herbs and those from crushed crude 
herbs. Other future direction might be to apply different extraction methods, such as differential 
extractions using ethanol and water. In the meantime if successive water boiling is to be carried 
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out, then it is strongly advisable that the two decoctions be pooled and then divided equally for 
administration. 
 
           Finally, based on the current study future directions and strategies for monitoring 
contaminants of herbal medicines in the future need to be considered. As mentioned in 
Discussion, to be totally confident of the safety, more stringent analytical monitor is needed. It is 
not possible at this stage for Australian authority to control the manufacturing processes in China. 
Therefore, the surest strategy to ensure safety with respect to metal contaminants in herbal 
products is firstly to set maximal residual metal levels for different types of herbal products that 
are relevant to the unique method of oral administration of Chinese medicines, and secondly 
introduce compulsory analytical certification of safety for every batch of imported products. This 
certification can be provided either by the supplier in China, or by the Australian importers 
before sales are permitted. Either way, laboratories that perform the analyses must be GLP-
accredited by the relevant Australian authority with regular audit. 
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CHAPTER 11 
INTRODUCTION 
 
11.1     Introduction 
 
            Having carried out extensive analyses of the 100 crude Chinese herbal materials, 50 
Chinese patent medicines, and 4 Chinese medicinal formulae, and demonstrated theoretically 
their relative safeties for therapeutic consumption according to recommended doses, it was 
appropriate to investigate further the safety issue in a clinical setting that reflects the real world of 
Chinese medicine practices. The objectives of this section of the research were (1)  to measure 
and compare the blood metal concentrations after patients have consumed a specially formulated 
herbal granulated medication for a period of 8 weeks, an interval comparable to most clinical 
cases of chronic conditions in Chinese medicine practice, with the baseline blood levels, i.e., the 
patients’ normal blood levels prior to treatment with the herbal granules; and (2) to assess the risk 
posed to consumers through ingestion of therapeutic doses of Chinese herbal granules 
contaminated with the heavy metals, lead and cadmium. The extent of increases in the blood 
metal concentrations, if any, will be a direct indication of the potential risk posed by this form of 
Chinese herbal medicines. 
 
 
11.2      Design of Randomized Clinical Trial   
 
          To achieve the above objectives, a double-blind randomised, placebo controlled clinical 
trial using a specially formulated prescription of Chinese herbal granules to treat perennial 
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allergic rhinitis was conducted. A total of over 100 patients were recruited initially. Participants 
were randomized into two groups, the placebo and the real treatment group, as described later in 
Methods. Blood samples were taken during the baseline period, after which participants were 
given placebo medications while subjects in the real treatment group were given the specially 
formulated Chinese herbal granules, to be administered two capsules per dose, three times a day 
for eight weeks. At the end of the 8-week treatment period, a second blood sample was taken. 
Both the baseline and post-treatment samples were analysed for serum lead and cadmium 
concentrations. 
 
 
11.3    Relevance of Measurement of Blood Metal Concentrations 
 
           Generally, exposure to lead at any levels is regarded as detrimental to health (FDA & 
CFSAN, 1993). Although there are regulatory guidelines for lead oral exposure, the assessments 
of health effects of lead are largely based on the concentrations of body fluids, or tissues, for 
example, blood, urine, hair and nails (U.S.DH&H, 1999a). Children are particularly prone to the 
neurotoxic effects of lead. In children, acute exposure may lead to death at blood levels of greater 
than 125 µg/dL, or to brain and kidney damage at 80 µg/dL, and chronic exposure with resultant 
blood levels of 50 to 80 µg/dL may cause anaemia (ATSDR, 1997). In adults, the toxic levels are 
slightly higher. Blood lead concentrations can be measured to assess potential toxicity if oral 
exposure to lead has occurred (ATSDR, 1997). Hence, there are many studies around the world 
measuring the blood metal concentrations to establish reference intervals as well as to monitor 
the effects of various environmental exposures to metals. Thus, Mortada, et al. (2002) (Mortada, 
Sobh, el-Defrawy, & Farahat, 2002) measured cadmium, lead, and mercury in blood, urine, hair 
and nails among residents in Mansoura city, Nile Delta, Egypt to determine the reference 
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intervals for residents of various cities, the effects of smoking, and of amalgam filings. It was 
concluded that reference ranges were affected not only by smoking habit and dental filings, but 
also by geographic factors. Therefore, each city should establish its own population reference 
intervals for risk interpretation or safety monitoring. These conclusions were supported by other 
studies in Sweden (Barany et al., 2002), in Czech Republic (Benes et al., 2002), in Thailand 
(Tantanasrikul et al., 2002), and in Bomay, India (Tripathi, Raghunath, & Krishnamoorthy, 1997). 
They further affirmed the influence of socio-economic factors, gender, and industrial 
environments on exposures and subsequent metal concentrations in body fluids. In this study, the 
theoretical contributions of dietary exposure and exposure from Chinese herbal medicines have 
been determined and discussed in previous chapters. Based on the recognised value of blood 
metal concentrations as an index of risk, the next step in this research project is to determine 
whether the ingestion of a particular form of Chinese herbal medicines would increase the normal 
blood metal concentrations in order to categorically evaluate any potential risk of Chinese herbal 
medicines, while at the same time reference intervals for lead and cadmium for a small cohort of 
population residing in the Melbourne metropolitan area will be established. 
 
11.4    Analytical Methodology         
 
            In analysing metals in serum, the selection of analytical method is critical because of the 
highly complex chemical matrix of serum. It is extremely difficult to prepare chemically matched 
standards so that the standards and serum samples have similar decomposition behaviour, since 
the matching requirements include viscosity, salt and protein contents as well as any interfering 
substances unique to serum. 
           With the standard addition method using the GFAAS, the problem of chemical complexity 
can be overcome, because the serum itself serves as the background matrix not only for the serum 
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whose metal analyte is being determined, but also for the added standards as well. Thus, the 
chemical matrixes are identical for both the standards and the serum.  
 
           In the GFAAS standard addition procedure a number of fixed volume of the sample are 
aspirated and mixed with increasing concentrations of the metal analyte (i.e., the standard) to a 
final particular volume, then dispensed to and analysed in the graphite tube. A typical calibration 
curve is shown in Figure 11.1.     
 
Figure 11.1  Example of standard addition graph           
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           As shown in Figure 11.1, the concentration of the metal analyte in the standard additions 
sample can be determined from the intercept on the concentration axis by extrapolation of the 
graph to zero absorbance. Furthermore, if the samples to be analysed are chemically and 
physically similar, then the calibration established from one set of addition standards will be 
analytically valid for all the samples to be analysed, i.e., , the serum samples, in the present 
research project. Otherwise, each serum sample must be analysed separately against a new set of 
standard additions. The latter approach is by far more tedious and time-consuming, but more 
accurate. In the present project, standard additions for each individual serum samples were 
chosen to ensure maximum accuracy, despite the extra time and effort required. 
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CHAPTER 12 
 
MATERIALS AND METHODS 
 
 
12.1       MATERIALS  
 
12.1.1    Chemicals  
 
              Most chemicals required for the analysis of metals in human serum were the same as 
listed in Chapter 8, Section 8.1.1.  Additional chemicals, Triton X-100 (Batch No. 108H0158), 
and antifoam A, concentrate (Batch No. 127F0242) were purchased from Sigma-Aldrich, Sydney, 
Australia.   
 
             Special BD Vacutainer tubes (7-mL) with sterile interior, and without preservative 
manufactured specifically for collection of blood for metal analysis (Batch No. 8002556; BD, 
Franklin Lakes, NJ 07417-1885) were purchased from BHD, Australia.   
 
 
12.1.2    Instruments and Laboratory Wares 
 
The atomic absorption spectrophotometer (SpectrAA 220, Version 4.10, Varian, 
Australia), equipped with a diode array detector, and a data handling system, coupled with a 
graphite tube atomizer, and a SPS-5 auto-sampler together with a 50-sample carousel (which has 
cup position for bulk standard, modifiers and make-up solutions) was used for metal analysis. 
Single-element cathode lamps for Pb and Cd were purchased from Varian Australia. The graphite 
furnace was non-platform partitioned graphite tube (Part No. 6310001200, Varian, Australia). 
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The instrument is capable of supplying alternate gases, in this case, Nitrogen and Air, during the 
analytical process. A bench-top centrifuge, Capsulefuge (Tomy PMC-060, Australia) was used 
for centrifuging mixture of serum and Triton X-100 diluent. Special polyethylene capped tubes 
(1.5 mL size) were purchased from Crown Scientific, Australia, and were used for containing the 
above serum and Triton-100 mixture. An Allegra X-22R centrifuge (Beckman Coulter, Australia) 
was used for general centrifuging, including separating serum from whole blood at 5000 rpm.      
       
12.1.3       Reagents 
 
12.1.3.1    1.0% Triton X-100 diluent was prepared by diluting a mixture of 100 µL of Triton X-
100 and a tiny drop of Antifoam A to 10 mL with MilliQ water, and mix well with a vortex. 
 
12.1.3.2    HNO3 5% in 0.05% K2Cr2O7 reagent was used to prepare metal standard solutions. 
This reagent was prepared by dissolving 0.05g of K2Cr2O7 in 100mL of 5% HNO3. 
 
12.1.3.3    NH4H2PO4 0.5% in 5% HNO3 – This 0.5% solution was used as chemical modifier for 
GFAAS analysis of lead (Pb). To prepare this reagent, 0.5g of NH4H2PO4 was dissolved in 
100mL of 5% HNO3 solutions. 
 
12.1.3.4   Pd(NO3)2 0.08% in 5% HNO3 was another chemical modifier used for the 
determination of cadmium (Cd). It was prepared by dissolving 0.08g of Pd(NO3)2 in 100 mL of 
5% HNO3.  
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12.1.4     Preparation of Standard Solutions 
 
12.1.4.1  Standard Solutions for Serum Lead (Pb) Determination 
 
               From the commercial AAS standard (SS) for Pb (1,014 µg/mL in 1wt% HNO3), a 
standard solution No.1 (S1) of 10 µg/mL (i.e.10,000 µg/L) was prepared by diluting 986.2 µL of 
SS to a volume of 100 mL with 5% HNO3  – 0.05% K2Cr2O7 (or 493.1 µL of SS diluted to 50 
mL). A second standard No. 2 (S2) of 0.1 µg/mL (i.e.100 µg/L) was prepared by diluting 1 mL of 
S1 to 100 mL with 5% HNO3 – 0.05% K2Cr2O7. The bulk standard of 50 µg/L was prepared fresh 
prior to GFAAS analysis by diluting 5 mL of S2 with 5 mL of 5% HNO3 – 0.05% K2Cr2O7. This 
solution was used as the bulk standard in the GFAAS analysis of Pb by standard addition method. 
The S1 standard solution was kept for up to 1 year. The S2 standard solution was discarded after 
one week. All solutions were kept refrigerated at 4º C. The above preparations are summarised in 
the Table 12.1 below: 
 
Table 12.1   Preparation of Standards for serum Pb analysis 
 
Standard Solution Pb Concentration Procedure of Preparation Comment 
SS 1014 µg/mL 1014 µg/mL in 1wt% HNO3 Commercial 
product 
S1 10  µg/mL 493.1µL of SS diluted to 
50mL  
Stored 1 year at 4o 
C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL 4o C; prepare 
weekly 
Bulk standard 50 µg/L 5 mL of S2 diluted 10 mL Prepare daily 
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12.1.4.2  Standard Solutions for Serum Cadmium (Cd) Determination 
 
The bulk standard concentration for Cd determination was 2.5 µg/L. Two levels of 
standard addition concentrations at 0.5µg/L and 1.5µg/L were automatically delivered by the 
instrument. The procedure for preparing the bulk standard from the commercial Cd standard was 
similar to those described for Pb above, and is shown in Table 12.2 below.   
 
Table 12.2   Preparation of Standards for serum Cd analysis 
 
 
 
 
12.2      ANALYTICAL METHODS 
 
12.2.1   Determination of Serum Lead (Pb) Concentration by Method of Standard   
             Addition Using GFAAS 
 
All blood samples collected from patients who took part in the randomised clinical trial 
(RCT) for seasonal allergic rhinitis (SAR), were kept in ice immediately after collection and 
transported to laboratory. The sera were centrifuged at 4o C at 5000 rpm for 8 minutes. The sera 
were transferred to acid-washed glass tubes and kept at -4o C until analysis. On day of analysis, 
the following steps were carried out: 
Standard Solution Cd Concentration Procedure of Preparation Comment 
SS 1001 µg/mL 1001 µg/mL in 1 wt% HNO3 Commercial 
product 
S1 10  µg/mL 999 µL of SS diluted to 
100mL  
Stored 1 year at 4o 
C 
S2 0.1 µg/mL 1 mL of S1 diluted to 100 mL  4o C; prepare 
weekly 
Bulk standard 2.5 µg/L 0.5 mL of S2 diluted to 20 mL Prepare daily 
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(1) Sera were thawed, vortexed briefly, and then centrifuged at 3500 rpm for 8 minutes; 
(2) 100µL of the supernatant were carefully pipetted into a polyethylene conical tubes 
(1.5mL size; 
(3) To each tube 100µL of the 1% Triton X-100 diluent were added and the tubes 
capped, and vortexed vigorously for 30 seconds (Note: 1 in 2 dilution); 
(4) The tubes were centrifuged in the bench-top Capsulefuge for 5 minutes, or until a 
pellet could be seen at the bottom of the tubes; 
(5) The supernatants were carefully transferred to auto-analyser cups ready for analysis 
of Pb.  
 
            In standard addition method, each serum sample was initially determined for the presence 
of Pb. This measurement served as the background. The sample was then re-analysed after the 
addition of a known concentration of standard, and further re-analysed after addition of a second 
higher concentration of standard, and so on. A linear curve of the standard additions was then 
constructed. The difference between the amount of metal added and the background signal 
therefore gave the intrinsic metal concentration of the metal in the serum sample. A typical 
Standard Addition calibration curve of Pb determination is shown in Figure 12.1. 
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Figure 12.1  A typical standard addition curve of serum lead analysis (taken from analysis of 
sample No. 170) showing absorbance and corresponding Pb concentrations of five additions of 
standard. 
Stan dard  Add ition s  - Cal. Se t 3
Pb ug/L
A bs
0.00
0.29
0.10
0.20
0.0000-23.2759 45.000020.0000
Calibrated
Zoom Ov erlay
 
 
 
Standard Additions Calibration Curve of Pb Analysis 
Sample No. Post 170; dilution 1/2             
Standard                Abs              Conc (ug/L) 
Reagent Blank        0.0194            0.00 
Addition 1              0.1236             5.0 
Addition 2              0.1457           10.0 
Addition 3              0.1792           20.0 
Addition 4              0.2226           30.0 
Addition 5              0.2868           40.0 
Sample No 170      0.1074           24.6936 
 
Serum Pb concentration  =  24.6936 x 2 = 49.3872 ug/L 
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12.2.1.1  Parameters of Method of Standard Addition Using GFAAS for Pb     
              Determination 
 
The bulk standard concentration for Pb was 50µg/L. Three standard additions were 
automatically delivered from this bulk standard by the instrument to construct a linear curve. The 
three addition concentrations were 10µg/L, 20µg/L, and 40µg/L. Ammonium dihydrogen 
phosphate (NH4H2PO4 0.5% or 2.5% in 5% HNO3) was used as chemical modifier, and the make-
up solution was 5% HNO3. The volumes used in the furnace analysis for the test samples, 
modifier, and the make-up solution were 10µL, 5µL and 10µL respectively making a total 
volume of 25µL of the analytical mixture. Nitrogen was used as the inert gas. During the 
pyrolysis step prior to atomization and absorbance reading, an alternate gas, air, was flushed 
through the furnace system at a very low flow rate of 0.5 L/min for 15 seconds. Each GFAAS 
result was the average of duplicate measurements. Full details of the instrument parameters for 
lead determination as recorded in the AAS instrument can be seen in Appendix 12.1, while the 
main parameters are shown below: 
 
 
Parameters: 
 
Element                                Lead 
Wavelength                          283.3 nm 
Slit width                             0.5 nm 
Lamp current                       10.0 mA 
Calibration mode                 Standard Additions 
Sampling mode                   AutoMix 
Background Correction       BC On 
Modifier                              NH4H2PO4 0.5% in 5% HNO3  
Addition 1:                          10.0 µg/L 
Addition 2:                          20.0 µg/L 
Addition 3:                          40.0 µg/L 
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Step                    Temp (C)      Time (s)     Flow (L/min)    Gas Type   Read    Signal Storage 
 
     
1  Drying        90                  45               3.0    Nitrogen       No            No 
2  Drying                120                20               3.0    Nitrogen       No            No 
3  Drying        300                8.0              3.0    Nitrogen       No             No 
4  Pyrolysis            450                7.0              0.5    Air        No            No 
5  Pyrolysis        480                8.0              0.5    Air                No           No 
6  Pyrolysis        480                5.0              3.0    Nitrogen       No            Yes 
7  Atomization       2600                2.0            0.0                 Nitrogen      Yes  Yes 
8  Atomization       2600              1.0              0.0    Nitrogen      Yes  Yes 
9  Cleaning        2600              3.0              3.0    Nitrogen       No            Yes 
__________________________________________________________________________ 
 
 
 
12.2.2  Determination of Serum Cadmium (Cd) Concentration by Method of Standard 
Addition Using GFAAS 
 
 
Procedures for analysing Cd in the frozen sera are similar to those described for Pb above 
with minor differences, as below:  
(1) Sera were thawed, vortexed briefly,and then centrifuged at 3500 rpm for 8 minutes; 
(2) 100µL of the supernatant were carefully pipetted into a polyethylene conical tubes 
(1.5mL size; 
(3) To each tube 200µL of the 1% Triton X-100 diluent were added and the tubes capped, 
and vortexed vigorously for 30 seconds (Note: 1 in 3 dilution); 
(4) The tubes were centrifuged in the bench-top Capsulefuge for 5 minutes, or until a 
pellet could be seen at the bottom of the tubes; 
(5) The supernatants were carefully transferred to auto-analyser cups ready for analysis 
of Cd. 
As for serum Pb analysis, standard addition method was also employed for the 
determination of serum cadmium. Two levels of Cd standard were added. A typical Standard 
Addition calibration curve of Cd determination is shown in Figure 12.
  
 290 
Figure 12.2    A typical standard addition curve of serum cadmium analysis (taken from analysis 
of sample No. 122) showing absorbance and corresponding Pb concentrations of 2 additions of 
standard. 
Standard Additions - Cal. Set 2
Cd ug/L
Abs
0.00
0.36
0.10
0.20
0.30
0.000-0.414 1.5000.500 1.000
Calibrated
Zoom Overlay
 
Standard Additions Calibration Curve of Cd Analysis, 5/4/06 
Sample No. 122 (Pre-treatment); dilution 1/3    
 
Standard Additions Calibration Curve - Calibrate on Pr 122 x3 
 
                            Absorbance   Background   Conc (ug/L) 
Reagent Blank     0.0133             0.0579             0.000 
Addition 1           0.1792             0.6374             0.50 
Addition 2           0.3538             0.5918             1.50 
Sample No.122   0.0715             0.5854             0.384     
      
Serum Cd concentration = 0.384 x 3 = 1.152 ug/L           
 
 
12.2.2.1 Parameters of Method of Standard Addition GFAAS for Cd Determination 
 
The bulk standard concentration for Cd was 2.5µg/L. Two standard additions were 
automatically delivered from this bulk standard by the instrument to construct a linear curve (see 
Figure 12.2). The two addition concentrations were 0.5 µg/L and 1.5 µg/L. Pd(NO3)2 0.08% in 
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5% HNO3 was used as chemical modifier, and the make-up solution was 5% HNO3. The volumes 
used in the furnace analysis for the test samples, modifier, and the make-up solution were 5µL, 
5µL and 5µL respectively making a total volume of 15µL of the analytical mixture. Nitrogen was 
used as the inert gas. During the pyrolysis step prior to atomization and absorbance reading, an 
alternate gas, air, was flushed through the furnace system at a very low flow rate of 0.5 L/min for 
10 seconds. Each GFAAS result was the average of duplicate measurements. Details of the 
instrument parameters for cadmium determination as recorded in the AAS instrument can be seen 
in Appendix 12.2, while some of the main parameters are shown below: 
 
Parameters: 
 
Element                                Cadmium 
Wavelength                          228.8 nm 
Slit width                             0.5 nm 
Lamp current                       4.0 mA 
Calibration mode                 Standard Additions 
Sampling mode                   AutoMix 
Background Correction       BC On 
Modifier                              Pd(NO3)2 0.08% in 5% HNO3  
Addition 1:                          0.5 µg/L 
Addition 2:                          1.5 µg/L 
 
 
 
Step                    Temp (C)      Time (s)     Flow (L/min)    Gas Type   Read    Signal Storage 
 
      
1  Drying        85                  5.0               3.0    Nitrogen       No            No 
2  Drying                95                  40.0             3.0    Nitrogen       No            No 
3  Drying        140                20.0             3.0    Nitrogen       No             No 
4  Pyrolysis            300                10.0             3.0    Nitrogen       No            No 
5  Pyrolysis        450                10.0             0.5    Air                No           No 
6  Pyrolysis        650                20.0             3.0    Nitrogen       No            Yes 
7  Atomization       2500              1.0               0.0                Nitrogen      Yes  Yes 
8  Atomization       2500              1.0               0.0    Nitrogen      Yes  Yes 
9  Cleaning        2500              1.0               3.0    Nitrogen       No            No 
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12.2.3   Determination of Lead and Cadmium Contents in Herbal Real Treatment   
             Capsules (NSAR) and in Placebo Capsules (CSAR) 
 
The contents of the real capsule and the placebo capsule used for the randomised clinical trial for 
the treatment of seasonal allergic rhinitis were weighed and dried overnight in oven at ~45o C. 
After measuring the dried weights, they were then digested in 5 mL of concentrated HNO3 at 
room temperature overnight before being slowly digested in a heater block as described in 
Chapter 9, Sections 9.2.2 and 9.2.3. Their lead and cadmium contents were determined during the 
analyses of crude Chinese herbal materials (CHM), as described in detail in Chapter 9.  The real 
capsules and placebo capsules were carried out in triplicates.  
 
12.2.4  Protocol of Patient Blood Collection from Randomised Clinical Trial for    
             Seasonal Allergic Rhinitis (SAR)  
 
12.2.4.1  Background 
 
               A double-blind placebo-controlled randomised clinical trial was conducted in the pollen 
season between September and December 2003 by a colleague to evaluate the efficacy and safety 
of a modified Chinese herbal formula. This particular aspect of investigating the effect of Chinese 
herbal granules in capsules on blood metal concentration was a collaborative study. The trial was 
conducted in the Clinical Trial Laboratory of the Division of Chinese Medicine at RMIT 
University, Bundoora West Campus, Victoria, Australia. The trial was approved by RMIT 
Human Research Ethics Committee and filed with the Therapeutic Goods Administration of 
Australia. In this thesis only information relevant to the metal study will be presented here. 
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12.2.4.2  Selection Criteria and Final Sample Size 
 
The final sample size of participants after dropouts who provided both pre-treatment and 
post-treatment blood samples was 33 Controls (Group B) and 38 Real treatment patients 
 (Group A).  
 
12.2.4.3  Inclusion Criteria  
 
 Subject who met the following criteria were included in the study (Casale et al., 1999): 
(a) Aged between 18 and 65 with two or more hayfever symptoms rated from moderate 
(score 2) to  severe (score 4) for two years or longer, and a total nasal symptom score 
(TNSS) of  ≥ 6;  
(b) Positive skin prick test to pollen; 
(c) Agreed to give written consent. 
 
12.2.4.4  Exclusion Criteria 
 Subjects having any one or more of the following conditions were excluded: 
(a) Being on immunotherapy since last SAR season;  
(b) HIV positive; 
(c) Other active respiratory disease such as asthma within 30 days of study; 
(d) Receiving oral corticosteroid treatment; 
(e) Pregnancy or lactation; 
(f) Nasal polyposis; 
(g) Unable to write or understand English. 
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12.2.4.5  Administration of RCT Medications, either Real Herbal Capsules or Placebo    
               Capsules 
 
All eligible participants were randomly assigned into either the real treatment (i.e., active) 
group or control group by means of choosing a randomised number placed in a sealed envelope. 
The numbers were generated using the MINITAB Statistical Package. Subjects in the active 
group A received real Chinese herbal medicine capsules (RCM-102), two capsules each time, 
three times per day for eight weeks, while subjects in the control group B received placebo 
capsules, also two capsules each time, three times per day, for eight weeks.  
 
Exact quantities of medications were supplied to all subjects fortnightly, and medication 
compliance was monitored by counting leftovers, and checking the medication records returned 
to the investigators. To ensure blinding to the patients and the investigators, randomized 
allocation of participants was handled by an external staff who also handed out the fortnightly 
supplies of real herbal or placebo medications.  
 
12.2.4.6 Blood Collection and Metal Assessment 
 
             Ten mL of blood samples were collected by registered nurses from each participant into 
vacutainer tubes specifically manufactured for metal analysis during baseline period prior to 
administration of RCT medications, and at the end of the eight-week treatment period. They 
represented the pre- and post-treatment samples of each groups. The blood samples were 
centrifuged and stored for future analysis as described in Section 12.2.1 above. Serum 
concentrations of Pb and Cd were determined and results were used to assess the absorption and 
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accumulation of the metals in blood as a result of ingestion of the capsules, and to compare the 
difference, if any, between the two groups and within the same groups.  
 
12.2.5   Details of Trial Medications 
 
Both the placebo and real medications were encapsulated in a standard capsule (38 mm 
white cello wadded T/Tell cap) by GMP Pharmaceuticals P/L Girraween, N.S.W., Australia (a 
TGA approved GMP manufacturer. Each capsule contained ~ 500 mg of either active Chinese 
herbal ingredients, or placebo. The two types of capsules were identical in weight and appearance, 
and were bottled in 185 HDPE tablet bottles with a sealed cap. 
 
 
12.2.5.1 The Placebo Medication 
 
 Each placebo capsule contained ~ 500 mg of rice starch powder supplied by Sigma 
Pharmaceuticals P/L, Melbourne, Victoria, Australia. 
 
 
 
12.2.5.2 The Active Chinese Herbal Medication (RCM-102) 
 
               Details of the composition of herbal ingredients in the Chinese herbal capsule (RCM-
102) are adopted from the thesis of Dr. George B Lenon, Division of Chinese Medicines, RMIT 
University. They are shown in Table 12.3 which also lists their Chinese medicine indications, the 
western therapeutic effects, and reported side effects. Each capsule contained a formulated 
mixture of concentrated extracts from eight Chinese herbal medicines. The herbal extracts were 
supplied by Koda Internationals Pty Ltd, (Lane Cove, N.S.W., Australia).
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Table 12.3  Composition of the active herbal medication (RCM-102), reported therapeutic effects 
and side effects (adapted from Dr George Lennon) 
Active 
ingredients 
Indications 
- CM 
Therapeutic effects Western 
Medicine 
Reported side effects 
Radix Astrgali 
(Huang Qi) 
Reinforce Qi 
and 
strengthen 
body’s 
resistance 
Immuno-modulating effect, anti-
histamine. (Huang, 1999; Zhu, 1998), 
antioxidant (P. Wang et al., 2003), 
anti-cancer (J. L. Lin, Dong, 
Oppenheim, & Howard, 2003), anti-
inflammatory effect (Shon, Kim, & 
KS., 2002) 
No side effect reported (Zhu, 1998, 
Huang, 1999) 
RadixBupleuri 
Chai Hu 
Relieve fever Antipyretic (anti-inflammatory), 
block increase in capillary 
permeability induced by histamine or 
%-HT (Huang, 1999; Zhu, 1998) 
antiproliferative activity (Hsu et al., 
2004), anticonvulsive (Liu, Wu, & 
Ge, 2002), antihistamine (Ikarashi, 
Yuzurihara, nakai, Hattori, & 
Maruyama, 2001) 
-Mild lassitude, sedation and 
drowsiness may occur, reactions did 
not affect day ime activity 
-Large dose: deep sedation in 80% of 
subjects and poor sleep in 17% (Zhu, 
1998, Huang, 1999) 
-Large doses cause gastrointestinal 
abdominal distention and constipation 
(Huang, 1999) 
Radix 
Glycyrrhizae 
Uralensis (Gan 
Cao) 
Tonify Qi 
and reduce 
potential side 
effect from 
other herbs 
Reduce hypersensitivity and capillary 
permeability, lower histamine 
toxicity, antitussive, anti-allergic 
effect (Huang, 1999; Zhu, 1998), 
immunomodulatory effect (Shon et 
al., 2002), anti-oxidant and oxygen 
radical-scavenging agent (Yokozawa, 
Chen, & Tanaka, 2000), restore 
cellular immunocompetence (I. Lin et 
al., 1999) 
 
-Continuous usage and over-dosage 
can cause sodium retention, water 
accumulation, oedema and 
hypertension in 20% of subjects (Zhu, 
1998) 
-Tendency to lower basal metabolic 
rate and decrease thyroid functon 
Flos Magnoliae 
(Xin Yin) 
Relieve nasal 
obstruction 
Anti-allergic effect (Zhu, 1998), anti-
irritant (Kim et al., 2003), anti-
rheumatic (Kobayashi, Kobayashi, 
Matsuuno, Kunura, & Kimura, 1998), 
anti-inflammatory (Kimura, 
Kobayashi, Luo, & Kimura, 1990; 
Kimura et al., 1985) 
 
Intranasal application of essential oil 
may cause irritation or lacrimation 
(Zhu, 1998) 
Herba Menthae 
Haplocalysis (Bo 
He) 
Clear 
obstruction 
and swelling 
of the eyes 
Reduce histamine-induced itching, 
promote permeability in airway 
epithelium (Huang, 1999; Zhu, 1998), 
antimycotic properties (Blaszck, 
Krzyzanowska, & Lamer-Zarawska, 
2000) 
No side effect reported (Huang, 1999) 
Herba 
Schizonepetae 
Tenuifoliae (Jing 
Jie) 
Dispel wind 
and relieve 
itchiness 
Anti-inflammatory (Huang, 1999; 
Zhu, 1998), antihistamine release 
(Fung & Lau, 2002; Shin et al., 1999) 
 
No side effect reported (Zhu, 1998, 
Huang, 1999) 
Radix 
Saposhnikoviae 
Divaricata (Fang 
Feng) 
Dispel wind, 
relieve pain 
and itchiness 
Anti-inflammatory (Huang, 1999; 
Zhu, 1998) 
No side effect reported (Zhu, 1998, 
Huang, 1999) 
Radix 
Scutellariae 
Baicalensis 
(Huang Qin) 
Clear fire and 
detoxicate 
Antimicrobial effect, anti-allergic 
effect, antipyretic effect 
hepatoprotective effect and 
antiarthritic (Chi, Lim, Park, & Kim, 
2003; Kubo et al., 1984) 
No side effect reported (Zhu, 1998, 
Huang, 1999) 
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CHAPTER 13 
RESULTS 
 
13.1     Demographics of Participants 
 
           The total number of participants in the clinical trial who completed the RCT medications 
and blood collections was 71. Of these 38 were in the real treatment group A, and 33 were in the 
control group B. In group A, the gender ratio between male and female was 20/18, while that in 
group B was 16/17. These details and their mean ages are shown in Table 13.1 below. 
                    
              Table 13.1      Distribution of age and gender between the two RCT groups 
 
 
 Real Treatment Group A Control Group B 
 Male Female Male Female 
No of 
subjects (n) 
20 18 16 17 
Mean Age 38.9 38.5 41.2 42.5 
SD 11.9 9.5 11.5 9.0 
 
 
 
13.2      Results of Metal Contents in RCT Capsules 
 
 
              The average weight of the powder in the real capsule was 0.501 ± 0.002 mg (Mean ±  Sd; 
n = 3), and that of placebo was 0.513 ± 0.003 mg (Mean ±  Sd; n = 3). The average result of Pb 
contents in the RCT active capsules was found to be approximately 6.3 times higher than that in 
the control capsules, being 1.45 µg/g, and 0.23 µg/g of the powder respectively. The average 
results for Cd contents in the RCT active capsules was approximately 2.6 times higher than that 
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in the control capsules, being 59.1 ng/g and 22.7 ng/g respectively. Results are summarised in 
Table 13.2. 
 
              Table 13.2      Pb and Cd concentrations in capsules 
 
 
Sample 
Code 
Sample 
Name 
(n = 3) 
Lead 
(Pb) 
µg/g 
Cadmium 
(Cd) 
ng/g 
RCM-102 Active 
Herbal 
Capsule  
1.45 
± 0.09 
59.1 
± 4.9 
RCM-101 Placebo 
Capsule 
0.23 
± 0.00 
22.7 
± 3.0 
Active Capsule :      
             Placebo Capsule 
6.3 : 1 2.6 : 1 
 
 
13.3    Effects of Storage on Metal Concentrations 
 
 
           All blood samples, once collected, were immediately centrifuged at 4º C and the separated 
sera stored in metal-free tubes and kept at - 70º C until analysis. Periodic analyses of the same 
serum samples were carried out ever one year period (the same stability checks were also carried 
out for herbal samples). There was no significant decrease in any metal concentrations.  
 
 
13.4     Results of Serum Lead Concentrations 
 
            The baseline mean serum Pb concentration in the control group B was 32.7 ± 17.4 µg/L 
(Mean ± SD; n = 33), and the post-treatment concentration was 37.8 ± 20.4 µg/L (Mean ± SD; n 
= 33). The baseline mean serum concentration in the real treatment group A was 28.7 ± 15.7 µg/L 
(Mean ± SD; n =38), and the post-treatment concentration was 28.6 ± 14.9 µg/L (Mean ± SD; n = 
38). Details of individual serum Pb concentrations for the control group and real treatment group 
are listed in Appendix 13.1 and Appendix 13.2 respectively. There was no significant difference 
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between the baseline and post-treatment mean Pb results in the control group B who ingested the 
placebo medication (Student’s t test, p = 0.23). Similarly there was also no significant difference 
between the baseline and post-treatment mean Pb results in the real treatment group A who 
ingested the RCM-102 Chinese herbal powder (Student’s t test, p = 0.94). There was also no 
significant difference in the mean baseline Pb concentrations between the two RCT groups (t test; 
p = 0.40), nor was there any significant difference in the post-treatment Pb results between the 
two groups (p = 0.06). These comparisons are shown graphically in Figure 13.1.  Student’s t test 
was used to analyse significance, based on a two-tailed distribution (= 2), and paired sample (=1). 
For calculation between two groups (e.g., comparing the post-treatment results between the 
Control and Real Herbal medicine groups), the two-sample equal variance (homoscedastic) = 2 
was used. 
 
 
Figure 13.1   Comparison of serum lead concentrations from SAR clinical trial (for statistical 
comparison, refer to text in section 14.3) 
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13.5       Results of Serum Cadmium Concentrations 
 
The baseline mean serum Cd concentration in the control group B was 0.36 ± 0.28 µg/L 
(Mean ± SD; n = 33), and the post-treatment concentration was 0.33 ± 0.21 µg/L (Mean ± SD; n 
= 33). The baseline mean serum concentration in the real treatment group A was 0.39 ± 0.29 µg/L 
(Mean ± SD; n =38), and the post-treatment concentration was 0.38 ± 0.25 µg/L (Mean ± SD; n = 
38). Details of individual serum Cd concentrations for the control group and real treatment group 
are listed in Appendix 13.3 and Appendix 13.4 respectively. There was no significant difference 
between the baseline and post-treatment mean Cd results in the control group B who ingested the 
placebo medication (Student’s t test, p = 0.45). Similarly there was also no significant difference 
between the baseline and post-treatment mean Cd results in the real treatment group A who 
ingested the RCM-102 Chinese herbal powder (Student’s t test, p = 0.81). There was also no 
significant difference in the mean baseline Cd concentrations between the two RCT groups (t test; 
p = 0.69), nor was there any significant difference in the post-treatment Cd results between the 
two groups (p = 0.50). These comparisons are shown graphically in Figure 13.2. The mean 
serum Cd concentration at baseline in the male participants (0.38 ± 0.300 µg/L; Mean ± SD) was 
much higher that that in the female participants (0.29 ± 0.25 µg/L; Mean ± SD).  
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Figure13.2   Comparison of cadmium concentrations in serum from SAR clinical trial 
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13.6    Reference Interval for Serum Lead and Cadmium 
 
           Serum reference intervals are usually expressed as the 95 percentile of the population, 
calculated as the mean ± 2 SD. In this study, they were calculated from the baseline lead and 
baseline cadmium serum concentrations separately for the male (n = 36) and female (n = 34) 
participants. The mean serum Pb concentrations at baseline between the adult male and the adult 
female participants were almost identical, being 29.4 ± 2.6 µg/L (Mean ± SD) and 29.4 ± 3.2 
µg/L (Mean ± SD) respectively. There was no significant difference between the two genders at 
baseline (p = 0.32). Hence, the reference intervals for serum lead for male and female adults in 
the metropolitan areas of Melbourne, Victoria, are 24. 2 – 34.6 µg/L (mean ± 2 SD), and 23.0 – 
35.8 µg/L (mean ± 2 SD) respectively.  
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The mean serum Cd concentration at baseline in the male participants (0.38 ± 0.300 
µg/L; Mean ± SD) was much higher that that in the female participants (0.29 ± 0.25 µg/L; Mean 
± SD). There appeared to be some significant difference in serum cadmium concentrations 
between the two genders (p = 0.058). Their reference intervals for serum cadmium are 0 – 0.98 
µg/L (mean ± 2 SD) for male adults, and 0 – 0.79 µg/L (mean ± 2 SD) for femal adults in 
Victorian metropolitan areas. 
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CHAPTER 14 
DISCUSSION AND CONCLUSION 
 
14.1      Discussion 
 
             This in vivo study from a randomized clinical trial (RCT) clearly demonstrated that 
Chinese medicines of this eight-herb formula in the form of concentrated extract granules 
encapsulated in pharmaceutical capsules did not result in any significant differences in serum 
concentrations of lead and cadmium after daily ingestion of two capsules per dose, three times 
per day for eight weeks when compared to the pre-treatment levels.  
 
14.1.1  Implications of Metal Concentrations in Capsules and in Serum 
 
            The RCM-102 herbal capsules were made from commercial concentrated extracts of 
Chinese herbal medicinal granules manufactured by Koda International Pty Ltd, (Lane Cove, N.S. 
W., Australia). Based on the average weight of the placebo powder and the dosage, the daily 
ingestion of the herbal granules was just over 3g which worked out to be 0.701 µg of Pb ingested 
per day, or 39.6 µg ingested over the whole 56-day treatment period. Similarly, the daily amount 
of cadmium ingested was calculated to be about 69.9 ng, or a total of 3914.4 ng (i.e., 3.914 µg) 
for the 56-day period. This daily dose of ~ 3 g of granules was similar to routine clinical practice 
where herbal powders are used. Thus, the herbal granules and the dose used in this study 
represented a real world situation practiced in Chinese medicine clinics in Victoria. Although the 
placebo was made of rice starch (supplied by Sigma, Australia), some metals were found to be 
present in low concentrations. This was in line with results from the Australian total dietary 
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survey which reported presence of Pb and Cd in rice and starch roots (FSANZ, 2003a), albeit in 
lower amounts. The contents of Pb and Cd in the Chinese herbal powder in RCM-102 capsules 
were 6.3 and 2.6 times respectively higher than the placebo (see Table 14.2), which amounted to 
a total ingestion of 249.5 µg of Pb and 10177.4 ng (i.e., 10.177 µg) of Cd over the 56-day period 
of real capsule administration. Yet, results in this study showed that at these therapeutic doses the 
body was efficient enough to excrete the ingested metals via urine and feces (Ishihara & 
Matsushiro, 1986) without increasing the serum levels of Pb and Cd. As far as measurement of 
serum/blood metal concentrations after ingestion of herbal medicines in a clinical trial is 
concerned, the present study appears to be the only one for Chinese herbal medicines. One other 
study investigated metal concentrations in urine from 65 South African patients, mostly children, 
who had been admitted to hospital following treatment with a traditional South African herbal 
remedy (muti). While many of them were severely ill apparently as a result of the muti, some 
with hepatic or renal pathology, their urine metal concentrations were mostly normal. Since blood 
(Bowers, Beck, & Karam, 1994; Mathee et al., 2002) and urine (Benes et al., 2002; Steenkamp, 
von Arb, & Stewart, 2000)concentrations are commonly used as indicators of metal accumulation 
and toxicity, it is therefore reasonable to conclude that the present finding of unchanged serum 
metal levels after routine therapeutic administrations of Chinese herbal extracts at doses 
recommended in Chinese herbal medicine clinic in Victoria did not pose any health risk.     
 
 
14.1.2    Reference Intervals of Serum Pb and Cd in Male and Female Adult populations  
 
 The mean serum lead concentrations for males (n = 36) and females (n = 34) were both 
29.4 µg/L for Victorian adults. These results lied in between values determined by two other 
groups of researchers. Barany et al. reported a low
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Swedish adults (Barany et al., 2002), whereas Mortada et al. obtained a much higher value of 
113.9 ± 48.8 µg/L among Egyptian males, and 92.7 ± 30.4 µg/L among females (Mortada et al., 
2002). Again, serum cadmium concentrations found in this study (0.38 ± 0.30 µg/L for males, 
and 0.29 ± 0.25 µg/L for females) also appeared to be in the middle of the results reported by the 
two groups. Barany et al. (2002) for example, obtained a very low mean Cd level of < 0.2 µg/L 
for non-smokers and 0.73 ± 1 µg/L for smokers residing in Sweden. On the other hand, Mortada 
et al. (2002) found significantly higher cadmium blood values among Egyptians, being 1.50 ± 
0.39 µg/L for males and 1.34 ± 0.48 µg/L for females. These gender differences of reference 
interevals for serum cadmium were supported by the present study which also demonstrated a 
slightly higher reference interval for men than for women. Such variations between different 
localities in the world demonstrate that reference intervals of lead and cadmium in blood are 
environmentally related parameters. Factors, such as gender, smoking, and dietary habit clearly 
influence the mean metal values, as shown in the large discrepancy in Cd concentrations between 
the two genders in the present study. Although the present investigation did not identify smokers 
from non-smokers, other studies clearly demonstrated that smoking greatly increase the blood 
level of cadmium (Barany et al., 2002).     
 
There are several limitations in the present in vivo serum study. Only two metals, Pb and 
Cd, were analyzed. Another limitation is that only one herbal formula was investigated. 
Nevertheless, results were sufficient to give some indication of the safety of Chinese herbal 
powder. Analysis of the concentrated powder extracts showed that their metal contents are much 
lower than herbal formulae made from raw herbs. Therefore, it would be valuable to repeat this in 
vivo study after routine administration of aqueous decoctions of raw herbal formulae in future 
investigations. 
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            Further, as this study was not intended to study the pharmacokinetics of metal distribution. 
No attempt was made to collect blood samples over different time intervals. The post-treatment 
samples represent the blood metal levels as a result of daily ingestion, bid, of the placebo or real 
herbal capsules for eight weeks.  If there is insignificant increase in blood metal levels 
immediately after 8-weeks of administration, pharmacokinetically it is unlikely that there would 
be any significant increase in metal levels in the blood in the follow-up period. 
            This study focuses on the blood metal levels only. Urine samples were not collected for 
analysis for comparison. It would be a worthwhile future project to investigate the 
pharmacokinetic and perhaps the pharmacodynamic profiles of metal ingestion which may 
include urine excretion as well. 
 
14.1.3     Validation of the Present Analytical Technique 
 
             Determination of blood or serum presents many analytical challenges, such as frothing 
which occurs during the drying stage, inaccuracy in dispensing whole blood, and not least, the 
high matrix materials in blood that is difficult to have a matching solution for preparing standards. 
The present method was designed to take on board the above considerations in order to provide 
reliable results. This was achieved firstly by diluting the serum sample with a mixture of 1% 
Triton X-100 and antifoam solution followed by vortexing. This mixture helped to dilute the 
background interferences and assist with accurate dispensing therefore improving precision. 
Because matching diluent for preparing standards was extremely difficult to find or prepare, 
standards addition method was chosen in which two to three additions were used. Thus, the 
serum itself provided its own matching matrix background. Further, a lower signal is generally 
obtained for lead in blood/serum matrix compared with aqueous solutions, and the standard 
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addition method was therefore necessary to obtain accurate results. Background correction was 
also employed.  
 
             The furnace operating conditions (see Section 12.2.2) for serum analysis differed from 
those applied for Chinese herbal medicines discussed in earlier chapters (such as the CHM, CPM, 
and CMF) in that a low flow of air gas alternate to the nitrogen was introduced in step 5 during 
pyrolysis for 10 seconds. This facilitated the ashing of serum samples, and the low gas flow 
minimized splashing and loss. This was followed by 20 seconds of nitrogen purging after ashing. 
The Air and Purge steps helped to improve the sensitivity which was important in measuring low 
metal concentrations.     
 
Ideally a pyrolytic platform graphite tube would have further increased the accuracy and 
sensitivity of the method since it would help to decrease the extent of splashing during the ashing 
step. Also, argon would be a better choice of inert gas than nitrogen. However, for economic 
reason, non-platform pyrolytic graphite tubes and nitrogen were used. Nevertheless, the present 
method with above-mentioned adaptations has provided sufficiently reliable and valid results. 
 
 
14.2      Conclusion 
 
This in vivo study was the first of its kind in a randomised clinical trial deign to actually 
measure the effect of routine therapeutic administration of Chinese herbal granules on the 
concentrations of metal in blood. The results were most encouraging. It is one of the more direct 
approaches to determine conclusively whether there is any potential risk posed by metal 
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contaminants in Chinese herbal medicines. More in vivo investigations based on the present 
design of RCT need to be conducted using various forms of Chinese herbal medicinal 
administration, including crude Chinese herbal medicines, Chinese patent medicines, and 
aqueous decoctions consisting of different herbal prescriptions using crude herbal materials. 
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Appendices 
 
 
 
Appendix 1.1 (Ref.  FDA/CFSAN April 9, 2001) 
 
 
BOTANICALS OR PRODUCTS AT RISK OF CONTAINING  
ARISTOLOCHIC ACIDS 
 
Group A – Botanicals Known or Suspected to Contain Aristolochic Acid 
 
Genus Botanical Name Common or  
Other Names 
Aristolochia spp. Aristolochia  
Guan mu tong 
Guang mu tong 
Aristolochia accuminata Lam. 
Syn. Aristolochia tagala Champ. 
Oval leaf 
Dutchman’s pipe 
Aristolochia argentina Griseb. 
 
Aristolochia baetica Linn. 
Syn. Aristolochia bracteolate Lam. 
 
Aristolochia bracteata Retz. Ukulwe 
Aristolochia chilensis Bridges in Lindl. 
 
Aristolochia cinnabarina C.Y. Cheng & J.L. Wu  
 
Aristolochia clematitis L. Birthwort 
Aristolochia contorta Bunge Ma dou ling 
Tian xian teng 
Aristolochia cymbifera Mart. & Zucc. Mil homens 
Aristolochia debilis Siebold & Zucc. 
Syn. A. longa Thunb. 
Syn. A. recurvilabra Hance 
Syn. A. Sinarum Lindl. 
Ma dou ling 
Tian xin teng 
Qing mu xiang Seimokou 
(Japanese) 
Birthwort 
Long birthwort 
Aristolochia elegans Mast. 
Syn. Aristolochia hassleriana Chodat 
 
Aristolochia esperanzae Kuntze  
Aristolochia fangchi Y.C. Wu ex L.D. Chow & 
S.M. Hwang 
Guang fang ji 
Fang ji 
Mokuboi (Japanese) 
Kwangbanggi (Korean) 
Fang chi 
Kou-boui (Japanese) 
Aristolochia fimbriata Cham.  
Aristolochia 
Aristolochia indica L. Indian birthwort 
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Appendix 1 (continued)    Group A – Botanicals Known or Suspected to Contain 
Aristolochic Acid (cont) 
 
Genus Botanical Name Common or  
Other Names 
Aristolochia kaempferi Willd. 
Syn. Aristolochia chrysops (Stapf) E.H. Wilson 
ex Rehder 
Syn. Aristolochia feddei H. Lev. 
Syn. Aristolochia heterophylla Hemsl. 
Syn. Aristolochia mollis Dunn 
Syn. Aristolochia setchuenensis Franch. 
Syn. Aristolochia shimadai Hayata 
Syn. Aristolochia thibetica Franch. 
Syn. Isotrema chrysops Stapf 
Syn. Isotrema heterophylla (Hemsl.) Stapf 
Syn. Isotremalasiops Stapf 
Yellowmouth 
Dutchman’s Pipe 
Aristolochia kwangsiensis Chun & F.C. How 
Syn. Aristolochia austroszechuanica C.B. Chien 
& C.Y. Cheng 
 
Aristolochia macrophylla Lam. 
Syn. Aristolochia siphon L’Her. 
Dutchman’s-pipe 
Aristolochia manshuriensis Kom. 
Syn. Hocquartia manshuriensis (Kom.) Nakai 
Syn. Isotrema manshuriensis (Kom.) H. Huber 
Manchurian birthwort 
Manchurian Dutchman’s 
pipe 
Guang mu tong 
Kan-Mokutsu (Japanese) 
Mokuboi (Japanese) 
Kwangbanggi (Korean) 
Aristolochia maurorum L.  
Aristolochia maxima Jacq. 
Syn. Aristolochia maxima var. Angustifolia 
Duchartre in DC. 
Syn. Howardia hoffmannii Klotzsch  
 
Aristolochia mollissima Hance 
 
Aristolochia pistolochia L.  
Aristolochia rigida Duch.  
Aristolochia rotunda Linn.  
Aristolochia serpentaria L. 
Syn. Aristolochia serpentaria var. Hastata (Nutt.) 
Duch. 
Virginia snakeroot 
Serpentaria 
Virginia serpentary 
Aristolochia watsoni Wooton & Standley or 
Aristolochia wasonii Wooton & Standley 
Syn. Aristolochia porphylla Pfeifer 
 
Aristolochia 
(cont) 
Aristolochia westlandii Hemsl. or  
Aristolochia westland Hemsl. 
Aristolochia 
 
  
 323 
Appendix 1 (continued)    Group A – Botanicals Known or Suspected to Contain 
Aristolochic Acid (cont) 
 
Genus Botanical Name Common or  
Other Names 
Aristolochia 
(cont) 
Aristolochiazollingeriana Miq. 
Syn. Aristolochia kankauensis Sasaki  
Syn. Aristolochia roxhurghiana subsp. 
Kankauensis (Sasaki) Kitam. 
Syn. Hocquartia kankauensis (Sasaki) Nakai ex 
Masam. 
Syn. Aristolochia tagala var. Kankauensis 
(Sasaki) T.Yamaz. 
 
Asarum canadense Linn. 
Syn. Asarum acuminatum (Ashe) E.P. Bicknell 
Syn. Asarum ambiguum (E.P. Bicknell) Daniels  
Syn. Asarum canadense var. Ambiguum (E.P. 
Bichnell) Farw. 
Syn. Asarum canadense var. Reflexum (E.P. 
Bicknell) B.L. Rob. 
Syn. Asarum furcatum Raf. 
Syn. Asarum medium Raf. 
Syn. Asarum parvifolium Raf. 
Syn. Asarum reflexum E.P. Bicknell  
Syn. Asarum rubrocinctum Peattie 
Wild ginger  
Indian ginger 
Canada snakeroot 
False coltsfoot 
Colic root 
Heart snakeroot 
Vermont snakeroot 
Southern snakeroot 
Asarum himalaicum Hook. F. & Thomson ex 
Klotzsch or  
Asarum himalaycum Hook. f. & Thomson ex 
Klotzsch 
Tanyou-saishin (Japanese) 
Asarum 
Asarum splendens (F. Maek.) C.Y. Cheng & 
C.S. Yang 
Do-saishin (Japanese) 
Bragantia Bragantia wallichii R.Br. 
Specimen exists at New York Botanical Gardens. 
Tropicos does not list this species as a synonym 
for any Thottea species. Kew Gardens Herbarium 
does not recognize the genera Bragantia. Until 
additional information is obtained we will use the 
name as cited in J.Nat.Products 45:657-666 
(1982) 
 
  
 324 
Appendix 1 (continued)    Group B – Botanicals Which May Be Adulterated With 
Aristolochic Acid  
 
Genus Botanical Name Common or  
Other Names 
Akebia Spp. Akebia 
Mu tong 
Ku mu tong 
Zi mutong 
Bai mutong 
Mokusu (Japanese) 
Mokt’ong (Korean) 
Akebia quinata (Houtt.) Decne. 
Syn. Rajania Quinata Houtt. 
Chocolate vine 
Fiveleaf akebia 
Mu tong 
Yu zhi zi 
Mokutsu (Japanese) 
Akebia 
Akebia trifoliata (Thunb.) Koidz. Mu tong  
Three leaf akebia 
Yu zhi zi 
Asarum forbesii Maxim. Batei-saishin (Japanese) 
Asarum heterotropoides F. Schmidt 
Syn. Asarum heterotropoides F. Schmidt 
Syn. Asiasarum heterotropoides (F.Schmidt) F. 
Maek. 
Keirin-saishin (Japanese) 
Chinese wild ginger 
Manchurian wild ginger 
Bei xi xin 
Xi xin 
Asarum 
Asarum sieboldii Miq. 
Syn. Asarum sieboldii fo. Seoulense (Nakai) C.Y. 
Cheng & C.S. Yang 
Syn. Asarum sieboldii var. Seoulensis Nakai 
Syn. Asiasarum heterotropoides var. Seoulense 
(Nakai) F. Maek. 
Syn. Asiasarum sieboldii (Miq.) F. Maek. 
Usuba-saishin (Japanese) 
Chinese wild ginger  
Xi Xin 
Hua Xi Xin 
Manchurian wildginger 
Siebold’s ginger 
Clematis Clematis spp. Clematidis 
Mufangji 
Clematidis 
Ireisen (Japanese) 
Wojoksum (Korean) 
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Appendix 1 (continued)    Group B – Botanicals Which May Be Adulterated With 
Aristolochic Acid (cont) 
Genus Botanical Name Common or  
Other Names 
Clematis armandii Franch. 
Syn. Clematis armandii fo. Farquhariana (W.T. 
Wang) Rehder & E.H. Wilson 
Syn. Clematis armandii var. biondiana (Pavol.) 
Rehder 
Syn. Clematis biondiana Pavol. 
Syn. Clematis ornithopus Ulbr. 
Armand’s clematis 
Chuan mu tong (stem) 
Xiao mu tong 
Armand’s virgin bower 
Clematis chinensis Osbeck. Chinese clematis  
Wei ling xian (root) 
Clematis hexapetala Pall.  
Clematis monatana Buch.-Ham. ex DC. 
Syn. Clematis insulari-alpina Hayata 
 
Clematis montana Buch.-Ham. ex DC.  
Clematis 
(cont) 
Clematis  uncainata Champ. ex Benth. 
Syn. Clematis alsomitrifolia Hayata 
Syn. Clematis chinensis var. Uncinata (Champ. 
ex Benth.) Kuntze  
Syn. Clematis drakeana H. Lev. & Vaniot 
Syn. Clematis floribunda (Hayata) Yamam. 
Syn. Clematis gagnepainiana H. Lev. & Vaniot 
Syn. Clematis leiocarpa Oliv. 
Syn. Clematis ovatifolia T. Ito ex Maxim. 
Syn. Clematis uncinata var. Biternata W.T.Wang 
Syn. Clematis uncinata var. Coriacea Pamp. 
Syn. Clematis uncinata var. Floribunda Hayata 
Syn. Clematis uncinata var. Ovatifolia (T. Ito ex 
Maxim.) Ohwi ex Tamura 
Syn. Clematis uncinata var. Taitongensis Y.C. 
Liu & C.H. Ou 
 
Cocculus spp. Cocculus 
Cocculus carolinus (L.) DC. 
Syn. Cebatha carolina Britton 
Syn. Epibaterium carolina (L.) Britton 
Syn. Menispermum carolinum L. 
 
Cocculus diversifolus DC. 
Syn. Cocculus madagascariensis Diels 
 
Cocculus hirsutus (L.) Diels 
Syn. Cocculus villosus DC. 
Syn. Menispermum hirsutum L. 
 
Cocculus indicus Royle 
Syn. Anamirta paniculata Colebr. 
Indian cookle 
Cocculus laurifolius DC. 
Syn. Cinnamomum esquirolii H. Lev. 
 
Cocculus 
Cocculus leaebe DC. 
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Appendix 1 (continued)    Group B – Botanicals Which May Be Adulterated With 
Aristolochic Acid (cont) 
 
Genus Botanical Name Common or  
Other Names 
Cocculus madagascariensis Diels 
Syn. Cocculs diversifolius DC.  
 
Cocculus orbiculatus DC. 
Syn. Cissampelos pareira Linn. 
 
Cocculus orbiculatus (L.) DC 
Syn. Cocculus cuneatus Benth. 
Syn. Cocculus sarmentosus (Lour.) Diels 
Syn. Cocculus sarmentosus var. Linearis 
Yamam. 
Syn. Cocculus sarmentosus var. Pauciflorus 
Y.C. Wu 
Syn. Cocculus sarmentosus var. Stenophyllus 
Merr. 
Syn. Cocculus thunbergii DC. 
Syn. Cocculus trilobus (Thunb.) DC. 
Syn. Menispermum trilobum Thumb. 
Syn. Menispermum trilobum Thunb. 
Syn. Nephroia sarmentosa Lour. 
Moku-boui (Japanese) 
Cocculus palmatus (Lam.) DC. 
 
Columba 
Columbo 
Cocculus pendulus Diel 
Syn. Cebatha pendula (J.R. & C.Forst.) Kuntze 
Syn. Epibaterium pendulus Forst. f. 
Syn. Cocculus Epibaterium DC. 
 
Cocculus pendulus (Forst. & Dorst.) Diels  
Cocculus palmatus Hook. 
Syn. Jateorhiza Miersii Oliver 
Colombo 
Cocculus  
(cont) 
Cocculus thundergii DC.  
Diploclisia affinis (Oliv.) Diels 
Syn. Diploclisia chinensis Merr. 
Syn. Cocculus affinis Oliver. 
 Diploclisia 
Diploclisia chinensis Merrill Xiangfangchi 
Menispernum Menispernum dauricum  
Saussurea Saussurea lappa (Decne.) Sch. Bip. Mokkou (Japanese) 
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Appendix 1 (continued)    Group B – Botanicals Which May Be Adulterated With 
Aristolochic Acid (cont) 
 
Genus Botanical Name Common or  
Other Names 
Sinomenium Sinomenium acutum (Thunb.) Rehder & E.H. 
Wilson 
Syn. Cocculus diversifolius var. cinereus Diels 
Syn. Cocculus heterophyllus Hemsl. & E.H. 
Wilson 
Syn. Menispermum acutum Thumb. 
Syn. Sinomenium acutum (Thunb.) Rehder & 
E.H. Wilson var. cinereum (Diels) Rehder & E.H. 
Wilson 
Syn. Sinomenium diversifolium (Diels) Diels 
Orientvine 
Xunfengteng 
Dafengteng 
Daqingmuxiang 
Zhuigusan 
Da ye qingshener 
Mufangji 
HanfangjiTuteng 
Zhuigufeng 
Maofangji 
Stephania spp. Stephania Stephania 
Stephania tetrandra S. Moore  Fen fang ji, fang ji 
Fang ji (root) 
Han fang ji 
Kanboi (Japanese) 
Hanbanggi (Korean) 
Fun-boui (Japanese) 
Vladimiria Vladimiria souliei (Franch.) Ling Sen-mokkou 
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Group C – Products Which Have Mu Tong And Fang Ji As Declared Ingredients            
 
Ba Zheng Wan 
Chun Yang Zheng Ji Wan 
Da Huang Qing Wei Wan 
Dang Gui Si Ni Wan 
Dao Chi Wan 
Dieda Wan 
Fu Ke Fen Quing Wan 
Guan Xin Su He Wan 
Ji Sheng Ju He Wan 
Kat Kit Wan 
Long Dan Xie Gan Wan 
Quell Fire 
Shi Xiang Fan Shen Wan 
Xin Yi Wan 
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Appendix 4.1   Composite ESI mass spectral fingerprints of the elevan HPLC samples selected 
for confirmation. 
 
 
 
 
     A typical MRM chromatogram of Aristolochic Acid standard showing the AA peak 
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Appendix 4.1 (continued) Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
    Sample No. 1:    Showing presence of AA in Chuan Xiong Cha Tiao Wan 
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Appendix 4.1 (continued)    Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 2:  Showing presence of AA in Xio Feng San 
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Appendix 4.1 (continued)   Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 3:  Showing absence of AA in Ba Zheng San 
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Appendix 4.1 (continued)  Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No.4:  Showing absence of AA in Xiao Qing Long Tang 
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Appendix 4.1 (continued)   Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 5:  Showing absence of AA in Xin Yi Wan 
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Appendix 4.1 (continued)   Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 6:  Showing absence of AA in Long Dan Xie Gan Tang   
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Appendix 4.1 (continued)   Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 7:  Showing presence of AA in crude herb Ma Dou Ling 
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Appendix 4.1 (continued)    Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 8:  Showing presence of AA in crude herb Guang Fang Ji 
Guang Fang Ji 
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Appendix 4.1 (continued)  Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 9:  Showing absence of AA in Dao Chi Pian  
Dao Chi Pian 
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Appendix 4.1 (continued)   Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
Sample No. 10:  Showing presence of AA in crude herb Guan Mu Tong  
Guan Mu Tong 
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Appendix 4.1 (continued)   Composite ESI mass spectral fingerprints of the elevan HPLC 
samples selected for confirmation.      
 
 Sample No. 11:  Showing presence of AA in crude herb Xi Xin (Bei) 
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Appendix 8.1   Detailed analytical parameters of GFAAS for determination of Lead 
 
Element - Matrix: Pb -  
Instrument Type: Furnace 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Concentration 
Measurement Mode: Peak Height 
Replicates Standard: 2 
Replicates Sample: 2 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 4 
 
Wavelength: 283.3 nm 
Slit Width: 0.5 nm 
Gain: 31 % 
Lamp Current: 10.0 mA 
Lamp Position: 3 
Background Correction: BC Off 
 
STANDARD 1: 5.0000 ug/L 
STANDARD 2: 10.0000 ug/L 
STANDARD 3: 20.0000 ug/L 
STANDARD 4: 40.0000 ug/L 
STANDARD 5: 50.0000 ug/L 
Reslope Rate: 60 
Reslope Standard No.: 3 
Reslope Lower Limit: 75.0 % 
Reslope Upper Limit: 125.0 % 
Recalibration Rate: 200 
Calibration Algorithm: New Rational 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Workhead Height: 0.0 mm 
Total Volume: 30 uL 
Sample Volume: 20 uL 
Vol. Reduction  Factor: 2 
Bulk Conc.: 50.0000 ug/L 
Bulk Vial No.: 51 
Makeup Vial No.: 52 
Sample No. of Injections: 1 
Sample Last Dry Step: 1 
Modifier 1 Mode: Co Inject 
Modifier 1 Vol.: 5 uL 
Last Dry Step: 0 
Injection Rate: 1 
Modifier 1 Pos.: 53 
No. of Injections: 1 
 
 Step Temp (C) Time (s) Flow (L/min) Gas Type Read Signal Storage 
 1 85 5.0 3.0 Normal No No 
 2 95 40.0 3.0 Normal No No 
 3 120 10.0 3.0 Normal No No 
 4 400 5.0 3.0 Normal No No 
 5 400 1.0 3.0 Normal No No 
 6 400 2.0 0.0 Normal No Yes 
 7 2100 1.0 0.0 Normal Yes Yes 
 8 2100 2.0 0.0 Normal Yes Yes 
 9 2100 2.0 3.0 Normal No Yes 
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Appendix 8.2   Detailed analytical parameters of GFAAS for determination of Arsenic 
 
 
Element - Matrix: As -  
Instrument Type: Furnace 
Conc. Units: ug/L 
 
Sampling Mode: Premix 
Calibration Mode: Concentration 
Measurement Mode: Peak Height 
Replicates Standard: 2 
Replicates Sample: 2 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 4 
 
Wavelength: 193.7 nm 
Slit Width: 0.5 nm 
Gain: 48 % 
Lamp Current: 10.0 mA 
Lamp Position: 1 
Background Correction: BC Off 
 
STANDARD 1: 2.5000 ug/L 
STANDARD 2: 5.0000 ug/L 
STANDARD 3: 10.0000 ug/L 
STANDARD 4: 20.0000 ug/L 
STANDARD 5: 40.0000 ug/L 
Reslope Rate: 60 
Reslope Standard No.: 2 
Reslope Lower Limit: 75.0 % 
Reslope Upper Limit: 125.0 % 
Recalibration Rate: 200 
Calibration Algorithm: New Rational 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Workhead Height: 0.0 mm 
Total Volume: 35 uL 
Sample Volume: 20 uL 
Vol. Reduction  Factor: 2 
Bulk Conc.: 50.0000 ug/L 
Bulk Vial No.: 51 
Makeup Vial No.: 52 
Sample No. of Injections: 1 
Sample Last Dry Step: 1 
Modifier 1 Mode: Co Inject 
Modifier 1 Vol.: 5 uL 
Last Dry Step: 0 
Injection Rate: 1 
Modifier 1 Pos.: 53 
No. of Injections: 1 
CAL ZEROPos: 45 
STANDARD 1Pos: 46 
STANDARD 2Pos: 47 
STANDARD 3Pos: 48 
STANDARD 4Pos: 49 
STANDARD 5Pos: 50 
  
 343 
 
 Step Temp (C) Time (s) Flow (L/min) Gas Type Read Signal Storage 
 1 85 5.0 3.0 Normal No No 
 2 95 40.0 3.0 Normal No No 
 3 120 10.0 3.0 Normal No No 
 4 1400 5.0 3.0 Normal No No 
 5 1400 1.0 3.0 Normal No No 
 6 1400 2.0 0.0 Normal No Yes 
 7 2600 0.6 0.0 Normal Yes Yes 
 8 2600 2.0 0.0 Normal Yes Yes 
 9 2600 2.0 3.0 Normal No Yes
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Appendix 8.3   Detailed analytical parameters of GFAAS for determination of Cadmium 
 
Element - Matrix: Cd -  
Instrument Type: Furnace 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Standard Additions 
Measurement Mode: Peak Height 
Replicates Standard: 1 
Replicates Sample: 1 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 3 
 
Wavelength: 228.8 nm 
Slit Width: 0.5 nm 
Gain: 42 % 
Lamp Current: 4.0 mA 
Lamp Position: 1 
Background Correction: BC On 
 
ADDITION 1: 0.500 ug/L 
ADDITION 2: 1.500 ug/L 
Recalibration Rate: 60 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Workhead Height: 0.0 mm 
Total Volume: 15 uL 
Sample Volume: 5 uL 
Vol. Reduction  Factor: 2 
Bulk Conc.: 2.500 ug/L 
Bulk Vial No.: 51 
Makeup Vial No.: 52 
Sample No. of Injections: 1 
Sample Last Dry Step: 1 
Modifier 1 Mode: Co Inject 
Modifier 1 Vol.: 5 uL 
Last Dry Step: 0 
Injection Rate: 1 
Modifier 1 Pos.: 53 
No. of Injections: 1 
 
 Step Temp (C) Time (s) Flow (L/min) Gas Type Read Signal Storage 
 1 85 5.0 3.0 Normal No No 
 2 95 40.0 3.0 Normal No No 
 3 140 20.0 3.0 Normal No No 
 4 300 10.0 3.0 Normal No No 
 5 450 10.0 0.5 Alternate No No 
 6 650 20.0 3.0 Normal No No 
 7 650 1.0 0.0 Normal No Yes 
 8 2500 1.0 0.0 Normal Yes Yes 
 9 2500 1.0 3.0 Normal No Yes 
 
  
 345 
Appendix 8.4   Detailed analytical parameters of GFAAS for determination of Chromium 
 
Element - Matrix: Cr -  
Instrument Type: Furnace 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Concentration 
Measurement Mode: Peak Height 
Replicates Standard: 2 
Replicates Sample: 1 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 4 
 
Wavelength: 357.9 nm 
Slit Width: 0.5R nm 
Gain: 33 % 
Lamp Current: 7.0 mA 
Lamp Position: 3 
Background Correction: BC Off 
 
STANDARD 1: 4.0000 ug/L 
STANDARD 2: 8.0000 ug/L 
STANDARD 3: 12.0000 ug/L 
STANDARD 4: 24.0000 ug/L 
Reslope Rate: 60 
Reslope Standard No.: 2 
Reslope Lower Limit: 75.0 % 
Reslope Upper Limit: 125.0 % 
Recalibration Rate: 200 
Calibration Algorithm: Linear 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Workhead Height: 0.0 mm 
Total Volume: 30 uL 
Sample Volume: 20 uL 
Vol. Reduction  Factor: 2 
Bulk Conc.: 40.0000 ug/L 
Bulk Vial No.: 51 
Makeup Vial No.: 52 
Sample No. of Injections: 1 
Sample Last Dry Step: 1 
Modifier 1 Mode: Co Inject 
Modifier 1 Vol.: 5 uL 
Last Dry Step: 0 
Injection Rate: 1 
Modifier 1 Pos.: 53 
No. of Injections: 1 
 
 Step Temp (C) Time (s) Flow (L/min) Gas Type Read Signal Storage 
 1 85 5.0 3.0 Normal No No 
 2 95 40.0 3.0 Normal No No 
 3 120 10.0 3.0 Normal No No 
 4 1000 5.0 3.0 Normal No No 
 5 1000 1.0 3.0 Normal No No 
 6 1000 2.0 0.0 Normal No Yes 
 7 2600 1.2 0.0 Normal Yes Yes 
 8 2600 2.0 0.0 Normal Yes Yes 
 9 2600 2.0 3.0 Normal No Yes 
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Appendix 8.5   Detailed analytical parameters of CVAAS for determination of Mercury in 
 
                         acid-digested solution 
 
Element - Matrix: Hg -  
Instrument Type: Vapor 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Concentration 
Measurement Mode: Integrate 
Replicates Standard: 2 
Replicates Sample: 1 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 4 
 
Wavelength: 253.7 nm 
Slit Width: 0.5 nm 
Gain: 39 % 
Lamp Current: 4.0 mA 
Lamp Position: 3 
Background Correction: BC Off 
 
STANDARD 1: 0.5000 ug/L 
STANDARD 2: 1.0000 ug/L 
STANDARD 3: 2.0000 ug/L 
STANDARD 4: 3.0000 ug/L 
STANDARD 5: 4.0000 ug/L 
Reslope Rate: 60 
Reslope Standard No.: 2 
Reslope Lower Limit: 75.0 % 
Reslope Upper Limit: 125.0 % 
Recalibration Rate: 200 
Calibration Algorithm: Linear 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Measurement Time: 5.0 s 
Pre-Read Delay: 35 s 
Vapor Type: Cold Vapor 
Burner Height: 0.0 mm 
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Appendix 8.6   Detailed analytical parameters of CVAAS for determination of Mercury in 
  
                        aqueous decoction 
 
Element - Matrix: Hg -  
Instrument Type: Vapor 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Concentration 
Measurement Mode: Integrate 
Replicates Standard: 2 
Replicates Sample: 1 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 4 
 
Wavelength: 253.7 nm 
Slit Width: 0.5 nm 
Gain: 36 % 
Lamp Current: 4.0 mA 
Lamp Position: 3 
Background Correction: BC Off 
 
STANDARD 1: 0.2500 ug/L 
STANDARD 2: 0.5000 ug/L 
STANDARD 3: 1.0000 ug/L 
STANDARD 4: 2.0000 ug/L 
STANDARD 5: 3.0000 ug/L 
Reslope Rate: 60 
Reslope Standard No.: 2 
Reslope Lower Limit: 75.0 % 
Reslope Upper Limit: 125.0 % 
Recalibration Rate: 200 
Calibration Algorithm: Linear 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Measurement Time: 5.0 s 
Pre-Read Delay: 35 s 
Vapor Type: Cold Vapor 
Burner Height: 0.0 mm 
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Appendix 8.7    Key to the photographs of the 100 Chinese herbal materials included in the metal 
investigation showing sample codes, Chinese Pin Yin names, pharmaceutical and botanical 
names. 
 
No. 
 
Code 
 
Chinese Name 
 
Pharmaceutical Name 
 
Botanical Name 
 
1 HWI3 Wu Zhu Yu Frucus Evoliae Rutaecarpae Evodia rutaecarpa (Juss.) Benth. 
2 HBS3 Dan Shen Radix Salvise Miltiorrhizae Sallvia miltiorrhiza Bge. 
3 HRQ5 Xiang Fu Rhizoma Cyperi Rotundi Cyperus roundus L. 
4 
 
HQT3 
 
Shan Yao 
 
Radix Dioscoreae Oppositae Dioscorea opposite Thunb. 
5 
 
HAS3 
 
Lian Zi 
 
Semen Nelumbinis 
Nuciferae 
Nelumbo nucifera Gaertn 
6 HWC4 Fang Feng Radix Ledebouriella Ledebouriella seseloides (Hoffm.) 
7 
 
HRQ7 
 
Yan Hu Suo 
 
Rhizoma Corydalis 
Yanhusuo 
Corydalis yanhusuo W. T. Wang.  
8 
 
HRQ6 
 
Wu Yao 
 
Radix Linderae 
Strychnifoliae 
Linders stychnifolia (Sieb. Et Zucc.) Villar 
9 
 
HWD3 
 
Sang Ji Sheng 
 
Ramulus Sangjisheng 
 
Taxillus chinensis (DC.) Danser or 
T.sutchuensensis (Lecomte) danser 
10 HBT1 Dang Gui Radix Angelicae Sinensis  Angelica sinensis (Oliv.) Diels 
11 
 
HRP3 
 
Qian Hu  
 
Radix Peucedani Peucedanum praeruptorum Dunn, or P. 
Decursivum (Miq.) Maxim. 
12 HBT4 Bai Shao Radix Paeoniae Lactiflorae Paeonia lactflora Pall. 
13 
 
HYN1 
 
Bei Sha Shen 
 
Radix Adenophorae seu 
Glehiae 
Adenophora tetraphylla (Thunb.), A. stricta 
Miq., or Glehnia littoralis F. Schmidt ex 
Miq. 
14 HSD4 Yuan Zhi Radix Polygalae Tenuifoliae Polygala tenuifolia Willd. 
15 
 
HYN3 
 
Yu Zhu 
 
Rhizoma Polygonati 
Odoeati 
Polygonatum odoratum (Mill.) Druce 
var.pluriflorum (Miq.) Ohwi 
16 
 
HDG2 
 
Mai Ya 
 
Fructus Hordei Vulgaris 
Germinantus 
Hordeum vulgare L. 
17 
 
HWC5 
 
Qiang Huo 
 
Rhizoma et Radix 
Notopterygii 
Notopterygium incisum Ting ex H. T. 
Chang 
18 HYN7 Nu Zhen Zi Fructus Ligustri Lucidi Ligustrum lucidum Ait. 
19 
 
HEH4 
 
Huang Bai 
 
Cortex Phellodendri 
 
Phellodendron amurense Rupr. or P. 
chinense Schneid. 
20 
 
HWC6 
 
Bai Zhi 
 
Radix angelicae Dahuricae 
Angelica dahurica (Fisch. Ex Hoffm.) 
Benth et Hook f.  
21 HYN5 Gou Qi Zi Fructus Lycii Lycium barbarum L. or L. chinense Mill. 
22 HCB4 Chi Shao Radix Paeoniae Rubrae Paeonia veitchii Lynch or P. lactiflora Pall. 
23 
 
HEH1 
 
Zhi Mu 
 
Rhizoma Anemarrhenae 
Asphodeloidis 
Anemarrhena asphodeloides Bge. 
 
24 
 
HQT4 
 
Gan Cao 
 
Radix Glycyrrhizae 
Uralensis 
Glycyrrhiza uralensis Fischer. 
25 
 
HCL2 
 
Gou Teng 
 
Ramulus cum Uncis 
Uncariae 
Uncardia ehynchophylla (MIq.), or U. 
sinensis 
26 HAS2 Fu Ziao Mai Semen Tritici Aestivi Levis Triticum aestivum L. 
27 HBS5 Hong Hua Flos Carthami Tinctorii Carthamus tinctorius L. 
28 
 
HYT1 
 
Du Zhong 
 
Cortex Eucommiae 
Ulmoidis 
Eucommia ulmoides Oliv. 
29 HYN4 Shan Zhu Yu Fructus Corni Officinalis Cornus officinalis Sieb. Et Zucc. 
30 
 
HAD1 
 
Cang Zhu 
 
Rhizoma Atractylodis 
 
Atractylodes lancea Thunb., or  A. 
chinensis Koidz. 
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31 
 
HSD2 
 
Suan Zao Ren 
 
Semen Zizyphi Spinosae Ziziphus spinosa Hu. Also known as Z. 
jujube Mill. 
32 
 
HPU1 
 
Da Huang 
 
Radix et Rhizoma Rhei 
 
Rheum palmatum L. or R. tanguticum 
Maxim. Et Reg.; or R. officinale Baill. 
33 HAN1 Da Fu Pi Percarpium Arecae Catechu Areca catechu L. 
34 HWH1 Bo He  Herba Menthae 
Haplocalycis 
Mentha haplocalyx Briq. 
35 
 
HWH3 
 
Chai Hu 
 
Radix Bupleuri 
 
Bupleurum chinense D.C. or B. 
Scorzoneraefolium Wild. 
36 
 
HDU2 
 
Ze Xie 
 
Rhizoma Alismatis 
Orientalitis 
Alisma plantago-aquatica L. var. orientale 
Samuels 
37 
 
HDC1 
 
Ku Xing Ren 
  
Semen Pruni Armeniacae Prunus armeniaca L. var. ansu Maxim., or 
P. armeniaca L. 
38 HWD1 Du Huo Radix Angelicae 
Pubescentis 
Angelica pubescens Maxim. 
39 
 
HDC2 
 
Bai Bu 
 
Radix Stemonae Stemona sessilifolia (Miq.) Franch. Et Sav., 
S. japonica (BL.) Miq., or S. tuberosa Lour. 
40 HRP1 Ban Xia Rhizoma Pinelliae Ternatae Pinellia ternata (Thunb.) Breit. 
41 HRQ3 Zhi Ke Fructus Citri Aurantii Citrus aurantium L. 
42 
 
HQT5 
 
Zhi Gan Cao 
 
Radix Gycyrrhizae 
Uralensis 
Glycyrrhiza uralensis Fischer. 
43 HYT2 Xu Duan Radix Dipsaci Asperi Dispsacus asper Wall. 
44 
 
HWC7 Xin Yi Hua 
 
Flos Magnoliae 
 
Magnolia lilflora Desr., M. biondii Pamp., 
M. sprengeri Pamp., or M. denudata Desr. 
45 
 
HHT2 
 
Lian Qiao 
 
Fructus Forsythiae 
Suspensae 
Forsythia suspensa (Thunb.) Vahl 
 
46 
 
HYT3 
 
Bu Gu Zhi 
 
Fructus Psoraleae 
Corylifoliae 
Psoralea corylifolia L. 
47 HDH1 Di Gu PI Cortex Lycii Radicis Lycium chinense Mill. or L. bararum L. 
48 HHM1 Ce Bai Ye Cacumen Biotae Orientalis Biota orientalis (L.) Endl. 
49 
 
HAD3 
 
Huo Xiang 
 
Herba Agastaches seu 
Pogostemi 
Agastache rugosa (Fish et Mey.) O. Ktze., 
or Pogostemon cablin (Blanco) Benth. 
50 
 
 
HBT3 
 
 
Shu Di Huang 
 
 
Radix Rehmanniae 
Glutinosae Conquitae 
Rehmannia glutinosa (Gaertn.) Libosch., or 
R. glutinosa Libosch. F. hueichingensis 
(Chao et Schih) Hsiao  
51 
 
HWC1 
 
Gui Zhi 
 
Ramulus Cinnamomi 
Cassiae 
Cinnamomum cassia Blume 
 
52 
 
HEH3 
 
Huang Qin 
 
Radix Scutellariae 
Baicalensis 
Scutllaria baicalensis Georgi 
 
53 
 
HQT1 
 
Huang Qi 
 
Radix Astrgali 
Membranaceus 
Astragalus membranaceus (Fish.) Bge., or 
A. membranaceus Bge. var. mongholicus 
Hsiao.  
54 
 
HWI1 
 
Gan Jiang 
 
Rhizoma Zingiberis 
Officinalis 
Zingiber officinale-Rosc 
 
55 HDG1 Shan Zha  Fructus Crataegi Crataegus pinnatifida Bge. 
56 
 
HQT2 
 
Bai Zhu 
 
Rhizoma Atractylodis 
Macrocephalae 
Atractylodes macrocephala Koidz. 
57 HSD1 Long Gu Os Draconis Not applicable 
58 
 
HAS1 
 
Wu Wei Zi 
 
Fructus Schisandrae 
chinensis 
Schisandra chinensis (Turcz.) Baill. 
59 HRQ4 Mu Xiang Radix Aucklandiae lappae Aucklandiae lappa Decne 
60 HEH2 Lu Gen Rhizoma Phragmitis Phragmites communis 
61 
 
HWC2 
 
Zi Su Ye 
 
Folium Perillae Frutescentis 
Perilla frutescens (L.) Britt. var. crispa
（thunb.) Hand.-Mazz. 
62 
 
HCB5 
 
Zi Cao 
 
Radix Arnebiae seu 
Lithospermi 
Lithospermum erythrorhizon Sieb. Et Zucc. 
or Arnebia euchroma (Royle) Johnst 
63 HWI2 Rou Gui Cortex Cinnanomi Cassiae Cinnamomum cassia Presl. 
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64 HRQ1 Ju Pi Percarpium Citri Reticulate Citrus reticulata Blanco 
65 
 
HRP4 
 
Gua Lou 
 
Fructus Trichosanthis Trichosanthes kirilowii Maxim., T. uniflora 
Hao, or T. rosthornii Harms 
66 HBS2 Yu Jin Tuber Curcumae Curcuma longa L., or C. aromatica Salisb. 
67 
 
HEH5 
 
Zhi Zi 
 
Fructus Gardeniae 
Jasminoidis 
Gardeniae jasminoides Ellis 
 
68 HDU3 Yi Yi Ren 
Semen Coicis lachrymal-
jobi Coix lachrymal jobi L. 
69 
 
HAD4 
 
Sha Ren 
 
Fructus Amomi 
 
Amomum villosum Lour. or A. xanthioides 
Wall. 
70 
 
HWD1 
 
Qin Jiao 
 
Radix Gentianae Qinjiao 
 
Gentiana macrophylla Pall, G. straminea 
Maxim 
71 HBS6 Chuan Niu Xi Radix Cyathulae Officinalis Cyathula officinalis Kuan. 
72 
 
HRQ2 
 
Qing Pi 
 
Percarpium Citri Reticulate 
Viride 
Citrus reticulata Blanco 
73 HSD3 Bai Zi Ren Semen Biotae Orientalis  Biota orientalis (L.) Endl 
74 HCB3 Mu Dan Pi Cortex Moutan Radicis  Paeonia suffruticosa Andr. 
75 
 
HEH6 
 
Ku Shen 
 
Radix Sophorae 
Flavescentis 
Sophora flavescens Ait 
 
76 HRP2 Jie Geng Radix Platycodi Grandiflori Platycodon grandflorum (Jacq.) A. DC. 
77 HRP5 Chuan Bei 
Mu 
Bulbus Fritillariae Cirrhosae Fritilaria cirrhosa D. Don. 
78 HBT2 He Shou Wu Radix Polygoni Multifori Polygonum multiflorum Thunb. 
79 HAD2 Huo Po Cortex Magnoliae Offinalis  Magnolia officialis Rhd. Et Wils  
80 HBS4 Ye Mu Cao Herba Leonuri Heterophylli Leonurus heterophyllus Sweet 
81 HDC3 Su Zi Fructus Perillae Frutescentis Perilla frutescens (L.) Britt. 
82 HDC5 Sang Bai Pi Cortex Mori albae Orientalis Morus alba L. 
83 
 
HCL1 
 
Tian Ma 
 
Radix Astrgali 
Membranaceus 
Gastrodia elata Blume 
84 HAS4 Qian Shi Semen Euryales Ferocis Euryale ferox Salisb. 
85 HHT1 Jin Yin Hua Flos Lonicerae Japonicae Lonicera japonica Thunb.  
86 HYN6 Mo Han Lian  Herba Ecliptae Prostratae Eclipta prostrata L. 
87 HWH2 Ju Hua Flos Chrysanthemi Morifolii Chrysanthemum morifolium Ramat 
88 
 
HYN2 
 
Mai Men 
Dong  
Tuber Ophiopogonis 
Japonici 
Ophiopogon japonicus Ker-Gawl 
89 
 
HBS7 
 
Huai Niu Xi 
 
Radix Achyranthis 
Bidentatae 
Achyranthes bidentata Bl. 
90 
 
HHT3 
 
Ban Lan Gen 
 
Radix Isatidis seu 
Baphicacanthi 
Baphicacanthus cusia (Nees) Brem., Isatis 
tinctoria L., or I. indigotica Fort. 
91 
 
HHM2 
 
Bai Mao Gen 
 
Rhizoma Imperatae 
Cylindricae 
Imperata cylindrica (L.) P. Beauv. Var. 
major (nees) C.E. Hubb. 
92 HBS1 Chuan Xiong Radix Ligustici Chuanxiong Ligusticum chuanxiong Hort. 
93 
 
HCB2 
 
Xuan Shen 
 
Radix Scrophulariae 
Ningpoensis 
Scrophularia ningpoensis Hemsl. 
 
94 
 
HWC3 
 
Jing Jie 
 
Herba seu Flos 
Schizonepetae Tenuifoliae 
Schizonepeta tenuifolia Briq. 
 
95 
 
HEH7 
 
Long Dan 
Cao 
Radix Gentianae 
Longdancao 
Gentiana scabra Bge, G. Triflom Pall., G. 
manshurica Kitag., or G. regescens Fransh. 
96 HCB1 Sheng Di 
Huang 
Radix Rehmanniae 
Glutinosae 
Rehmannia glutinosa (Gaertn.) Libosch 
97 HDU1 Fu Ling Sclerotium Poriae Cocos Poria cocos (Schw.) Eolf 
98 HSD5 Mu Li Concha Ostreae Ostrea gigas Thunb., O. rivularis Gould 
99 HDC3 Zi Wan Radix Asteris Tatarici Aster tataricus L. 
100 
 
HYT4 
 
Ron Cong 
Rong  
Herba cistanches 
Deserticolae 
Cistanche deserticola Y. C. Ma 
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Photographs of the 100 raw Chinese herbal 
medicines selected for investigation in this 
thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please refer to key for name of the 
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Appendix  8.8     Key to the photographs of the 50 Chinese proprietary medicines (CPM), Chinese 
and English names and their manufacturers. 
No. Chinese Name English Name Aust L 
No. 
Manufacturer Batch  
No. 
01 Xiao Feng Wan  
(Batch: 010904) 
Eliminate Wind Powder  L 67163 Lanzhou Foci, China 010904 
02 Ba Zheng San  Eight-Herb Powder for Rectification L 73121 Lanzhou Foci, China 000601 
03 Xiao Qing Long Tang Minor Blue Green Dragon 
Decoction plus Gypsum  
L 11727 Lanzhou Minshan, China 010608 
04 Long Dan Xie Gan Tang Gentiana Longdancao Decoction to 
Drain the Liver  
L 11692 Lanzhou Tai Bao, China 030125 
05 Xin Yi Wan Magnolia Flower Powder L 11736 Lanzhou Minshan, China 020418 
06 Tao Chih Pien  Guide Out the Red Powder L 57730 Tianjin Drug Co., China  N / A 
07 Chuan Xiong Cha Tiao 
Wan 
Ligusticum Chuanxiong Powder 
to be Taken with Green Tea 
L 68047 Lanzhou Foci, China 0203061
08 Ba Zhen Tang Eight-Treasure Decoction L 11654 Lanzhou Tai Bao, China 040218 
09 Liu Wei Di Huang Wan Six-Ingredient Pill with Rehmannia L 55976 Lanzhou Foci, China 0305158
010 Po Chai Pills Po Chai Pills Chinese 
Grocery
Li Chung Shing Tong, 
Hong Kong 
20512 
011 Duo Huo Ji Sheng Tang Angelica Pubescens and 
Sangjisheng Decoction  
L 55488 Lanzhou Foci, China 0210041
012 Jian Pi Wan Strengthen the Spleen Pill L 55430 Lanzhou Foci, China 9901137
013 Bu Zhong Yi Qi Wan Tonify the Middle and Augment the 
Qi Decoction 
L 11663 Lanzhou Minshan, China 031208 
014 Er Chen Tang Two-Cured Decoction L 11676 Lanzhou Tai Bao, China 030702 
015 Zhi Sou San & Addition Stop Coughing Powder L 11747 Lanzhou Tai Bao, China 2000031
5 
016 Shen Ling Bai Zhu San Ginseng, Poria, and Atractylodes 
Macrocephala Powder 
L 11704 Lanzhou Minshan, China 030101 
017 Yu Ping Feng San Jade Windscreen Powder  L 11742 Lanzhou Minshan, China 040509 
018 Chai Hu Shu Gan San Bupleurum Powder o Spread the 
Liver 
L 55432 Lanzhou Foci, China 0210011
019 Huo Xiang Zheng Qi San Agastache Power to Rectify the 
Qi 
L 11684 Lanzhou Tai Bao, China 020809 
020 Xiao Chai Hu Tang Minor Bupleurum Decoction L 11724 Lanzhou Minshan, 
China 
030830 
021 Qing Qi Hua Tan Wan Clear the Qi and Transform Phlegm 
Pill 
L 55977 Lanzhou Foci, China 030706 
022 Xiao Yao San Rambling Powder L 55893 Lanzhou Foci, China 2004064
7 
023 Bao He Wan (Sheng Neng 
P/L) 
Preserve Harmony Pill (9 Herbs) L 55807 Lanzhou Foci, China 020511 
024 Yin Qiao Wan Honeysuckle and Forsythia Powder L 11740 Lanzhou Minshan, 
China 
031009 
025 Tian Wang Bu Xin Dan Emperor of Heaven’s Special Pill to 
Tonify the Heart 
L 55810 Lanzhou Foci, China 2004021
0-2 
026 Fang Feng Tong Sheng San Ladebouriella Powder that Sagely  
Unblocks  
L 69602 Lanzhou Foci, China 990801 
027 Niu Huang Qing Xin Wan Cattle Gallstone Pill to Clear the 
Heart 
   N / A Beijing Tong Ren Tang, 
China 
0010281
028 Tian Wang Bu Xin Wan Emperor of Heaven’s Special Pill to 
Tonify the Heart 
L 11713 Lanzhou Minshan, China  010220 
029 An Shen Ding Zhi Wan Calm the Spirit & Settle the 
Emotions Pill  
L 68036 Lanzhou Foci, China 990501 
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030 Gui Pi Wan  Restore the Spleen Decoction L 55974 Lanzhou Foci. China 970412 
031 Huang Lian Jie Du Tang Coptis Decoction to Relieve 
Toxicity 
L 11683 Lanzhou Mian San, 
China 
031102 
032 Xue Fu Zhu Yu Tang Drive Out Stasis in the Mansion of 
Blood Decoction 
L 11738 Lanzhou Tai Bao, China 040606 
033 Sang Ju Wan Mulberry Leaf and Chrysanthemum 
Decoction 
L 73299 Lanzhou Foci, China 0305022
034 Mai Wei Di Huang Wan N / A L 46687 Lanzhou Foci, China 970909 
035 Shen Qi Da Bu Wan N / A L 41617 Lanzhou Minshan, China 030723 
036 Tao Hong Si Wu Wan Four-Substance Decoction with 
Safflower and Peach Pill 
L 11711 Lanzhou Minshan, China 040410 
037 Tian Ma Gou Teng Wan Gastrodia and Uncaria Decoction L 11712 Lanzhou Tai Bao, China 040530 
038 Qian Bai Bi Yan Pian N / A L 60817 Guangzhou Qixing, China C 0901 
039 Zuo Gui Wan Restore the left (Kidney) Pill L 11748 Lanzhou Minshan, China 030117 
040 You Gui Wan Restore the Right (Kidney) Pill L 59014 Lanzhou Foci, China 0211021
041 Bao He Wan 
(Cathay P/L) 
Preserve Harmony Pill (6 Herbs) L 11660 Lanzhou Foci, China 970711 
042 Bu Zhong Yi Qi Tang Tonify the Middle and Augment the 
Qi Decoction 
L 60713 Lanzhou Foci, China 971035 
043 Zhi Sou San & Addition Stop Coughing Powder L 11747 Lanzhou Foci, China 970801 
044 Gui Pi Tang Restore the Spleen Decoction L 11682 Lanzhou Tai Bao, China 030520 
045 Xiao Feng Wan  
(Batch:9903027) 
Eliminate Wind Powder  L 67163 Lanzhou Foci, China 9903027
046 Wen Dan Tang Warm the Gallbladder Decoction L 11717 Lanzhou Tai Bao, China 031202 
047 Zhi Bai Ba Wei Wan Anemarrhena, Phellodendron, 
and Rehmannia Pill 
L 11746 Lanzhou Minshan, China 990115 
048 Tao Hong Si Wu Wan Four-Substance Decoction with 
Safflower and Peach Pit 
L 67284 Lanzhou Foci, China 2004052
3 
049 Bi Min Gan Pian Hayfever Tablet L 76471 King Tim International, 
Australia 
041109 
050 Kun Bao Wan Women’s Treasure Pills L 78816 Tong Ren Tong, 
Australia 
0307022
 
Legend to Table 8.7 above: 
Note: English names are based on Bensky & Barolet: Formulas and Strategies, Eastland Press, 
1990. N /A = not available         
No. 23 and 41 – Produced by same company, same product name but different List numbers.  No.23 
has 9 herbs against 6 herbs in No.41 in the prescription. They are packaged by same manufacturer for 
export to two different companies in Australia, the Shen Neng P/L, NSW, and the Cathay Wholesale 
P/L, NSW. 
No. 15 and 43 – Produced by two different companies. Company that manufactured No.15 was 
formerly related to company that manufactured No.43. The same List number was retained even 
though quality assurance may be entirely different. 
No. 1 and 45 – Same products (from same company), but different batches. Selected to highlight 
possible variations in quality control between batches.
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Photographs of the 50 Chinese proprietary 
medicines selected for investigation in this 
thesis 
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Appendix 12.1   Detailed analytical parameters of GFAAS for determination of serum Lead 
 
                            by standard addition method. 
Element - Matrix: Pb -  
Instrument Type: Furnace 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Standard Additions 
Measurement Mode: Peak Height 
Replicates Standard: 1 
Replicates Sample: 1 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 4 
 
Wavelength: 283.3 nm 
Slit Width: 0.5 nm 
Gain: 31 % 
Lamp Current: 10.0 mA 
Lamp Position: 3 
Background Correction: BC On 
 
ADDITION 1: 10.0000 ug/L 
ADDITION 2: 20.0000 ug/L 
ADDITION 3: 40.0000 ug/L 
Recalibration Rate: 60 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Workhead Height: 0.0 mm 
Total Volume: 25 uL 
Sample Volume: 10 uL 
Vol. Reduction  Factor: 2 
Bulk Conc.: 50.0000 ug/L 
Bulk Vial No.: 51 
Makeup Vial No.: 52 
Sample No. of Injections: 1 
Sample Last Dry Step: 1 
Modifier 1 Mode: Co Inject 
Modifier 1 Vol.: 5 uL 
Last Dry Step: 0 
Injection Rate: 1 
Modifier 1 Pos.: 53 
No. of Injections: 1 
 
 Step Temp (C) Time (s) Flow (L/min) Gas Type Read Signal Storage 
 1 90 45.0 3.0 Normal No No 
 2 120 20.0 3.0 Normal No No 
 3 300 8.0 3.0 Normal No No 
 4 450 7.0 0.5 Alternate No No 
 5 480 8.0 0.5 Alternate No No 
 6 480 5.0 3.0 Normal No Yes 
 7 480 2.0 0.0 Normal Yes Yes 
 8 2600 1.0 0.0 Normal Yes Yes 
 9 2600 3.0 3.0 Normal No Yes 
  
 380 
Appendix 12.2   Detailed analytical parameters of GFAAS for determination of serum  
 
                            Cadmium by standard addition method. 
 
Element - Matrix: Cd -  
Instrument Type: Furnace 
Conc. Units: ug/L 
 
Sampling Mode: AutoMix 
Calibration Mode: Standard Additions 
Measurement Mode: Peak Height 
Replicates Standard: 1 
Replicates Sample: 1 
 
Expansion Factor: 1.0 
Minimum Reading: Disabled 
Smoothing: 7 point 
Conc. Dec. Places: 3 
 
Wavelength: 228.8 nm 
Slit Width: 0.5 nm 
Gain: 42 % 
Lamp Current: 4.0 mA 
Lamp Position: 1 
Background Correction: BC On 
 
ADDITION 1: 0.500 ug/L 
ADDITION 2: 1.500 ug/L 
Recalibration Rate: 60 
Cal. Lower Limit: 20.0 % 
Cal. Upper Limit: 150.0 % 
 
Workhead Height: 0.0 mm 
Total Volume: 15 uL 
Sample Volume: 5 uL 
Vol. Reduction  Factor: 2 
Bulk Conc.: 2.500 ug/L 
Bulk Vial No.: 51 
Makeup Vial No.: 52 
Sample No. of Injections: 1 
Sample Last Dry Step: 1 
Modifier 1 Mode: Co Inject 
Modifier 1 Vol.: 5 uL 
Last Dry Step: 0 
Injection Rate: 1 
Modifier 1 Pos.: 53 
No. of Injections: 1 
 
 Step Temp (C) Time (s) Flow (L/min) Gas Type Read Signal Storage 
 1 85 5.0 3.0 Normal No No 
 2 95 40.0 3.0 Normal No No 
 3 140 20.0 3.0 Normal No No 
 4 300 10.0 3.0 Normal No No 
 5 450 10.0 0.5 Alternate No No 
 6 650 20.0 3.0 Normal No No 
 7 650 1.0 0.0 Normal No Yes 
 8 2500 1.0 0.0 Normal Yes Yes 
 9 2500 1.0 3.0 Normal No Yes 
